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3Abstract
Using registry data to estimate the effects of long-term treatment use in cystic fibrosis
Cystic fibrosis (CF) is a disease affecting over 10,000 people in the UK. It has no cure, but
there are many treatments to help improve health. Randomised controlled trials are the
gold standard for establishing treatment efficacy, but most trials for CF treatments have
no more than one year of follow-up. In practice treatments are commonly used for many
years, and it is therefore important to evaluate their long-term effectiveness.
The UK CF Registry collects annual data on almost all people with CF in the UK. The
overall aim of this work is to investigate how data from such registries can be harnessed
to provide insights into the effects of long-term treatment use. My research illustrates the
potential of registry data by investigating two CF treatments: DNase and ivacaftor.
DNase is a common CF treatment and generally, once started, it continues to be used
indefinitely. Despite this, no studies have investigated its long-term effects. Estimating
these effects using registry data is difficult due to time-dependent confounding. I investi-
gate five methods that can account for this: sequential conditional mean models, inverse
probability weighting of marginal structural models (MSM), history-adjusted MSM, g-
computation formula and g-estimation of structural nested models. The performance of
these methods is assessed through simulation studies, where it is shown that all methods
perform similarly under correct model specification, suggesting that more than one met-
hod could be applied to assess consistency of results. My analysis of the UK CF Registry
data suggests that DNase provides a step-change improvement in lung function only in
individuals with ppFEV1 < 70% (e.g. for a person starting DNase with ppFEV1 of 20%,
the one-year treatment effect was a 1.6% absolute difference in ppFEV1, 95% CI 0.4, 2.8).
However, the slope of lung function decline over five years remained unchanged.
Ivacaftor was introduced in the UK in 2012, but it is only available to people with a gating
mutation. In this subgroup, it appears to be so beneficial that almost all eligible people are
now receiving it. In this situation, it is difficult to estimate the treatment effect, because
there are no eligible people not receiving treatment. Two possible comparator groups
were identified: 1) those currently receiving ivacaftor, but using their data from years
prior to its introduction, 2) those ineligible to receive ivacaftor due to their genotype. This
work shows how analyses using negative controls can be used to assess the comparability
of the different groups, and how differences between groups not due to treatment can be
mitigated. Our analysis suggests that these two groups are comparable to people who are
currently receiving ivacaftor, and the results of the analysis show that ivacaftor not only
provides an initial step-change improvement in lung function (5.9% absolute difference
in ppFEV1, 95% CI 4.7, 7.1), but also decrease the rate of lung function decline (0.5%
absolute decrease in ppFEV1 decline per year, 95% CI 0.02, 1.0).
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Chapter 1
Introduction
1.1 Introduction
The work in this thesis was undertaken as part of the Cystic Fibrosis Epidemiological
Network (CF-EpiNet), a Strategic Research Centre funded by the Cystic Fibrosis Trust.
The network is carrying out several projects with the overall aim of harnessing registry
data to improve the lives of people with cystic fibrosis (CF). This project specifically aims to
investigate how national registries can be used to estimate the effects of long-term treat-
ment use.
Randomised controlled trials (RCTs) are known to be the gold-standard for estimating
treament effects, but there are many situations where it is not possible to run a RCT.[1]
For example, when we wish to estimate the effects of long-term treatment use, it may
not be feasible to run a trial for such a long period of time and furthermore it may not
be ethical to continue witholding a treatment from patients if it has already been pro-
ven to be beneficial in the short-term. In such situations, we can try to use observational
data, such as registries, to obtain estimates of the treatment effects. However, estimation
of treatment effects using observational data is not straightforward, as the people recei-
ving treatment can be systematically different from those not receiving treatment, making
comparisons difficult. These difficulties can be exacerbated when the data are longitudi-
nal, due to there not only being differences between people at baseline, but also during
follow-up, and also because people may start and stop treatments over time. The field
of causal inference provides a conceptual framework to formally define what is meant
by a ‘treatment effect’, even in longitudinal settings, and based on these clear definiti-
ons, together with clearly articulated assumptions, a wide variety of statistical methods
have been developed that can be used to estimate causal effects of treatments in these
challenging settings.
The overall aim of this thesis is to investigate the use of causal inference methods with
national registry data to be able to accurately estimate the effects of long-term treatment
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use in CF. This chapter contains a brief overview of CF and the basis of the causal infe-
rence methods that will be considered in this thesis. The chapter ends with an outline of
the whole thesis.
1.2 Cystic Fibrosis
CF is one of the most common life-threatening genetic diseases in the world and in the
United Kingdom (UK) there are approximately 10,500 people living with the disease.[2]
CF is caused by a mutation in the cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene which affects the way that salt and water move between cells. There
are a number of different CF-causing mutations, and depending on the severity of the
mutation, the synthesis, processing or regulation of the CFTR protein can be impaired.
Overall, these issues result in a thick mucus which clogs up internal organs.
The most seriously affected organ is the lung, where the build-up of mucus causes brea-
thing difficulties and leads to an increase in respiratory infections. Long term this results
in a general trend of deteriorating lung function, but there can also be more sudden drops
in lung function as well as periods when lung function improves. There are a number
of bacterial and viral infections that commonly affect people with CF. Often these can at
first be successfully eradicated, but long term many people end up with chronic infecti-
ons. In order to avoid cross contamination, it is generally recommended that people with
CF avoid contact with other people with CF.
As lung function deteriorates to very low levels it is often desirable for people to receive
lung transplants. Sometimes other organs are also transplanted, but the most common
transplant is a double lung transplant. Obviously, this depends on the availability of suit-
able donor organs, and in 2016 in the UK there were 96 people added onto the transplant
wait list with 51 transplants performed (46 of which were double lung transplants).[3]
After a lung transplant, people still have CF, but they no longer have CF lungs and as
such they are generally very different from people who have not had a transplant, espe-
cially in terms of lung function. For this reason, for all the work in this thesis we will
censor people after the date of their transplant.
The digestive system is also commonly affected by mucus which prevents the proper ab-
sorption of food. This can lead to difficulties in obtaining adequate nutrition and people
will often receive enzyme supplements to aid digestion.
There is currently no cure for CF, but nowadays there are many treatments available to
help people with CF live longer, healthier lives. In 1959 the median survival age of people
with CF in England and Wales was estimated to be between 0 and 4 years.[4] However
this has increased greatly and in 2017 the median predicted survival age was estimated to
be 47 in the UK.[5] With people with CF living longer, treatments are also being used for
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longer durations, as many treatments are expected to be used continuously once initiated.
However, most treatments have only been shown to be efficacious in clinical trials with
follow-up times of around one or two years.
The majority of these treatments target specific symptoms of CF, meaning that people
often have to take many treatments for every area of health that is affected by the disease.
This has led to treatment burden being a common complaint among people with CF; for
example, a 2009 study from the United States of America (USA) showed that the median
number of daily therapies per person was 7, requiring a mean time of 108 minutes per
day.[6] One of the most common treatments available to people with CF is dornase alfa
(DNase), which is administered by inhalation using a jet nebuliser. The treatment helps
break down mucus in the airways with the aim of improving lung function. It has been
licensed in the UK since 1994, but despite being available for over 20 years, no studies
have looked at the effects of taking the treatment for more than four years. This will be
the first treatment investigated as part of this thesis.
More recently there has been increased interest in disease-modifying treatments. A disease-
modifying treatment would be a treatment that directly improves CFTR function, and
therefore ideally it would improve all areas of health affected by CF.[7, 8] The first of
these treatments to become available is a CFTR potentiator called ivacaftor, which has
been available in the UK since 2012. It is only effective in a subset of people with CF,
those with a gating-mutation, and this is approximately 5% of the UK CF population.
However, there are a number of combination therapies in the pipeline and it is hoped
that when combined with ivacaftor these treatments will be effective in a much larger
proportion of the CF population. In fact, one such combination, ivacaftor and lumacaf-
tor, is now available in some countries, but it is not yet generally available in the UK. For
this reason, ivacaftor will be the second treatment that we investigate in this thesis, but
restricted to its effect in people with a gating mutation.
1.3 Causal Inference of Treatment Effects
In this thesis, our main target of inference is a comparison of the mean outcome if hypot-
hetically everybody received treatment for x years versus the mean outcome if hypothe-
tically nobody received treatment for the same x years. In general, by ‘everybody’ we are
referring to the UK CF population, but we may also be interested in specific subsets of
this population in some analyses.
Ignoring all issues of feasibility, cost and ethics, the best way to estimate the causal effect
of a treatment would be to perform a RCT. Half of the population would be randomised
to receive treatment for x years and the other half would be randomised to not receive
treatment over the same time period. There would be a number of additional steps,
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such as using a placebo to ensure that people are blinded as to which group they in, but
provided that the trial was well-designed and there were no issues during follow-up, we
would then just compare the average level of outcome between the two groups at the end
of follow-up and this would be our estimate of the causal effect of x years of treatment.
In reality, it is often not possible to perform a RCT and we therefore have to find other
ways to obtain estimates of the causal effect of treatment. In observational settings, those
receiving treatment will generally not be directly comparable to those not receiving treat-
ment, for example people typically start treatment due to a deterioration in their health.
Furthermore, people might not always receive treatment continuously, instead stopping
and starting during follow-up, and the reasons for this may depend on their underlying
health status, including prior measures of the outcome of interest. This is generally refer-
red to as confounding by indication, and in longitudinal settings, there is often also the
issue of time-dependent confounding, which will be introduced in Chapter 4. Depending
on the specific situation, there are a number of methods that have been developed that
can estimate causal effects from the analysis of observational data even in the presence
of confounding by indication or time-dependent confounding. These methods all work
in different ways, but overall they aim to remove any differences not due to treatment
between those receiving treatment and those not receiving treatment, in order to provide
an estimate of the causal effect of treatment.[9] In order to obtain these estimates, it is
generally necessary to make a number of assumptions regarding how the data were ge-
nerated. The treatment effect estimates will only be reliable if these assumptions are valid
and it is therefore important to be explicit about any assumptions, so that it is possible to
assess whether it is plausible that the results obtained are trustworthy.
1.4 Outline
This thesis is divided into four parts. In the remaining chapter of Part I, we will introduce
the UK CF Registry which is the dataset that will be used throughout this thesis. The
chapter gives details on how data are collected and contains a description of the key
variables that will be important in our analyses. We end the chapter by discussing some
of the strengths and weaknesses of the registry.
Part II will focus on the long-term effects of dornase alfa (DNase). Chapter 3 is a syste-
matic review of studies that have investigated the effects of this treatment. This can be
used as a starting point for our own investigations, finding out what is already known
about the effects of the treatment and where there are gaps in knowledge.
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Chapter 4 introduces the different statistical methods that we will consider for our ana-
lysis of the UK CF Registry to estimate the long-term effects of DNase. The main chal-
lenge of such an analysis is an issue known as time-dependent confounding. We in-
troduce why this is a problem and then consider five methods that have been develo-
ped to provide unbiased estimates of long-term treatment effects even in the presence of
time-dependent confounding: inverse probability weighting of marginal structural mo-
dels, history-adjusted marginal structural models, g-computation formula, g-estimation
of structural nested models, and sequential conditional mean models. In our analysis
of the UK CF Registry we will focus on two outcomes: lung function and the annual
number of days receiving intravenous antibiotics. The first of these can be measured as a
continuous outcome, but the latter is measured as a count outcome, which brings some
specific challenges for analysis and interpretation. We will therefore give details of how
all the methods can handle outcomes that are most naturally modelled using non-linear
models.
In Chapter 5 we take the five methods introduced in the previous chapter and perform si-
mulation studies to assess their performance in a number of scenarios motivated by chal-
lenges faced in the analysis of routinely collected longitudinal data such as that found in
the UK CF Registry. All five methods are known to be able to provide unbiased estimates
of the treatment effect of interest in ideal settings. However with real data there will ge-
nerally be some peculiarities that could cause issues in the analysis. It is not clear if some
of the methods we consider will perform better than others when analysing the real UK
CF Registry, and we therefore perform simulation studies to assess the performance of
the methods to help guide an analysis strategy for the real data.
Based on the findings from the simulation studies, in Chapter 6 we perform an analysis
of the UK CF Registry to estimate the effects of up to five-years of DNase use on two out-
comes. The simulation studies suggested that any of the methods could be suitable for
this analysis, depending on what assumptions are considered appropriate, and we there-
fore present the results from using all five available methods. We end the chapter with a
discussion of our findings, comparing these to findings of previous studies identified in
the systematic review.
In Part III, we focus on a second treatment, ivacaftor, and as with Part II, we start with a
systematic review of studies that have investigated the effects of this treatment.
Chapter 8 will then look at the methods that could be used to analyse the long-term effects
of ivacaftor using the UK CF Registry. Unlike with DNase, time-dependent confounding
is not an issue for ivacaftor, because all people who are eligible for the treatment are
currently receiving it. However, this leads to another challenge: namely that there are no
directly comparable people who are not receiving treatment to be able to estimate what
would happen to people if they did not receive ivacaftor. In this chapter, we consider
different groups that could be used as comparator groups to those currently receiving
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treatment and introduce the use of negative controls to assess whether the assumption
that these groups are comparable is valid.
In Chapter 9 we then present the analysis of the UK CF Registry to investigate the effects
of using ivacaftor for up to four years. As with the analysis of the effects of DNase, we
consider two outcomes: lung function and annual number of days receiving intravenous
antibiotics. In the analysis, we consider three different statistical models: marginal mo-
dels, fixed-effects models and mixed-effects models. We compare the results from these
three methods and also assess the usefulness of negative controls. Finally, we compare
our findings to the findings of the studies identified in the systematic review.
Finally, Part IV of this thesis contains a summary of all of our findings and a discussion
of some of the strengths and limitations of our analyses. We also consider some areas of
potential future work, before concluding.
The thesis also contains a number of appendices. Appendix A contains a copy of the data
resource profile of the UK CF Registry that was published in the International Journal
of Epidemiology in 2018.[10] I was a co-author on this paper and it forms the basis of
Chapter 2 of this thesis. Appendix B contains a copy of a paper published in Statistics
in Medicine in 2018, which is based on the simulation studies found in Chapter 5 of this
thesis, and on which I am the first author.[11] Appendix C contains some supplementary
tables and figures of the simulation studies of Chapter 5. Appendix D contains a copy of
a paper published in the Journal of Cystic Fibrosis in 2018 investigating the long-term ef-
fects of DNase on lung function.[12] It is based on the work presented in Chapter 6 of this
thesis and I am the first author. Finally Appendices E and F contain supplementary tables
and figures of the analyses of DNase (Chapter 7) and ivacaftor (Chapter 9) respectively.
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Chapter 2
The UK Cystic Fibrosis Registry
2.1 Introduction
The UK Cystic Fibrosis Registry is a national database sponsored and managed by the
Cystic Fibrosis Trust. First established in 1996, it aims to record annual health data on
all people with CF in England, Wales, Scotland and Northern Ireland, and to date has
captured data on over 12,000 individuals.
This chapter introduces the UK CF Registry, giving details of how the data are collected
and some of the key variables that will be used in our analyses. The CF-EpiNet group
published a data resource profile of the registry in the International Journal of Epidemi-
ology in 2018. I was a co-author on that paper, and that work forms the basis of this
chapter. A copy of the paper can be found in Appendix A.
2.2 Data Collection
In the UK, people with CF are treated in specialist centres. In 2016 data were submitted to
the registry from 32 paediatric centres. At between 16 years and 18 years of age, children
transfer to an adult specialist centre, and in 2016 data were submitted to the registry from
28 adult centres. The geographical distribution of these centres in the UK can be seen in
Figure 2.1. When people with CF first attend a CF centre in the UK, they or their parents
consent to information on their health and treatment being collected and stored in the
registry. When transitioning to adult services or when changing primary centre of care,
there is the opportunity to confirm or withdraw consent.
People with CF attend their specialist centre once a year specifically for an annual re-
view. Data collected during this annual review are then submitted to the UK CF Registry
through an online portal. Provided that consent is given, data are therefore usually first
collected within one year from diagnosis. Future reviews are then carried out annually,
with the aim that the reviews will be approximately twelve months apart. However,
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(A) Paediatrics (B) Adults
FIGURE 2.1: Map of CF centres providing data to the UK CF Registry in
2016 (Note that there are four paediatric and four adult centres in London)
according to the Registry’s protocol, annual reviews are also supposed to be conducted
during a period of disease stability, and therefore, there is some variability in the spacing
between annual reviews. Figure 2.2 shows a histogram of the number of months bet-
ween two consecutive annual reviews since 2007. Overall, over 50% of annual reviews
take place between eleven and thirteen months since the last annual review and over 80%
take place between nine and fifteen months since the last annual review.
Figure 2.3 gives an overview of the number of individuals and annual reviews per year.
The total number of individuals with data in the registry has been steadily increasing
since the start of the registry, and the number of annual reviews carried out has also been
increasing, except for a sharp dip in 2006, which was the year prior to the nationwide
roll-out of the registry. In the most recent three years for which data were available (2014-
2016), the number of annual reviews has been quite stable with just under 10,000 reviews
carried out annually. Since 2007, the mean number of new people in the registry each
year was 469 people (range 318 to 696). The number of deaths and losses to follow-up
show more fluctuation, but with an overall upward trend consistent with the increasing
total number of people in the registry. A person is defined as lost to follow-up if they
miss two consecutive annual reviews.
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FIGURE 2.2: Histogram of number of months between consecutive annual
reviews carried out between 2007 and 2016
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FIGURE 2.3: Summary of number of annual reviews, individuals, deaths
and losses to follow-up in the UK CF Registry
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At the first annual review, a number of demographic variables are collected, such as sex,
ethnicity, genotype class and diagnosis date. Generally these variables will only need to
be entered for the first annual review and will then remain fixed for all future annual
reviews, but they can be updated to correct any mistakes or if previously missing data
becomes available.
Most data collection for the annual review refers to events that have happened since
the last annual review (i.e. the past twelve months for most people). For example, the
number of hospitalisations since the last review, what treatments individuals have been
receiving and any health complications that have happened in the past year. However,
a number of variables are specific to the annual review date, such as height, weight and
lung function, which are all measured at the annual review.
For Part II of this thesis, only data collected since 2007 is used, i.e. since the UK CF Re-
gistry was rolled out nationally, as a number of important variables were not routinely
collected prior to this. For Part III, as ivacaftor is a very recently introduced treatment, the
analyses are further restricted to data collected since 2008, which corresponds to the four
years before the introduction of ivacaftor and four years of data since its introduction. In
the following section, we will give an overview of the key variables that we will use for
our analyses, restricting these summaries to data collected since 2007.
2.3 Key Variables
2.3.1 Demographic Data
Since 2007, there have been 11,373 unique individuals with at least one annual review
in the UK CF Registry. Of these, 6,009 (52.8%) are male and 5,364 (47.2%) are female.
In terms of ethnicity, the vast majority are white (10,830 people, 95.2%) and most of the
remaining people report other or mixed ethnicity (501 people, 4.4%). Only 39 people are
black (0.3%) and 3 people are East Asian (0.03%).
Figure 2.4 shows a histogram of the year of birth of all the people with at least one annual
review between 2007 and 2016. Over a third of the individuals were born since the year
2000 (4,097 people, 36.0%), 61.2% were born since 1990 (6,961 people) and 82.4% since
1980 (9,377 people). However, there are 19 people who were born before 1940 (0.2%), and
78 people born before 1950 (0.7%). It is also noticeable that there are very few people with
a date of birth in 2016, and this shows that most people born with CF do not have their
first annual review until the year after their birth.
Nowadays, most people with CF will be genotyped to record which CF-causing mutation
they have; of those with an annual review between 2007 and 2016, only 174 (1.5%) do not
have a genotype recorded. The most common CF-causing mutation is f508del, and almost
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half of people have two f508del mutations (5,581 people, 50.1%). A further 4,447 people
(40.0%) have one f508del mutation and one other mutation, leaving 1,102 people (9.9%)
with two non-f508del mutations.
The date of death will clearly not be captured at an annual review, but it is retrospecti-
vely added to the previous annual review through linkage with the Office of National
Statistics. In total, there were 1,287 deaths recorded before 2018 (11.3%) for those with at
least one annual review between 2007 and 2016. Figure 2.5 shows a plot of age at death
against date of death; it can be seen that there is a slight upward trend in the age at de-
ath between 2007 and 2018, but note that this does not correspond to a formal survival
analysis.
2.3.2 Treatment Data
The registry contains data on 30 different types of treatment within which there are 87
specific treatments. In this work we will focus on estimating the long-term effects of two
treatments: dornase alfa (DNase) and ivacaftor, and more details about these treatments
will be given in Parts II and III respectively.
In general, for each treatment, the Registry contains a marker to show if an individual
has been receiving the treatment in the previous year. Therefore, this variable is either
marked as "Yes" or is missing, and for this reason all missing values are assumed to be
"No", which could affect the quality of the data. For example, Table 2.1 lists the ten most
commonly used treatments in 2016, and it can be seen that overall 76.1% of patients were
marked as using either Creon 10000 or Creon 25000. The proportion of CF patients who
are pancreatic insufficient, and therefore, who would likely be receiving these enzyme
replacement treatments is actually over 90%. The reason for this could be that the enzyme
replacement treatments are so common that people do not always enter the same data
every year, and it is hoped that this issue does not affect other data such as that on DNase
use.
There is space to collect more detailed information about the treatment, such as exact
start and stop dates, dosage and frequency, but these are not reliably collected and are
missing for most people.
The data collected in the registry corresponds to the fact that the individual has been
prescribed the specific treatment, but there is no data collected on whether they actually
adhered to the treatment. Taking all annual reviews carried out in 2016 as an example,
there were only 336 people (3.5%) who were not recorded to receive any treatments that
year. The median number of treatments per person was 9 (IQR 7 to 12).
Table 2.1 lists the ten most commonly used treatments in 2016. The most common treat-
ment was DNase, recorded for 5,830 people (60.6%)
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FIGURE 2.4: Histogram of year of birth for people with at least one annual
review between 2007 and 2016
FIGURE 2.5: Scatter plot of age at death against date of death for people
with at least one annual review between 2007 and 2016 and date of death
before 2018
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Treatment Name Treatment Type Frequency (%)
Dornase Alfa Mucolytic 5830 (60.6)
Salbutamol Bronchodilator 4623 (48.0)
Creon 10000 Pancreatic Enzyme 4438 (46.1)
Proton Pump Acid Blocker 4261 (44.3)
Vitamin E Vitamin 4216 (43.8)
Oral Azithromycin Oral Antibiotic 3501 (36.4)
Hypertonic Saline Osmotic Therapy 2889 (30.0)
Creon 25000 Pancreatic Enzyme 2853 (29.6)
Vitamin D Vitamin 2539 (26.4)
Promixin Inhaled Antibiotic 1996 (20.7)
TABLE 2.1: List of the ten most commonly used treatments in 2016
2.3.3 Lung Function
Measures of lung function are the most common outcomes used in CF studies, and this
is because long-term lung function decline is very closely linked to survival, and it is
therefore recognised by regulatory authorities as one of the key measures of treatment
efficacy.[13] Unlike survival studies, which would generally require very long follow-
up, changes in lung function can often be detected over much shorter periods of time,
meaning that studies can often be shorter in duration when using lung function as the
primary outcome. However, to really prolong the life of someone with CF it would be
necessary to not only provide a one-off step-change increase in lung function, but also to
provide a slope-change, decreasing the rate of lung function decline. This is often harder
to investigate with short-term studies and is one of the key reasons why it is important
to continue to investigate the long-term effects of treatments after the clinical trial phase.
Of the different lung function measures available by far the most commonly used is the
forced expiratory volume in one second (FEV1), which is the amount of air a person can
blow out in one second.[14, 15] The absolute value of this measure is known to depend on
age, sex, height and ethnicity, and therefore it is common to calculate percent-predicted
values for these measures. The percent-predicted FEV1 (ppFEV1) is the ratio of a per-
son’s measured FEV1 and their expected FEV1 given their age, sex, height and ethnicity,
based on a prediction equation. The normal range of ppFEV1 for a healthy lung function
would be expected to be between 80% and 100%. There are a number of different for-
mulae that can be used to calculate the percent-predicted values, but for the work in this
thesis we will always use those recently proposed by the Global Lung Function Initia-
tive (GLI).[16] These GLI values are thought to deal with changes between childhood
and adult lung function better than previously used prediction equations and are recog-
nised as an international gold standard by major international respiratory societies.[17]
Because the percent-predicted values are corrected for age, in a healthy population, we
would expect the value to stay around 100%, but in people with CF we observe a long-
term decline of on average approximately -1.5% per year. However, this trajectory is not
linear, and each individual’s lung function trajectory can be very variable, with sudden
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drops, but also recoveries over time. This is shown in Figure 2.6 where a random selection
of people’s lung function trajectories are shown as well as the lowess-smoothed line of
the population-average lung function trend. The population average slope will not be a
good representation of an individual’s long-term expected lung function as it is affected
by survivor bias, whereby only those with healthy levels of lung function survive to older
ages.
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FIGURE 2.6: Graph showing ppFEV1 measures against age between 2007
and 2016 (Highlighted in red are a random selection of individual trajecto-
ries and the black line shows the population average)
Two other common measures of lung function are forced vital capacity (FVC) and forced
expiratory flow 25–75% (FEF25−75). FVC is the total amount of air a person can blow
out in one complete breath after taking a deep breath in, and FEF25−75 is the flow (or
speed) of air coming out of the lung during the middle portion of the FVC.[15] Similarly
to FEV1, these two measures can also be adjusted to percent-predicted values (ppFVC
and ppFEF25−75 respectively). FVC is thought to be less sensitive to acute changes in
lung function than FEV1, which is why FEV1 is generally preferred in clinical trials.[18]
FEF25−75, on the other hand, is believed to be able to pick up the early stages of lung
disease better than FEV1, but unfortunately the variability of the measure is much greater
than FEV1 meaning that these changes can be lost in the noise of random variability.
Figures 2.7 and 2.8 show the FVC and FEF25−75 measures from the UK CF registry with
a random selection of specific people’s trajectories highlighted as well as the lowess-
smoothed population-average slope. A recent study showed little difference between the
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choice of these three lung function measures when used as an outcome measure, which
is not surprising as all three measures would come from the same pulmonary function
test and are therefore closely related to each other.[19] One drawback of using either of
these measures as an outcome in this thesis is that they are less reliably collected than
FEV1 in the UK CF Registry and therefore the available sample size for these analyses
will generally be lower.
Due to the non-linearity of lung function decline, it can be difficult to accurately model
long-term lung function trends. Approaches such as the use of splines or stationary Gaus-
sian process models have been proposed to more accurately model individuals’ lung
function trajectories.[20, 21] For the work in this thesis, we will only be considering tre-
atment effects out to five years, and we will therefore either assume a linear trend over
this shorter time-period or assess lung function discretely at yearly intervals.
One of the main drawbacks of these lung function measures is that they cannot be perfor-
med reliably in children under the age of six. This means that other outcome measures
are generally needed when aiming to investigate treatment efficacy in young children.
For the purposes of this thesis we will restrict our analyses to people over the age of six.
There are also other measures of lung function, such as the lung clearance index (LCI),
which have been claimed to be better than the more traditional lung function measures at
detecting the early signs of lung function deterioration.[22] However, this is not currently
captured in the UK CF Registry due to the complexity of the equipment needed to take
this measurement.[23]
2.3.4 Exacerbations & Number of Days Receiving Intravenous Antibiotics
As well as the overall long-term decline in lung function, people with CF often suffer
exacerbations. These are periods where there is a sudden decrease in lung function often
due to infections. There is no universal definition of what constitutes an exacerbation
in CF, but it is an outcome that is often used in clinical trials where each trial will have
a strict definition of what constitutes an exacerbation in their study. It is important to
try to reduce the rate of exacerbations in the CF population as research has shown that
in approximately one third of cases lung function measures do not recover to their pre-
exacerbation levels.[24, 25]
The UK CF Registry does not specifically collect data on whether a person has suffered
an exacerbation or not during a year, but a proxy is available, which is whether the per-
son has received any intravenous antibiotics (IVs) during the year. Generally, if someone
suffers an exacerbation they will receive IVs, therefore using this as a proxy should cap-
ture almost all exacerbations. However, some people receive IVs even during periods of
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FIGURE 2.7: Graph showing ppFVC measures against age between 2007
and 2016 (Highlighted in red are a random selection of individual trajecto-
ries and the black line shows the population average)
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FIGURE 2.8: Graph showing ppFEF25−75 measures against age between
2007 and 2016 (Highlighted in red are a random selection of individual
trajectories and the black line shows the population average)
Chapter 2. The UK Cystic Fibrosis Registry 33
disease stability, meaning that using this variable would overestimate the rate of exacer-
bations. IVs can either be administered at home or in hospital and this data is collected
separately in the Registry. However, for the purposes of this thesis, we use the combined
total annual number of IV days.
In a given year, approximately half of the people in the UK CF Registry do not have any
IV days. For people who do receive IV days the most common practice would be to
receive them for two weeks. The number of people with more IV days per year quickly
tails off, but there are a handful of patients who are receiving IVs for almost the whole
year. This is shown in Table 2.2, which shows a breakdown of the number of annual IV
days each person had in 2007.
Annual
Frequency %
Cumulative
IV Days %
0 2,995 56.4 56.4
1-14 810 15.3 71.6
15-28 483 9.1 80.7
29-42 389 7.3 88.1
43-56 307 5.8 93.8
57-70 155 2.9 96.8
70-98 98 1.8 98.6
98-365 74 1.4 100.0
TABLE 2.2: Breakdown of total number of annual IV days observed in 2007
2.3.5 Other Variables
There are a number of other variables, which will not be considered as outcomes of in-
terest in the work presented in this thesis, but which could be important confounders
in the analyses. This includes the demographic variables, which have previously been
discussed as well as the variables introduced in this subsection.
Cystic fibrosis related diabetes (CFRD) is one of the main long-term complications of
CF.[18] The prevalence of CFRD has been steadily increasing in line with the increasing
survival age of the population. In 2016, the prevalence of CFRD in those under the age
of 10 was 1.2%, in those between 10 and 20 was 15.4%, in those between 20 and 30 was
30.3% and in those over 30 was 38.1%.
People with CF are prone to a number of different respiratory infections. The two most
common infections are Staphylococcus aureus and Pseudomonas aeruginosa, but there are
a number of other important infections as well, such as Aspergillus fumigatus, meticillin-
resistant Staphylococcus aureus (MRSA), influenza, Stenotrophomonas maltophilia and
Burkholderia cepacia complex. Each year the annual assessment records whether a specific
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infection was present in the lungs in the previous year. Figure 2.9 shows the prevalence
of all of these infections by age group in 2016.
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FIGURE 2.9: Bar chart showing prevalence of infections by age group in
2016
Data on whether a person smokes or not is collected at every annual assessment. The
number of smokers appears to be very low, but we have no way of knowing how reliably
people answer this question. For example, in 2007, only 97 of the 5,311 annual asses-
sments report smoking (1.8%). Exposure to second-hand smoke is also thought to be an
important predictor of long-term health in CF, but unfortunately this data is not currently
captured in the UK CF Registry.[26]
2.4 Strengths & Weaknesses
One of the main strengths of the UK CF Registry is that it is estimated to contain data
on over 99% of people with CF in the UK. Furthermore, new born screening for CF was
implemented nationwide in 2007 (since 2003 in Scotland), meaning that since this date
almost all people born with CF will be diagnosed soon after birth, allowing continual
longitudinal data collection from a very early age. The numbers lost to follow-up are
also very small and are generally due to people emigrating. These efforts combined with
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the overall population size of the UK means that it is one of the largest CF datasets in the
world.[27]
Data are supposed to be collected annually and Figure 2.2 shows good adherence to this
protocol. As well as a wide range of demographic data, at each visit a wide range of data
are collected, allowing both population level analyses as well as longitudinal analyses of
individual health trajectories. Furthermore, the number of variables collected allow for
careful adjustment for appropriate covariates in any statistical analyses, reducing the risk
of unobserved confounders.
One drawback of annual review data is that any acute changes within a specific year
may not be picked up. For example, if a person’s lung function suddenly dropped, but
then recovered before the next annual review, this would not be picked up in the data
collected in the Registry. Some national registries collect data at more regular intervals,
such as quarterly or monthly, but there is no evidence that this leads to improved analyses
of long-term trends. Other registries also collect data on an encounter basis, which has
the benefit of obtaining data on all clinic visits, but has the drawback that sicker patients
will tend to end up with more data, which could easily bias analyses if not appropriately
accounted for in the analysis. Related to this issue is that in the UK, the annual review
is supposed to take place during a time of disease stability. This is what leads to visits
not always being equally spaced apart, but even so, a recent study of a single centre in
Sheffield found that approximately 20% of visits could have occurred during a period of
instability according to their definition.[28]
Finally, although the number of variables that can be collected during an annual asses-
sment is very extensive, and while many important variables including ppFEV1, IV days
and demographics are recorded with little missing data, not all variables are reliably
collected. Just taking lung function as an example, Figure 2.6 of ppFEV1 measures is ba-
sed on 61,668 observations, whereas Figure 2.8 of ppFEF25−75 measures is based on only
23,238 observations. A number of binary variables, such as treatments or infections are
collected via a yes tick box, leading to there artificially being no missing data, as all those
without a tick are assumed to be no. This has been improved recently and the input sy-
stem was updated for the 2016 data collection, but it remains a limitation for any data
collected prior to this.
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Chapter 3
Dornase Alfa Use in Cystic Fibrosis:
A Systematic Review
3.1 Overview
One of the most common symptoms of CF is a build up of mucus in the lungs, which
leads to an increased prevalence of bacterial growth in the airways and a decline in lung
function.[29] Therefore, it is common for people with CF to use aerosolized mucoactive
agents, which help to break down the layer of mucus in the lungs making clearance
easier.[18] Recombinant human deoxyribonuclease, commonly known as dornase alfa
(DNase), and marketed under the name Pulmozyme R©, is one such treatment which was
authorised for use in January 1994.[30] Since then, it has become the most commonly
used mucolytic treatment in CF in the UK, used by almost 60% of people in 2016.[3]
This chapter contains a systematic review of the studies that have investigated the effects
of DNase use in CF, in order to summarise what is already known about the treatment
and to identify the gaps in knowledge. This is followed in the next three chapters by
work that will look at how the UK CF Registry data can be analysed to answer some of
these questions.
3.2 Objectives
The main objective of this systematic review is to identify all studies which investigate
the association between DNase use and outcomes for patients with CF.
The aim is then to use these studies, summarising their results, to obtain a broad under-
standing of what is already known about the overall effect of DNase use over different
lengths of time. It was found that many of the studies investigated different outcomes
over different lengths of follow-up, and for this reason a qualitative summary of results
was deemed more appropriate then a quantitative meta-analysis.
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3.3 Methods
The review was carried out with reference to the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) Statement which provides guidelines for how
to conduct and report a systematic review.[31]
Studies were eligible for inclusion if the following PICOS criteria were met:
• Participants: People with CF
• Interventions: DNase given at any dose and frequency
• Comparisons: Placebo, no treatment and/or another mucolytic treatment, e.g. hy-
pertonic saline
• Outcomes: All outcomes were considered
• Study Designs: All study designs were considered
All studies published prior to July 2009 were considered for inclusion in the Cochrane
Review of Dornase Alfa for Cystic Fibrosis, and this review therefore contains references
to all available studies.[32] However, the criteria for the review meant that only RCT were
actually included in the review. Therefore for the purposes of this review both included
and excluded studies were assessed for eligibility.
In order to identify studies carried out since July 2009 two search strategies were used:
• Hand search of two journals: Pediatric Pulmonology and Journal of Cystic Fibrosis
• Electronic search of two databases: MEDLINE and EMBASE.
Pediatric Pulmonology and the Journal of Cystic Fibrosis were hand searched, because in
addition to publishing many relevant papers, they also contain the annual proceedings
of the North American and European Cystic Fibrosis Conferences respectively.
The search strategy for the electronic databases was for any of the following terms to be
included in the title of the article: DNase, d-nase, d nase, rhDNase, dornase, pulmozyme,
or deoxyribonuclease. In addition to this, the term ‘cystic fibrosis’ needed to be included
in the title, abstract or key words. Finally the searches were limited to papers published
since July 2009, as papers published prior to this have already been identified through
the Cochrane Review. The search criteria for the Cochrane Review were very similar to
those employed here, including an electronic search of MEDLINE and EMBASE and a
hand search of Pediatric Pulmonology and Journal of Cystic Fibrosis. Both the electronic
and hand searches were originally performed in January 2016, and again in January 2018.
The abstracts of all papers identified from the Cochrane Review and the database se-
arches were reviewed to ascertain whether any of the PICOS criteria listed above were
violated and to exclude these papers from further review. All remaining papers were
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then included in the full-text review which involved three elements: ensuring that all the
PICOS criteria were fulfilled, extracting key data, and assessing the quality of the study.
For each study the following data were collected: date of publication, type of study,
length of DNase administration, sample size, dose and frequency of treatment, baseline
age and lung function data, the outcome measures, the results and the statistical methods.
In order to assess the quality of studies in systematic reviews it is common to use the ‘risk
of bias’ tool developed by the Cochrane collaboration.[33] However, this was designed
for RCTs, so it was not considered suitable for this review. A systematic review compa-
ring all available tools for evaluating non-randomised studies was carried out in 2003
and out of 194 tools identified they recommended The Newcastle-Ottawa Scale or the
Downs & Black scale.[34] Upon review, the Newcastle-Ottawa Scale is only suitable for
cohort or case-control studies, whereas the Downs & Black scaled can assess the quality
of any randomised or non-randomised study.[35, 36] Therefore each study included in
the systematic was assessed against the Downs & Black checklist which contains 27 que-
stions within five sub-scales of quality: reporting, external validity, bias, confounding
and power. The scale assigns scores ranging from 0 to 32, where a higher score indicates
a higher quality of study.
A qualitative review was carried out to summarise the findings of the effects of DNase
on all available outcomes. However no formal meta-analyses were performed due to
that fact that there was little overlap between papers containing the same outcomes and
lengths of follow-up, making it difficult to synthesize the findings quantitatively.
The electronic and hand searches, the abstract and full-paper reviews, the quality asses-
sment with the Downs & Black scale, and the qualitative review of included studies were
carried out by me.
3.4 Results
In total there were 31 studies fulfilling all five PICOS criteria: 22 RCTs and 9 observational
studies. Figure 3.1 gives a detailed flowchart of the number of studies identified at each
stage of the search process. 43 studies were initially taken forward for the full-text review,
but upon closer examination, twelve of them did not fulfil the inclusion criteria. This was
mainly due to the studies not containing a suitable control group for comparison. Details
of these studies with the reason for exclusion can be found in table 3.1.
Table 3.2 contains a summary of the 31 studies included in the systematic review. The
median length of follow-up time was 12 weeks (range 1 week to 4 years) and the median
number of patients in each study was 70 (range 9-8200). There were three studies only
involving children under six years old, ten more studies only included patients under the
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49 records
identified in
Cochrane Review
95 records
identified in
EMBASE
40 records
identified in
MEDLINE
10 records
identified in
hand search
after abstract review27 records
selected from
Cochrane Review
after abstract review
14 records
selected from
EMBASE
after abstract review
6 records
selected from
MEDLINE
after abstract review
43 records after duplicates removed
43 full-text articles
assessed for eligibility
12 studies excluded
after full-text review
31 studies included
in qualitative synthesis
FIGURE 3.1: Flowchart of the number of studies at each stage of the DNase
systematic review
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Publication Authors Title Reason for Full
Date Exclusion Reference
Jun-95 Heijerman et
al.
Effect of rhDNase on lung function and
quality of life in adult cystic fibrosis
patients
No control
group
[37]
Aug-95 Shah et al. Two years experience with recombinant
human DNase I in the treatment of
pulmonary disease in cystic fibrosis
No control
group
[38]
Feb-01 Furuya et al. Efficacy of human recombinant DNase
in pediatric patients with cystic fibrosis
No control
group
[39]
Jul-04 Barker et al. Effect of DNase on exercise capacity in
cystic fibrosis
No control
group
[40]
Jan-06 Riethmueller
et al.
Recombinant human deoxyribonucle-
ase shortens ventilation time in young,
mechanically ventilated children
Not cystic
fibrosis pa-
tients
[41]
Dec-08 McPhail et al. Improvements in lung function out-
comes in children with cystic fibrosis
are associated with better nutrition, fe-
wer chronic pseudomonas aeruginosa
infections, and dornase alfa use
No Control
Group
[42]
Sep-10 McPhail et al. Initiation of dornase alfa before age six
years is associated with improvements
in the rate of decline in lung function in
children who are "rapid early decliners"
No control
group
[43]
Sep-10 Rozov et al. Dornase alfa improves the health-
related quality of life among Brazilian
patients with cystic fibrosis - A one-
year prospective study
No control
group
[44]
Oct-13 Dasenbrook
et al.
Combination inhaled 7% hypertonic
saline and rhDNase: Retrospective
cohort study of the US CFF national
patient registry
No outcome [45]
Dec-13 Rozov et al. A first-year dornase alfa treatment im-
pact on clinical parameters of patients
with cystic fibrosis: the Brazilian cystic
fibrosis multicenter study
No control
group
[46]
Oct-15 VanDevanter
et al.
Chronic high dose dornase alfa use in
CF 1994-2005
No outcome [47]
Nov-16 Shenoy et al. The effects of early initiation with dor-
nase alfa on childhood lung function in
cystic fibrosis
No control
group
[48]
TABLE 3.1: Studies excluded from DNase systematic review after full-text
review
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age of nineteen, and four studies only considered adults. The remaining fourteen studies
included both children and adults. In terms of baseline lung function, two studies only
included patients with an FEV1 less than 40% predicted, for twelve studies the mean
FEV1 at baseline was between 40% and 80% predicted, and for six studies it was greater
than 80%. Eleven studies did not report baseline FEV1.
It should be noted that whilst the standard dose of DNase is now 2.5mg once per day,
some earlier studies (before 2000) prescribed 2.5mg twice per day. However, studies
have shown similar effects irrespective of dose frequency and for this reason all doses
were considered equally in this review.[49, 50]
When assessing the quality of studies, the mean score from the Downs & Black question-
naire was 18.7 (SD 5.9) out of a possible 32. Looking at RCTs and observational studies
separately shows that in general RCTs performed better (mean score 20.3 (SD 5.2) com-
pared to 14.9 (SD 5.8). However, this can partly be explained by the weightings given
to different sections: observational studies tended to perform well in terms of external
bias and power, where the total possible scores were 3 and 5 respectively, whereas RCTs
often performed poorly in these two areas, but performed better in internal bias and con-
founding, which respectively could contribute 6 and 7 points to the total score. Figure 3.2
presents a histogram showing the distribution of the Downs & Black scores.
0
1
2
3
4
5
Fr
eq
ue
nc
y
0 5 10 15 20 25 30
Downs & Black Score
Observational Study
Randomised Trial
FIGURE 3.2: Histogram of Downs & Black scores for studies included in
the DNase systematic review
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Mar-
92
Hubbard
et al.
A preliminary study of aerosolized recom-
binant human deoxyribonuclease I in the
treatment of cystic fibrosis
RCT 20 1 16 27.0±3.3 45.0±20.0 L [51]
Jul-
93
Ranasinha
et al.
Efficacy and safety of short-term adminis-
tration of aerosolized recombinant human
DNase I in adults with stable stage cystic
fibrosis
RCT 25 1.5 71 26.2±7.9
(16 – 55)
46.8±19.4
(17 – 88)
L Q [52]
Jul-
93
Ramsey et
al.
Efficacy and safety of short-term adminis-
tration of aerosolized recombinant human
deoxyribonuclease in patients with cystic
fibrosis
RCT 25 1.5 181 19.2±9.5
(8 – 65)
62.5±25.7 L Q O [53]
Sep-
94
Fuchs et
al.
Effect of aerosolized recombinant human
DNase on exacerbations of respiratory
symptoms and on pulmonary function in
patients with cystic fibrosis
RCT 28 24 968 19.9±9.0
(5 –54)
60.7±26.1
(17 – 142)
L E Q [49]
Jun-
95
Shah et al. Recombinant human DNase I in cystic fi-
brosis patients with severe pulmonary di-
sease: A short-term, double-blind study
followed by six months open-label treat-
ment
RCT 22 2 70 25.5±9.4
(5 – 48)
21.5±5.9
(12 – 39)
L Q [54]
Feb-
96
Laube et
al.
Effect of rhDNase on airflow obstruction
and mucociliary clearance in cystic fibrosis
RCT 19 1 20 26.0
(18 – 44)
54.9 L O [55]
Jun-
96
Wilmott et
al.
Aerosolized recombinant human DNase
in hospitalized cystic fibrosis patients with
acute pulmonary exacerbations
RCT 22 2 80 19.9±9.2
(5 – )
40.0±18.9 L Q [56]
Oct-
96
McCoy et
al.
Effects of 12-week administration of dor-
nase alfa in patients with advanced cystic
fibrosis lung disease
RCT 27 12 320 26.0±9.4
(7 – 57)
21.7±5.4
(9.2 – 39.2)
L E Q [57]
Sep-
99
Weck et al. Efficacy of DNase in individual children
using the N-of-1 study design
RCT 14 4 16 10.2
(5 – 17) ( – 40)
L Q [58]
Jul-
00
Robinson
et al.
Effect of a short course of rhDNase on
cough and mucociliary clearance in patients
with cystic fibrosis
RCT 19 1 13 25.1±5.3
(18 – 38)
62.8±25.2
(27 – 103)
L O [59]
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, Quality of life, Bacterial infection, and Other
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Apr-
01
Shah et al. A case-controlled study with dornase alfa to
evaluate impact on disease progression over
a 4-year period
Obs 15 208 60 25
(17 – 38)
42.5±13.1 L E B [60]
Oct-
01
Suri et al. Comparison of hypertonic saline and
alternate-day or daily recombinant human
deoxyribonuclease in children with cystic
fibrosis: a randomised trial
RCT 22 12 44 12.6±2.8
(7 – 17)
48.0±15.0
(14 – 77)
L E [50]
Dec-
01
Quan et
al.
A two-year randomized, placebo-controlled
trial of dornase alfa in young patients with
cystic fibrosis with mild lung function ab-
normalities
RCT 29 96 474 8.3±1.5
(6 – 10)
85.0±30.0 L E O [61]
Mar-
02
Ballman
& von der
Hardt
Hypertonic saline and recombinant hu-
man DNase: A randomised cross-over pilot
study in patients with cystic fibrosis
RCT 15 3 14 13.3±2.9 L [62]
Sep-
02
Robinson Dornase alfa in early cystic fibrosis lung
disease
RCT 26 96 474 8.3±1.5
(6 – 10)
85.0±30.0 L [63]
Nov-
03
Hodson et
al.
Dornase alfa in the treatment of cystic fibro-
sis in Europe: A report from the epidemio-
logic registry of cystic fibrosis
Obs 19 104 4299 15.0±8.3
(6 – )
75.7±24.3 L E [64]
Dec-
03
ten Berge
et al.
DNase in stable cystic fibrosis infants: A
pilot study
RCT 18 2 9 1.4±0.4
(0 – 2)
L [65]
Mar-
04
Paul et al. Effect of treatment with dornase alpha on
airway inflammation in patients with cystic
fibrosis
RCT 19 156 105 11.9±6.2
(5 – 37)
96.9±14.0 O [66]
Jun-
04
Adde et
al.
Hypertonic saline X recombinant human
DNase: A randomised cross-over study in
18 cystic fibrosis patients
RCT 13 4 18
(8 – 25)
48.0±16.6 L B [67]
Sep-
06
Frede-
riksen et
al.
Effect of aerosolized rhDNase
(Pulmozyme R©) on pulmonary coloniza-
tion in patients with cystic fibrosis
RCT 17 52 72 8.4
(0 – 25)
L B [68]
Sep-
08
Konstan Dornase alfa and progression of lung dise-
ase in cystic fibrosis
Obs 18 104 6697
(8 – 38)
84.2 L [69]
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, Quality of life, Bacterial infection, and Other
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Sep-
09
Kraemer
et al.
Long-term effect of dornase alfa on lung
function in patients with CF evaluated over
an age period of 5 to 18 years
Obs 8 170
(5 – 18)
L B [70]
Sep-
09
Castile et
al.
Effects of nebulized recombinant human
deoxyribonuclease (dornase alfa) in infants
with CF evaluated using infant pulmonary
function testing and high resolution compu-
terized tomographic imaging of the chest
RCT 12 26 24 0.8±0.6 FEV0.5
98.1±13.4
L [71]
Nov-
09
Minasian
et al.
Comparison of inhaled mannitol, daily rhD-
Nase and a combination of both in children
with cystic fibrosis: a randomised trial
RCT 22 12 20 13.2±2.4 64.4±10.4 L [72]
Mar-
10
Bonestroo
et al.
No positive effect of rhdnase on the pul-
monary colonization in children with cystic
fibrosis
Obs 19 78 70 9.5±4.1
(1 – 18)
87.9±20.1
(47 – 143)
L E B [73]
Apr-
11
Amin et
al.
The effect of dornase alfa on ventilation in-
homogeneity in patients with cystic fibrosis
RCT 22 4 17 10.3±3.4
(6 –18)
90.7±9.1 L [74]
Jun-
11
Konstan et
al.
Clinical use of dornase alfa is associated
with a slower rate of FEV1 decline in cystic
fibrosis
Obs 23 104 8200 14.5±6.5
(8 – 38)
83.7±23.0 L [75]
Nov-
11
Pasta et al. A mixed-effects piecewise linear model of
the rate of lung function decline before and
after the clinical use of dornase alfa in an
observational study of cystic fibrosis
Obs 17 104 8200
(8 – 38)
L [76]
Sep-
14
Singh et
al.
Clinical effectiveness of dornase alfa in
children six years of age and younger with
cystic fibrosis
Obs 7 130
( – 6)
L [77]
Sep-
14
Singer et
al.
Effects of dornase alfa and hypertonic saline
on gas mixing in lung periphery in children
with cystic fibrosis
RCT 11 4 17 L [78]
Apr-
15
Stuckey et
al.
The effect of dornase alfa (rhDNase) on
recurrent gram negative infections in adult
cystic fibrosis lung transplant recipients
Obs 8 78 52 B [79]
TABLE 3.2: Key details of studies included in systematic review of DNase
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, Quality of life, Bacterial infection, and Other
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There were many different outcomes measured across the studies, but these were catego-
rised into five groups: lung function, exacerbations, quality of life, bacterial colonisation,
and other outcomes. The following sections detail the findings in each of these areas.
3.4.1 Lung Function
All but two studies contained results relating to the effect of DNase on lung function. The
most common lung function measurements were FEV1 and FVC, but there was a lot of
variability between papers on which measurements were used.
Children
There were thirteen studies whose participants were under the age of 18. Of these, two
studies only investigated infants under 2 years old. Due to their age, this group of pa-
tients is unable to perform the same spirometry tests as used in older populations and
different measurements are used to assess lung function. The RCT by ten Berge et al.
used maximal flow at functional residual capacity as the primary outcome, and they
found that after four weeks of DNase treatment it increased by an average of 72ml/s
(95% confidence interval [CI] 38 to 107, p = 0.002), whereas the change in those trea-
ted with placebo was not statistically significant.[65] However, they did not formally test
whether the DNase and placebo groups differed. The study by Castile et al. used several
different infant pulmonary function tests as well as controlled ventilation high resolution
computerised tomographic chest imaging, but reported that there was no detectable dif-
ference in any of these measurements between DNase and placebo patients over the six
month follow-up period.[71]
In older children, three studies reported no statistically significant effects of DNase on
FEV1. Over a four week period Amin et al. found that in the DNase group the absolute
change in predicted FEV1 was 0.076% higher than in the placebo group (p = 0.97), and
Bonestroo et al. found the difference to be 4.3% (p = 0.22) over a one year period.[73, 74]
Kraemer et al. also noted no statistically significant effects of DNase on any lung function
measures, but did not specify any of the estimates or p-values.[70] In contrast to these
results, the papers by Quan et al. and Robinson et al., which were actually based on the
same RCT, found that after 96 weeks those receiving DNase had maintained very similar
FEV1 levels, whereas those receiving placebo had worsened, resulting in a difference in
absolute FEV1 change of 3.2% (p = 0.006).[61, 63] A forest plot of these results can be
seen in Figure 3.3.
Two of the above studies included results of other lung function tests. Quan et al. repor-
ted that FEF25−75 was 7.9% higher in the DNase group (p = 0.0008) and VE50 was 8.2%
higher (p = 0.0002), but FVC was only 0.7% better in the DNase group, which was not
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Kraemer at al. (2009)
Quan et al. (2001)
Bonestroo et al. (2010)
Amin et al. (2011)
52 weeks
4 weeks
96 weeks
13 years
−5 0 5 10
Difference in Absolute Change of FEV1 (% predicted)
No Estimate
95% C.I.
P > 0.05
Minasian et al. (2009)
Suri et al. (2001)
Ballmann & von der Hardt (2002)
3 weeks (vs Hypertonic Saline)
12 weeks (vs. Hypertonic Saline)
12 weeks (vs. Mannitol)
−5 0 5 10 15
Difference in Relative Change of FEV1 (% predicted)
FIGURE 3.3: Forest plot of studies estimating effect of DNase on FEV1 in
children (Some CIs are approximations based on reported p-values)
statistically significant (p = 0.51).[61] Amin et al. also reported on FEF25−75 and FVC,
again finding a positive treatment effect on FEF25−75 of 6.09% (p = 0.03), but FVC was
actually estimated to be 3.61% worse in the DNase group, though this result was not sta-
tistically significant (p = 0.14).[74] These results can be seen in the forest plot in Figure
3.4.
Quan et al. (2001)
Amin et al. (2011)
96 weeks
4 weeks
−5 0 5 10 15
Difference in FEF25−75 Change (% Predicted)
95% C. I.
Quan et al. (2001)
Amin et al. (2011)
96 weeks
4 weeks
−8 −6 −4 −2 0 2
Difference in FVC Change (% Predicted)(Dornase alfa vs Placebo)
FIGURE 3.4: Forest plot of studies estimating effect of DNase on
ppFEF25−75 and ppFVC in children (Some CIs are approximations based
on reported p-values)
The study by Singh et al. produced equivocal results, as they used two methods to as-
sess the effect of DNase on lung function: a propensity score adjustment method showed
a statistically non-significant difference (p > 0.05), but using the centre-specific pres-
cription rate of DNase as an instrumental variable showed that ppFEV1 was statistically
significantly higher in the DNase takers (p < 0.01).[77]
Compared to the population average effects in all of the above studies, Weck et al. used an
N-of-1 study design to individually assess for each patient whether they would benefit
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from DNase. Of the sixteen children included in their study the results suggested that
only four (25%) benefited from DNase.[58]
Most studies compared DNase to placebo or no treatment. However, two studies, whose
results are shown in Figure 3.3, compared DNase to hypertonic saline and one study
compared it to mannitol, both of which are other available mucolytic treatments. The
study by Ballmann & von der Hardt found that over three weeks DNase increased FEV1
by an average of 9.3% when compared to baseline (p < 0.05), but the difference was not
statistically significant when compared to hypertonic saline.[62] Conversely, Suri et al.
found that over twelve weeks the relative change of FEV1 was 8% higher in the DNase
group compared to the hypertonic saline group (95% CI 2 to 14, p = 0.01).[50] In the
study comparing DNase to mannitol, DNase was shown to increase FEV1 by 7.2% (p =
0.029) over 12 weeks, but this increase was slightly worse than the increase seen when
receiving mannitol; the increase being 2.8% higher in the mannitol period than the DNase
period (95% CI -4.2% to 10.4%, p = 0.42).[72]
Ventilation inhomogeneity measured via multiple-breath washout tests was an outcome
for three studies. Two of the studies used LCI and reported a statistically significant effect
of DNase on ventilation inhomogeneity: Amin et al. showed that four weeks of DNase
treatment statistically significantly improved LCI compared to placebo by an average of
0.9 (p = 0.02), and Kraemer et al. also reported a statistically significant improvement in
LCI for DNase users (p = 0.024).[70, 74] Singer et al. measured the average alveolar phase
III slopes during the wash-out tests and found that the slope decreased by an average of
63.1% (95% CI 20.0 to 121.6) when using DNase.[78]
General Population
When considering adults and children three studies only administered DNase for one
week, but there were some apparent treatment effects even over this short time period.
Laube et al. noted that at the end of six days the relative change in ppFEV1 and FVC were
11.2% and 12.3% higher respectively in the DNase group (both p < 0.05).[55] Robinson et
al. found that in DNase users compared to placebo the mean percent change in predicted
values from baseline was 4.1% for FEV1, 7.6% for FVC and 3.8% for FEF25−75, but only
the change in FVC was statistically significant (p < 0.05).[59] Hubbard et al. reported
similarly that taking DNase resulted in greater improvement in both FEV1 and FVC (both
p < 0.01).[51]
Two more studies had 1.5 weeks follow-up and found similar results as above. Ranasinha
et al. reported that for the DNase group compared to placebo the relative change from
baseline in FEV1 was 13.5% (95% CI 7.6 to 19.4, p < 0.001) and FVC was 4.9% (p >
0.05).[52] In the same measurements, Ramsey et al. found a 15.4% better improvement in
FEV1 and a 11.3% better improvement in FVC (both p < 0.001).[53]
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The study by Fuchs et al. had six months follow-up, but again the results are similar to
those above. They found that the relative change in ppFEV1 was 5.8% better (p < 0.01)
in the DNase group, and FVC was 3.8% better (p = 0.01).[49]
Two studies specifically investigated patients with severe pulmonary disease, only enrol-
ling patients with an FEV1 less than 40% predicted. Over two weeks the study by Shah
et al. showed a 2.8% better relative change in ppFEV1 and a 4.9% better relative change
in ppFVC, but neither of these were statistically significant.[54] Over twelve weeks, the
study by McCoy et al. showed statistically significant results in both of these measures:
a 7.3% better relative change in ppFEV1 (p < 0.001) and a 5.1% better relative change in
ppFVC (p < 0.01).[57]
The study by Wilmott et al. only recruited patients currently suffering from an exacerba-
tion, but over fourteen days of treatment there were no statistically significant differences
in either FEV1 or FVC.[56] This and all the above results can be seen summarised in Fi-
gure 3.5.
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FIGURE 3.5: Forest plot of studies estimating relative effect of DNase on
ppFEV1 and ppFVC (Some CIs are approximations based on reported p-
values)
Adde et al. compared the effects of DNase and hypertonic saline, but the results showed
no statistically significant effect of DNase compared either to baseline or to hypertonic
saline.[67]
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Looking at longer follow-up (52 weeks) Frederiksen et al. reported the median absolute
increase in ppFEV1 was 6.4% better in DNase users than the placebo group after one year
(p < 0.05).[68] Using the same measurement Hodson et al. found that after one year the
difference between treated and untreated was 3.6% (95% CI 1.8 to 5.3), but by two years
this difference had become slightly attenuated to 2.5% (95% CI 0.7 to 4.4).[64] A forest
plot of these results can be seen in Figure 3.6.
Hodson et al. (2003)
Frederiksen et al. (2006)
Adde et al. (2004)
2 weeks (vs Hypertonic Saline)
52 weeks
52 weeks
104 weeks
−5 0 5 10 15
Difference in Absolute Change of FEV1 (% predicted)
95% C.I.
P > 0.05
FIGURE 3.6: Forest plot of studies estimating absolute effect of DNase on
FEV1 (Some CIs are approximations based on reported p-values)
Unlike all of the above studies, which investigated change in lung function at specific
time points, four studies (Shah et al. [2001], Konstan [2008], Pasta et al. [2011] and Kon-
stan et al. [2011]) instead attempted to investigate the effects of DNase on the slope of
lung function decline. All of these studies noted similarly to the findings above that upon
initiation of DNase there was an acute improvement in FEV1. Furthermore the mean rate
of FEV1 decline also appeared to be attenuated in those taking DNase.[76] In the first
study by Konstan, DNase was estimated to result in a 46% relative reduction (p < 0.001)
in the annual rate of FEV1 decline.[69] However the later study by Konstan et al. reported
smaller reductions: a 32.1% relative improvement in children (p < 0.001), and a 28.8%
relative improvement in adults (p = 0.068).[75] However, none of these three studies
formally compared these improvements with the group of non-users. Shah et al. used a
matched study design to compare the change in slope to a group of non-users over a four
year period and found that in DNase users the annual rate of ppFEV1 decline improved
by 0.93% compared to a worsening rate of decline in non-users of 1.43% (p = 0.002).[60]
3.4.2 Exacerbations
Four RCTs and three observational studies have been published which included exacer-
bations as an outcome. Unfortunately there is no standardised definition of what con-
stitutes an exacerbation and the criteria did vary between studies. Figure 3.7 presents a
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forest plot summarising the findings from these seven studies.
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FIGURE 3.7: Forest plot of studies estimating effect of DNase on pulmo-
nary exacerbations (Some CIs are approximations based on reported p-
values)
Two of the RCTs only involved children. The study by Suri et al. reported no difference
in the effect of DNase or hypertonic saline on the number of exacerbations during the
twelve week follow up.[50] The papers by Quan et al. and Robinson et al. reported that
over a 96 week period the relative risk (RR) of a respiratory tract infection in the DNase
group was 0.66 (95% CI 0.44 to 1.00, p = 0.048) compared to placebo.[61, 63]
The other two trials contained a larger age range of patients, but the findings were simi-
lar. Over a twelve week period McCoy et al. found no evidence of a difference in risk
of exacerbations when using DNase (RR 0.93, 95% CI 0.69 to 1.21, p = 0.52), whereas
with a follow-up time of 24 weeks Fuchs et al. reported a RR of 0.72 (95% CI 0.52 to 0.98,
p = 0.04).[49, 57]
The three observational studies by Hodson et al., Bonestroo et al. and Shah et al. had
longer follow-up times of one year, one and a half years and four years respectively. Shah
et al. reported that DNase users suffered 1.85 fewer exacerbations per year than non-users
(p = 0.035), whereas the study by Bonestroo et al. reported that children using DNase
suffered 0.95 more exacerbations per year than non-users (p = 0.11).[60, 73] However,
neither of these studies adjusted for patients’ average number of exacerbations prior to
starting treatment. The study by Hodson et al. did adjust for baseline exacerbation rates
and found that those taking DNase had 0.25 (95% CI 0.12 to 0.39) fewer exacerbations per
year compared to those not on treatment.[64]
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3.4.3 Quality of Life
Well-being and dyspnoea (breathlessness) were measured in seven studies. Five of these
studies (Ranasinha et al., Shah et al., Wilmott et al., McCoy et al. and Weck et al.) reported
no statistically significant difference in either outcome during follow-up, but they did not
give any further details.[52, 54, 56–58]
However, despite the trial by Ramsey et al. also only containing 1.5 weeks follow-up, they
reported a statistically significant change in dyspnoea (-45.8% DNase compared to -7.6%
placebo, (p < 0.05). They also reported that several measures of well-being improved in
the DNase group during the trial but none of them reached statistical significance.[53]
The trial by Fuchs et al. contained 24 weeks’ follow-up and a larger number of patients
than the other studies. It reported statistically significant improvements (p < 0.05) in
both dyspnoea (on a 100mm scale a 2.1mm decrease in the DNase group compared to a
0.4mm increase in the placebo group) and well-being (on a 5-point scale a 0.019 impro-
vement over baseline for the DNase group compared to a deterioration of 0.058 in the
placebo group).[49]
3.4.4 Bacterial Colonisation
There were two RCTs and four observational studies which investigated the effects of
DNase on bacterial colonisation of the lungs.
Only the trial by Frederiksen et al. reported evidence of an impact of DNase on bacteria
cultures. They reported that after one year of treatment bacteria cultures were found in
72% of patients randomised to DNase compared to 82% of those randomised to placebo
(p < 0.05).[68] However, they do not report the baseline figures for comparison.
The other RCT by Adde et al. only administered DNase for four weeks and compared it
to hypertonic saline. Both P. aeruginosa and S. aureus growth were investigated, but over
this short time-frame there was no statistically significant change in either group.[67]
The study by Bonestroo et al. observed patients for one and a half years but found no sta-
tistically significant difference in the percentage of positive cultures at the end of follow-
up after adjusting for baseline values (2% increase in users compared to a 4% increase
in non-users).[73] Similarly Shah et al. followed patients for four years, but observed no
systematic change in bacterial colonisation.[60] Kraemer et al. investigated the onset of
chronic P. aeruginosa infection during childhood and found that among users of DNase
the median age of this was 7.3 years, compared to 13.3 years in non-users. However, this
difference was not statistically significant.[70]
Finally the study by Stuckey et al. specifically investigated lung transplant recipients.
The incidence of gram-negative infections over one year was found to be similar (20%
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DNase vs 23% non-DNase) and the median time to infection was also not found to differ
(32 days [IQR 14-46] DNase vs 38 days [IQR 13-219] non-DNase).[79]
3.4.5 Other Outcomes
Two studies investigated whether there was any evidence of DNase use improving mu-
cociliary clearance, which was measured as the rate of retention of a dose of radioactivity.
Both studies were RCTs with one-week follow-up time. Robinson et al. found an absolute
increase of 2.9% in total lung clearance over 150 minutes after one week’s use of DNase,
compared to a decrease of 1.6% in the placebo group, but this difference was not statis-
tically significant (p = 0.2).[59] The study by Laube et al. also reported that the mean
percent retention remained unchanged between the two study groups. This study also
investigated changes in aerosol distribution homogeneity, but again found no statistically
significant differences between the treatment groups.[55]
The study by Paul et al. was the only study to investigate airway inflammation. When
looking at the percentage of neutrophils in a bronchoalveolar lavage fluid sample, they
noted that there was no change between the baseline and 3-year follow-up percentages
in those randomised to DNase, whereas there was a statistically significant increase (p <
0.02) in the control group. However a test to formally compare the two groups was not
performed.
None of the studies in the systematic review were powered to study mortality as an
outcome and in most studies there were no deaths. In studies where deaths occurred they
were reported as adverse events and no statistical analyses were performed to compare
mortality between groups.
3.5 Discussion
3.5.1 Findings
Even though the results were not always statistically significant, all studies investigating
the effect of DNase on lung function have found that FEV1 is better among DNase users
than among non-users. However, looking at time-trends does suggest that the benefits of
DNase are most apparent immediately after initiating DNase and become more attenu-
ated over time, although at two years there still appears to be a small, but statistically
significant, benefit. The findings seem to be similar among both adults and children with
one study suggesting it may even be beneficial in infants under two years old.
The few studies that investigated change in slope of FEV1 decline showed promising
results. However, only one of them formally compared DNase users and non-users.
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The results for other lung function measures were equivocal and were measured in fewer
studies, making it hard to draw conclusions.
Four of the seven studies analysing exacerbation rates reported beneficial results. Howe-
ver, all the improvements were modest with only borderline statistical significance. It is
difficult to draw conclusions from a small number of studies, however the studies with
the longest follow-up time showed the largest improvements, which could suggest that
prolonged DNase use is more beneficial.
The clinical trial by Fuchs et al. was the only study to find that DNase improved well-
being in patients. All other studies that investigated well-being found no evidence of
an effect of DNase on well-being. However, each study used different tools to measure
well-being making comparison between studies difficult.
Almost all the studies investigating bacterial colonisation found very similar rates in
DNase users and non-users. The only study which found a statistically significant diffe-
rence did not adjust for baseline prevalence of bacterial colonisation in the participants.
However, there have been relatively few studies with bacterial colonisation as an out-
come and in most studies the prevalence was already quite high at baseline making it
difficult to notice any differences.
3.5.2 Limitations
One of the key limitations of this systematic review is the difficulty of synthesising the
findings. It was not considered appropriate to perform any meta-analyses due to the
small number of studies with overlapping follow-up times and outcomes.
Many studies in fact investigated many outcomes, for example many studies contained
several lung function outcomes, but then only reported the results that were statistically
significant, whereas all the other measured outcomes would often just be listed as not
statistically significant with no further details.
The inclusion and exclusion criteria were very specific in many studies, especially in
terms of baseline lung function, which could reduce the generalisability of their findings.
However, few studies have investigated whether the effects of DNase differ between
groups of patients, such as children or patients with severe pulmonary disease, which
means questions remain as to whether DNase is equally effective in all patients.
Many of the RCTs only administered DNase for relatively short periods of time, whereas
most of the observational studies had longer follow-up time and also larger sample sizes,
but unfortunately many of them did not use appropriate statistical methods to control for
confounding in a longitudinal setting. Often results at the end of follow up were com-
pared between DNase users and non-users without accounting for baseline differences
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between the two groups, or baseline values would be taken into account, but then no
formal comparison would be made between the DNase users and non-users.
3.5.3 Conclusions
All of the results suggest that DNase does not have harmful effects on any of the outco-
mes, but it remains difficult to objectively assess the degree of benefit that DNase pro-
vides. It seems that the benefits may be modest (although still clinically important) and
measuring these improvements accurately would require large datasets.
Furthermore, although a therapy which increases lung function is beneficial, if the rate
of lung function decline remains unchanged, the initial improvement would soon be lost
and the lifespan of the patient would not be considerably lengthened. Conversely, if the
treatment is able to slow the rate of decline, this can have a much bigger impact on the
prognosis of the disease.[69] For this reason it is important to find out if the observed
improvement in lung function upon initiating DNase is sustained long term.
Similarly, so far only one study (Weck et al. [58]) has aimed to quantify the proportion of
patients for whom DNase would be effective. Using a much larger dataset, it could be
possible to investigate this further and see which patients respond well to DNase and if
there are groups of patients who may benefit more from other available treatments.
A final point to mention is that most studies did not consider the rates of adherence to
DNase. The administration of DNase can be time consuming and as the length of follow-
up time increases patients may begin to feel that the treatment burden is too much. This
could cause the adherence rates to drop, which could be a reason why observational
studies with longer follow-up show more attenuated benefits.
Implications
• Although studies have shown that DNase treatment improves lung function, it is
unclear if these improvements are sustained long term.
• The effect of DNase appears to be quite heterogeneous: some patients show a large
benefit whereas others show no or minimal response.
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Chapter 4
Statistical Methods to Estimate
Effects of Dornase Alfa
4.1 Introduction
We wish to estimate the effect of long-term DNase use on health outcomes using the
UK CF Registry data, and in this chapter the methods identified as possible options for
enabling estimation of the effects of interest are introduced. Five separate methods are
considered: inverse probability weighting (IPW) of marginal structural models (MSM),
history-adjusted MSM (HA-MSM), g-computation formula, g-estimation of structural
nested models (SNM) and sequential conditional mean models (SCMM).
We start by introducing the notation that will be used throughout the chapter and then
explain the complexities faced in obtaining valid estimates of the long-term treatment
effects using observational data, such as the UK CF Registry. For our analysis of the
UK CF Registry data we focus on two outcomes: lung function (a continuous outcome)
and IV days (a count outcome). We introduce each method in turn with reference to
a continuous outcome, and afterwards we discuss how the methods can be altered to
handle a count outcome. We end the chapter with an overview and comparison of the
five methods and also discuss the assumptions that the methods rely on.
Work from this chapter and the following chapter formed the basis of a paper entitled
"Estimating long-term treatment effects in observational data: a comparison of the per-
formance of different methods under real-world uncertainty", which was published in
Statistic in Medicine in May 2018.[11] The accepted version of this paper can be found in
Appendix B.
4.1.1 Notation
We present the methods below in generic notation, but with reference to the way that
data are collected in the UK CF Registry. In this set up, every individual will attend a
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health assessment annually, and the outcome of interest, Y, is measured at every visit. If
a person has T annual assessments, they would therefore have T outcome measures, Yt
(t = 1, ..., T). The annual assessment also records whether the person has been exposed
to the treatment of interest since the last annual assessment, Xt, and other health related
data, which could have affected the decision to start treatment or not and which could
also affect the outcome of interest, Vt. The variables contained in Vt are taken to be time-
varying, whereas we also separately refer to variables B, which are non-time-varying
variables measured only once at baseline.
Xt is a vector denoting the treatment history for an individual from visit 0 up to and in-
cluding visit t, and similarly for other variables. Xs,t would refer to the treatment history
between visits t and s (t < s). We use the counterfactual notation Yxt=1t to refer to the
outcome that would have been observed at visit t if an individual had received treatment
at all visits up to and including visit t. Furthermore, YXs,t=1,Xt=0s would refer to the out-
come that would have been observed at visit s if an individual had received treatment
between visits s and t, but had not received treatment prior to visit t.
We assume that if an individual attends a visit at time t, all variables are measured and
there are no missing data. However, a person can become censored at any time, Ct = 1,
for example due to death or loss to follow-up, and no measurements would be recorded
for this individual at time t. We assume that once an individual is censored that they
remain censored, i.e.
Ct = 1 =⇒ Cs = 1 ∀s > t.
4.1.2 Time-Dependent Confounding
Figure 4.1 presents a directed acyclic graph (DAG) of the assumed causal pathways be-
tween treatment, outcome and other time-varying covariates. The non-time-varying ba-
seline variables, B, have not been included in Figure 4.1 for clarity, but we assume these
baseline variables can affect all other variables. The DAG visualises the outcome Yt−1
affecting treatment Xt, time-varying covariates Vt affecting treatment Xt, treatment Xt
affecting the outcome Yt and other time-varying covariates Vt+1, and direct longitudinal
effects of treatment, outcome and other time-varying covariates on later instances of the
same variable.
This DAG highlights the main challenge of estimating long-term treatment effects: time-
dependent confounding. If we consider just the effect of X1 on Y1, we see that V1 con-
founds this effect. Conventional statistical methods could easily be used to adjust for
this confounding to give a valid estimate of the effect of X1 on Y1. However, if we are
interested in the effect of X2, i.e. the joint effect of X1 and X2, on Y2, we see that V2 is
a confounder of the effect of X2 on Y2, but V2 also mediates some of the effect of X1 on
Y2. As we are interested in both the effect of X1 and X2 on Y2, it is not clear how to deal
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FIGURE 4.1: DAG of assumed causal pathways between treatment (X),
outcome (Y) and time-varying confounders (V)
with V2 using standard approaches. Variables such as V2 in this case are referred to as
time-dependent confounders. A particular variable Vt is a time-dependent confounder if
it fulfils the following three criteria[80]:
• Vt is affected by previous treatment Xt−1
• Vt affects the probability of starting, stopping or continuing treatment Xt
• Vt affects the outcome of interest Yt
4.1.3 Treatment Effects
In this work, we wish to estimate the cumulative effect of treatment over time compared
to never receiving treatment. We define the one-year effect of treatment as the effect of
Xt on Yt. This is represented by the expected difference in the counterfactual outcomes
YXt,t−1=1,Xt−1=0t and Y
Xt=0
t , and we label this expectation φ1.
In general, we define φs−t+1 as the effect of Xt on Ys (1 ≤ t ≤ s ≤ T) not mediated
through future treatment. The cumulative effect of receiving treatment for s− t+ 1 years
compared to not receiving treatment over that period is then defined as:
E
(
YXs,t=1,Xt=0s −YXs=0s
)
=
s−t+1
∑
i=1
φi. (4.1)
4.1.4 Assumptions
The following five sections give the details of the methods that we will consider for the
analysis of the UK CF Registry: IPW of MSM, HA-MSM, g-computation formula, g-
estimation of SNM and SCMM. All of these methods have been developed to estimate
treatment effects in the presence of time-dependent confounding
For all five methods we make the following four assumptions: no interference, positivity,
consistency, and no unmeasured confounding. No interference means that for a given
individual their counterfactual outcome Yxt is not affected by the treatment that another
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individual receives.[81] Positivity means that all individuals have a conditional proba-
bility strictly greater than 0 and strictly less than 1 of receiving treatment at all visits
given their history, 0 < P(Xt = 1|Xt−1, Yt−1, Vt, B) < 1.[82] Consistency means that for
each individual, the counterfactual outcome under the observed treatment is equal to
the observed outcome, Yi = Y
xi
i when xi = Xi.[83] Finally, no unmeasured confounding
means that conditional on the past observed variables the treatment received at visit t is
independent of the counterfactual outcome, Yxtt ⊥ Xt|Xt−1, Yt−1, Vt, B.[80]
Thinking specifically about analysing the UK CF Registry, interference should not be an
issue, because CF is a non-infectious condition. Furthermore, people with CF are gene-
rally kept out of direct contact with one another to avoid cross-infection of respiratory
microorganisms.[18] The assumption of positivity is also likely to be valid, because alt-
hough guidelines do exist to help advise when patients might benefit from DNase, it is
not uncommon for patients to receive or not receive treatment despite the guidelines.
Once DNase treatment has been initiated, it is usual to continue to receive the treatment
indefinitely, but a number of people do also stop taking treatment for various reasons.
Consistency concerns the definition of the intervention. The standard dosage and fre-
quency of DNase is 2.5mg once a day, but a small number of patients receive a diffe-
rent dosage or frequency. Unfortunately, dosage data are not routinely collected in the
Registry. However, consistency is considered to hold under an intervention defined as
"receives DNase as prescribed by doctor". Finally, thanks to the large number of vari-
ables available in the UK CF Registry, we do not believe that there are likely to be any
important unmeasured confounders.
4.2 Inverse Probability Weighting of Marginal Structural Mo-
dels
IPW of MSM[84] has become an increasingly popular method to deal with time-dependent
confounding. We consider MSM of the following form:
E
(
Yx¯ss
)
= β0 +
s
∑
i=1
φs−i+1xi. (4.2)
However, due to confounding, the conditional expectation E(Ys|Xs = xs) is not equal to
the expected counterfactual E(Yx¯ss ).
Under the assumptions listed in Section 4.1.4, IPW of the observations enables consistent
estimation of the parameters of MSM by reweighting observations so that, at each point
in time, the levels of past confounding and exposure variables become equally balanced
between treated and untreated individuals at that time. This is achieved by assigning
large weights to individuals who were estimated to be unlikely to receive the treatment
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they actually received and downweighting observations for which there are lots of ob-
servations receiving the same treatment history.
To calculate the weights, one first estimates the propensity score, which is the probability
of receiving treatment at each visit. Considering a binary treatment, this could therefore
be estimated by fitting the following logistic regression model:
P
(
Xt = 1
∣∣∣Xt−1, Yt−1, Vt, B) = expit(β0 + βXXt−1 + βYYt−1 + βVVt + βBB). (4.3)
This model, with its parameters estimated from the data, is then used to calculate the
estimated probability that each person received the treatment they actually received, i.e.
for those who did receive treatment we use the estimated probability from the above
model and for those who did not receive treatment we use one minus the estimated
probability.
P
(
Xt
∣∣∣Xt−1, Yt−1, Vt, B) =
P
(
Xt = 1
∣∣∣Xt−1, Yt−1, Vt, B), if Xt = 1
1− P
(
Xt = 1
∣∣∣Xt−1, Yt−1, Vt, B), if Xt = 0 (4.4)
The most simple method to create weights is to take the inverse of product of these esti-
mated probabilities from visit 1 up to visit of the outcome, s, so that people who, based
on their observed history, are estimated to be unlikely to have received the treatment they
did receive, are assigned the highest weights.
Ws =
s
∏
i=1
1
P
(
Xi
∣∣∣Xi−1, Yi−1, Vi, B) (4.5)
It can be shown that such IPW leads to consistent estimation of parameters of MSM under
the assumptions of Section 4.1.4 if, additionally, the statistical models used to estimate the
weights are of the correct functional form.[84]
One problem that arises in this approach is that when the predictors of treatment are very
strong the estimated probabilities can become very small for some individuals, resulting
in extremely large weights. This has the negative consequence that the estimates for the
final MSM will have large variances.[84] This problem can be mitigated to a certain ex-
tent by readjusting the weights using any covariates which do not cause time-dependent
confounding, e.g. baseline covariates. These stabilised weights are created by changing
the numerator of Equation 4.5 to the estimated probability that an individual received
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their treatment history given only variables which are not time-dependent confounders:
SWs =
P
(
Xs
∣∣∣Xs−1, B)
P
(
Xs
∣∣∣Xs−1, Ys−1, Vs, B) =
s
∏
i=1
P
(
Xi
∣∣∣Xi−1, B)
P
(
Xi
∣∣∣Xi−1, Yi−1, Vi, B) . (4.6)
If the numerator of the stabilised weights only includes previous treatment history, then
the final MSM can then be fit following Equation 4.2 where the observations are weig-
hted using the estimated weights. However, any baseline confounders included in the
numerator of Equation 4.6 must then also be included in the MSM:
E
(
Yx¯ss
∣∣∣B) = β0 + βBB + s∑
i=1
φs−i+1Xi. (4.7)
This would result in a conditional interpretation for the MSM parameters, meaning that if
a marginal interpretation is desired then no baseline variables should be included in the
numerator, so that they can also be excluded from the MSM. For the particular example
of Equation 4.7, the conditional and marginal estimands of the treatment effect are equal,
because there are no interactions between B and X, and because it is a linear MSM, the
parameters of which have the property of collapsibility. However, in general this would
not be the case, for example when there are interactions or other non-linearities, e.g. with
a logistic MSM, which would give rise to non-collapsible parameters.
Due to the fact that time-varying covariates are not included in the MSM, this method
does not allow for the estimation of effect modification by time-varying covariates. Ho-
wever, the method also does not make an assumption that there is no effect modification
and will estimate consistent effects, marginal with respect to the time-dependent covari-
ates, even if the effect of treatment is different at different levels of these time-dependent
covariates.
Using stabilised weights helps to reduce the variability in the weights, but in cases where
there are strong time-varying predictors of treatment the weights can remain highly va-
riable which can lead to instability. Therefore, it can sometimes be preferable to truncate
the most extreme weights, even though this may introduce some bias.[85] In general, the
increase in bias due to the truncation of weights is greater than the decrease in precision,
and therefore it has been suggested to only use minimal truncation, such as the 1st and
99th percentile.[86]
In the presence of censoring, it is also possible to incorporate censoring weights into
the analysis. Similarly to the previously described weights, we weight individuals with
stabilised inverse weights of their estimated probability of being censored, C, before visit
s. An individual’s observations will only be included in the analysis up until they are
censored. We are, therefore, interested in the cumulative probability through time that
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individuals remain uncensored:
CWs =
P
(
Cs = 0
∣∣∣B)
P
(
Cs = 0
∣∣∣Xs−1, Ys−1, Vs−1, B) =
s
∏
i=1
P
(
Ci
∣∣∣B)
P
(
Ci
∣∣∣Xi−1, Yi−1, Vi−1, B) . (4.8)
Using this method we assume that future visits are missing at random, i.e. censoring is
affected by previously measured variables. The estimated censoring weights can then be
multiplied by the estimated stabilised weights at each time point to give the weights to
be used to account for bias due to both confounding and censoring.
4.3 History-Adjusted Marginal Structural Models
As stated in the previous section, one limitation of IPW of MSM is that effect modification
of the treatment effect by time-varying covariates cannot be estimated. Therefore, in cases
where the estimation of an interaction term is desired, HA-MSM are an extension to IPW
of MSM which do allow for this.[87] However, this is a different method to standard IPW
of MSM and can be used even if there is no effect modification by time-varying covariates.
In the standard MSM described in the Section 4.2, observations are reweighted based on
all covariates measured after baseline, t = 1 until the visit of the outcome of interest. In
a HA-MSM, the reweighting is only done for variables measured between the time of
treatment t and the time of outcome, s (t ≤ s). Because this does not reweight for any
covariates measured prior to the treatment at time t, these must be included in the final
HA-MSM. Therefore, the MSM is only marginal with respect to any variables measured
between t and s, but is conditional on the history prior to time t.
Formally, the stabilised weights at time s for an individual exposed at time t are given by
HA-SWts =
s
∏
i=t+1
P
(
Xi
∣∣∣Xi−1, B)
P
(
Xi
∣∣∣Xi−1, Yi−1, Vi, B) . (4.9)
Note that in the case where t = s, the weights are equal to 1, as there is no time-varying
confounding for the weights to correct in the one-year treatment effect estimation.
An example of a HA-MSM is:
E
(
Yx¯ss
∣∣∣xt−1, yt−1, vt, b) =
β0 + βbb + βvvt + βxxt−1 + βyyt−1 +
s
∑
i=t
φs−i+1xi +
s
∑
i=t
φints−i+1 xiyt−1.
(4.10)
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In equation 4.10, we have included an interaction term between previous measures of
the outcome (itself a time-varying confounder) and treatment. This would allow us to
estimate how the effect of treatment changes depending on previous levels of the out-
come. Note that what is being estimated here is the extent to which the treatment effects
(Xt, ..., Xs) are modified by Yt−1, with the model being agnostic as to the presence of any
effect modification by later outcomes. This is in contrast to g-estimation (see Section 4.5),
where the modification of the treatment effects of Xt, ..., Xs by the most recent outcome
measure (Yt−1, ..., Ys−1), respectively, is estimated.
As with IPW of MSM, extreme weights can be truncated to reduce the variance, but this
would result in the same issue as explained in Section 4.2 that even small amounts of
truncation could potentially lead to large increases in bias. It is also possible to estimate
censoring weights, in this case estimating an individual’s probability of being censored
between visits t and s, and multiplying these weights with the stabilised weights.
CWts =
s
∏
i=t+1
P
(
Ci
)
P
(
Ci
∣∣∣Xi−1, Yi−1, Vi−1, B) . (4.11)
Again, it can be noted that in the case where t = s the censoring weights are equal to 1,
as data on Xt and Yt are collected at the same time, so there is no possibility of censoring
when estimating this effect.
4.4 G-Computation Formula
The g-computation formula (hereafter referred to as g-formula) first described by Ro-
bins[88] is another method that can deal with the issue of time-dependent confounding
to give consistent estimates of long-term treatment effects under the assumptions given
in Section 4.1.4, with a different set of parametric assumptions to those involved in IPW
of MSM. In this method short-term models, i.e. models for one-year effects, for the out-
come and all time-varying covariates (in our example, Y and V) are specified. Although
analytic methods can in some instances then be used in order to estimate the parame-
ters of MSM using these fitted "one-year ahead" models, more commonly the integration
involved is not tractable, and thus a more practical alternative is to approximate such
integrals using Monte Carlo simulation. This has the advantage of being intuitively quite
appealing: counterfactual outcomes under different treatment trajectories are simulated
sequentially through time.
For example, the time-varying continuous outcome Y could be modelled as follows:
E
(
Yt
∣∣∣Xt, Yt−1, Vt, B) = β0 + βX1 Xt + βX2 Xt−1 + βYYt−1 + βVVt + βBB, (4.12)
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and counterfactuals for Y1 could then be simulated setting everyone either receiving or
not receiving treatment at visit 1 (and assuming nobody received treatment prior to the
start of follow-up):
Y˜x1=11 = βˆ0 + βˆYY0 + βˆVV1 + βˆBB + βˆX1 + ε˜, (4.13)
Y˜x1=01 = βˆ0 + βˆYY0 + βˆVV1 + βˆBB + ε˜, (4.14)
where ε˜ is a different, independent, random draw for each individual in the dataset
from a normal distribution whose standard deviation is the model-estimated root-mean-
square error, resulting in simulated counterfactual measures that have the correct distri-
bution, if the assumptions in Section 4.1.4 hold, together with the parametric model 4.12,
as well as an assumption of normally-distributed errors for model 4.12.
Similar short-term models would need to be specified for all time-varying covariates V
to allow the counterfactuals for all covariates to be simulated.
The process can then be repeated sequentially for all visits up to T. For example, at visit
2 there would be four counterfactuals simulated for each individual, corresponding to:
1) receiving treatment at both visits, 2) at the first visit only, 3) at the second visit only or
4) never receiving treatment. These counterfactuals could be simulated respectively as
follows:
Y˜x1=1,x2=12 = βˆ0 + βˆYY˜
x1=1
1 + βˆVV˜
x1=1
2 + βˆBB + βˆX1 + βˆX2 + ε˜, (4.15)
Y˜x1=1,x2=02 = βˆ0 + βˆYY˜
x1=1
1 + βˆVV˜
x1=1
2 + βˆBB + βˆX1 + ε˜, (4.16)
Y˜x1=0,x2=12 = βˆ0 + βˆYY˜
x1=0
1 + βˆVV˜
x1=0
2 + βˆBB + βˆX2 + ε˜, (4.17)
Y˜x1=0,x2=02 = βˆ0 + βˆYY˜
x1=0
1 + βˆVV˜
x1=0
2 + βˆBB + ε˜. (4.18)
Note that in Equations 4.15 to 4.17, we do not use the observed values of Y1 and V2, but
rather the counterfactuals for these that were simulated in the previous step.
Depending on the total number of visits, the number of possible treatment trajectories can
become infeasible large to simulate all trajectories. There will be 2T possible trajectories,
and for each visit of each trajectory one would have to not only simulate the outcome for
that visit, but also all the time-varying covariates. However, depending on the question
of interest, it is possible to only simulate a subset of the trajectories. For example, if we are
interested in estimating the effect of receiving treatment for T years compared to never
receiving treatment, we would only need to simulate trajectories corresponding to those
two regimes.
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Having simulated the desired trajectories, the simulated counterfactual outcomes can
then be compared with a MSM, e.g.:
E
(
Yx¯ss
)
= β0 +
s
∑
i=1
φs−i+1xi. (4.19)
As with IPW of MSM, because the final model is marginal, effect modification cannot be
estimated with this method. Another well-known drawback of the use of this method
with non-linear models is the g-null paradox.[88, 89] This is an issue whereby given a
large enough sample size the causal null hypothesis will always be rejected even if there
is in fact no treatment effect. This is due to the fact that the combination of different
parametric models will be inconsistent with the null hypothesis.
4.5 G-Estimation of Structural Nested Models
The fourth method we will consider is g-estimation of SNM.[90] This method has been
utilised less than the previously described methods and this may partly be due to the
perceived difficulty of applying the method with standard statistical software.[91] Ho-
wever, a recent paper by Vansteelandt and Sjolander revisits g-estimation, showing how
it can be implemented with standard software.[92]
Similar to HA-MSM, this method estimates the effect of receiving treatment continuously
from visit t on outcomes at visits s where t ≤ s.
The procedure for g-estimation as outlined by Vansteelandt and Sjolander consists of five
steps[92]:
1. Estimate the propensity score of receiving treatment at each visit. This can be esti-
mated in the same way as in IPW of MSM as given in Equation 4.3
2. Obtain an estimate for the one-year effect of treatment Xs on Ys, represented by φ1
in the following equation, where ps is the propensity score for treatment at time s:
E
(
Ys
∣∣∣Xs, Ys−1, Vs, B, ps) =
βs + βXs−1 Xs−1+βYs−1Ys−1 + βVs Vs + βBB + βps ps + φ1Xs,
(4.20)
3. Use the estimates φj to construct counterfactuals of what the outcome would have
been if people had not received treatment at between times j and s. (In the first
iteration, we only have an estimate for φ1, and j = s− 1):
Hsj = Ys −
s
∑
u=j+1
φs−u+1Xu. (4.21)
Chapter 4. Statistical Methods to Estimate Effects of Dornase Alfa 66
4. Fit a model to estimate the effect of treatment Xj on Hsj (j ≤ s):
E
(
Hsj
∣∣∣X j, Y j−1, Vj, B) =
βs + βXs Xj−1 + βYsYj−1 + βVs Vj + βBs B + βps pj +
s
∑
i=t
zφs−i+1Xj,
(4.22)
where z = 1 if i = j and 0 otherwise.
5. Iterate steps 3 and 4 until all desired estimates φs−j+1 have been obtained where
t ≤ j ≤ s.
Iteration of steps 3 and 4 progressively allows for the estimation of longer-term treatment
effects. For example, on the first run of the above procedure, we would obtain the one-
year effect estimate at step 2, φ1. Then, in step 3, the first time, we can only estimate Hsj
for j + 1 ≥ s, which means that step 4 will only provide estimates of φ1 and φ2 the first
time around. However, now that we have an estimate for φ2, repeating step 3, allows
us to additional estimate Hsj for j + 2 ≥ s, and with these estimates step 4 will now
additionally estimate φ3.
The procedure as described in the simple example given above assumes that the effect of
covariates on Ys is the same regardless of j, i.e. it would assume that the effect of Y1 on Y5
is the same as the effect of Y4 on Y5. We believe it is more realistic that these effects would
change depending on the length of time between j and s. Therefore we fit models which
do not assume these pooled effect estimates. This can be done by changing Equation 4.22
to the following equation:
E
(
Hsj
∣∣∣X j, Y j−1, Vj, B, pj) =
s
∑
i=t
z
(
βi + βXi Xj−1 + βYiYj−1 + βVi Vj + βBi B + βpi pj + φs−i+1Xj
)
,
(4.23)
where z = 1 if i = j and 0 otherwise.
Censoring weights can also be incorporated into g-estimation and are calculated in the
same way as for HA-MSM as given in Equation 4.11, weighting individuals by their
estimated probability of being censored between visits t and s.
4.5.1 Effect Modification in G-Estimation
Modification of the treatment effect by time-varying covariates can also be estimated with
g-estimation. To do this, the relevant product terms would be included in Equations 4.20,
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4.21, and 4.22 or 4.23. For example, Equation 4.23 could be replaced with:
E
(
Hsj
∣∣∣X j, Y j−1, Cj, B, pj) =
s
∑
i=t
z
(
βi + βXi Xj−1 + βYiYj−1 + βVi Vj + βBi B + βpi pj + βpinti pjYj−1
+ ψs−i+1Xj + ψints−i+1 XjYj−1
)
,
(4.24)
where z = 1 if i = j and 0 otherwise.
This allows the effect of treatment Xj on outcome Ys to differ depending on Yj−1. We
could then calculate the total effect of treatment for given values of Yj−1 as:
E
(
YXs,t=1,Xt=0s −YXs=0s
∣∣∣Ys−1) = s∑
j=t
ψs−j+1 + ψints−j+1Yj−1. (4.25)
The intercept and interaction treatment effect terms ψi and ψinti from g-estimation differ
from the intercept and interaction treatment effect terms φi and φinti estimated by HA-
MSM. This is because the interaction effect in g-estimation is based on Yj−1, where t ≤
j ≤ s, whereas in HA-MSM the interaction effect is always based on Yt−1. It may be more
relevant to model the effect of treatment being modified by the most recent level of the
time-varying covariate, rather than the level of the covariate at the start of the treatment
period of interest. However, when wishing to estimate a cumulative treatment effect, it
would be more appropriate to just specify Yt−1, rather than having to specify each value
of Yj−1, which is necessary if using Equation 4.25.
In the case of a continuous outcome, the estimates ψi and ψinti from Equation 4.25 can be
used to estimate φi and φinti . For this, we wish to specify a value for yt−1 and then predict
yj, where t < j ≤ s, using the estimates from Equation 4.24:
yj = β j + βYj yt−1 + βVj vt + βBj b + βpj pt + βpintj ptyt−1 +
j−t
∑
i=1
ψi + ψinti yi−1. (4.26)
The above equation would need to be iterated s− t times, the first time we would obtain
a prediction for yt, then yt+1, up to ys−1. It is also necessary to specify values of vt, b
and pt, for example their mean values could be used. The predicted values yj can then
be put into Equation 4.25 to estimate the treatment effect for a given value of yt−1. This
directly compares to φi and φinti from HA-MSM. To show this, let Ft−1 = 0 and Fj where
t < j ≤ s be the parts of Equation 4.26 that are not multiplied by yt−1, and let Gt−1 = 1
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and Gj where t < j ≤ s be the parts of Equation 4.26 that are multiplied by yt−1, i.e.:
Fj = β j + βVj Vt + βBj B + βpj pt +
j−t
∑
i=1
ψi + ψinti Fi−1 (4.27)
Gj = βYj + βpintj pt +
j−t
∑
i=1
ψinti Gi−1. (4.28)
Then we can rearrange Equation 4.25:
E
(
YXs,t=1,Xt=0s −YXs=0s
∣∣∣Ys−1) = s∑
j=t
ψs−j+1 + ψints−j+1Yj−1 (4.29)
=
s
∑
j=t
ψs−j+1 + ψints−j+1 Fj−1 + ψints−j+1 Gj−1Yt−1 (4.30)
=
s
∑
j=t
φs−j+1 + φints−j+1Yt−1. (4.31)
The cumulative intercept term is therefore:
s
∑
j=t
φs−j+1 =
s
∑
j=t
ψs−j+1 + ψints−j+1 Fj−1, (4.32)
and the cumulative interaction term with Yt−1 is:
s
∑
j=t
φints−j+1 =
s
∑
j=t
ψints−j+1 Gj−1 (4.33)
The above decompositions are only possible because Y is continuous with the identity
link function, allowing the y to be broken down into intercept and interaction terms f
and g. In general with other link functions, the cumulative effect of treatment for a given
value yt−1 could still be calculated, but it would not be possible to simplify it into one
intercept and one interaction term.
4.6 Sequential Conditional Mean Models
Even in the presence of time-dependent confounding it is still possible to use standard
regression methods, but these methods can only estimate total effects.[93] The total effect
of a treatment, Xt, on an outcome Ys (s ≥ t) would include not only the direct effect of
Xt on Ys and the indirect effects of Xt on Ys mediated through time-varying covariates,
but also the indirect effect of Xt on Ys mediated through future exposures. An example
of this two-year total effect is shown in the left panel of 4.2, and can be compared to the
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two-year effect as estimated by the other methods introduced in this chapter, which is
shown in the right panel of the same figure.
Yt−1Vt−1 YtVt Yt+1Vt+1 Yt−1Vt−1 YtVt Yt+1Vt+1
Xt−1 Xt Xt+1 Xt−1 Xt Xt+1
FIGURE 4.2: DAGs highlighting in green the different two-year treatment
effects estimated by SCMM (left panel) compared to other methods (right
panel)
Both of these long-term estimates are valid estimates of a treatment effect, but they ans-
wer different questions. The total effect as shown in the left panel of Figure 4.2 would
answer the question: "What is the effect of starting treatment now on the outcome of in-
terest in two-years’ time compared to not starting treatment?". In this question, people
who start treatment at time t may in fact discontinue treatment at time t + 1, and simi-
larly people untreated at time t could start at time t+ 1, with the effect of being treated at
time t+ 1 likely to be affect by whether or not treatment is taken at time t. We would thus
be estimating the total effect of taking treatment at time t, including its likely knock-on
effect via the treatment taken at time t + 1. This can be compared to the effect shown in
the right panel of Figure 4.2, which would answer the question: "What is the effect of
receiving treatment combination xt and xt−1 versus some other treatment combination x′t
and x′t−1?", e.g. being treated for both of these two years versus being treated for none
of these two years. The fact that Xt likely affects Xt+1 is not relevant in this estimand:
instead, we imagine manipulating both of them. For this work, we are more interested
in answering questions of the latter type, and therefore, this would suggest a preference
towards the other methods introduced in this chapter over SCMM. Nevertheless, in our
example, people are assumed to only start or stop treatment at each visit t, and therefore,
in the case of the effect of Xt on Yt (the one-year effect), the SCMM estimate coincides
with the estimates of the other methods.
These SCMM will give a consistent estimate of the total effect of treatment as long as
we appropriately control for all confounding effects of the effect of interest and correctly
specify the parametric model involved. For example, the following model would suffice
for the one-year effect if the most recent measures of all covariates were sufficient to
remove confounding:
E
(
Yt
∣∣∣Xt, Yt−1, Vt, B) = β0 + βX1 Xt + βX2 Xt−1 + βYYt−1 + βVVt + βBB. (4.34)
It is also possible to incorporate propensity scores into the SCMM to provide a doubly
robust estimator. For a binary treatment, the propensity score can be calculated as it was
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in the IPW method by using Equation 4.3, and this is then incorporated into the SCMM
as follows:
E
(
Yt
∣∣∣Xt, Yt−1, Vt, B, pt) = β0 + βX1 Xt + βX2 Xt−1 + βYYt−1 + βVVt + βBB + βp pt.
(4.35)
Equations 4.35 and 4.20 are the same and this means that for the one-year effect, g-
estimation and SCMM are in fact identical. This also means that similarly to g-estimation,
SCMM can also estimate modification of the treatment effect by including the relevant in-
teraction term in the model. Note that for any interaction term involving the treatment
variable, Xt, the corresponding interaction term with the propensity score pt should also
be included.
The paper by Keogh et al. also gives details of an extension to this method that tests
whether there is evidence of a long-term effect of treatment, i.e. after having estimated
the effect of Xs on Ys, we can test whether there is any evidence of any additional effect
of Xt on Ys (t < s) not mediated through Xs.[93] The test is performed in three stages:
1. Fit the model as given in Equation 4.35 to estimate the effect of Xt on Yt.
2. Use this model to estimate the counterfactual Yˆxt=0t , i.e. what the observed outco-
mes would have been if everybody had not received treatment at time t (by setting
Xt to 0):
Yˆxt=0t = β0 + βX2 Xt−1 + βYYt−1 + βVVt + βBB + βp pt. (4.36)
3. Estimate whether conditional on other covariates there is any residual association
between Yˆxt=0t and previous treatment Xt−1:
E
(
Xt−1
∣∣∣Xt−2, Yt−1, Vt−1, B, Yˆxt=0t ) =
expit
(
γ0 + γXXt−2 + γYYt−2 + γVVt−1 + γBB + γYˆYˆ
xt=0
t
)
.
(4.37)
A bootstrap method incorporating these three steps should be used to obtain valid stan-
dard errors (SEs) and CIs for parameter γYˆ in order to assess where there is any evidence
of any effect of Xt on Ys (t < s).
Although SCMM cannot provide estimates for the effects of varying lengths of treatment
duration, the simplicity of the method is appealing, and the one-year treatment effect es-
timates do coincide with the one-year treatment effect estimates from the other methods.
Furthermore, if the test of no long-term treatment effects was not statistically significant,
this could suggest that it is sufficient to only estimate the one-year treatment effect with
a SCMM without resorting to the use of a more complex method.
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4.7 Extension to Count Outcomes
For our motivating example we have two outcomes of interest, lung function and annual
IV days. The first of these is a continuous outcome and all five of the methods can ea-
sily handle this outcome as outlined in the sections above. More care is needed when
considering a count outcome.
Upon investigation, IV days can be considered approximately distributed as a zero-
inflated negative binomial distribution. Modelling outcomes of this type requires two
separate estimation procedures: 1) logistic regression to estimate the odds of zero count,
and 2) negative binomial regression to estimate the rate of the count. Therefore, there are
two separate parts to the treatment effect: the effect of treatment on having a zero count
and the effect of treatment on the overall count.
4.7.1 IPW of MSM and g-formula
IPW of MSM and g-formula can both handle different types of outcome by just changing
the final MSM, e.g.:
E
(
Yx¯ss
)
= expit
(
β0 +
s
∑
i=1
βs−i+1xi
)
exp
(
γ0 +
s
∑
i=1
γs−i+1xi + ui
)
, (4.38)
where the expit term is a model for the odds of a zero count and the exponential term is
a model for the rate of the count, which includes ui to account for overdispersion:
eui ∼ Gamma(1/α, α). (4.39)
We then summarise the cumulative treatment effect as two separate processes. Firstly,
the odds of having a zero count after receiving treatment for s− t + 1 years compared to
not receiving treatment for s− t + 1 years:
P
(
YXs,t=1,Xt=0s = 0
)
P
(
YXs=0s = 0
) = expit( s−t+1∑
i=1
βi
)
, (4.40)
Secondly, the rate of the count after receiving treatment for s− t + 1 years compared to
not receiving treatment for s− t + 1 years:
E
(
YXs,t=1,Xt=0s
)
E
(
YXs=0s+1
) = exp( s−t+1∑
i=1
γi
)
. (4.41)
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4.7.2 HA-MSM and SCMM
Similarly, HA-MSM can also easily handle this outcome by changing the final conditi-
onal model, and as with continuous outcomes, both can also include interaction terms
between treatment and time-varying covariates. An example of a HA-MSM with an in-
teraction term is:
E
(
Yx¯ss
∣∣∣xt−1, yt−1, vt, b) =
expit
(
β0 + βbb + βvvt + βxxt−1 + βyyt−1 +
s
∑
i=t
βs−i+1xi + βints−i+1 xiyt−1
)
exp
(
γ0 + γbb + γvvt + γxxt−1 + γyyt−1 +
s
∑
i=t
γs−i+1xi + γints−i+1 xiyt−1 + ui
)
,
(4.42)
where
eui ∼ Gamma(1/α, α). (4.43)
The two cumulative treatment effects would then be given by:
P
(
YXs,t=1,Xt=0s = 0
∣∣∣xt−1, yt−1, vt, b)
P
(
YXs=0s = 0|xt−1, yt−1, vt, b
) = expit( s−t+1∑
i=1
βi + βintiYt−1
)
(4.44)
E
(
YXs,t=1,Xt=0s
∣∣∣xt−1, yt−1, vt, b)
E
(
YXs=0s+1
∣∣∣xt−1, yt−1, vt, b) = exp
( s−t+1
∑
i=1
γi + γintiYt−1
)
. (4.45)
For a SCMM, we could fit an unweighted model similar to Equation 4.42, including the
propensity score and only the terms corresponding to the one-year effect, β1x1 and γ1x1.
4.7.3 G-Estimation
Unlike the other four methods, which can easily handle different types of outcome, the
method of g-estimation described in Section 4.5 has until recently only been described
for continuous outcomes. However, a recent paper has shown how this method can be
adapted to allow for a count outcome using a gamma distribution.[94] This allows for the
estimation of the effect of treatment on the rate of the count, but would not allow for the
zero inflation as the other methods do.
The procedure for estimating an incidence rate ratio (IRR) in g-estimation follows the
same 5-step procedure as for continuous outcomes given in Section 4.5. In step 2, we
Chapter 4. Statistical Methods to Estimate Effects of Dornase Alfa 73
would fit a gamma generalized linear model with a log link function and a scale parame-
ter of one:
E
(
Ys
∣∣∣Xs, Ys−1, Vs, B, ps) =
exp
(
βs + βXs−1 Xs−1+βYs−1Ys−1 + βVs Vs + βBB + βps ps + φ1Xs
)
.
(4.46)
In step 3 the counterfactuals are now estimated as:
Hsj = Ys
s
∏
u=j+1
e−φs−u+1Xu . (4.47)
And, in step 4, we would again fit a gamma generalized linear model with a log link
function and a scale parameter of one:
E
(
Hsj
∣∣∣X j, Y j−1, Vj, B, pj) =
exp
(
z
(
βi + βXi Xj−1 + βYiYj−1 + βVi Vj + βBi B + βpi pj +
s
∑
i=t
φs−i+1Xj
))
,
(4.48)
where z = 1 if i = j and 0 otherwise.
The cumulative effect of receiving treatment for s− t+ 1 years compared to not receiving
treatment over that time is then given by the IRR:
E
(
YXs,t=1,Xt=0s
∣∣∣xt−1, yt−1, vt, b, pt)
E
(
YXs=0s+1
∣∣∣xt−1, yt−1, vt, b, pt) = exp
( s−t+1
∑
i=1
φi
)
. (4.49)
Effect modification by time-varying covariates can again be incorporated into this g-
estimation procedure, by including the desired product term in Equations 4.46, 4.47 and
4.48. The cumulative effect of receiving treatment for s − t + 1 years compared to not
receiving treatment over that time given Yj−1 would then be:
E
(
YXs,t=1,Xt=0s
∣∣∣xt−1, yt−1, vt, b, pt)
E
(
YXs=0s+1
∣∣∣xt−1, yt−1, vt, b, pt) = exp
( s−t+1
∑
i=1
φi + φintiYj−1
)
. (4.50)
As with the continuous case, we may wish to only specify yt−1, rather than every yj−1
(t ≤ j ≤ s). We can use the model given in Equation 4.48 with the interaction term
included to sequentially predict yj starting with a specific yt−1.
yj = exp
(
β j + βYj yt−1 + βVj vt + βBj b + βpj pt + βpintj ptyt−1 +
j−t
∑
i=1
ψi + ψinti yi−1
)
. (4.51)
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We can then calculate the cumulative treatment effect for a given yt−1 by inputting all the
predicted yj into Equation 4.50. Due to the exponential term in Equation 4.51, it is not
possible to decompose the cumulative effect into an intercept and interaction term as it
was with a continuous outcome. This would make it difficult to succinctly summarise the
treatment effect, which is a problem not suffered by HA-MSM. However, the g-estimation
procedure may be more relevant as it estimates how the treatment effect is modified by
the most recent measure of the covariate rather than only providing an estimate of how
treatment is modified by the level of the covariate at exposure time t.
4.8 Overview & Comparison of Methods
We have introduced five methods that we will consider for the analysis of the UK CF
Registry when investigating the effects of long-term DNase use on two health outcomes.
We are interested in estimating the effect of using DNase continuously for a number of
years compared to never receiving DNase. Four of the methods we have introduced are
suitable for this, but one method, SCMM, will only be able to be used to estimate the effect
of one-year of DNase use. SCMM can estimate some long-term effects: these are total
effects including the indirect effects mediated through future treatment use. However,
SCMM is the simplest of the methods to implement and along with its test of whether
there are any long-term effects, it could be used as a first step before deciding if the more
complex methods may be necessary.
In addition to being the simplest method, one further benefit of SCMM is that the model-
based SE will be approximately correct when the propensity score is well estimated, me-
aning that the bootstrap does not need to be used and results can be obtained much faster
than using the other methods presented in this paper. The asymptotic SEs have been de-
rived for IPW of MSM, but only in a time-fixed setting,[95] and the difficulty of deriving
these in a longitudinal setting necessitate the use of the bootstrap for all the methods ot-
her than SCMM. This is because all the methods contain a number of steps of estimation
and just using the final model-based SE would fail to account for the uncertainty from the
earlier steps.[86, 87, 96, 97] The bootstrap provides valid results as all of these methods
produce regular estimators.[98]
All of the methods except for g-formula make use of the propensity score. However, in
the case of IPW of MSM and HA-MSM, the propensity scores are used to calculate the
estimated probability of the observed treatment for each individual, and because of this,
the methods become much more complicated if we wish to use a non-binary treatment.
G-estimation and SCMM do not have this issue and can easily handle treatments that are
not binary, such as a continuous measure of dose of treatment received. Nevertheless, in
our example, we only have reliable data for a binary marker indicating receiving or not
receiving treatment, so this will not be discussed further here.
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For continuous outcomes, conditional and marginal estimates are the same due to col-
lapsibility. However, we also wish to use the methods with a count outcome, where the
issue of non-collapsibility will be present. Both IPW of MSM and g-formula provide mar-
ginal estimates and would therefore be expected to give the same estimates on average
if there are no issues with the analysis. Although, note that IPW of MSM will only pro-
vide a marginal estimate if no baseline covariates are included in the numerator of the
weights. HA-MSM, g-estimation and SCMM provide conditional estimates, and due to
non-collapsibility these estimates will not coincide with the marginal estimates from IPW
of MSM and g-formula, even if all models are correct. Furthermore, SCMM condition on
the propensity score, whereas HA-MSM do not, and therefore, these would be two diffe-
rent conditional estimates and would not be expected to be the same.
For all methods other than g-estimation we will model the count outcome using a zero-
inflated negative binomial distribution, but for g-estimation, we instead use a gamma
distribution. The results from this method cannot, therefore, be compared directly with
the results from the other methods.
Linked to the issue of conditionality is the estimation of treatment effect modification by
time-varying covariates. As IPW of MSM and g-formula give marginal estimates, it is not
possible for them to estimate effect modification by time-varying covariates, but they do
provide valid population average estimates even in the presence of effect modification,
as neither method assumes that effect modification is not present. Conversely, the other
three methods can estimate treatment effect modification by time-varying covariates, and
in fact would not give valid estimates if there is effect modification but the interaction
terms are not included in the models.
When considering modification of long-term treatment effects, HA-MSM and g-estimation
differ in their approach. We use the example where the treatment effect is modified by
previous levels of the outcome. HA-MSM estimates how the total effect of receiving tre-
atment from Xt to Xs on Ys is modified by Yt−1, whereas g-estimation estimates how the
effect of Xt on Ys is modified by Yt−1, and how the effect of Xt+1 is modified by Yt, etc,
up to the effect of Xs on Ys being modified by Ys− 1. It may be more relevant to esti-
mate how the effect of treatment at each time-point is modified by the most recent level
of the outcome, rather than the level of the outcome at the start of the treatment period
of interest, suggesting that g-estimation may provide more useful estimates of any effect
modification.
The five methods introduced in this chapter are not the only methods that can be used.
Two other methods that are sometimes used to analyse Registry data are methods invol-
ving patient matching or methods based on instrumental variables. The most common
method involving matching patients is to match based on the propensity score.[99] This
results in a method which is very similar to IPW by the propensity score, but when using
matching methods, matched patients are given a weight of one and everyone else would
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be given a weight of zero (i.e. excluded from the analysis). However, the use of matching
methods can be challenging in longitudinal settings, as it is unlikely that there would be
many patients who could be matched consistently over many years of follow-up.[100]
For this reason, we chose to focus on IPW by the propensity score.
An instrumental variable is a variable that satisfies three conditions: 1) the variable af-
fects the probability of receiving treatment, 2) the variable’s only effect on the outcome
is mediated through the treatment, and 3) there are no confounders between the variable
and the outcome.[101] In our setting, it is difficult to find a variable which is predictive
of treatment, but which does not itself affect either of our outcomes of interest. This is
because the predictors of treatment are generally based on their health status. One po-
tential instrumental variable could be CF centre, because there are noticeable differences
between the proportion of people receiving DNase between CF centres. However, lung
function and the use of IVs also varies between centres, plausibly for reasons other than
the different treatment use, thus even this would probably not satisfy criteria two. It is
for this reason that we did not consider using an instrumental variable approach in our
analysis of the long-term effects of DNase.
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Chapter 5
Simulation Studies to Assess the
Performance of Statistical Methods
5.1 Introduction
The previous chapter introduced five methods that could potentially be used to analyse
the UK CF Registry data in order to estimate the effects of long-term DNase use. Howe-
ver, there are no clear guidelines on when one method might be preferred over another.
In an ideal setting, where we could be sure that all assumptions are met and that all mo-
dels are correctly specified, any one of the available methods could be used to obtain
consistent treatment effect estimates, albeit with some methods more efficient than ot-
hers. However, with real data, it can be difficult to know if assumptions hold and all
models will be misspecified to some degree.
In this chapter, we perform simulation studies under a number of different scenarios in
order to help assess which of the methods might be the most appropriate for the analysis
of the UK CF Registry data. The primary aims of these simulation studies are twofold:
1. Compare the ability and appropriateness of the different analysis methods for ad-
dressing the questions of interest, including to estimate effect modification by time-
varying covariates and to handle different outcome types
2. Investigate the robustness of the different methods to handling practical challenges
arising in longitudinal observational data, such as uncertainty about the relative
temporality of measures and loss to follow-up.
We will consider all five methods introduced in the previous chapter: IPW of MSM, HA-
MSM, g-formula, g-estimation of SNM, and SCMM. For IPW of MSM and HA-MSM we
will consider the methods both with and without the use of truncated weights.
The results from these simulation studies will be used to help guide which methods
could be used to analyse the UK CF Registry and specifically whether any of the met-
hods should not be used.
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As with the previous chapter, work from this chapter was also incorporated into the
paper published in Statistics in Medicine which can be found in Appendix B.
5.2 Features & Challenges in the Analysis of the UK CF Registry
As is usual with most observational data, there are a number of issues which need to be
considered when approaching the analysis of the UK CF Registry data.
One challenge is the use of the available methods with different types of outcomes. One
of our outcomes of interest, lung function measured with ppFEV1, is continuous and can
be reasonably approximated by a conditionally normal distribution. All of the methods
described in the previous chapter can easily accommodate such an outcome. However
the other outcome, IV days, is a count outcome ranging from 0 to 365, with approximately
half of the population having 0 days in a given year. We will model this outcome with a
zero-inflated negative binomial distribution. As was discussed in the previous chapter,
four of the methods can be used with zero-inflated negative binomial data, whereas,
although g-estimation can handle count data, it models this with a gamma distribution,
so it might not be the most suitable method if the real data are best approximated by
a zero-inflated negative binomial distribution. Nevertheless, we will consider all five
methods with the count outcome.
In addition to considering two different types of outcome, we have identified five key
features of the analysis of the UK CF registry that post different challenges. The first
three of these concern the ability and appropriateness of the different analysis methods
to estimate the treatment effect:
1. whether there exists any treatment effect at all,
2. whether there are only short-term or also long-term effects, and
3. whether there is effect modification of the treatment effect by time-varying covari-
ates.
The second category of challenges are those that may arise because of the nature of the
data available to investigate the above questions:
4. uncertainty of the direction of causal pathways between variables, and
5. the presence of censoring
The following subsections give further details on each of these five issues.
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5.2.1 Causal Null Hypothesis
Figure 5.1 shows the assumed causal pathways between DNase (D) and the two outco-
mes lung function (L) and IV days (V) in the UK CF Registry. This DAG allows for a
causal effect of treatment on both outcomes of interest. To date, RCTs have demonstra-
ted the efficacy of DNase treatment in improving lung function, but no studies have yet
shown a statistically significant effect of the treatment on reducing the rate of IV days.
Furthermore, in a non-trial setting, where, for example, adherence levels may not be as
high as in clinical trials, the findings of a causal effect of treatment may not be replicated.
For this reason, methods that benefit from a degree of robustness to model misspecifica-
tion at the causal null, i.e. when there is in truth no treatment effect, would be attractive.
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FIGURE 5.1: DAG of assumed causal pathways between DNase (D) and
the two outcomes of interest: lung function (L) and IV days (V) (Other
time-varying and baseline confounders are not shown for clarity)
5.2.2 Long-Term Treatment Effects
We define a long-term treatment effect as an effect of Dt on either Ls or Vs+1 (s > t) not
mediated via intermediate treatments. No studies have previously looked at the effects of
DNase beyond two years, and it therefore remains unknown how the effect of treatment
might change with length of use. Taking the example of lung function, two possible ways
in which the treatment may affect the outcome are:
1. The lung function trajectories of those receiving and not receiving treatment conti-
nue to grow apart indefinitely through time, or
2. after the initial increase in lung function that has been observed at the start of taking
treatment, the effectiveness of treatment may decrease with the two counterfactual
trajectories no longer diverging.
These two hypothetical lung function trajectories compared to the trajectory when not
receiving treatment are shown in Figure 5.2. As it is unknown how the effect of treat-
ment might change through time, it is important that the methods are flexible enough to
identify the true long-term effects.
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FIGURE 5.2: Two possible trajectories of lung function with long-term
DNase use
5.2.3 Effect Modification by Time-Varying Covariates
We hypothesise that the effect of treatment may depend on previous lung function and
number of IV days. This is because if a person starts treatment when they already have a
high lung function, it is unlikely that treatment could further improve their lung function,
whereas it is realistic that the treatment could be much more effective in an individual
with very low lung function. For informing practice, rather than just identifying the
population average effect of treatment, it is important to gain understanding of how the
effect of treatment might change depending on other covariates, and for this reason, it
would be preferable to use a method which can test for the presence and estimate the
strength of any effect modification.
5.2.4 Misspecification of the Direction of Causal Pathways
The DAG in Figure 5.1 includes assumptions about the direction of the causal pathways.
For some variables the appropriate direction of the causal pathway is clear due to the
timing of when they are measured, i.e. causal pathways cannot go backwards in time. For
example, the pathway from total IV days in one year to lung function measured at the end
of the year could not possibly be in the other direction. However, a number of variables
are summaries of the past year, and the causal pathways between these variables could
conceivably go in either direction.
The direction of the causal pathway between treatment and number of IV days is particu-
larly uncertain. Both variables are summaries of the previous year, and some individuals
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may have had lots of IV days at the start of the year which prompted them to start tre-
atment, whereas others may have started treatment earlier, but then had IV days later in
the year. Figure 5.1 shows that we assumed that Vt affects Dt with Dt in turn affecting
Vt+1. However, the way the data are collected could also be compatible with the DAG
shown in Figure 5.3, where Vt−1 affects Dt and Dt affects Vt.
Visit
L1
1
V1 L2
2
V2 L3
3
V3 L4
4
V4 L5
5
V5 LT
T
VT
D1 D2 D3 D4 D5 DT
... ... ...
... ... ...
... ... ...
... ... ...
FIGURE 5.3: DAG showing possible reversed causal pathways between
DNase (D) and IV days (V)
In reality, the causal pathway between Dt and Vt is likely to go both ways, or one way
in some people and another way in other people, but in the methods investigated in
this chapter it will be necessary to specify just one direction for this pathway. When
considering IV days as an outcome, we have decided to focus on investigating the effect
of Dt on Vt+1, as, due to temporality this pathway can only be directed this way, and to
treat Vt as a potential confounder of this effect. In the real UK CF Registry data we cannot
know whether the time ordering of certain variables in the DAG is misspecified or not,
and therefore it is important to understand the potential extent of the bias in treatment
effect estimates under different methods when the direction of this pathway has been
misspecified.
5.2.5 Censoring
We are fortunate that there are very few people lost to follow-up in the UK CF Registry
and each year there are relatively few deaths compared to the total number of people in
the registry. Nevertheless, it is possible that the fact that some individuals are censored
due to loss-to-follow-up or death may bias the results. Therefore, we also wish to in-
vestigate how the different methods handle censoring. Although in reality there would
likely be different processes affecting the probability that an individual dies or is lost to
follow-up, in this chapter we only consider one missing at random scenario where an in-
dividual’s probability of being censored at a given time depends on previously measured
variables.
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5.3 Simulation Study Scenarios
In order to assess the five challenges and features, we simulated datasets under six diffe-
rent scenarios as shown in Figure 5.4. In each DAG, the arrows highlighted in red show
the specific differences compared to the other scenarios.
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FIGURE 5.4: Simplified DAGs showing data generation process for the sce-
narios investigated (The actual simulation data were generated up to 5 vi-
sits, with an additional baseline confounder, age, affecting all variables)
The first scenario is the standard scenario, which will be the baseline to assess the per-
formance of all methods and to compare this to their performance in the other scenarios.
In this scenario there is a one-year treatment effect, but no direct long-term effects. There
are, however, long-term effects mediated through other time-varying covariates. This is
the scenario for which all the methods will be correctly specified and as such we would
expect all methods to provide consistent estimates for the treatment effects in this scena-
rio.
In the second scenario we simulate data where there is no treatment effect. This may
affect the results obtained from g-computation formula due to an issue known as the g-
null paradox, which can lead to the method providing incorrect treatment effect estimates
in situations when there is no treatment effect.[88, 89]
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The third scenario adds long-term direct effects of treatment. In this case, the long-term
direct effects are actually negative effects, slightly counteracting the beneficial one-year
effects, resulting in a decrease in the treatment effect through time. All of the methods
should be able to deal with this scenario and provide consistent estimates of the treatment
effect.
The fourth scenario simulates modification of the treatment effect by time-varying cova-
riates. Although effect modification is generally not shown in DAGs, we have included
arrows in Figure 5.4 to help illustrate this feature. The effect of Dt on Lt is modified by
Lt−1 and the effect of Dt on Vt+1 is modified by Vt. Only three of the methods can pro-
vide estimates of treatment effect modification: HA-MSM, g-estimation and SCMM, but
the other methods should still provide consistent estimates of the population-average
treatment effect, as the models used do not assume no treatment effect modification.
The fifth scenario reverses the direction of the causal pathway between treatment and
IV days in the same year. In our analyses, we will always assume that the direction of
the causal pathway is from Vt to Dt, even when the data have actually been simulated
the other way around, i.e. Dt affects Vt. This is a key issue in the UK CF Registry due
to the fact that all data are collected at the end of each year, but many variables actually
summarise the previous year (e.g. the total number of IV days since the previous annual
assessment). Misspecifying the models means that all methods will probably perform
poorly in this setting, but it is not clear to what extent they will show bias and whether
some methods will be more affected than others.
In the final scenario some individuals are censored and so have fewer than five visits. The
data were generate such that an individual’s probability of being censored is affected by
variables measured at the previous visit. This corresponds to a missing at random sce-
nario, whereby the probability of being censored only depends on observed variables.
Three of the methods (IPW of MSM, HA-MSM and g-estimation) can be extended to ac-
count for censoring by using censoring weights, and provided the censoring weights are
correctly specified, these methods should therefore not be affected by censoring. SCMM
should not be affected by censoring, because they only estimate short-term effects, and
g-formula uses these same short-term models to then simulate data without censoring
and so should similarly be unaffected by censoring.
5.4 Design of Simulation Studies
Simulation studies were performed following the guidelines given by Burton et al.[102]
in order to investigate how the five features and challenges identified in Section 5.2 affect
the performance of the methods described in Chapter 4 in each of the scenarios given
above. The aims of the simulation studies are to understand how the performance of the
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analysis methods might be affected by these challenges and to help provide a framework
for the best analysis strategy for the real UK CF Registry data.
All simulations and analyses were carried out using Stata (Version 15). For each scena-
rio, we simulated 1000 datasets, and we applied all the analysis methods to each dataset.
This results in moderately independent simulations where for each scenario a new set of
datasets was generated, but within each scenario the same set of simulated independent
datasets was used to compare the statistical methods. The data were generated so as to
imitate the observed data in the registry. In the real data, there are many treatments that
individuals could be receiving and also many covariates which might be confounders.
For the simulation studies we kept just one binary treatment, D, and the two outcome
variables, lung function (L) and annual IV days (V), which also act as time-dependent
confounders. Lung function was simulated as a continuous variable with a normal dis-
tribution, conditional on observed history, and IV days as a count outcome following a
zero-inflated negative binomial distribution, conditional on observed history. In addition
to these three variables, we also generated age from a beta distribution corresponding to
what was observed in the real data, to act as a baseline confounder.
5.4.1 Simulation of Datasets
For each scenario the starting seeds used to generate each simulated dataset were pseudo-
random numbers generated from a uniform distribution using the following formula:
Seed = floor(unif(0, 1)× 1000000+ 1000000× (n− 1)) (1 ≤ n ≤ 1000). (5.1)
For each scenario datasets were simulated with 7500 individuals with 6 visits (t = 0, ..., 5).
The data were simulated sequentially starting with visit 0. Table 5.1 lists the variables that
were simulated.
Name Variable Type Distribution Range
Visit T Integer - 0-5
Censored C Binary Bernoulli 0, 1
Baseline Age A Continuous Beta 6-90
Dornase Alfa D Binary Bernoulli 0, 1
Lung Function L Continuous Normal 10-
IV Days V Integer Zero Inflated Negative Binomial 0-365
Exacerbation (IV Days > 0 ) E Binary Bernoulli 0, 1
TABLE 5.1: List of simulated variables
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The data for visit 0 were simulated using the following formulae:
a = 6+ 84 ∗ beta(1.1, 5) (5.2)
v0 = min
(
365,
(
1
(
unif(0, 1) < expit(0.004a− 0.6)))
× poisson
(
gamma
(
2, 0.5exp(2.4− 0.002a)))) (5.3)
e0 = 1(v0 > 0) (5.4)
d0 = 0 (5.5)
l0 = max
(
10, norm(95− 0.65a− 5.8e0 − 0.3v0, 20)
)
(5.6)
c0 = 0 (5.7)
Data for visits 1 to 5 were then simulated sequentially using the following formulae,
where α, β and γ were varied to create the six different scenarios (see Table 5.2):
vt = min
(
365,
(
1
(
unif(0, 1) < expit(1+ (α1 + α2et−1 + α3vt−1)dt−1
+ (α4 + α5et−1 + α6vt−1)
t−1
∑
i=0
xi
+ et−1 + 0.05vt−1 − 0.025lt−1 − 0.02a)
))
∗ poisson
(
gamma
( 1
0.3
, 0.3exp(3.6+ (α7 + α8et−1 + α9vt−1)dt−1
+ (α10+ α11et−1 + α12vt−1)
t−1
∑
i=0
di
+ 0.1et−1 + 0.01vt−1 − 0.0075lt−1 − 0.003a)
)))
(5.8)
et = 1(vt > 0) (5.9)
dt = 1
(
unif(0, 1) < expit(4dt−1 + 0.7et + 0.001vt − 0.01lt−1 − 0.02a− 0.4)
)
(5.10)
lt = max
(
10, norm(10+ (β1 + β2lt−1)xt + (β3 + β4lt−1)
t
∑
i=0
di
+ 0.9lt−1 − 0.7et − 0.06vt − 0.08a, 10)
) (5.11)
ct = γ ∗ 1
(
unif(0, 1) < expit(0.02a− 0.03lt − 0.9et + 0.02vt − 0.1dt − 2
)
(5.12)
The only scenario for which the data were simulated differently was the reversed causal
pathways scenario, where treatment (dt) was simulated prior to IV days (vt), i.e. Equa-
tion 5.10 was simulated before Equation 5.8, with vt and et replaced by vt−1 and et−1
respectively in Equation 5.10, and dt−1 replaced by dt in Equation 5.8.
The simulated datasets were checked to ensure that the previous formulae resulted in
data which is distributed similarly to that observed in the real UK CF registry.
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Scenario α1 α2 α3 α4 α5 α6 α7 α8 α9
Standard -2 0 0 0 0 0 -0.8 0 0
No Effect 0 0 0 0 0 0 0 0 0
Decreasing Effect -2 0 0 0.25 0 0 -0.8 0 0
Effect Modification -0.8 -0.4 -0.02 0.1 0.05 0.0025 -0.2 -0.2 -0.02
Reversed Causal Pathway -2 0 0 0 0 0 -0.8 0 0
Censoring -2 0 0 0 0 0 -0.8 0 0
Scenario α10 α11 α12 β1 β2 β3 β4 γ
Standard 0 0 0 4 0 0 0 0
No Effect 0 0 0 0 0 0 0 0
Decreasing Effect 0.1 0 0 4 0 -0.5 0 0
Effect Modification 0.025 0.025 0.0025 8 -0.08 -1 0.01 0
Reversed Causal Pathway 0 0 0 4 0 0 0 0
Censoring 0 0 0 4 0 0 0 1
TABLE 5.2: Parameter values used in Equations 5.2 to 5.12 to simulate the
six different scenarios
5.4.2 Analysis of Simulated Datasets
We analysed the data generated under each scenario using seven methods: IPW of MSM,
IPW of MSM with truncated weights, HA-MSM, HA-MSM with truncated weights, SCMM,
g-formula and g-estimation. The methods were all implemented as described in Chapter
4. For the methods involving truncation, the weights are truncated to the 1 and 99 percen-
tile. We fit all seven methods without any interaction terms to estimate the population-
average effect, even in the scenario where there was in fact some effect modification. Ad-
ditionally, for the four methods that can accommodate estimation of interactions between
treatment and time-varying covariates (HA-MSM, HA-MSM with truncation, SCMM and
g-estimation), we analysed simulated data from three of the scenarios (no effect scenario,
standard scenario and effect modification scenario) with interaction terms included.
For each scenario we perform analyses for two outcome variables: the first considering
lung function (continuous) as the outcome and the second annual IV days (count) as the
outcome. For each simulation, the coefficients corresponding to the cumulative treatment
effects will be stored. For the continuous outcome, this is:
E
(
LDs=1,Dt=0s − LDs=0s
)
=
s−t+1
∑
i=1
φi, (5.13)
and for the count outcome, there are two sets of coefficients. The first corresponding to
the odds ratio (OR) of having a zero count:
P
(
VDs=1,Dt=0s+1 = 0
)
P
(
VDs=0s+1 = 0
) = exp( s−t+1∑
i=1
βi
)
, (5.14)
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and the second corresponding to the IRR of the count:
E
(
VDs=1,Dt=0s+1
)
E
(
VDs=0s+1
) = exp( s−t+1∑
i=1
γi
)
. (5.15)
For SCMM, as discussed in Chapter 4, only the coefficient corresponding to one-year of
treatment will be stored. For all other methods we estimate the effects of one-, two-,
three-, four-, and five-years’ treatment use on the continuous outcome, i.e. in Equation
5.13 for s− t+ 1 = 1, ..., 5. For the count outcome, we only estimate the one-, two-, three-
and four-year treatment effects (s− t+ 1 = 1, ..., 4 in Equations 5.14 and 5.15). The reason
for this difference is that in the UK CF Registry, we define the one-year effect of treatment
on lung function (continuous) as Dt → Lt, whereas the one-year effect of treatment on IV
days is defined as Dt → Vt+1. As such, there is always one extra year of data available
for the lung function outcome in the UK CF Registry, and we keep this consistent in the
simulation study.
As detailed in Section 4.5.1, it is more complicated to calculate the cumulative effect of
treatment when there is an interaction term with a time-varying variable included in the
models. However, it is possible to do this for all methods when the outcome is continu-
ous, and therefore in this case, we do present the results of the cumulative interaction
terms per 10 change in Lt−1:
E
(
LDs=1,Dt=0s
∣∣∣Lt−1 = 10)− E(LDs=1,Dt=0s ∣∣∣Lt−1 = 0) = 10 s−t+1∑
i=1
φinti , (5.16)
where s− t + 1 = 1, ..., 5.
For the count outcome, in g-estimation, it is not possible to give one cumulative inte-
raction effect, and therefore for the count outcome, rather than the cumulative effects, we
present each separate interaction effect estimate per 14 day change in Vt (equivalent to
a 2-week course of IVs): 14ψinti (i = 1, ..., 4). Similarly, although it would be possible to
give the cumulative interaction effect estimates in HA-MSM, for comparison purposes,
we will present the separate interaction effects 14βinti (for the zero count process) and
14γinti (for the rate of the count).
We compare the methods in terms of the bias, empirical SE and mean squared error.
Although it is known that the model-based SEs are biased for most of these methods, we
will also store the estimated robust SEs so as to compare them to the empirical SEs. We
also count the number of simulated datasets for which each method failed to converge.
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5.5 Results of Simulation Studies
In the following two subsections we present the results of the simulation studies for the
continuous and count outcomes respectively.
5.5.1 Continuous Outcome
Figure 5.5 shows kernel density plots showing the results of the simulation studies for
the conditionally normally-distributed continuous outcome. Table 5.3 presents the same
results, showing the number of simulated datasets for which an estimate was obtained,
the mean effect estimate, the bias, the empirical SE, the model-based SE and the mean
squared error (MSE). We only present results for the one-year effect and the five-year
effect to show the two extremes of short- to long-term effects. In all cases, the results
for the two- to four-year effects followed the trend between the one-year and five-year
effects. The results can be seen in full in Figure C.1 and Tables C.1 and C.2 of Appendix
C.
Almost all methods appear to provide consistent estimators in the ‘standard’ scenario
where all the models are correctly specified. The only method which performs poorly
here is IPW of MSM with truncation of extreme weights, but this is to be expected as it
is known that due to truncation of the weights this method no longer fully accounts for
confounding. The five-year treatment effect estimates are slightly biased, but when using
a much larger sample size all methods were unbiased, therefore we believe this residual
bias is due to the sample size, which we have kept at 7500 individuals as it is unlikely
that we would ever obtain a larger sample from the UK CF Registry.
These findings are repeated for the scenarios where there is no treatment effect, where
the treatment effect decreases over time and where there is censoring (provided that cen-
soring weights are used for IPW, HA-MSM and g-estimation).
For the scenario where the causal pathway between a confounder and treatment is rever-
sed and the assumed direction is incorrect in the analysis, we find that the situation is
the opposite: all methods are biased, but IPW and HA-MSM perform comparatively well
when the weights are truncated. However, untruncated they perform very poorly with
very large variability and even fail to converge in many simulated datasets.
When considering effect modification by time-varying covariates, all the methods can
still be used to provide an estimate for the population-average effect. For the one-year
effects all the methods appeared to provide consistent estimators, however at five-years
there was some noticeable bias for g-estimation and HA-MSM. These are the two met-
hods which can incorporate the estimation of effect modification by time-varying co-
variates, and not including these interactions terms when they are in fact present has
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introduced bias. Conversely, although IPW and g-formula cannot estimate interaction
terms, they do not assume that there is no effect modification and can therefore provide
consistent estimators for the population-average effect.
If the aim is to estimate the extent of any effect modification by time-varying covariates,
then it would be necessary to use HA-MSM, SCMM, or g-estimation and these results for
the one- and five- year effects are presented in Figure 5.6 and Table 5.4. (The two-, three-
and four-year effect results are given in Figure C.2 and Tables C.3 and C.3 of Appendix C).
We see that in the case where is no treatment effect all three methods correctly estimate no
interaction effect on average. However, in the scenario where there is a treatment effect,
but no effect modification, incorrectly including the interaction terms in these models has
introduced bias, and the methods estimate that there is some effect modification. When
there is effect modification and hence including the interaction term is correct, then all
three methods perform similarly well in estimating the strength of the effect modification.
When considering the SE, only in SCMM and HA-MSM did the model-estimated SEs ap-
proximate the empirical SEs. This is theoretically known in the case of SCMM with the
propensity score known, and therefore the model-based SEs will be approximately cor-
rect when the propensity score is well estimated. In the case of HA-MSM, we believe this
to be a peculiarity of our simulation setting and it is unlikely to be true generally. For this
reason, for all methods other than SCMM, a bootstrap procedure should be used to obtain
reliable estimates of the SEs. Comparing the methods, g-formula consistently shows the
smallest empirical SEs, followed by SCMM, g-estimation and HA-MSM with similar SEs,
and finally IPW with the largest SEs. In the scenario of reversed causal pathways, IPW
and HA-MSM had especially large SEs when untruncated weights were used.
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FIGURE 5.5: Kernel density plots of population-average effect estimates
for a continuous outcome (The vertical line shows the correct effect)
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FIGURE 5.6: Kernel density plots of the interaction effect estimates for a
continuous outcome (The vertical line shows the correct effect)
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Scenario Method n 1 Year Treatment Effect (φ1) Cumulative 5 Year Treatment Effect (∑
5
i=1 φi)
Mean Bias Empirical SE Model SE MSE Mean Bias Empirical SE Model SE MSE
Standard
φ1 = 4.00
∑51 φi =
20.00
IPW of MSM 1000 3.94 -0.057 0.20 0.39 0.044 19.82 -0.18 0.87 1.05 0.79
IPW of MSM (truncated) 1000 3.63 -0.37 0.20 0.38 0.18 18.66 -1.34 0.86 1.01 2.53
HA-MSM 1000 4.02 -0.020 0.21 0.21 0.044 20.13 0.13 0.70 0.73 0.50
HA-MSM (truncated) 1000 3.99 -0.007 0.21 0.21 0.042 19.81 -0.19 0.68 0.72 0.50
SCMM 1000 3.97 -0.027 0.14 0.14 0.020 NA NA NA NA NA
G-Formula 1000 3.96 -0.038 0.15 0.15 0.025 19.62 -0.38 0.58 0.33 0.49
G-Estimation 1000 3.97 -0.027 0.14 0.14 0.020 20.12 0.12 0.69 1.19 0.49
No Effect
φ1 = 0.00
∑51 φi =
0.00
IPW of MSM 1000 -0.020 -0.020 0.21 0.39 0.044 0.050 0.005 0.92 1.08 0.85
IPW of MSM (truncated) 1000 -0.32 -0.32 0.21 0.38 0.14 -1.09 -1.09 0.90 1.04 2.01
HA-MSM 1000 -0.006 -0.006 0.22 0.22 0.047 -0.029 -0.029 0.72 0.73 0.53
HA-MSM (truncated) 1000 -0.011 -0.011 0.21 0.22 0.046 -0.35 -0.35 0.72 0.72 0.64
SCMM 1000 -0.007 -0.007 0.15 0.14 0.024 NA NA NA NA NA
G-Formula 1000 -0.014 -0.014 0.16 0.15 0.026 -0.008 -0.008 0.61 0.33 0.37
G-Estimation 1000 -0.007 -0.007 0.15 0.14 0.024 -0.006 -0.006 0.75 1.22 0.56
Decreasing
Effect
φ1 = 3.50
∑51 φi =
13.03
IPW of MSM 1000 3.46 -0.039 0.21 0.39 0.046 13.02 -0.007 0.89 1.05 0.79
IPW of MSM (truncated) 1000 3.15 -0.35 0.21 0.38 0.16 11.87 -1.16 0.88 1.01 2.12
HA-MSM 1000 3.42 -0.082 0.21 0.22 0.052 13.51 0.48 0.71 0.73 0.73
HA-MSM (truncated) 1000 3.40 -0.098 0.21 0.21 0.053 13.18 0.15 0.70 0.72 0.51
SCMM 1000 3.48 -0.016 0.14 0.14 0.021 NA NA NA NA NA
G-Formula 1000 3.48 -0.023 0.16 0.15 0.062 12.76 -0.27 0.61 0.33 0.44
G-Estimation 1000 3.48 -0.016 0.14 0.14 0.021 13.12 0.088 0.72 1.19 0.53
Effect Mo-
dification
φ1 = 1.97
∑51 φi =
9.34
IPW of MSM 1000 1.96 -0.008 0.21 0.38 0.043 9.34 -0.0002 0.77 0.90 0.59
IPW of MSM (truncated) 1000 1.65 -0.32 0.21 0.37 0.14 8.34 -1.00 0.76 0.86 1.58
HA-MSM 1000 1.94 -0.029 0.20 0.22 0.041 10.31 0.97 0.67 0.67 1.39
HA-MSM (truncated) 1000 1.91 -0.057 0.20 0.21 0.043 9.90 0.56 0.66 0.66 0.76
SCMM 1000 1.97 -0.004 0.15 0.14 0.022 NA NA NA NA NA
G-Formula 1000 1.92 -0.054 0.15 0.14 0.026 9.27 -0.067 0.57 0.30 0.33
G-Estimation 1000 1.97 -0.004 0.15 0.14 0.022 10.03 0.69 0.67 1.12 0.92
Reversed
Causal
Pathway
φ1 = 4.67
∑51 φi =
20.38
IPW of MSM 942 -31.45 -36.12 19.36 3.37 1679.12 32.14 11.76 20.64 5.01 563.79
IPW of MSM (truncated) 1000 4.85 0.19 0.24 0.43 0.090 19.03 -1.35 0.99 1.15 2.80
HA-MSM 926 -4.62 -9.29 10.18 2.54 189.74 23.44 3.06 8.19 2.97 76.34
HA-MSM (truncated) 1000 4.65 -0.022 0.21 0.22 0.043 19.09 -1.29 0.71 0.73 2.16
SCMM 1000 4.00 -0.67 0.15 0.14 0.46 NA NA NA NA NA
G-Formula 1000 4.00 -0.67 0.16 0.15 0.47 18.25 -2.13 0.58 0.32 4.89
G-Estimation 1000 4.00 -0.67 0.15 0.14 0.46 18.18 -2.20 0.71 1.23 5.36
C
hapter
5.
Sim
ulation
Studies
to
A
ssess
the
Perform
ance
ofStatisticalM
ethods
93
Scenario Method n 1 Year Treatment Effect (φ1) Cumulative 5 Year Treatment Effect (∑
5
i=1 φi)
Mean Bias Empirical SE Model SE MSE Mean Bias Empirical SE Model SE MSE
Censoring
φ1 = 4.00
∑51 φi =
20.00
IPW of MSM 1000 3.94 -0.058 0.23 0.45 0.058 19.20 -0.80 1.49 1.59 2.86
IPW of MSM (truncated) 1000 3.63 -0.37 0.23 0.43 0.19 17.94 -2.06 1.46 6.38 1.54
HA-MSM 1000 4.02 0.018 0.24 0.25 0.058 19.69 -0.31 1.17 1.46 1.16
HA-MSM (truncated) 1000 3.99 -0.011 0.24 0.056 0.25 19.27 -0.73 1.15 1.14 1.87
SCMM 1000 3.97 -0.035 0.16 0.17 0.027 NA NA NA NA NA
G-Formula 1000 3.96 -0.041 0.18 0.17 0.035 19.33 -0.67 0.76 0.55 1.02
G-Estimation 1000 3.97 -0.035 0.16 0.17 0.027 19.70 -0.30 1.10 1.68 1.31
TABLE 5.3: Simulation study results of population-average effects for continuous outcome (Dt → Lt) (NA signifies that the
method does not estimate that effect)
Scenario Method n 1 Year Interaction Effect (10φint1 ) Cumulative 5 Year Interaction Effect (10∑
5
i=1 φinti )
Mean Bias Empirical SE Model SE MSE Mean Bias Empirical SE Model SE MSE
No Effect
10φint1 = 0.00
10∑51 φinti = 0.00
HA-MSM 1000 0.003 0.003 0.088 0.087 0.008 0.088 0.088 0.29 0.30 0.092
HA-MSM (truncated) 1000 0.004 0.004 0.086 0.085 0.007 0.19 0.19 0.29 0.30 0.12
SCMM 1000 -0.0002 -0.0002 0.060 0.060 0.004 NA NA NA NA NA
G-Estimation 1000 -0.0002 -0.0002 0.060 0.060 0.004 0.009 0.009 0.28 0.46 0.080
Standard (no effect
modification)
10φint1 = 0.00
10∑51 φinti = 0.00
HA-MSM 1000 -0.009 -0.009 0.084 0.085 0.007 -0.63 -0.63 0.30 0.30 0.48
HA-MSM (truncated) 1000 -0.004 -0.004 0.081 0.083 0.007 -0.52 -0.52 0.29 0.30 0.35
SCMM 1000 0.018 0.018 0.054 0.058 0.003 NA NA NA NA NA
G-Estimation 1000 0.018 0.018 0.054 0.058 0.003 -0.69 -0.69 0.29 0.45 0.56
Effect Modification
10φint1 = −0.80
10∑51 φinti = −2.80
HA-MSM 1000 -0.75 0.050 0.085 0.087 0.010 -3.06 -0.26 0.27 0.27 0.14
HA-MSM (truncated) 1000 -0.74 0.056 0.084 0.085 0.010 -2.95 -0.15 0.27 0.27 0.096
SCMM 1000 -0.78 0.022 0.061 0.060 0.004 NA NA NA NA NA
G-Estimation 1000 -0.78 0.022 0.061 0.060 0.004 -2.79 0.012 0.28 0.39 0.077
TABLE 5.4: Simulation study results of interaction effects for continuous outcome. Results show change in effect of Dt on Lt per
10 change in Lt−1 (NA signifies that the method does not estimate that effect)
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5.5.2 Count Outcome
Unlike with the continuous outcome, due to the issue of non-collapsibility, we do not
compare the effect estimates for the count outcome to a ‘correct’ value. However, Figures
5.7 and 5.8, and Tables 5.5 and 5.6 present the one- and four-year effect estimates and SEs
for both the odds of a zero count and the rate of the count. As with the continuous out-
come, results for the two- and three- year effects can be found in Appendix C in Figures
C.3 and C.4, and Tables C.5 and C.6.
Both IPW and g-formula provide marginal effect estimates, and in almost all cases pro-
vide very similar estimates. The only scenario in which they do not provide similar es-
timates is the case of reversed causal pathways where IPW performs very poorly with
very large variability, as was also seen for the continuous outcome.
Considering the three methods which provide conditional effect estimates, (HA-MSM,
g-estimation and SCMM), we note that the methods are not in general in agreement, and
this is due to the fact that the final models condition on different subsets of variables. In
the case of g-estimation, due to the fact that the method can only estimate a rate, (rather
than also accounting for the separate process of excess zeroes), the estimates from this
method are generally very different from all other methods.
The only scenario in which all five methods are in agreement is when there is no tre-
atment effect. Here both the marginal and conditional effect estimates are zero. This
suggests that any method could be used to perform a test of the null hypothesis of no
treatment effect, but the strength of any effect estimates cannot directly be compared be-
tween methods.
The results for the one- and four-year interaction terms are presented in Figures 5.9 and
5.10, and Tables 5.7 and 5.8. (Appendix C contains the results for the two- and three-
year interaction effects in Figures C.5 and C.6, and Tables C.7 and C.8). The findings are
similar to those found in the case of interaction terms with continuous outcomes, except
for the results from g-estimation: even when there is no effect modification in the data
generation process, this method did not on average indicate no effect modification. This
is again due to non-collapsibility, where although there is no effect modification present
when assuming the outcome follows a zero-inflated negative binomial distribution, there
may be under different outcome models.
As we found for the continuous outcome the model estimated SEs from HA-MSM and
SCMM approximated the empirical SEs well, but again we would recommend a boot-
strap procedure to be used for all methods other than SCMM.
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FIGURE 5.7: Kernel density plots of the population-average effect estima-
tes for the odds of a zero count
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FIGURE 5.8: Kernel density plots of the population-average effect estima-
tes for the rate of a count
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FIGURE 5.9: Kernel density plots of the interaction effect estimates for the
odds of a zero count
FIGURE 5.10: Kernel density plots of the interaction effect estimates for the
rate of a count
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Scenario Estimate Method n
1 Year Treatment Effect
Log OR of Zero Count (β1) Log IRR of Count (γ1)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Standard
Marginal
IPW of MSM 1000 1.28 0.033 0.040 -0.56 0.037 0.038
IPW of MSM (truncated) 1000 1.27 0.033 0.039 -0.55 0.037 0.038
G-Formula 1000 1.28 0.031 0.016 -0.57 0.026 0.017
Conditional
HA-MSM 1000 1.63 0.043 0.045 -0.67 0.023 0.024
HA-MSM (truncated) 1000 1.64 0.043 0.045 -0.67 0.023 0.023
SCMM 1000 2.08 0.057 0.060 -0.82 0.025 0.024
G-Estimation 1000 NA NA NA -2.28 0.063 0.016
No Effect
Marginal
IPW of MSM 1000 -0.0007 0.028 0.035 0.003 0.019 0.022
IPW of MSM (truncated) 1000 -0.011 0.028 0.035 0.014 0.018 0.020
G-Formula 1000 -0.001 0.026 0.012 0.002 0.015 0.008
Conditional
HA-MSM 1000 -0.0008 0.037 0.039 0.001 0.015 0.016
HA-MSM (truncated) 1000 0.0005 0.037 0.039 0.001 0.015 0.0169
SCMM 1000 -0.0007 0.047 0.048 0.0004 0.016 0.017
G-Estimation 1000 NA NA NA 0.002 0.030 0.016
Decreasing
Effect
Marginal
IPW of MSM 1000 1.12 0.032 0.038 -0.49 0.033 0.034
IPW of MSM (truncated) 1000 1.11 0.033 0.038 -0.48 0.033 0.033
G-Formula 1000 1.12 0.029 0.015 -0.50 0.022 0.015
Conditional
HA-MSM 1000 1.39 0.041 0.042 -0.55 0.021 0.022
HA-MSM (truncated) 1000 1.40 0.041 0.042 -0.56 0.021 0.022
SCMM 1000 1.82 0.057 0.055 -0.72 0.022 0.022
G-Estimation 1000 NA NA NA -1.94 0.055 0.016
Effect
Modification
Marginal
IPW of MSM 1000 0.92 0.034 0.039 -0.96 0.030 0.031
IPW of MSM (truncated) 1000 0.91 0.034 0.039 -0.95 0.028 0.029
G-Formula 1000 0.92 0.030 0.014 -0.72 0.023 0.010
Conditional
HA-MSM 1000 1.11 0.041 0.042 -0.75 0.026 0.027
HA-MSM (truncated) 1000 1.11 0.041 0.042 -0.076 0.026 0.026
SCMM 1000 1.33 0.052 0.052 -0.84 0.028 0.029
G-Estimation 1000 NA NA NA -1.24 0.049 0.016
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Scenario Estimate Method n
1 Year Treatment Effect
Log OR of Zero Count (β1) Log IRR of Count (γ1)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Reversed
Causal
Pathway
Marginal
IPW of MSM 758 -2.09 2.71 0.48 0.96 0.86 0.10
IPW of MSM (truncated) 1000 1.21 0.051 0.058 -0.37 0.088 0.089
G-Formula 1000 1.06 0.042 0.017 -0.41 0.033 0.014
Conditional
HA-MSM 727 1.19 0.29 0.14 -0.11 0.50 0.37
HA-MSM (truncated) 1000 1.35 0.049 0.049 -0.47 0.032 0.032
SCMM 1000 1.42 0.060 0.061 -0.54 0.034 0.036
G-Estimation 1000 NA NA NA -1.72 0.071 0.016
Censoring
Marginal
IPW of MSM 1000 1.30 0.044 0.050 -0.60 0.033 0.034
IPW of MSM (truncated) 1000 1.27 0.043 0.049 -0.59 0.032 0.033
G-Formula 1000 1.32 0.042 0.020 -0.60 0.029 0.017
Conditional
HA-MSM 1000 1.70 0.059 0.059 -0.68 0.031 0.030
HA-MSM (truncated) 1000 1.71 0.059 0.058 -0.69 0.029 0.028
SCMM 1000 2.08 0.082 0.081 -0.81 0.034 0.034
G-Estimation 1000 NA NA NA -2.29 0.083 0.082
TABLE 5.5: Simulation study results of one-year population-average effects for count outcome (Dt → Vt+1) (NA signifies that the
method does not estimate that effect)
Scenario Estimate Method n
Cumulative 4 Year Treatment Effect
Log OR of Zero Count (∑4i=1 βi) Log IRR of Count (∑
4
i=1 γi)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Standard
Marginal
IPW of MSM 1000 3.13 0.16 0.16 -1.27 0.15 0.14
IPW of MSM (truncated) 1000 3.08 0.16 0.16 -1.22 0.17 0.15
G-Formula 1000 3.12 0.11 0.067 -1.27 0.085 0.067
Conditional
HA-MSM 1000 3.71 0.17 0.17 -1.39 0.11 0.11
HA-MSM (truncated) 1000 3.68 0.17 0.17 -1.37 0.11 0.10
G-Estimation 1000 NA NA NA -4.30 0.19 0.042
No Effect
Marginal
IPW of MSM 1000 -0.0007 0.071 0.075 0.006 0.047 0.053
IPW of MSM (truncated) 1000 -0.042 0.071 0.074 0.042 0.045 0.048
G-Formula 1000 -0.002 0.056 0.027 0.001 0.030 0.018
Conditional
HA-MSM 1000 -0.002 0.073 0.074 0.004 0.039 0.041
HA-MSM (truncated) 1000 -0.012 0.073 0.074 0.013 0.038 0.039
G-Estimation 1000 NA NA NA 0.0006 0.058 0.042
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Scenario Estimate Method n
Cumulative 4 Year Treatment Effect
Log OR of Zero Count (∑4i=1 βi) Log IRR of Count (∑
4
i=1 γi)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Decreasing
Effect
Marginal
IPW of MSM 1000 1.89 0.098 0.10 -0.79 0.074 0.076
IPW of MSM (truncated) 1000 1.84 0.097 0.099 -0.75 0.074 0.074
G-Formula 1000 1.88 0.077 0.040 -0.78 0.048 0.031
Conditional
HA-MSM 1000 2.37 0.11 0.11 -0.92 0.065 0.063
HA-MSM (truncated) 1000 2.35 0.11 0.11 -0.90 0.062 0.062
G-Estimation 1000 NA NA NA -2.46 0.12 0.042
Effect
Modification
Marginal
IPW of MSM 1000 1.75 0.097 0.098 -0.81 0.065 0.066
IPW of MSM (truncated) 1000 1.71 0.096 0.097 -0.78 0.058 0.060
G-Formula 1000 1.68 0.076 0.039 -0.56 0.042 0.025
Conditional
HA-MSM 1000 2.08 0.10 0.10 -0.82 0.060 0.058
HA-MSM (truncated) 1000 2.06 0.10 0.10 -0.81 0.058 0.057
G-Estimation 1000 NA NA NA -1.87 0.096 0.042
Reversed
Causal
Pathway
Marginal
IPW of MSM 758 10.69 60.95 1.76 -0.93 12.37 0.18
IPW of MSM (truncated) 1000 2.21 0.16 0.16 -0.76 0.13 0.12
G-Formula 1000 2.16 0.11 0.057 -0.74 0.069 0.042
Conditional
HA-MSM 727 3.13 2.19 0.65 -0.83 0.68 0.69
HA-MSM (truncated) 1000 2.44 0.15 0.15 -0.81 0.11 0.11
G-Estimation 1000 NA NA NA -2.63 0.16 0.043
Censoring
Marginal
IPW of MSM 1000 3.14 0.28 0.28 -1.21 0.19 0.18
IPW of MSM (truncated) 1000 3.01 0.27 0.27 -1.17 0.19 0.17
G-Formula 1000 3.12 0.18 0.11 -1.25 0.11 0.080
Conditional
HA-MSM 1000 3.68 0.28 0.29 -1.32 0.18 0.17
HA-MSM (truncated) 1000 0.28 0.28 0.28 -1.30 0.18 0.17
G-Estimation 1000 NA NA NA -4.32 0.31 0.32
TABLE 5.6: Simulation study results of four-year population-average effects for count outcome (Dt → Vt+1) (NA signifies that
the method does not estimate that effect)
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Scenario Estimate Method n
1 Year Interaction Effect
Log OR of Zero Count (14βint1 ) Log IRR of Count (14γint1 )
Mean Empirical SE Model SE Mean Empirical SE Model SE
No Effect Conditional
HA-MSM 1000 -0.002 0.038 0.039 -0.001 0.010 0.009
HA-MSM (truncated) 1000 -0.002 0.038 0.039 -0.0002 0.009 0.009
SCMM 1000 -0.005 0.080 0.079 -0.0009 0.010 0.010
G-Estimation 1000 NA NA NA -0.0009 0.013 0.015
Standard
(no effect
modification)
Conditional
HA-MSM 1000 -0.012 0.041 0.040 -0.003 0.012 0.011
HA-MSM (truncated) 1000 -0.009 0.040 0.039 -0.001 0.012 0.011
SCMM 1000 0.001 0.070 0.069 0.003 0.012 0.012
G-Estimation 1000 NA NA NA 0.25 0.028 0.016
Effect
Modification Conditional
HA-MSM 1000 0.15 0.039 0.039 -0.23 0.023 0.019
HA-MSM (truncated) 1000 0.15 0.038 0.038 -0.23 0.020 0.017
SCMM 1000 0.29 0.064 0.064 -0.28 0.014 0.013
G-Estimation 1000 NA NA NA -0.16 0.020 0.015
TABLE 5.7: Simulation study results of one-year interaction effects for count outcome. Results show change in effect of Dt on
Vt+1 per 14 day change in Vt (NA signifies that the method does not estimate that effect)
Scenario Estimate Method n
4 Year Interaction Effect
Log OR of Zero Count (14βint4 ) Log IRR of Count (14γint4 )
Mean Empirical SE Model SE Mean Empirical SE Model SE
No Effect Conditional
HA-MSM 1000 -0.004 0.060 0.059 0.005 0.025 0.023
HA-MSM (truncated) 1000 -0.006 0.060 0.058 0.006 0.024 0.023
G-Estimation 1000 NA NA NA -0.0005 0.030 0.024
Standard
(no effect
modification)
Conditional
HA-MSM 1000 0.060 0.098 0.092 -0.035 0.075 0.051
HA-MSM (truncated) 1000 0.058 0.097 0.092 -0.035 0.076 0.051
G-Estimation 1000 NA NA NA -0.015 0.10 0.026
Effect
Modification Conditional
HA-MSM 1000 0.012 0.077 0.074 -0.011 0.047 0.043
HA-MSM (truncated) 1000 0.009 0.076 0.074 -0.008 0.045 0.042
G-Estimation 1000 NA NA NA -0.070 0.072 0.025
TABLE 5.8: Simulation study results of four-year interaction effects for count outcome. Results show change in effect of Dt on
Vt+1 per 14 day change in Vt (NA signifies that the method does not estimate that effect)
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5.6 Discussion
In this chapter we have investigated the suitability of seven methods for estimating short-
and long-term treatment effects in longitudinal observational data using simulation stu-
dies. The focus was on five scenarios that could be encountered in the UK CF Registry.
Our simulation studies showed that all the methods could be suitable for analysing the
UK CF Registry data to investigate long-term treatment effects. Specifically in the stan-
dard scenario, where all models are correctly specified, all methods performed very si-
milarly. However, the main issue is that when analysing the real UK CF Registry data
we are not able to tell if the data are similar to the data simulated under the standard
scenario, or whether one of the other scenarios is more realistic.
In the case of IPW, for example, there were noticeable differences between the results
from applying the method with truncated and untruncated weights. In most scenarios,
the untruncated weights performed best, but in the situation of the direction of causal
pathways being misspecified the truncated weights showed much better performance.
In a real data analysis, we would not know which scenario we are in; it would therefore
be difficult to know when weights should be truncated or not. It may be sensible to only
truncate when there are ‘extreme’ weights, but there is no clear definition of how large a
weight must be before it is ‘extreme’. This would suggest, therefore, in situations where
there is uncertainty in the correct direction of causal pathways, that IPW not be used.
HA-MSM performed similarly to IPW of MSM in cases where there is no effect modifica-
tion, but as it is a more complex method, it would be preferable to use standard IPW of
MSM over HA-MSM in most cases.
For estimating the one-year effect of treatment, SCMM would probably be the preferred
method due to its good performance in the simulation studies and its simplicity to im-
plement. The obvious drawback is that the method cannot be used to estimate long-term
effects, but we recommend that this method be used alongside other methods to check
whether the more complex methods are in agreement with the one-year effect estimate
of the SCMM. In cases where the one-year effect estimate is markedly different between
SCMM and another method, this could act as a flag of potential issues with the analysis.
Another benefit of SCMM is that the model-based SEs will be approximately correct
when the propensity score is well estimated, meaning that the bootstrap does not need to
be used and results can be obtained much faster than using the other methods presented
in this paper. The asymptotic SEs have been derived for IPW of MSM, but only in a time-
fixed setting,[95] and the difficulty of deriving these in a longitudinal setting necessitates
the use of the bootstrap for all the methods other than SCMM.
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G-formula tended to perform as well as other methods, only performing poorly where
other methods also performed poorly. The SEs were consistently smaller than for ot-
her methods, which would always be preferable in cases where we are confident in the
specified models for the time-varying covariates. However, in cases where there is mis-
specification of these models the SEs remain small, and with real data it is unlikely that
all the assumptions necessary for g-formula would be completely correct, which could
result in a tight CI around an incorrect effect estimate. In our scenarios, we did not en-
counter any issue with the g-null paradox. This is because, for the g-null paradox to arise
it is necessary for treatment to affect a time-dependent confounder without having any
direct or indirect effect on the outcome.[103] In our ‘no effect scenario’ treatment had no
effect on either lung function or IV days which are acting as both the outcome and the
time-dependent confounders.
For continuous outcomes, g-estimation performed well with the SEs generally lying be-
tween those of g-formula and IPW, with the advantage that the method can also esti-
mate effect modification by time-varying covariates, without the drawbacks of unstable
weights which were sometimes observed in HA-MSM. However with the count outcome
g-estimation used a gamma model rather than the zero-inflated negative binomial mo-
del like the other methods presented in this paper. This made comparison with other
methods difficult. In situations where the count outcome is not as skewed as the annual
IV days in the UK CF registry data, g-estimation may be a suitable method, but in our
setting the other methods were generally preferable. A further complexity of the count
outcome is the issue of non-collapsibility. In the simulations we found that when there
is truly no treatment effect, both marginal and conditional estimates were correctly con-
sistent with there being no treatment effect. However, in cases where there is a treatment
effect, comparison between marginal and conditional estimates is not appropriate.
In most settings, more than one of the available methods would be suitable for the types
of investigation considered in this paper. However, the results of the simulation studies
suggest that IPW of MSM and HA-MSM will perform particularly poorly if the direction
of the causal pathways is misspecified. This is a potential issue in the UK CF Registry due
to that way that some data are collected. Therefore, even though we will still consider
using these methods in the next chapter, it would not be unexpected if the results from
these two methods are inconsistent with the results from other methods.
In conclusion, in many cases it may be beneficial to consider using more than one avai-
lable method, to see if the results are consistent. Of course, in cases where two methods
give the same effect estimate, this does not mean it is correct, but does add some reli-
ability to the results. In cases where the methods gave very different effect estimates,
this would act as a flag to re-examine the data, the assumptions of the methods and the
suitability of the analyses performed.
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Chapter 6
Estimating the Effects of Long-Term
Dornase Alfa Use
6.1 Introduction
In Chapter 3 we performed a systematic review of studies that have investigated the
effects of DNase. In a phase III clinical trial, using DNase over 24 weeks was shown
to improve ppFEV1 and reduce the risk of exacerbations.[49] Subsequently, a number
of studies have examined the effect of longer-term use of DNase. For example, after 96
weeks of follow-up, DNase was shown to statistically significantly improve lung function
and reduce the risk of respiratory tract infections in children aged 6 to 10.[61, 63]
Most studies have focused on the absolute effect of DNase on lung function over a spe-
cified time period, i.e. on a step-change effect. Its impact on the rate of lung function
decline is also important and this has been investigated in two studies. These studies
showed that during DNase use the rate of lung function decline was less than the rate
of decline in the same patients prior to starting treatment and also less than the rate of
decline in a comparator group of patients who never received treatment.[64, 75]
Only one study has attempted to evaluate the impact of using DNase for more than two
years. This was a study with 76 patients and it was found that those receiving treatment
over four years had a more gradual slope of decline in lung function and also suffered
fewer exacerbations per year.[60]
In this chapter, we use the UK CF Registry to investigate the effects of one-, two-, three-,
four- and five-years of DNase use on lung function and annual number of IV days. Long-
term effects of treatment are particularly important for lung function as the hope is that
treatments can modify the overall lung-function trajectory rather than just providing a
one-off increase.[69, 104] Figure 5.2 in Chapter 5 shows two hypothetical lung-function
trajectories for an individual treated with DNase compared to the lung-function trajec-
tory of someone not receiving treatment. These trajectories show how treatment could
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either be disease modifying, where the lung function of those receiving treatment con-
tinues to grow wider apart from the lung function of those not receiving treatment, or
alternatively how the overall lung-function trajectory could remain unchanged after an
initial increase.
Furthermore, we aimed to investigate whether there is evidence that treatment is more
effective in younger people, as has previously been reported.[64] We also hypothesised
that the effect of DNase on lung function may differ depending on lung function, and
that its effect on IV days may differ depending on previous number of IV days.
For the main analysis, we have the choice of the five methods that were introduced in
Chapter 4: IPW of MSM, HA-MSM, g-formula, g-estimation and SCMM. The simulation
studies from Chapter 5 suggest that any of the methods could be used with little diffe-
rence between the methods if all assumptions and models are correct. SCMM can only
be used in our setting to estimate the effect of using DNase for one-year. However, it is
the simplest method and can be supplemented by a test for evidence of any longer-term
effects. All of the other methods can be used to estimate long-term effects, but in the case
of IPW of MSM and g-formula they can only be used to estimate population-average
effects, and therefore these methods cannot be used when we wish to investigate effect
modification by a time-varying covariate. In this chapter, we will present the results from
all available methods, as any major differences between the results from different met-
hods would suggest potential violation of the assumptions made and inform subsequent
investigations.
The work from this chapter formed the basis of a paper published in the Journal of Cystic
Fibrosis in August 2018. A copy of this paper can be found in Appendix D.
6.2 Methods
6.2.1 UK Cystic Fibrosis Registry
The UK CF Registry was introduced in Chapter 2. For this analysis, we use annual review
data from 2007 to 2015. At each annual assessment, the treatment section records whether
a person has been receiving DNase since the last annual assessment. Although there is
space to record a start date, this is not reliably collected, and for this analysis we assume
that they have been receiving DNase since their last assessment.
People were eligible for inclusion in the study if they had at least two consecutive years
of data in the registry between 2007 and 2015, had not received DNase prior to 2007,
were not receiving DNase at their first visit, were at least six years old, had lung function
data for at least two consecutive visits and had not received a lung transplant. The first
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visit for everyone was therefore at a time when they were not and had never before been
recorded to have received DNase treatment. Follow-up data were collected up to 2015 if
available, or the most recent annual assessment otherwise. Figure 6.1 shows a flow chart
of the number of people included and excluded from the study population.
The primary outcome is change in lung function expressed as absolute change over time
in ppFEV1 calculated using the GLI equations.[16] The secondary outcome was change in
rate of IV Days. Sensitivity analyses for lung function were also conducted with ppFVC
and ppFEF25−75. The results of the sensitivity analyses are included in Appendix E.
As well as previous measures of the outcomes and DNase, we also adjusted for the fol-
lowing time-varying covariates: other muco-active treatments, smoking status, CFRD,
and pseudomonas infection; and the following non-time-varying variables: baseline age,
gender, ethnicity and genotype class. These were identified from the data collected in the
registry as variables that could affect both outcomes and the decision to initiate DNase.
6.2.2 Statistical Methods
In a preliminary exploration of the data, baseline covariates, i.e. those measured at the
first visit, were summarised overall and separately for those who never received DNase
during subsequent follow-up and those who received DNase for at least one year. Base-
line covariates were also summarised in the subgroups of those who received DNase for
at least five years and people who stopped DNase during follow-up. Time-varying cova-
riates were summarised at the first visit, and separately at visits when people were not
receiving DNase, the first visit when people received treatment, subsequent visits among
people receiving treatment and visits after people stopped treatment.
We start the main analysis by estimating the effect of one year of treatment using SCMM.
As well as estimating the population average effect, we also allow modification of the
treatment effect by baseline age or by previous lung function with both linear interaction
terms and restricted cubic splines. Subsequent to this, we perform a test to assess the
existence of longer-term effects. We then use IPW of MSM, HA-MSM, g-formula and g-
estimation to estimate the effects of long-term DNase use. All four methods are used to
estimate the population-average effects, and HA-MSM and g-estimation are also used to
assess whether there was modification of the treatment effect.
The potential confounding variables listed above were included in all possible models,
i.e. the same variables were included in the propensity score models, the censoring mo-
dels and the final models for all methods. The only exception to this was in the case
of g-formula, where due to the complexity of the method when there are many time-
varying covariates, each of which would need a parametric model, the only time-varying
confounders adjusted for were previous levels of lung function and IV days.
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Total people in Registry since 2007
n = 11, 083 Exclusions
Received transplant before 2007
n = 166
Aged less than 6
n = 1, 284
Receiving DNase at first visit
n = 3, 260
Missing lung function data
n = 985
People with only one visit
n = 1, 190
People included in analysis
n = 4, 198
Never used DNase
n = 1, 814
DNase use ≥ 1 year
n = 2, 384
DNase use ≥ 2 years
n = 1, 741
DNase use ≥ 3 years
n = 1, 339
DNase use ≥ 4 years
n = 1, 050
DNase use ≥ 5 years
n = 787
FIGURE 6.1: Flowchart of people included in DNase analysis
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The majority of the additional covariates included in the models were binary: the use
of other muco-active treatments, CFRD, pseudomonas infection, gender, and ethnicity.
The last of which marking whether an individual was white or not. Genotype class is a
variable with three levels: high, low, and not assigned. Smoking has four levels: none
smoker, occasional smoker, smokes less than one packet per day, and smokes at least one
packet per day. Some of these variables have missing data, and so as not to drop variables
a missing category was also included for those variables. Previous DNase use was also
adjusted for as a categorical variable equal to the sum of the total numbers of years that
an individual has used treatment for prior to the current year.
The three continuous variables, baseline age, annual number of IV days and ppFEV1,
were included in the models using restricted cubic splines with four knots. However, for
the models which considered interaction terms with these variables, we present models
using linear terms to ease interpretability.
All analyses were performed using Stata (Version 15). SEs were estimated using a non-
parametric bootstrap with 5000 resamples for all methods except for SCMM, where the
model-based SEs were used.[105]
The following five subsections give further details of how each method was implemented
for the continuous outcome, ppFEV1. For IV days, the same methods were applied with
the alterations for count outcomes as detailed in Chapter 4. We refer to DNase treatment
as a binary variable, D, lung function as a continuous variable, L, IV days as a time-
varying confounder, V, and age as a baseline confounder, A. We do not include other
time-varying and baseline confounders in the equations below for conciseness, but they
are all incorporated into the following models in the same way as V and A respectively.
The rest of the notation is the same as detailed in Section 4.1.1.
Sequential Conditional Mean Models
First, we estimate the propensity score:
pt = P
(
Dt = 1
∣∣∣Dt−1, Lt−1, Vt, A) = expit(γ0 + γdDt−1 + γl Lt−1 + γvVt + γa A). (6.1)
Then we fit the SCMM:
E
(
Lt
∣∣∣Dt, Lt−1, Vt, A, pt) =
β0 +
t−1
∑
j=1
βdj Dj + βl Lt−1 + βvVt + βa A + βp pt + φ1Dt.
(6.2)
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We also fit additional models to investigate effect modification. In these cases, the desired
interaction terms are included with treatment and also with the propensity score. The
first model investigates effect modification by baseline age:
E
(
Lt
∣∣∣Dt, Lt−1, Vt, A, pt) =
β0 +
t−1
∑
j=1
βdj Dj + βl Lt−1 + βvVt + βa A + βp pt + βi2 pt A + φ1Dt + φinta Dt A.
(6.3)
The second model investigates effect modification by previous lung function:
E
(
Lt
∣∣∣Dt, Lt−1, Vt, A, pt) =
β0 +
t−1
∑
j=1
βdj Dj + βl Lt−1+βvVt + βa A + βp pt + βi2 ptLt−1 + φ1Dt + φint1 DtLt−1.
(6.4)
Finally, we test for evidence of longer-term effects by obtaining the predicted counterfac-
tual, Lˆdt=0t , as the fitted value from Equation 6.2 with Dt set to 0. We then fit the following
model to see if there is any residual associated between these counterfactuals and previ-
ous treatment:
E
(
Dt−1
∣∣∣Dt−2, Lt−1, Vt−1, A, Lˆdt=0t ) =
expit
(
γ0 + γlˆ Lˆ
dt=0
t + γA A +
t−2
∑
j=0
γdDj + γl Lj + γVVj+1
)
.
(6.5)
Inverse Probability Weighting of Marginal Structural Models
We calculate the stabilised weights:
SWt =
P
(
Dt
∣∣∣Dt−1, A)
P
(
Dt
∣∣∣Dt−1, Lt−1, Vt, A) =
t
∏
i=1
P
(
Di
∣∣∣Di−1, A)
P
(
Di
∣∣∣Di−1, Li−1, Vi, A) , (6.6)
where the denominator is estimated as given in Equation 6.1 and the numerator similarly
estimated by removing Yt−1 and Vt from the model.
We also incorporate censoring weights, which are calculated as follows, and then multi-
plied by the stabilised weights to create the weights to be used for the MSM.
CWt =
P
(
Ct = 0
∣∣∣A)
P
(
Ct = 0
∣∣∣Dt−1, Lt−1, Vt−1, A) =
t
∏
i=1
P
(
Ci
∣∣∣A)
P
(
Ci
∣∣∣Di−1, Li−1, Vi−1, A) . (6.7)
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Population average effects are then estimated by fitting the following MSM:
E
(
Ld¯tt
∣∣∣A) = β0 + βa A + t∑
j=1
φjDj. (6.8)
This method is used with both non-truncated and truncated weights, where in the latter
case the weights are truncated to the 1 and 99 percentile.
History-Adjusted Marginal Structural Models
The stabilised weights for HA-MSM are calculated similarly to those given above, except
that the multiplication of the weights is not done from visit 1, but rather for time from
the visit directly after exposure, t + 1, up to and including the time of the outcome, s.
SWts =
s
∏
i=t+1
P
(
Di
∣∣∣Di−1, A)
P
(
Di
∣∣∣Di−1, Li−1, Vi, A) , (6.9)
where s− t + 1 ≤ 5.
The censoring weights are also calculated equivalently:
CWts =
s
∏
i=t+1
P
(
Ci
∣∣∣A)
P
(
Ci
∣∣∣Di−1, Li−1, Vi−1, A) . (6.10)
The HA-MSM, given below, is then weighted by the product of the stabilised and censo-
ring weights:
E
(
Ld¯ss
∣∣∣dt−1, lt−1, vt, a) = β0 + βaa + βvvt + t−1∑
j=1
βdj Dj + βl lt−1 +
s
∑
j=t
φjdj. (6.11)
The interaction effect of interest can also be incorporated into the above equation, e.g. by
adding
s
∑
j=t
φintj djlt−1
to the model given above.
Similarly to IPW of MSM, this method is used with both non-truncated and truncated
weights, where in the latter case the weights are truncated to the 1 and 99 percentile.
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G-Computation Formula
For g-formula, a parametric model needs to be specified for all time-varying covariates.
Because of this complication, unlike with the other methods, where we included a num-
ber of time-varying covariates, in g-formula, we only consider the two most important
time-varying covariates, lung function and annual IV days. These two variables are mo-
delled as follows:
E
(
Vt
∣∣∣Dt−1, Lt−1, Vt−1, A) =
expit
(
γ0 + γd1 Dt−1 +
t−2
∑
j=1
γdj Dj + γl Lt−1 + γVVt−1 + γa A
)
exp
(
δ0 + δd1 Dt−1 +
t−2
∑
j=1
δdj Dj + δl Lt−1 + δVVt−1 + δa A
)
,
(6.12)
E
(
Lt
∣∣∣Dt, Lt−1, Vt, A) = β0 + βd1 Dt + t−1∑
j=1
βdj Dj + βl Lt−1 + βVVt + βa A. (6.13)
For every individual, we simulate all the monotonic trajectories, whereby people can
only start treatment and, once initiated, treatment is continued until the end of follow-
up. The simulated counterfactual outcomes from the different treatment trajectories are
then compared with a MSM:
E
(
Ld¯tt
)
= β0 +
t
∑
i=1
φidi. (6.14)
G-Estimation of Structural Nested Models
We estimate the propensity score as in Equation 6.1 and the censoring weights as in Equa-
tion 6.10. Then we estimate the one-year effect:
E
(
Ls
∣∣∣Ds, Ls−1, Vs, A, ps) =
βs + βds−1 Ds−1+βls−1 Ls−1 + βVs Vs + βaa + βps ps + φ1Ds.
(6.15)
The following two steps are then iterated four times to sequentially estimate the coun-
terfactuals of what the outcome would have been if people had not received treatment
between visits t and s, where s− t + 1 ≤ 5:
Hsj = Ls −
s
∑
u=j+1
φs−u+1Du, (6.16)
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E
(
Hsj
∣∣∣Dj, Lj−1, V j, A, pj) =
s
∑
i=t
z
(
βi + βdi Dj−1 + βli Lj−1 + βvi Vj + βai A + βpi pj + φs−i+1Dj
)
,
(6.17)
where z = 1 if i = j and 0 otherwise.
Interaction terms can also be incorporated into Equations 6.15, 6.16 and 6.17. When a
time-varying interaction term is included, then the cumulative treatment effect can be
estimated by following the procedure given in Section 4.5.1.
6.3 Results
Overall, 4,198 people were included in the analysis, with a combined total of 26,363 an-
nual assessments. The median number of follow-up visits per person was 6 (IQR 4-8).
During follow-up, 2,384 (56.8%) people received DNase for at least one year, and most pe-
ople who started using DNase continued to receive it indefinitely, with only 441 (18.5%)
people stopping during follow-up. In total, 821 (34.5%) people had five or more consecu-
tive years of DNase use.
Table 6.1 summarises the variables that were considered as confounders for the main
analysis. When looking at this summary of the data, we found that those taking DNase
tend to have worse disease. This is expected, because those needing treatment are ex-
pected to be in worse health. This finding is part of the phenomenon of confounding by
indication. Particularly, the mean ppFEV1 measured prior to visits when people were not
receiving DNase was 80% compared to 72% prior to the visit when people started to re-
ceive DNase. Furthermore, the group who ever received DNase had a higher proportion
of people with a high genotype class compared with those who never received DNase
(75% vs 57%), a higher proportion with CFRD (23% vs 18%) and had more annual IV
days (mean 19 vs 9). Table 6.1 also summarises the group of people who stopped taking
DNase during follow-up, but there were no noticeable differences between this group of
people and those who continued to take DNase throughout follow-up.
6.3.1 Lung Function
One-Year Treatment Effect
The SCMM estimated that the effect of using DNase for one year was a -0.07% absolute
change in ppFEV1 (95% CI -0.47, 0.33, p = 0.73). There was no evidence that the treat-
ment effect was modified by baseline age: linear interaction p = 0.93, spline interaction
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Demographics (4,198 people)
All
(n=4,198)
Never used
DNase
(n=1,814)
DNase use
≥ 1 year
(n=2,384)
DNase use
≥ 5 year
(n=821)
Stopped
DNase du-
ring follow-
up (n=441)
Baseline Age (years) 19.8 (12.7) 21.4 (13.5) 18.7 (11.9) 19.2 (11.1) 21.0 (11.1)
Female 1,923 (45.8) 806 (44.4) 1,117 (46.9) 380 (46.3) 210 (47.6)
Caucasian 4,061 (96.7) 1,761 (97.1) 2,300 (96.5) 792 (96.5) 432 (98.0)
Genotype Class
High 2,828 (67.4) 1,031 (56.8) 1,797 (75.4) 659 (80.3) 333 (75.5)
Low 563 (13.4) 353 (19.5) 210 (8.8) 52 (6.3) 35 (7.9)
None Assigned 153 (3.6) 77 (4.2) 76 (3.2) 28 (3.4) 17 (3.9)
Missing 654 (15.6) 353 (19.5) 301 (12.6) 82 (10.0) 56 (12.7)
Longitudinal Data (26,363 observations)
First Vi-
sit [no
DNase use]
(n=4,198)
Other visits
where never
used DNase
(n=12,194)
First year
using
DNase
(n=2,384)
Subsequent
years using
DNase
(n=6,633)
Years after
stopping
DNase
(n=954)
Previous ppFEV1 *** 80.1 (20.9) 72.4 (21.3) 68.4 (21.5) 67.8 (21.5)
Annual Change in
ppFEV1
*** -1.0 (9.9) -0.4 (12.5) -1.6 (9.5) -1.4 (9.1)
Previous ppFVC* *** 90.1 (17.1) 84.8 (18.2) 82.4 (18.1) 82.4 (18.1)
Annual Change in
ppFVC*
*** -0.7 (10.1) -0.3 (12.1) -1.2 (10.1) -0.7 (9.8)
Previous ppFEF25−75** *** 71.4 (31.2) 63.7 (28.9) 59.2 (26.7) 62.6 (34.3)
Annual Change in
ppFEF25−75**
*** -1.3 (21.7) 0.1 (26.7) -1.1 (19.4) -3.5 (17.9)
Annual IV Days 8.2 (17.1) 9.2 (19.4) 19.4 (27.5) 23.1 (31.6) 21.2 (32.9)
Smoker
No 3,058 (72.8) 10,567 (86.7) 2,138 (89.7) 5,949 (89.7) 845 (88.6)
Occasionally 33 (0.8) 126 (1.0) 19 (0.8) 53 (0.8) 12 (1.3)
<1 packet per day 49 (1.2) 256 (2.1) 24 (1.0) 59 (0.9) 21 (2.2)
≥1 packet per day 20 (0.5) 69 (0.6) 6 (0.3) 18 (0.3) 7 (0.7)
Missing 1,038 (24.7) 1,176 (9.6) 197 (8.3) 554 (8.4) 69 (7.2)
Pseudomonas infection 2,453 (58.4) 6,460 (53.0) 947 (39.7) 2,336 (35.2) 321 (33.6)
CFRD
No 2,226 (53.0) 7,455 (61.1) 1,360 (57.0) 3,418 (51.5) 483 (50.6)
Yes 504 (12.0) 2,150 (17.6) 550 (23.1) 2,088 (31.5) 297 (31.1)
Missing 1,468 (35.0) 2,589 (21.2) 474 (19.9) 1,127 (17.0) 174 (18.2)
Other Muco-Active
Treatments
200 (4.8) 1,578 (12.9) 502 (21.1) 2,229 (33.6) 356 (37.3)
Acetylcysteine 15 (0.4) 133 (1.1) 41 (1.7) 112 (1.7) 11 (1.2)
Hypertonic Saline 184 (4.4) 1,440 (11.8) 469 (19.7) 2,095 (31.6) 340 (35.6)
Mannitol 2 (0.05) 39 (0.3) 13 (0.5) 145 (2.2) 14 (1.5)
TABLE 6.1: Descriptive statistics of key variables: Data presented as mean
(SD) for continuous variables and n (%) for binary and categorical variables
(*FVC data based on 26,086 observations, **FEF25−75 data based on 4,452
observations, ***First visit, so no previous measures available)
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p = 0.77. This is shown in Figure 6.2a where it can be seen that including an interaction
term does not result in a statistically significantly different treatment effect than not in-
cluding an interaction term. Conversely, there was strong evidence of modification of
the treatment effect by previous ppFEV1: linear interaction p = 0.003, spline interaction
p = 0.007. These results are shown in Figure 6.2b. The model with an interaction in-
cluding restricted cubic splines shows that the relationship is not entirely linear, but for
ease of interpretability, we use the linear interaction term from now on. The results from
the population average model and the two models with linear interaction terms are also
shown in Table 6.2.
The interaction effect with previous ppFEV1 suggests that treatment is most beneficial in
people with lower lung function, with the effect estimated to decrease by 0.32% (95% CI
0.11, 0.53) for every 10% increase in ppFEV1. This model estimates that treatment would
improve lung function at one year if starting treatment with a ppFEV1 less than 69.7%.
The test for longer-term effects was highly statistically significant (p < 0.0001) suggesting
that the effect of DNase on lung function changes with increasing years of DNase use.
Long-Term Treatment Effect
Results from the methods that can estimate long-term effects are shown in Figure 6.3 and
Table 6.3. G-formula and g-estimation gave similar one-year effect estimates as SCMM,
but IPW of MSM and HA-MSM both estimated a statistically significant decrease in lung
function after one year of treatment: IPW of MSM -2.24% (95% CI -3.31, -1.16, p < 0.0001),
and HA-MSM -0.93 (95% CI -1.48, -0.39, p < 0.001). These two results were very similar
even when the most extreme weights were truncated.
Looking at longer-term effects all four methods showed a trend to the decrease in lung
function becoming larger over time. In the cases of HA-MSM and g-estimation this de-
crease was modest: at five years the estimated treatment effect for HA-MSM was -1.93%
(95% CI -3.43, -0.42, p = 0.012) and g-estimation -3.18% (95% CI -4.48, -1.88, p < 0.0001).
However, IPW of MSM and g-formula estimated a stronger negative effect: five-year ef-
fect using IPW of MSM -5.65% (95% CI -7.66, -3.63, p < 0.0001), using g-formula -5.54%
(95% CI -6.72, -4.36, p < 0.0001).
HA-MSM and g-estimation gave similar results when considering effect modification by
previous ppFEV1. These results are shown in Figure 6.4 and Table 6.4. For example, for
an individual starting DNase with a ppFEV1 of 20%, after one year their lung function
was estimated to increase by 1.59% (95% CI 0.38, 2.79, p = 0.010) using g-estimation and
to increase by 1.54% (95% CI -0.09, 3.16, p = 0.064) using HA-MSM. These estimates re-
mained more or less stable out to five years, although with much larger CIs: at five years,
g-estimation estimate 2.98% (95% CI -1.46, 7.42, p = 0.19), HA-MSM estimate 2.79% (95%
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FIGURE 6.2: Estimated one-year effect of DNase on ppFEV1 depending on
baseline age or previous ppFEV1
Method 1 Year Treatment EffectEst. 95% CI p
Population Average -0.071 -0.47, 0.33 0.73
Modified by Age Intercept -0.11 -0.89, 0.67 0.78Interaction -0.013 -0.32, 0.29 0.93
Modified by Previous ppFEV1
Intercept 2.23 0.61, 3.84 0.007
Interaction -0.32 -0.53, -0.11 0.003
TABLE 6.2: Estimated one-year effects of DNase on ppFEV1 (The intercept
term is the estimated effect if the age or previous ppFEV1 is 0, and the
interaction term is the change in effect per 10 increase in the modifier)
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CI -1.64, 7.21, p = 0.22). For individuals starting DNase with a ppFEV1 of 100% the re-
sults were again similar between the two methods, with a negative effect at one year of
-0.97% (95% CI -1.65, -0.29, p = 0.005) for g-estimation and -2.10% (95% CI -2.87, -1.33,
p < 0.0001) for HA-MSM. This negative effect became slightly more pronounced at five
years: g-estimation estimate -5.75% (95% CI -7.82, -3.69, p < 0.0001), HA-MSM estimate
-4.36% (95% CI -6.65, -2.08, p < 0.001). Overall, the results for HA-MSM with truncated
weights were very similar to the results without truncation of weights shown above.
Including the interaction with previous ppFEV1, it was estimated that DNase would im-
prove lung function over one-year for anyone starting treatment with a ppFEV1 less than
69.6% (g-estimation) or less than 53.8% (HA-MSM). At five years, treatment was estima-
ted to be improve lung function in anyone who had started treatment with a ppFEV1 less
than 47.3% (g-estimation) or 51.2% (HA-MSM).
We also repeated the same analyses using ppFVC and ppFEF25−75 as outcomes and obtai-
ned broadly similar results. The results from these analyses can be seen in Appendix E
in Figures E.1 to E.6 and Tables E.1 to E.6.
6.3.2 Annual IV Days
One-Year Treatment Effect
Using SCMM, one year of DNase use was estimated to decrease an individual’s odds of
having zero IV days by 20% (95% CI 0.72, 0.88, p < 0.0001) and increase the overall rate
of IV days by 8% (95% CI 1.04, 1.12, p < 0.0001). However, there was estimated to be a
statistically significant change in the effect of DNase by both baseline age (p = 0.009) and
previous number of IV days (p = 0.003), and both these interaction terms also remained
statistically significant when included in the model together. This model estimated that
for an individual aged 6 with zero IV days in the previous year, the odds of having zero
IV days in the following year decreased by 40% if using DNase (95% CI 0.50, 0.70, p <
0.0001), and the overall rate of IV days increased by 12% (95% CI 1.05, 1.19, p < 0.001).
For every 10 year increase in age, the odds of having zero IV days were estimated to
increase by 14% (95% CI 1.04, 1.24, p = 0.005) and the rate of IV Days was estimated to
decrease by 1% (95% CI 0.96, 1.02, p = 0.46). For every 14 day increase in the number of
IV days in the previous year, the odds of having zero IV days were estimated to increase
by 18% (95% CI 1.06, 1.30, p = 0.001) and the rate of IV days was estimated to decrease
by 1% (95% CI 0.97, 1.01, p = 0.21). These results can be seen in Figures 6.5 and 6.6, and
Table 6.5. In the figures, we again also include the results showing the interaction using
restricted cubic splines as well as the linear interaction terms.
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FIGURE 6.3: Estimated population-average effects of DNase on ppFEV1
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Method 1 Year Treatment Effect Cumulative 2 Year Treatment Effect Cumulative 3 Year Treatment EffectEst. 95% CI p Est. 95% CI p Est. 95% CI p
IPW of MSM -2.24 -3.31, -1.16 <0.0001 -2.50 -3.85, -1.15 <0.001 -3.63 -5.74, -1.78 <0.001
IPW of MSM (truncated) -2.65 -3.53, -1.77 <0.0001 -3.25 -4.26, -2.23 <0.0001 -4.71 -5.89, -3.54 <0.0001
HA-MSM -0.93 -1.48, -0.39 <0.001 -0.92 -1.54, -0.31 0.003 -0.87 -1.68, -0.06 0.036
HA-MSM (truncated) -0.92 -1.41, -0.43 <0.001 -0.97 -1.56, -0.38 0.001 -1.08 -1.81, -0.34 0.004
G-Formula -0.045 -0.49, 0.40 0.85 -1.07 -1.73, -0.42 0.001 -2.46 -3.28, -1.64 <0.0001
G-Estimation -0.071 -0.46, 0.32 0.72 -0.82 -1.40, -0.24 0.006 -1.55 -2.33, -0.78 <0.0001
Method Cumulative 4 Year Treatment Effect Cumulative 5 Year Treatment EffectEst. 95% CI p Est. 95% CI p
IPW of MSM -5.37 -7.05, -3.69 <0.0001 -5.65 -7.66, -3.63 <0.0001
IPW of MSM (truncated) -6.32 -7.71, -4.94 <0.0001 -6.71 -8.34, -5.08 <0.0001
HA-MSM -1.33 -2.39, -0.27 0.014 -1.93 -3.43, -0.42 0.012
HA-MSM (truncated) -1.59 -2.55, -0.64 0.001 -2.06 -3.39, -0.73 0.002
G-Formula -4.22 -5.22, -3.21 <0.0001 -5.54 -6.72, -4.36 <0.0001
G-Estimation -2.35 -3.36, -1.35 <0.0001 -3.18 -4.48, -1.88 <0.0001
TABLE 6.3: Estimated cumulative population average effects of DNase on ppFEV1
Method 1 Year Treatment Effect Cumulative 2 Year Treatment Effect Cumulative 3 Year Treatment EffectEst. 95% CI p Est. 95% CI p Est. 95% CI p
HA-MSM Intercept 2.45 0.32, 4.58 0.024 1.85 -0.50, 4.20 0.12 0.84 -2.48, 4.15 0.62Interaction -0.46 -0.72, -0.19 <0.001 -0.37 -0.67, -0.069 0.016 -0.23 -0.65, 0.20 0.30
HA-MSM (truncated) Intercept 2.53 0.68, 4.37 0.007 2.03 -0.16, 4.21 0.069 1.60 -1.22, 4.41 0.27Interaction -0.46 -0.69, -0.23 <0.001 -0.40 -0.68, -0.12 0.006 -0.35 -0.71, 0.008 0.056
G-estimation Intercept 2.23 0.62, 3.84 0.007 1.51 -0.92, 3.95 0.22 0.44 -2.80, 3.68 0.79Interaction -0.32 -0.53, -0.11 0.003 -0.30 -0.61, 0.007 0.056 -0.25 -0.65, 0.16 0.23
Method Cumulative 4 Year Treatment Effect Cumulative 5 Year Treatment EffectEst. 95% CI p Est. 95% CI p
HA-MSM Intercept 5.26 0.63, 9.89 0.026 4.57 -1.28, 10.43 0.13Interaction -0.89 -1.48, -0.32 0.003 -0.89 -1.64, -0.15 0.019
HA-MSM (truncated) Intercept 4.97 1.11, 8.84 0.012 5.57 0.51, 10.64 0.031Interaction -0.89 -1.38, -0.39 <0.001 -1.05 -1.71, -0.38 0.002
G-estimation Intercept 3.60 -0.80, 7.99 0.11 5.16 -0.68, 11.00 0.083Interaction -0.80 -1.35, -0.26 0.004 -1.09 -1.82, -0.36 0.003
TABLE 6.4: Estimated cumulative effects of DNase on ppFEV1 modified by previous ppFEV1. The intercept term is the estimated
effect if previous ppFEV1 was 0%, and the interaction term is the change in effect per 10% increase in previous ppFEV1.
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These results suggest that DNase would be least useful in young people with no previous
IV days. For example, for a six year old, treatment would not be estimated to increase
the odds of having zero IV days unless they had previously had at least 45 IV days, and
would not decrease the overall rate of IV days unless they had had at least 148 previous
IV days. However, by age 18, the number of previous IV days necessary for treatment to
appear beneficial would only be 31 days for the odds of zero IV days and 130 days for
the rate of IV days.
The test for long-term effects was not statistically significant, p = 0.17, suggesting that
the estimated results as given above will remain the same no matter how long DNase is
used for.
Long-Term Treatment Effect
The results from IPW of MSM and HA-MSM concord with the test for long-term effects
from the SCMM. Both methods show a decrease in the odds of zero IV days after one
year: IPW of MSM OR 0.67 (95% CI 0.60, 0.75, p < 0.0001), HA-MSM OR 0.75 (95% CI
0.67, 0.84, p < 0.0001), and an increase in the rate of IV days: IPW of MSM IRR 1.12
(95% CI 1.03, 1.22, p = 0.009), HA-MSM IRR 1.12 (95% CI 1.07, 1.18, p < 0.0001). These
estimates then remained stable with increased length of DNase use, for example after four
years the OR of zero IV days compared to never using DNase was 0.66 (95% CI 0.55, 0.80,
p < 0.0001) for IPW of MSM and 0.88 (95% CI 0.72, 1.07, p = 0.20) for HA-MSM), and the
IRR of IV days was 1.04 (95% CI 0.90, 1.20, p = 0.58) for IPW of MSM and 1.16 (95% CI
1.06, 1.28, p = 0.002) for HA-MSM. As with the lung function outcome, truncation of the
most extreme weights did not result in statistically significantly different results. These
results can be seen in Figures 6.7 and 6.8 and Table 6.6. The results from g-formula and
g-estimation can also been seen in the same figures and tables, but both of these methods
estimated the effects of DNase on both the odds of zero IV days and the rate of IV days
to become stronger through time. For g-formula, the OR of zero IV days was estimated
to be 0.84 (95% CI 0.77, 0.91, p < 0.0001) at one year and changed to 0.66 (95% CI 0.57,
0.76, p < 0.0001) after four years. The IRR similarly changed from 1.04 (95% CI 0.99,
1.09, p = 0.11) at one year to 1.20 (95% CI 1.10, 1.32, p < 0.0001) after four years. For
g-estimation, which only estimates an overall rate of IV days, the IRR was estimated to
be 1.23 (95% CI 1.15, 1.33, p < 0.0001) at one year and 1.56 (95% CI 1.56, 1.80, p < 0.0001)
after four years.
The results from methods which can include interaction terms are shown in Figures 6.9
to 6.13 and Table 6.7. As with the SCMM, there was strong evidence of an interaction
between treatment and the previous number of IV days. In the figures, the number of
previous IV days changes from 0 in the left column to 42 in the right column, and it can
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FIGURE 6.5: Estimated one-year effect of DNase on IV Days depending on
baseline age
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FIGURE 6.6: Estimated one-year effect of DNase on IV Days depending on
previous IV days
Method 1 Year Treatment EffectOR 95% CI p IRR 95% CI p
Population Average 0.80 0.72, 0.88 <0.0001 1.08 1.04, 1.12 <0.0001
Modified by Age Intercept 0.61 0.50, 0.75 <0.0001 1.10 1.03, 1.18 0.006Interaction 1.14 1.05, 1.26 0.003 0.99 0.96, 1.02 0.45
Modified by
Previous IV days
Intercept 0.70 0.62, 0.80 <0.0001 1.10 1.05, 1.15 <0.0001
Interaction 1.16 1.06, 1.28 0.002 0.99 0.97, 1.00 0.18
Modified by Age &
Previous IV days
Intercept 0.55 0.45, 0.68 <0.0001 1.12 1.04, 1.21 0.002
Interaction by Age 1.14 1.04, 1.24 0.005 0.99 0.96, 1.02 0.46
Interaction by
Previous IV days
1.18 1.06, 1.30 0.001 0.99 0.97, 1.01 0.21
TABLE 6.5: Estimated one-year effects of DNase on odds of zero IV days
(OR) and rate of total IV days (IRR) (The intercept term is the estimated
effect if the age or previous IV days is 0, and the interaction term is the
change in effect per 10 increase age or per 14 increase in IV days)
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FIGURE 6.7: Estimated population-average effects of DNase on IV Days
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FIGURE 6.8: Estimated population-average effects of DNase on IV Days
(2)
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Method 1 Year Treatment EffectOR 95% CI p IRR 95% CI p
IPW of MSM 0.67 0.60, 0.75 <0.0001 1.12 1.03, 1.22 0.009
IPW of MSM (truncated) 0.66 0.60, 0.73 <0.0001 1.14 1.06, 1.22 <0.001
HA-MSM 0.75 0.67, 0.84 <0.0001 1.12 1.07, 1.18 <0.0001
HA-MSM (truncated) 0.76 0.68, 0.84 <0.0001 1.12 1.07, 1.17 <0.0001
G-formula 0.84 0.77, 0.91 <0.0001 1.04 0.99, 1.09 0.11
G-estimation - - - 1.23 1.15, 1.33 <0.0001
Method Cumulative 2 Year Treatment EffectOR 95% CI p IRR 95% CI p
IPW of MSM 0.65 0.57, 0.74 <0.0001 1.07 0.98, 1.18 0.14
IPW of MSM (truncated) 0.63 0.55, 0.71 <0.0001 1.11 1.02, 1.20 0.015
HA-MSM 0.78 0.69, 0.89 <0.001 1.09 1.04, 1.15 <0.001
HA-MSM (truncated) 0.78 0.68, 0.88 <0.0001 1.10 1.05, 1.15 <0.001
G-formula 0.69 0.62, 0.77 <0.0001 1.08 1.02, 1.16 0.011
G-estimation - - - 1.39 1.26, 1.53 <0.0001
Method Cumulative 3 Year Treatment EffectOR 95% CI p IRR 95% CI p
IPW of MSM 0.67 0.58, 0.78 <0.0001 1.07 0.95, 1.19 0.25
IPW of MSM (truncated) 0.65 0.57, 0.75 <0.0001 1.11 1.01, 1.23 0.025
HA-MSM 0.88 0.75, 1.02 0.083 1.15 1.07, 1.23 <0.001
HA-MSM (truncated) 0.86 0.74, 0.99 0.038 1.16 1.09, 1.24 <0.0001
G-formula 0.66 0.59, 0.74 <0.0001 1.18 1.10, 1.28 <0.0001
G-estimation - - - 1.45 1.28, 1.64 <0.0001
Method Cumulative 4 Year Treatment EffectOR 95% CI p IRR 95% CI p
IPW of MSM 0.66 0.55, 0.80 <0.0001 1.04 0.90, 1.20 0.58
IPW of MSM (truncated) 0.63 0.53, 0.75 <0.0001 1.10 0.98, 1.24 0.097
HA-MSM 0.88 0.72, 1.07 0.20 1.16 1.06, 1.28 0.002
HA-MSM (truncated) 0.84 0.69, 1.02 0.075 1.20 1.10, 1.31 <0.0001
G-formula 0.66 0.57, 0.76 <0.0001 1.20 1.10, 1.32 <0.0001
G-estimation - - - 1.56 1.35, 1.80 <0.0001
TABLE 6.6: Estimated long-term population-average effects of DNase on
odds of zero IV days (OR) and rate of total IV days (IRR)
be seen that the estimated effects all become weaker as the number of previous IV days
increases. The interaction with baseline age was estimated to be less strong than had
been estimated with SCMM, but there were still statistically significant changes in the
estimates as baseline age increased. This can be seen in the rows of Figures 6.9 to 6.13,
where increasing age appears to result in less negative treatment effect estimates. Howe-
ver, even in the case of an individual aged 30 with 42 previous IV days at baseline (the
bottom-right graph of each figure), the effect estimates are still generally only sugges-
ting no effect of treatment on IV days, and treatment is never estimated to be statistically
significantly beneficial on either the odds of zero IV days or the overall rate of IV days.
As in the case of the population-average results, using truncated weights did not noticea-
bly change the results from HA-MSM. The results from g-estimation once again estimated
a much strong treatment effect on the rate of IV days than HA-MSM, and this is because
g-estimation does not give a separate estimate for the odds of zero IV days.
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FIGURE 6.9: Estimated effects from HA-MSM of DNase on odds of zero IV
days modified by baseline age and previous IV Days
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FIGURE 6.11: Estimated effects from HA-MSM of DNase on rate of IV days
modified by baseline age and previous IV Days
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FIGURE 6.12: Estimated effects from HA-MSM with truncated weights of
DNase on rate of zero IV days modified by baseline age and previous IV
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FIGURE 6.13: Estimated effects from g-estimation of DNase on rate of IV
days modified by baseline age and previous IV Days
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Method 1 Year Treatment EffectOR 95% CI p IRR 95% CI p
HA-MSM
Intercept 0.57 0.46, 0.70 <0.0001 1.05 0.94, 1.18 0.36
Interaction by Age 1.08 0.99,1.17 0.093 1.05 0.99, 1.10 0.10
Interaction by Previous IV
days
1.21 1.07, 1.36 0.002 0.98 0.96, 1.01 0.18
HA-MSM
(truncated)
Intercept 0.56 0.46, 0.69 <0.0001 1.09 0.99, 1.20 0.072
Interaction by Age 1.08 0.99, 1.18 0.077 1.03 0.99, 1.08 0.18
Interaction by Previous IV
days
1.23 1.09, 1.38 <0.001 0.98 0.96, 1.00 0.062
G-estimation
Intercept - - - 1.67 1.43, 1.95 <0.0001
Interaction by Age - - - 0.88 0.83, 0.95 <0.001
Interaction by Previous IV
days
- - - 0.94 0.90, 0.98 0.002
Method Additional 2
nd Year Treatment Effect
OR 95% CI p IRR 95% CI p
HA-MSM
Intercept 0.81 0.64, 1.03 0.086 1.11 0.98, 1.26 0.095
Interaction by Age 1.15 1.05, 1.27 0.003 0.94 0.89, 1.00 0.052
Interaction by Previous IV
days
0.96 0.86, 1.07 0.49 0.99 0.97, 1.02 0.57
HA-MSM
(truncated)
Intercept 0.82 0.65, 1.03 0.093 1.07 0.97, 1.19 0.17
Interaction by Age 1.14 1.04, 1.25 0.005 0.96 0.92, 1.01 0.090
Interaction by Previous IV
days
0.96 0.86, 1.07 0.44 1.00 0.98, 1.02 0.83
G-estimation
Intercept - - - 1.33 1.15, 1.55 <0.001
Interaction by Age - - - 0.96 0.90, 1.03 0.23
Interaction by Previous IV
days
- - - 0.95 0.92, 0.99 0.007
Method Additional 3
rd Year Treatment Effect
OR 95% CI p IRR 95% CI p
HA-MSM
Intercept 1.12 0.87, 1.44 0.37 1.23 1.11, 1.37 <0.001
Interaction by Age 0.98 0.88, 1.09 0.69 0.95 0.91, 0.99 0.015
Interaction by Previous IV
days
1.03 0.92, 1.16 0.62 0.97 0.95, 1.00 0.038
HA-MSM
(truncated)
Intercept 1.10 0.87, 1.41 0.43 1.21 1.09, 1.33 <0.001
Interaction by Age 0.98 0.89, 1.09 0.74 0.95 0.91, 0.99 0.024
Interaction by Previous IV
days
1.02 0.91, 1.15 0.71 0.98 0.95, 1.00 0.090
G-estimation
Intercept - - - 1.27 1.07, 1.51 0.008
Interaction by Age - - - 0.97 0.89, 1.06 0.49
Interaction by Previous IV
days
- - - 0.94 0.90, 0.98 0.008
Method Additional 4
th Year Treatment Effect
OR 95% CI p IRR 95% CI p
HA-MSM
Intercept 0.99 0.72, 1.35 0.93 1.00 0.88, 1.15 0.97
Interaction by Age 1.01 0.88, 1.15 0.91 0.99 0.93, 1.05 0.71
Interaction by Previous IV
days
0.99 0.84, 1.18 0.94 1.02 0.99, 1.06 0.24
HA-MSM
(truncated)
Intercept 0.97 0.71, 1.33 0.86 1.00 0.88, 1.15 0.96
Interaction by Age 1.00 0.88, 1.14 0.97 0.99 0.94, 1.05 0.85
Interaction by Previous IV
days
0.99 0.84, 1.18 0.95 1.02 0.99, 1.06 0.19
G-estimation
Intercept - - - 1.39 1.10, 1.76 0.007
Interaction by Age - - - 0.97 0.87, 1.07 0.50
Interaction by Previous IV
days
- - - 0.94 0.88, 0.99 0.027
TABLE 6.7: Estimated long-term effects of DNase on odds of zero IV days
(OR) and rate of total IV days (IRR) (The intercept term is the estimated
effect if the age or previous IV days is 0, and the interaction term is the
change in effect per 10 increase age or per 14 increase in IV days)
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6.4 Comparison of Methods
In Chapter 5, we assessed the performance of five different methods that could be used
to analyse the UK CF Registry data to estimate the effects of long-term DNase use. The
results from these simulation studies suggested that any of the methods could be used to
provide consistent effect estimates in an ideal scenario where all models are correctly spe-
cified and all assumptions are met. In this chapter, we analysed the UK CF Registry data
with all available methods as any discrepancies between the methods could highlight
potential problems.
We started by analysing the data using SCMM, as although this method can only estimate
the effect of one-year of treatment in our setting, the method is much simpler than the
other available methods, and a subseqeunt test can be used to test for the presence of
longer-term effects. In our setting, the results of this test suggested that there is an effect
of long-term DNase use on lung function, but that in the case of IV days the estimated
effects of long-term treatment use would be similar to the one-year effect estimates. For
lung function, this finding was borne out in the results from the methods which allow
estimation of long-term effects, as all four other methods did show that the estimated
effect of treatment on lung function changed as the cumulative number of years using
DNase increased. For IV days the results on long-term effects were more ambiguous,
as two of the methods (IPW of MSM and HA-MSM) showed that the estimated effect
stayed the same through years one to five, but g-formula and g-estimation estimated that
the effect did change with continuous use of DNase. In the case of g-estimation, however,
the CIs were quite wide and could be consistent with no long-term effect.
The long-term treatment effects obtained using the four methods did not differ substan-
tially, and the overall conclusions would be the same no matter which results were used.
However, there did appear to be important modification of the treatment effect by age or
previous levels of the outcome, and as such we show a preference towards HA-MSM and
g-estimation which can estimate the desired interaction terms. The results from these two
methods were remarkably similar. Another issue that was highlighted in the simulation
studies in Chapter 5 was that the results would be biased if a causal pathway between
two variables was specified in the wrong direction. In the UK CF Registry data, number
of IV days and treatment status are collected over the same time period and it is there-
fore not clear which direction this causal pathway should be specified. In the simulation
studies, misspecifying the pathway often led to very extreme weights for HA-MSM and
the method performed very poorly unless truncated weights were used. We saw in our
analysis of the UK CF Registry data that there were no very extreme weights and trunca-
tion had hardly any effect on the effect estimates. This suggests that misspecification of
the causal pathway was not an important issue in this analysis.
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6.5 Discussion
We used UK CF Registry data to estimate long-term effects of DNase use, controlling
for confounding by indication by using state-of-the-art statistical methodology not pre-
viously applied to CF registry data. For individuals with a reduced lung function and
not using DNase, we have shown that initiating DNase treatment and using it for one
year brings a benefit such that ppFEV1 is higher after one year than it would have been
had those individuals not initiated DNase treatment. This beneficial effect appeared to
remain with continued use of DNase out to five years, but with no overall modification
of the lung function trajectory, as the estimated effect remained stable between years one
and five.
Crude comparisons between those who received and did not receive DNase clearly in-
dicate that there is confounding by indication, such that individuals taking DNase tend
to have worse health status than those not taking DNase. If this is not appropriately
handled in the analysis, any estimates of the treatment effect would not have a causal
interpretation. In this study, we made use of appropriate statistical methods to address
the confounding by indication, accounting for the longitudinal setting, thereby showing
how registries can be used to evaluate the long-term effects of treatment. RCTs are the
gold standard for establishing treatment efficacy, but as previously discussed, it is prefe-
rable for a CF treatment to alter lung function trajectory rather than to provide a one-off
improvement, and assessing change in trajectory requires longer follow-up than would
typically be feasible in trials.[20] The analyses we have used take advantage of clear he-
terogeneity in treatment practices as the proportion of patients receiving DNase at indi-
vidual CF centres ranges from less than 20% to more than 80%.[3] As the groups who
receive and do not receive DNase include individuals with wide-ranging clinical charac-
teristics, the statistical methods used in this paper can correct for confounding by indi-
cation as long as data on all confounders have been collected. We were able to adjust
for a large number of variables using the data available in the UK CF Registry, but it is
not possible to verify whether confounding by indication has ever been completely dealt
with and the causal interpretation of our results therefore depends on the assumption of
no unmeasured confounding.[106]
The results from our analysis appear to show a much weaker treatment effect than has
been reported in previous studies. For example, a previous registry study by Hodson et
al. of the European Epidemiologic Registry of Cystic Fibrosis estimated a one-year treat-
ment effect of DNase on ppFEV1 of 3.6% (95% CI 1.8% to 5.3%) and a two-year treatment
effect of 2.5% (0.7% to 4.4%).[64] These are larger population-average treatment effect
estimates than obtained in our study, but the population for those studies had lower
average baseline ppFEV1, who were the patients we found benefited most from treat-
ment.
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Only two previous studies have investigated the effects of DNase in people with ppFEV1
> 80% and only one of these included lung function as an outcome.[66, 74] That study
only administered DNase for four weeks and found no effect of treatment on ppFEV1.[74]
In our study, for individuals with higher lung function, those on DNase treatment had
steeper trajectories of lung function decline than comparable individuals not receiving
treatment. This may suggest that it would be more beneficial, in terms of lung function
outcomes, to wait until lung function starts to decline before initiating DNase. Howe-
ver, as with all observational studies, it is possible that unobserved confounders affect
these results. With the rich registry data, we believe we have accounted for the covaria-
tes that could affect both lung function and the probability of receiving DNase treatment
to account for confounding by indication, but it is possible that there are some unme-
asured health-related variables that affected the decisions to initiate treatment in these
individuals. For example, although an individual may have had a high lung function
measurement at the previous annual assessment, we do not have an assessment of their
overall lung function decline during the previous year, and it would be plausible that the
patients who did start to receive DNase with a high lung function measure in the Regi-
stry might have been starting to show signs of lung function deterioration that were not
picked up by having only one lung function measure per year.
The results from the analysis with IV days as the outcome do not appear to agree with the
findings from previous studies that investigated the effects of DNase on exacerbations.
Although most of these studies did not have statistically significant results, all but one
previous study has estimated DNase to result in a reduction in the risk of exacerbations.
Although there did appear to be statistically significant effect modification of the treat-
ment effect by age and previous number of IV days, this only resulted in DNase being
estimated to be beneficial in older people with many previous IV days, which is a very
small proportion of the general CF population. However, one of the limitations of the
way the data on IV days is collected in the UK CF Registry is that sometimes people are
prescribed IV days as a protective measure rather than to actually treat an exacerbation.
It seems plausible that people who are more likely to received DNase may also be more
likely to receive these additional non-exacerbation-related IV days. This practice is more
common in children than adults, which would also explain why DNase appeared more
harmful in younger people. Overall, this seems to suggest that the results from this ana-
lysis are unreliable and that the way IV days are collected in the UK CF registry could be
enhanced by recording the reason they are being given.
Upon initiation of DNase, most people continue to receive the treatment indefinitely, with
only very small numbers of people stopping treatment. Due to this, with the sample size
available, it was not possible to estimate the effect of stopping treatment. However, as
we observed that treatment only appeared to be beneficial in individuals with reduced
lung function, future studies could investigate whether treatment needs to be continued
Chapter 6. Estimating the Effects of Long-Term Dornase Alfa Use 134
in people who recover to higher levels of lung function.
A major strength of this study is the use of the UK CF Registry data, which are collected
at regular intervals according to a standardised protocol. The data include a large num-
ber of variables that we could account for as potential confounders. One of the main
limitations of this study is that there are no data available on levels of adherence to
treatment. It is known to be particularly hard to measure adherence levels, but previ-
ous studies have estimated that average adherence levels to nebulised therapies, such as
DNase, may range between 60% and 70%.[107, 108] Specifically, for a longitudinal study,
we may expect adherence levels to be higher at treatment initiation and decrease through
time, which may partly explain why the estimated effects are not as pronounced as those
estimated from RCTs, where adherence would typically be higher.[109]
It is also acknowledged that spirometry measures, such as FEV1, may not be sufficiently
sensitive to detect the early stages of lung function decline, and it has been suggested
that other measures such as LCI may give a better indication of early lung function dete-
rioration.[22, 110] Unfortunately, LCI is not collected in the UK CF Registry, so it was not
possible to investigate this. However, FEF25−75 is collected in the registry, albeit less relia-
bly than FEV1 (3,320 FEF25−75 measurements compared to 20,923 FEV1 measurements in
this analysis), and the results showed similar findings to the findings with FEV1, but with
much larger CIs, reflecting the smaller sample size and higher variability of this measure
(see Appendix E).
In conclusion, we have shown a beneficial long-term effect of DNase in people with re-
duced lung function, but with no overall change in lung-function trajectory. There is a
differential effect of treatment based on lung function at treatment initiation with no im-
provements in lung function seen in individuals initiating treatment with ppFEV1 higher
than 70%, suggesting that, in terms of lung function, it could be more effective to initiate
treatment only when lung function starts to decline. Finally, these analyses highlight the
potential of registries in investigating the effects of long-term treatment use and that is-
sues of confounding by indication can be addressed with appropriate statistical methods.
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Chapter 7
Systematic Review of Ivacaftor Use
in Cystic Fibrosis
7.1 Overview
Part II of this thesis focussed on DNase, which works by reducing the viscosity of mucus
in the airways helping to combat the effects of CF on the lungs. Unfortunately, it does
not tackle the underlying cause of the disease and until recently all other available treat-
ments had similarly only reduced the symptoms of the disease. Recently there has been
a push to discover treatments that can target and correct the underlying problems with
the synthesis and function of the CFTR protein. The first of these treatments to become
available was ivacaftor (trade name Kalydeco R©).
Ivacaftor works by increasing the open probability of the ion channel.[111] Figure 7.1
shows the different CFTR mutations grouped by functional class and their effect on CFTR
protein synthesis and function.[112] In this figure, it can be seen how in a class III mu-
tation, the CFTR protein is synthesised almost as normal and reaches the cell wall, but
the gating of the protein is defective and the ion channel remains closed. Ivacaftor was
developed for this class of mutation, allowing the gating regulation to be corrected. More
recently, studies have investigated the potential effectiveness of ivacaftor in people with
other classes of mutation, but for this thesis we only consider the effects of ivacaftor on
people with a class III mutation.
Ivacaftor has been available to people with an eligible CF mutation through the NHS in
the UK since 2012, meaning that there are four years’ of data available in the UK CF Regi-
stry up to 2016. During this period, almost all people with a gating mutation have started
to receive ivacaftor, with most people starting to receive it as soon as it became availa-
ble. However, due to its recent availability there remain a lot of unanswered questions
about its effects, especially its long-term effects. However, even in this relatively short
time there have been many studies published about ivacaftor and therefore this chapter
contains a systematic review of the studies investigating the effects of ivacaftor on people
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FIGURE 7.1: Diagrams of how different CFTR mutations interfere with
CFTR protein synthesis and function (Taken from Hodson and Geddes’
Cystic Fibrosis. Taylor & Francis; 2015)
with a gating mutation. This will be followed in the next two chapters by analyses of the
UK CF Registry data investigating the four-year effects of ivacaftor.
There have been some more recent studies which suggest that ivacaftor may be effective
in people with a residual function mutation, but so far in the UK only people with gating
mutations have been eligible to receive ivacaftor.[113, 114] Any analysis we can currently
perform with the UK CF Registry data would thus only be applicable to people with a
gating mutation, and therefore, we will only consider the treatment effect of ivacaftor in
those with a gating mutation in this thesis.
7.2 Objectives
This systematic review aims to identify and summarise relevant studies which have in-
vestigated the effects of ivacaftor in people with a CF-causing gating mutation.
The results of the studies identified in the systematic review will be used to compare the
results of the analysis of the UK CF registry data presented in this PhD. Therefore, we will
only include studies in the systematic review if they contain an outcome that is collected
in the UK CF Registry.
7.3 Methods
As with the systematic review of DNase in Chapter 3, this review was carried out with
reference to the PRISMA Statement.[31]
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Studies were eligible for inclusion if they fulfilled the following PICOS criteria:
• Participants: People with a CF-causing gating mutation (the comparator group not
receiving ivacaftor may have a different CF-causing mutation).
• Interventions: Ivacaftor given at any dose and frequency.
• Comparisons: Placebo or no treatment
• Outcomes: We consider two outcomes: lung function measured by FEV1, and exa-
cerbations and/or number of IV days. We restrict the review to these outcomes, as
these are the ones we consider for the our analysis in Chapter 9.
• Study Designs: Both RCTs and observational studies, but treatment must be com-
pared to a group of people not receiving ivacaftor, i.e. studies only comparing
change since baseline are not included.
Two search strategies were employed to identify potential studies for the systematic re-
view:
• Hand search of two journals: Pediatric Pulmonology and Journal of Cystic Fibrosis
• Electronic search of two databases: MEDLINE and EMBASE.
The hand search was carried out on all issues, including supplements, of both journals
since 2008. The search strategy for the electronic databases was for any of the following
terms to be included in the title of the article: ivacaftor, VX-770, CFTR potentiator, or
Kalydeco. These searches were performed in January 2018.
After removing any papers which did not fulfil all of the PICOS criteria listed above, the
following data were collected from all of the remaining studies: publication date, type
of study, follow-up time, sample size, baseline distribution of age and lung function, the
outcome measures, the comparator group used and the results. The quality of the studies
was also assessed using the Downs & Black checklist.[36]
The findings of the systematic review are summarised in the following section. During
the systematic review many of the identified papers and abstracts were found to come
from the same studies, but at different time points. For this reason, the results reported
in these papers would generally include the same participants, and therefore no meta-
analyses have been performed on the results as the observations are not all independent.
The electronic and hand searches, the abstract and full-paper reviews, the quality asses-
sment with the Downs & Black scale, and the qualitative review of included studies were
carried out by me.
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7.4 Results
After combining the results of the searches from EMBASE, MEDLINE, the Journal of Cys-
tic Fibrosis and Pediatric Pulmonology there were 141 potential papers for inclusion in
the systematic review (see Figure 7.2). However, after the full-text review of these stu-
dies, 95 of them were not in fact eligible to be included in the systematic review. This was
due to two reasons: the studies either did not contain one of the prespecified outcomes
of interest, or they did not contain any comparator group. The most common outcomes
in these excluded studies were sweat chloride levels or growth variables such as weight
or BMI. Tables 7.1 and 7.2 list the studies that were excluded due to having no outcome
of interest and no comparator group respectively.
603 records
identified in
EMBASE
142 records
identified in
MEDLINE
93 records
identified in
hand search
after abstract review121 records
selected from
EMBASE
after abstract review
20 records
selected from
MEDLINE
after abstract review
141 records after duplicates removed
141 full-text articles
assessed for eligibility
95 studies excluded
after full-text review
46 studies included
in qualitative synthesis
FIGURE 7.2: Flowchart of the number of studies at each stage of the ivacaf-
tor systematic review
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Oct-09 Boyle et al. Effect of VX-770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D-CFTR
mutation
[115]
Jun-10 Rowe et al. Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in sub-
jects with cystic fibrosis and the G551D-CFTR mutation
[116]
Jun-12 Borowitz et al. Measures of nutritional status in two Phase 3 trials of Ivacaftor in subjects with cystic fibrosis who have the G551D-
CFTR mutation
[117]
Jun-13 Plant et al. Lung function, weight and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation
treated with ivacaftor: A secondary analysis
[118]
Sep-13 Elborn et al. Lung function, weight and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation
treated with ivacaftor: A secondary analysis
[119]
Oct-13 De Boeck et al. Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non-G551D-CFTR gating mutation: Phase 3, Part 1
results
[120]
Apr-14 Wainwright et al. The effect of ivacaftor in individuals with cystic fibrosis and severe lung disease: analysis of data from the Australian
named patient programme
[121]
Jun-14 De Boeck et al. The effect of Ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation,
the KONNECTION study
[122]
Jun-14 Sawicki et al. The effect of ivacaftor on weight over three years in patients with CF and a G551D-CFTR mutation [123]
Sep-14 Heltshe et al. Ivacaftor is associated with Pseudomonas Aeruginosa reduction in cystic fibrosis patients with G551D-CFTR [124]
Sep-14 Pace et al. Ivacaftor improves linear growth in G551D pre-pubertal children [125]
Sep-14 Wainwright et al. The effect of ivacaftor in individuals with CF and severe lung disease [126]
Nov-14 Varghese et al. Outcomes after 1 year of Ivacaftor treatment in CF patients with at least one G551D-CFTR mutation: a single centre
experience
[127]
May-15 Konstan et al. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis [128]
Jun-15 McKay et al. The effect of ivacaftor on exocrine pancreatic function in patients with cystic fibrosis and the G551D CFTR mutation
who are naïve for ivacaftor
[129]
Jun-15 Pope et al. Short-term and long-term effects of ivacaftor treatment on sputum microbiota in people with the G551D CFTR muta-
tion
[130]
Jun-15 Prosser et al. Transformational care at the All Wales Adult CF Centre (AWACFC) - is ivacaftor making us fat? The impact of ivacaf-
tor (Kalydeco R©) on body composition
[131]
Jun-15 Rosenfeld et al. An open-label study of the safety, pharmacokinetics and pharmacodynamics of ivacaftor in patients aged 2 to 5 years
with cystic fibrosis and a CFTR gating mutation: The KIWI study
[132]
Jun-15 Tierney et al. Ivacaftor and its effects on body composition in adults with G551D realted cystic fibrosis [133]
Oct-15 Barry et al. Ivacaftor decreases mortality in G551D patients with severe lung disease [134]
Oct-15 Rosenfeld et al. Extended evaluation of ivacaftor treatment in pediatric patients with cystic fibrosis and a CFTR gating mutation [135]
Oct-15 Stalvey et al. Ivacaftor improves linear growth in G551D cystic fibrosis children: Results of a multicenter, placebo-controlled study [136]
Dec-15 Davies et al. Ivacaftor treatment in preschool children with cystic fibrosis and a CFTR gating mutation: extended evaluation [137]
Jan-16 Borowitz et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with ivacaftor [138]
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Jun-16 Stalvey et al. Ivacaftor improves linear growth in children with cystic fibrosis (CF) and a G551D-CTFR mutation: data from the
ENVISION study
[139]
Oct-16 Adam et al. Quantitative CT scan assessment of lung structure and function after one year of Ivacaftor therapy [140]
Oct-16 Looi et al. Ivacaftor therapy increases BMI but does not affect serum cholesterol in patients with gating mutations [141]
Oct-16 Rosenfeld et al. Long-term safety and efficacy of ivacaftor in pediatric patients aged 2-5 years with CF and a CFTR gating mutation [142]
Feb-17 Stalvey et al. Growth in prepubertal children with cystic fibrosis treated with ivacaftor [143]
Sep-17 McCullagh et al. Long term microbiological outcomes of Ivacaftor use. A single-centre retrospective study [144]
TABLE 7.1: Studies excluded from the ivacaftor systematic review after full-text review due to no relevant outcome
Publication Authors Title Full
Date Reference
Oct-08 Accurso et al. Interim results of phase 2a study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity
in cystic fibrosis subjects with G551D
[145]
Jun-09 Accurso et al. Final results of a 14- and 28-day study of VX-770 in subjects with CF [146]
Oct-11 McKone et al. Long-term safety and efficacy of investigational CFTR potentiator, VX-770, in subjects with CF [147]
Jun-12 McKone et al. Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation [148]
Sep-12 McKone et al. Long-term safety and efficacy of ivacaftor in persons with cystic fibrosis who have the G551D-CFTR mutation [149]
Sep-12 McKone et al. Long-term safety and efficacy of ivacaftor in subjects with CF who have the G551D-CFTR mutation [150]
Apr-13 Wood et al. Observational study of the clinical effects of ivacaftor in patients with severe cystic fibrosis (CF) lung disease [151]
May-13 Mondal et al. Postmarketing experience with ivacaftor therapy in cystic fibrosis patients having G551D mutation [152]
Jun-13 Barry et al. UK and Ireland review of Ivacaftor in severe CF: Impact on lung function and weight [153]
Jun-13 Hubert et al. Ivacaftor in French patients with cystic fibrosis and a G551D mutation in the real world setting [154]
Oct-13 Hubert et al. Ivacaftor in French patients with cystic fibrosis and a G551D mutation [155]
Oct-13 McGarry et al. Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic
fibrosis with mutation S549N
[156]
Oct-13 McKone et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the G551D-CFTR mutation:
response through 144 weeks of treatment (96 weeks of PERSIST)
[157]
Oct-13 Rowe et al. Results of the G551D observational study: The effect of Ivacaftor in G551D patients following FDA approval [158]
Oct-13 Spencer-Clegg et al. Ivacaftor in the real world - early experience in a large adult CF centre [159]
Oct-13 Trinh et al. Ivacaftor in adults with cystic fibrosis: one-year experience in the real world setting [160]
Dec-13 Barry et al. Sweat chloride is not a useful marker of clinical response to Ivacaftor [161]
Dec-13 Ewence et al. Does Ivacaftor improve objective measurements of health in patients with the G551D cystic fibrosis transmem-
brane conductance regulator (CFTR) protein mutation? The experience of a UK cystic fibrosis centre
[162]
Dec-13 Hebestreit et al. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation [163]
Jun-14 Barry et al. Sweat chloride is not a useful marker of clinical response to ivacaftor [164]
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Jun-14 Green et al. The effect of ivacaftor therapy on clinical and PCR-identified microbial diversity of cystic fibrosis lung infection [165]
Jun-14 Jenkins et al. The use of LCI as an effective tool for monitoring clinical response to Ivacaftor therapy in CF patients with at least
one G551D-allele
[166]
Jul-14 Rowe et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-
mediated cystic fibrosis
[167]
Sep-14 Adam et al. Ivacaftor rapidly improves airway distensibility and vascular tone in people with G551D-CFTR suggesting a CF-
related smooth muscle abnormality
[168]
Sep-14 Carnovale et al. Effects of Ivacaftor in cystic fibrosis patients carrying the G1244E mutation with severe lung disease [169]
Sep-14 Harman et al. Exploring indices derived from multibreath washout (MBW) following treatment with Ivacaftor [170]
Sep-14 Reilly et al. Sustained effects of ivacaftor on muscle strength, body composition, anxiety and depression scores [171]
Sep-14 Sawicki et al. The effect of ivacaftor treatment on the rate of lung function decline in CF patients with a G551D-CFTR mutation [172]
Nov-14 McKone et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR muta-
tion: a phase 3, open-label extension study (PERSIST)
[173]
Dec-14 Green et al. The effect of Ivacaftor therapy on the microbial diversity of cystic fibrosis lung infection [174]
Dec-14 Harman et al. Changes in indices derived from multibreath washout (MBW) following treatment with Ivacaftor in patients with
cystic fibrosis
[175]
Jan-15 Sheikh et al. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D muta-
tion
[176]
Feb-15 Sheikh et al. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with
G551D mutation
[177]
Mar-15 Heltshe et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor [178]
Jun-15 Grasemann et al. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis [179]
Jun-15 Ronan et al. Clinical outcomes of real-world Klaydeco (CORK) study - a prospective 12 month analysis addressing the impact
of CFTR modulation on the cystic fibrosis lung
[180]
Jun-15 Zwolsman et al. Partial recovery of exocrine pancreatic function and intestinal fat absorption after ivacaftor treatment [181]
Sep-15 Grasemann et al. Airway nitric oxide production in patients with cystic fibrosis increases with Ivacaftor therapy [182]
Oct-15 Einarsson et al. The effect of Ivacaftor treatment on airway microbial community dynamics in patients with G551D (The "Celtic"
mutation)
[183]
Oct-15 Fink et al. Treatment response to Ivacaftor in clinical practice: analysis of the US CF foundation patient registry [184]
Oct-15 Kane et al. Lung clearance index response in CF patients with class III CFTR mutations [185]
Oct-15 Ronan et al. The impact of CFTR modulation with ivacaftor on circulating inflammatory mediators and their correlation with
clinical parameters in patients with the G551D mutation
[186]
Jan-16 Taylor-Cousar et al. Effect of ivacaftor in patients with advance cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an
expanded access program in the United States
[187]
Feb-16 Davies et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-years with cystic fibrosis and a
CFTR gating mutation (KIWI): An open-label single-arm study
[188]
Jun-16 Bertin et al. Clinical effects of ivacaftor on chronic rhinosinusitis [189]
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Jun-16 Button et al. Increased maximal exercise capacity is associated with increased wellness across the spectrum of age and lung
function in adults with cystic fibrosis (CF) after treatment with ivacaftor
[190]
Jun-16 Iacotucci et al. Effects of ivacaftor in cystic fibrosis patients carrying a non-G551D gating mutation [191]
Jun-16 Stallings et al. 3-month ivacaftor (Kalydeco) treatment resulted in weight gain, decreased resting energy expenditure and gut
inflammation, and increased pulmonary function, muscle mass and strength, and growth status
[192]
Jun-16 Zeybel et al. Ivacaftor treatment is associated with a decline in symptoms of extra-oesophageal reflux in patients with cystic
fibrosis and the G551D mutation
[193]
Sep-16 Aziz et al. Ivacaftor - as effective in clinical practice? [194]
Oct-16 Button et al. Increased total exercise time and maximal exercise capacity are associated with increased wellness in adults with
CF across spectrum of age and lung function after treatment with Ivacaftor
[195]
Oct-16 Sainath et al. Improvement in weight, pulmonary function and other outcomes with 3-month ivacaftor treatment differed by
exocrine pancreatic status in people with cystic fibrosis gating mutations
[196]
Oct-16 Sainath et al. Exocrine pancreatic status effects outcomes following 3-month ivacaftor therapy in subjects with cystic fibrosis
gating mutations
[197]
Oct-16 Schall et al. 3-month ivacaftor treatment resulted in weight gain, improved pulmonary function and growth status, and redu-
ced resting energy expenditure and gut inflammation in people with cystic fibrosis gating mutations
[198]
Oct-16 Schall et al. Improved pulmonary function and weight gain, reduced resting energy expenditure, and improved gut inflam-
maton after 3-month ivacaftor treatment in cystic fibrosis
[199]
Jan-17 Mesbahi et al. Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non
p.Gly551Asp gating mutations treated with ivacaftor
[200]
Feb-17 Stallings et al. Ivacaftor treatment in cystic fibrosis and improvement in resting energy expenditure gut inflammation and fat
absorption
[201]
Jun-17 Luna-Paredes et al. Impact of treatment with Ivacaftor on Spanish cystic fibrosis patients with gating mutations [202]
Jul-17 Strang et al. Pseudomonas eradication and clinical effectiveness of ivacaftor in four hispanic patients with S549N [203]
Sep-17 Dagan et al. Ivacaftor for the p.ser549arg gating mutation - the Israeli experience [204]
Sep-17 Mouzaki et al. Weight increase in CF patients on Kalydeco is due to decrease in resting energy expenditure and associated with
increase in adipose tissue
[205]
Sep-17 Sainath et al. Effect of ivacaftor treatment on dietary intake in Italian and North American subjects with cystic fibrosis [206]
Nov-17 Mouzaki et al. Increase in body weight of patients with cystic fibrosis receiving Kalydeco treatment is due to increase in adipose
tissue
[207]
Nov-17 Sainath et al. Changes in dietary intake with ivacaftor treatment in Italian and North American subjects with cystic fibrosis [208]
Jan-18 Dryden et al. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the
G551D mutation: a review
[209]
TABLE 7.2: Studies excluded from the ivacaftor systematic review after full-text review due to no comparator group
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Details of the 46 studies which fulfilled all the criteria can be found in Table 7.3. In to-
tal there were 21 RCTs and 25 observational studies. The median length of follow-up
time was 48 weeks (range 2 weeks to 4 years), and the median number of patients in
each study was 99 (range 8 to 9056). The sample sizes varied greatly depending on the
comparator group used: in RCTs only people with a gating mutation would be eligible
for inclusion, limiting the available population for these studies, whereas in some of the
observational studies people receiving ivacaftor were compared to controls with other
CF-causing mutations, hence the total sample size could be much bigger in these stu-
dies. Compared to the findings of the DNase systematic review in Chapter 3, the median
follow-up time is much longer (48 weeks compared to 12 weeks for the DNase studies)
and the median sample size is also larger (99 compared to 70) despite the number of pe-
ople who would be eligible for ivacaftor being much smaller than the number of people
eligible for DNase.
Assessing the quality of the studies with the Downs & Black questionnaire showed a
mean score of 19.7 (SD 4.8) out of a total of 32. This is only slightly higher than the
average of the studies included in the DNase systematic review (mean 18.7, SD 5.9), and
as in that review, we again found here that RCTs tended to score more highly than obser-
vational studies: the mean score for RCTs was 22.8 (SD 3.4) compared to 17.2 (SD 4.2) for
observational studies. A histogram of these scores is shown in figure 7.3
0
1
2
3
4
5
6
Fr
eq
ue
nc
y
0 5 10 15 20 25 30
Downs & Black Score
Observational Study
Randomised Trial
FIGURE 7.3: Histogram of Downs & Black scores for studies included in
the ivacaftor systematic review
Most of the studies included in the systematic review contained both children and adults,
but there were four studies that only contained children between 6 and 12 years old, and
five studies only looking at adults. None of the studies selected included participants
under 6 years old, as although there have been some studies investigating the effects of
ivacaftor in younger patients, the outcome measures are generally different for young
children and these are not routinely collected in the UK CF Registry.
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Nov-
10
Accurso et
al.
Effect of VX-770 in persons with cystic fi-
brosis and the G551D+CFTR mutation
RCT 24 2 8
(19 – 48) (42 – 97)
L [210]
Sep-
11
Plant et al. VX-770, an investigational CFTR poten-
tiator, in subjects with CF and the G551D
mutation
RCT 19 48 161
(12 – )
L E [211]
Oct-
11
Aherns et
al.
VX-770 in subjects 6 to 11 years with Cystic
Fibrosis and the G551D-CFTR mutation
RCT 28 24 52 8.9±2.0
(6-11)
84.2
(40 – 105)
L [212]
Oct-
11
Ramsey et
al.
Efficacy and safety of VX-770 in subjects
with cystic fibrosis and the G551D-CFTR
mutation
RCT 20 48 161
(12 – )
L E [213]
Nov-
11
Ramsey et
al.
A CFTR potentiator in patients with cystic
fibrosis and the G551D mutation
RCT 28 48 161 25.5
(12 – )
63.6
(32 – 98)
L E [214]
May-
12
Elborn et
al.
Pulmonary effects of the investigational
CFTR potentiator, Ivacaftor, in two phase
3 trials in subjects with CF who have the
G551D-CFTR mutation
RCT 25 48 161
(5 – ) (40 – 105)
L E [215]
Jun-
12
Davies et
al.
Ivacaftor in subjects 6 to 11 years of age
with cystic fibrosis and the G551D-CFTR
mutation
RCT 21 48 52
(6 – 11)
84.2±18.1
(40 – 105)
L [216]
Jun-
12
Davies et
al.
Effect of Ivacaftor on lung function in sub-
jects with CF who have the G551D-CFTR
mutation and mild lung disease: a com-
parison of lung clearance index (LCI) vs.
spirometry
RCT 20 4 14 14.0±8.6
(6 – ) (90 – )
L [217]
Jun-
12
Greiese et
al.
Pulmonary exacerbations in a Phase 3 trial
of Ivacaftor in subjects with cystic fibrosis
who have the G551D-CFTR mutation
RCT 24 48 161
(12 – ) (40 – 90)
E [218]
Sep-
12
Davies et
al.
Lung clearance index to evaluate the effect
of Ivacaftor on lung function in subjects
with CF who have the G551D-CFTR muta-
tion and mild lung disease
RCT 19 4 34
16.6±10.9
(6 – )
97.2±10.6
(90 – )
L [219]
Sep-
12
Elborn et
al.
Effects of the CFTR potentiator, Ivacaftor, in
two phase 3 trials in subjects with CF who
have the G551D-CFTR mutation
RCT 25 48 161
(6 – ) (40 – 105)
L E [220]
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, and Survival
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Sep-
12
Ratjen et
al.
Effect of ivacaftor on lung clearance index
and FEV1 in subjects with CF who have
the G551D-CFTR mutation and mild lung
disease
RCT 24 4 40
16.6±10.9
(6 – )
97.2±10.6
(90 – )
L [221]
Dec-
12
Davies et
al.
Lung clearance index to evaluate the effect
of Ivacaftor on lung function in subjects
with CF who have the G551D-CFTR muta-
tion and mild lung disease
RCT 196 4 34
16.6±10.9
(6 – )
97.2±10.6
(90 – )
L [222]
Jun-
13
Barry et
al.
UK and Ireland review of Ivacaftor in se-
vere CF: Impact on hospitalisations and
antibiotic use
Obs 12 26 32
( – 40)
E [223]
Jun-
13
Davies et
al.
Efficacy and safety of ivacaftor in patients
aged 6 to 11 years with cystic fibrosis with a
G551D mutation
RCT 26 48 52 8.9
(6 – 12)
84.2
(44 – 133.8)
L E [224]
Jun-
13
Flume et
al.
Pulmonary exacerbations in CF patients
with the G551D-CFTR mutation treated
with ivacaftor
RCT 20 48 161
(6 – )
L E [225]
Jun-
13
Davies et
al.
Assessment of clinical response to ivacaftor
with lung clearance index in cystic fibro-
sis patients with a G551D-CFTR mutation
and preserved spirometry: a randomised
controlled trial
RCT 27 4 34
16.6±11.2
(8 – 43)
97.2±10.8
(90 – )
L [226]
Oct-
13
Elborn et
al.
Effect of Ivacaftor in patients with cystic
fibrosis at the G551D-CFTR mutation who
have baseline FEV1>90% of predicted
RCT 19 7 28
(6 – )
99.2
(90 – )
L [227]
May-
14
Ronan et
al.
Real world sustained efficacy, tolerability
and satisfaction with ivacaftor use in a sin-
gle adult cystic fibrosis centre cohort
Obs 16 26 30
(16 – )
E [228]
Jun-
14
Ronan et
al.
Clinical outcomes of real world Kalydeco
(CORK) study
Obs 11 26 58
(6 – )
E [229]
Jul-
14
Barry et
al.
Effects of ivacaftor in patients with cystic
fibrosis who carry the G551D mutation and
have severe lung disease
Obs 20 34 56 22.6
(20 – 31)
28.9±7.6
( – 40)
L E [230]
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, and Survival
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Oct-
14
Nedevska
et al.
Ivacaftor: a new treatment for cystic fibrosis
which results in reduced sweat chloride and
improved clinical outcomes
Obs 10 52 22 23.5
(6 – 36)
E [231]
Dec-
14
De Boeck
et al.
Efficacy and safety of ivacaftor in patients
with cystic fibrosis and a non-G551D gating
mutation
RCT 27 8 78 22.8
(6 – 57)
78.4
(43 - -119)
L [232]
Jun-
15
Guha-
niyogi et
al.
Transformational care at the All Wales
Adult CF Centre (AWACFC) - the impact
of Ivacaftor (Kalydeco R©) one year on
Obs 15 52 22 28±13 63.5±26.2 E [233]
Sep-
15
Edge-
worth et
al.
Exercise improvements in ivacaftor treated
G551D cystic fibrosis patients are not solely
related to FEV1 and sweat changes
RCT 18 17 40 L [234]
Oct-
15
Bai et al. Ivacaftor long-term safety study: Analysis
of 2013 US CF Foundation patient registry
data
Obs 18 73 5931 E S [235]
Oct-
15
Sawicki et
al.
Sustained benefit from ivacaftor demonstra-
ted by combining clinical trial and cystic
fibrosis patient registry data
Obs 26 156 1075
21.5±10.7
67.2±20.3 L [236]
Jun-
16
Bai et al. Real-world outcomes in patients (pts) with
cystic fibrosis (CF) treated with ivacaftor
(IVA): analysis of 2014 US and UK CF regis-
tries
Obs 22 52 7456 E S [237]
Jun-
16
Bai et al. Real-world outcomes in young (6- to 12-
year-old) patients (pts) with cystic fibrosis
(CF) treated with ivacaftor (IVA): analysis of
2014 US and UK CF registries data
Obs 22 52 1324
(6 – 12)
E [238]
Jun-
16
Fila et al. Ivacaftor in cystic fibrosis adults: Czech
experience with six years of follow-up
Obs 12 52 10 28.6
(21 – 36)
45
(16 – 85)
L [239]
Jun-
16
Hassan et
al.
Reduction in pulmonary exacerbations
(Pex) after initiation of Ivacaftor: a retro-
spective cohort study among patients with
cystic fibrosis (CF) treated in real-world
settings
Obs 15 52 168
22.1±12.7
(6 – )
E [240]
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, and Survival
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Jun-
16
Hubert et
al.
Retrospective observational study of French
patients with cystic fibrosis and a G551D
mutation after 1 and 2 years of treatment
with ivacaftor
Obs 14 104 110 17.7
(6 – 52)
72.3±26.5 E [241]
Jun-
16
Iacotucci
et al.
Effects of ivacaftor in cystic fibrosis patients
carrying a non-G551D gating mutation with
severe lung disease
Obs 9 52 26 35.1±14.3
(40 – )
E [242]
Jun-
16
Volkova et
al.
Disease progression in patients (pts) with
cystic fibrosis (CF) treated with ivacaftor
(IVA): analysis of real-world data from the
UK CF registry
Obs 18 104 1642 71.3±23.8 L E [243]
Oct-
16
Bessonova
et al.
Analysis of real-world outcomes in patients
with CF treated with Ivacaftor from the
2014 US and UK CF registries
Obs 20 52 7456 E S [244]
Oct-
16
Hassan et
al.
One-year evaluation of pulmonary exacer-
bation outcomes among patients with cystic
fibrosis initiated on Ivacaftor in a multistate
medicaid population
Obs 17 52 88 13.1±6.7
(6 – )
E [245]
Oct-
16
Volkova et
al.
Analysis of disease progression in patients
with CF treated with ivacaftor in the real
world using data from the UK CF registry
Obs 18 104 1642 71.3±23.8 L E [246]
Jun-
17
Bessonova
et al.
Disease progression in patients (pts) with
cystic fibrosis (CF) treated with ivacaftor
(IVA): analysis of real-world data from the
UK CF Registry
Obs 19 156 1549 L [247]
Jun-
17
Bessonova
et al.
Real-world outcomes in patients (pts) with
cystic fibrosis (CF) treated with ivacaftor
(IVA): analysis of 2015 US and UK CF regis-
tries
Obs 20 52 9056 E S [248]
Jun-
17
Kirwan et
al.
Temporal trends in key outcome measures
in cystic fibrosis patients treated with Iva-
caftor: real-world data from the Irish CF
registry
Obs 17 130 228 E [249]
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, and Survival
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Date Authors Title Type of Quality2 Follow-Up Sample Age Baseline Outcomes4 Full
Study1 (Weeks) Size (Years)3 FEV1(%)3 Reference
Jul-
17
Edge-
worth et
al.
Improvement in exercise duration, lung
function and well-being in G551D-cystic
fibrosis patients: a double-blind, placebo-
controlled, randomized, cross-over study
with ivacaftor treatment
RCT 24 4 40 32
(18 – 65)
54
(23 –110)
L [250]
Sep-
17
Volkova et
al.
Disease progression in patients with CF tre-
ated with ivacaftor: Analyses of real world
data from the US and UK CF Registries
Obs 18 208 3024 82.1±23.2 L E [251]
Sep-
17
Volkova et
al.
Real-world outcomes in patients with CF
treated with Ivacaftor: 2015 US and UK CF
Registry analyses
Obs 17 52 9056 E S [252]
Oct-
17
Dagan et
al.
Ivacaftor for the p.Ser549Arg (S549R) gating
mutation - The Israeli experience
Obs 18 52 16 21±10
(12 – 40)
74 E [253]
Jan-
18
Flume et
al.
Recovery of lung function following a pul-
monary exacerbation in patients with cystic
fibrosis and the G551D-CFTR mutation trea-
ted with ivacaftor
RCT 21 48 161
(12 – )
63.6±16.4
(40 – 90)
E [254]
Jan-
18
Hubert et
al.
Retrospective observational study of
French patients with cystic fibrosis and a
Gly551Asp-GFTR mutation after 1 and 2
years of treatment with ivacaftor in a real-
world setting
Obs 25 104 113
21.5±13.1
(6 – 52)
72.3±26.4 E [255]
TABLE 7.3: Key details of studies included in the systematic review of ivacaftor
1 Randomised Controlled Trial or Observational Study
2 Calculated using Downs & Black scale, maximum score possible is 32
3 Mean±SD (Range)
4 The abbreviations refer to the following outcomes: Lung function, Exacerbations, and Survival
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In terms of baseline lung function most studies either had no exclusion criteria or had a
wide range of eligibility. There were, however, three studies which only included people
with severe lung disease (defined in the studies as FEV1<40% predicted) and six studies
which only included people with FEV1>90% predicted.
Of the two outcome measures we considered, exacerbations and/or IV days were the
most commonly reported outcomes, with 31 studies analysing these. FEV1 was an out-
come measure in 26 studies. The following two subsections look at the findings in each
of these outcomes in turn.
7.4.1 Exacerbations & IV Days
The most common way to estimate the effect of ivacaftor on exacerbations was to look at
the RR of having an exacerbation during the follow-up period between those receiving
ivacaftor and those not. However, the way this was measured differed markedly bet-
ween studies. Firstly, there is no universal definition of an exacerbation, and therefore,
each study used its own definition. Secondly, some studies obtained a RR by comparing
the proportions of people who had at least one exacerbation in the study period in the
ivacaftor and comparison groups, whereas other studies obtained a RR based on the total
number of exacerbations during the study period in the two groups. These two issues,
combined with the fact that RR are non-collapsible, means that the estimates from diffe-
rent studies will not technically be comparable. However, Figure 7.4 shows a forest plot
of all the estimated RR of exacerbations regardless of the specific definitions to help show
the overall trend of change in exacerbations when taking ivacaftor.
Three studies had follow-up of approximately half a year (24 weeks or 26 weeks) and all
three showed very large reductions in the risk of exacerbations in people taking ivacaftor.
The study by Ramsey et al. was a RCT in patients aged over 12 and the estimated RR of
an exacerbation in the ivacaftor group relative to the control group was 0.38 (95% CI
0.22, 0.64).[214] The other two studies were observational studies carried out in Ireland
by Ronan et al. and estimated the RR of requiring IVs. In adults the estimated RR was
0.15 (95% CI 0.02, 1.0), and in a group containing both adults and children it was 0.069
(95% CI 0.01, 0.49).[228, 229] These were the two most extreme RR estimates, but they
also have much larger CIs due to the smaller sample sizes of these two studies.
The majority of studies looked at the risk of exacerbations over a one-year period (either
48 weeks or 52 weeks). Of these studies, three only included children aged between 6
and 12 years. Two of these studies were RCTs and actually reported a higher risk of
exacerbations in the group receiving ivacaftor: Davies et al. reported RR 1.33 (95% CI
0.33, 5.38), Flume et al. reported RR 1.75 (95% CI 0.58, 5.27).[224, 225] These were the
only two studies to report a negative effect of ivacaftor, but in both studies the overall
rate of exacerbations was very low and the CIs were wide. The third study to only report
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FIGURE 7.4: Forest plot of studies comparing the risk of exacerbations in
those taking ivacaftor compared to controls (Some CIs are approximations
based on reported p-values and papers reporting the same results are only
plotted once)
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the effect in children was by Bai et al. and reported separate RR for the US and UK: US
RR 0.34 (95% CI 0.22, 0.52), UK RR 0.56 (95% CI 0.36, 0.88).[238]
Of the studies reporting one-year exacerbation rates, there were no studies reporting the
effects of ivacaftor on exacerbations only in adults, but nine studies did only include
people over the age of 12. Four of these papers reported on the same RCT which showed
a RR of 0.45 (95% CI 0.28, ,0.73) of an exacerbation in the ivacaftor group.[211, 213, 215,
220] In another two papers, the reported RR was 0.60 (95% CI 0.42, 0.86)[225, 254], another
RCT reported a RR of 0.43 (95% CI 0.27, 0.67)[218], and the final RCT reported almost the
exact same result of 0.43 (95% CI 0.27, 0.68)[214]. The one observational study to look at
the one-year exacerbation risk in patients over 12 compared the number of exacerbations
in patients receiving ivacaftor to the number of exacerbations they had suffered in the
year prior to starting ivacaftor. The reported RR here was 0.6 (95% CI 0.2, 1.7).[253]
The other studies to report on one-year exacerbation risks were all observational studies
with a minimum age of six, but no upper age limit. The majority of these studies looked
at the rate of exacerbations in the UK and US CF registries separately, comparing those
receiving ivacaftor to matched controls. These papers reported the RR of exacerbations
in the years 2012, 2013, 2014 and 2015, but did not account for the length of time using
ivacaftor. In the US in 2012 the estimated RR was 0.67 (no CI reported)[251]. In 2013, the
estimated RR in the US was 0.62 (95% CI 0.56, 0.69) and in the UK in 2013 it was 0.87 (CI
not reported).[235, 243, 246] In 2014, the estimated RR in the US was 0.64 (95% CI 0.58,
0.70), and in the UK was 0.61 (95% CI 0.53, 0.70).[237, 244]. In 2015, the estimated RR in
the US was 0.69 (95% CI 0.63, 0.76), and in the UK was 0.61 (95% CI 0.53, 0.70).[248, 252]
Two other studies were also carried out in the USA and reported one-year exacerbation
RR of 0.52 (95% CI 0.36, 0.77) and 0.58 (95% CI 0.35, 0.95).[240, 245] The last study esti-
mating one-year exacerbation rates was carried out in Italy and only included patients
with severe lung disease; here the RR of exacerbations in patients receiving ivacaftor was
0.49 (95% CI 0.30, 0.80) compared to the same patients in the year prior to starting ivacaf-
tor.[242]
There were only four studies which investigated the effect of receiving ivacaftor for lon-
ger than a year on exacerbations. Three studies analysed the US and UK CF registries
separately, and only included people who had started ivacaftor during its first year of
availability. In those patients, in the second year of treatment, the RR of exacerbations
in the USA was estimated to be 0.56 (no CI reported) and in the UK was 0.60 (no CI re-
ported).[243, 246, 251] In the third year in the USA the RR was 0.57 (no CI reported) and
in the UK was 0.63 (no CI reported), and in the fourth year in the US it was 0.56 (no CI
reported).[251] There is no four year estimate for the UK as ivacaftor became available
one year later in the UK than the USA.
The final study to look at the risk of exacerbations had a follow-up period of 30 months.
In this study by Kirwan et al. the RR of exacerbations in the 30 months after starting
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ivacaftor was 0.64 (no CI reported) compared to the 30 months prior to starting treat-
ment.[249]
Seven studies estimated the effect of ivacaftor on the total number of IV days. One study
was a RCT and it estimated the mean number of annual IV days to be 4.4 lower in those
receiving ivacaftor (95% CI 0.7, 8.0).[254] The observational study by Hubert et al. estima-
ted the number of IV days to decrease by 7.1 (95% 1.5, 12.7) in the first year of treatment
compared to the year prior to starting treatment.[241, 255] Two other studies also esti-
mated this difference: Guhaniyogi et al. -32.5 (95% CI -51.8, -13.2) and Nedevska et al.
-12.6 (no CI reported).[231, 233] Two studies only included patients with severe lung di-
sease and showed a more extreme decrease in the number of annual IV days of 41 (95%
CI 16,67) and 46 (95% CI 21, 71).[223, 230] The study by Hubert et al. also estimated the
difference between number of IV days in the second year of ivacaftor treatment compa-
red to the year prior to treatment and showed a mean decrease of 7.3 days (95% CI 1.4,
13.2).[241, 255]
Five of the seven studies with total IV days as an outcome also investigated the effect of
ivacaftor on just hospital IV days. The two studies of people with severe lung disease
showed mean decreases in the annual number of hospital IV days of 24 (95% CI 7, 41)
and 15 (95% CI 6, 24).[223, 230] However, none of the other studies found statistically
significant effects of ivacaftor on this outcome: estimated decrease in annual hospital
IV days in first year of treatment 1.2 (no CI reported, p > 0.5) and 3.7 (no CI reported,
p > 0.5).[231, 241, 255] Similarly, the estimated effect in the second year of treatment
was also not statistically significant, with an estimated decrease in the mean number of
annual IV days of only 0.2 (no CI reported, p > 0.5).[241, 255] All of these results can be
seen in Figure 7.5.
7.4.2 Lung Function
There were 26 studies measuring absolute change in ppFEV1. The follow-up time of these
studies ranged from just two weeks to four years, with most of the shorter studies being
RCTs (range 2 weeks to 48 weeks) and the longer studies being observational (range 34
weeks to 4 years). All of the results from these studies can be seen in Figure 7.6.
The shortest studies were just two weeks long, but even over this short time period the
observed treatment effect was still quite large: Accurso et al. showed a 9.8% increase in
ppFEV1 (95% CI -1.9, 21.5) and De Boeck et al. an 8.3% increase (95% CI 4.5, 12.1).[210,
232] The estimated effect was slightly larger at four weeks: De Boeck et al. 10.0% (95%
CI 6.2, 13.8) and Edgeworth et al. 13.7% (95% CI 7.0, 20.3).[232, 250], but at eight weeks
remained similar to four weeks: 10.7% (95% CI 7.3, 14.1).[232]
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FIGURE 7.5: Forest plot of studies investigating the effect of ivacaftor on
annual total and annual hospital IV Days (Some CIs are approximations
based on reported p-values and larger estimates are plotted separately on
right figure)
In studies with similarly short follow-up times of between 2 and 7 weeks, but restricted
to people with baseline ppFEV1 above 90%, the observed treatment effects were similar.
At two weeks Davies et al. observed a 11.0% increase (95% CI 2.3, 19.7)[226], and slightly
longer at 3.5 weeks a similar 12.8% (no CI reported) increase was seen in children aged
between 6 and 11, but only a 5.9% (no CI reported) increase in people aged over 12,
and by 7 weeks these had changed to 16.8% (no CI reported) and 5.9% (no CI reported)
respectively.[227] At four weeks, in studies not stratified by age the estimated treatment
effects were an increase of 7.2% (95% CI -2.0, 16.4), 7.0% (95% CI 1.6, 12.4), 5.5% (no CI
reported), and 7.01% (95% CI 1.8, 12.2).[217, 219, 221, 222, 226, 227].
Three RCTs had 8 weeks, 12 weeks and 17 weeks of follow-up and respectively the esti-
mates of the treatment effect from these studies were 10.7% (95% CI 7.3, 14.1), 9.3% (no
CI reported) and 11.7% (95% CI 5.3, 18.1).[214, 232, 234]
Although many papers reported on the treatment effect observed at 24 weeks, they were
all based on just two RCTs: one in people aged 6 to 11 and one in people aged over 12. In
the former, the estimated treatment effect was 12.5% (95% CI 6.3, 18.7), and in the latter it
was 10.6% (95% CI 5.3, 15.9).[211–216, 220, 224]
The shortest observational study estimated the treatment effect at 34 weeks and was re-
stricted to people with ppFEV1 less than 40%. The treatment effect estimated here was
more modest with an increase of only 3.2% (95% CI 0.8, 5.6).[230]
The one-year treatment effect was estimated in two RCTs, again one involving children
aged 6 to 11 and the other anyone aged 12 or over. The estimated treatment effect was
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very similar in both groups, however, with the 6 to 11 year old estimated treatment effect
being 10.0% (95% CI 4.3, 15.7) and those aged 12 or over having an estimated treatment
effect of 10.5% (95% CI 5.3, 15.7).[211, 213, 214, 216, 224]
An observational study of patients in the Czech Republic estimated the one year treat-
ment effect to be 3.6% (95% CI 0.1, 7.1).[239] In the USA, Sawicki et al. estimated the one-,
two- and three-year treatment effects to be 8.3% (95% CI 3.4, 13.2), 9.9% (95% CI 4.0, 15.8),
and 10.7% (95% CI 4.4, 17.0) respectively.[236] A separate study in the US estimated the
one-, two-, three- and four-year effects to be 3.2%, 5.6%, 6.2% and 7.2% (no CI repor-
ted),[251] and in the UK slightly larger estimates were obtained for the one-, two- and
three-year effects: 6.0%, 7.8% and 8.9%.[243, 246, 247, 251]
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FIGURE 7.6: Forest plot of studies estimating the effect of ivacaftor on ab-
solute change in ppFEV1 (Some CIs are approximations based on reported
p-values and papers reporting the same results are only plotted once)
Two RCTs reported the relative change in lung function as well as the absolute change.in
lung function and these results are shown in Figure 7.7. The study by Aherns et al. was
carried out in patients aged between 6 and 11 and showed a 17.4% (95% CI 8.7, 26.1)
mean relative change in ppFEV1 compared to placebo at 24 weeks.[212] In patients aged
over 12, the study by Ramsey et al. showed a similar result of 16.9% (95% CI 13.6, 20.2)
over 24 weeks, and this remained similar at 48 weeks: 16.8% (95% CI 13.5, 20.1).[214]
Only one study has so far estimated the effect of ivacaftor on the annual rate of lung
function decline. This observation study by Sawicki et al. used data from the US CF
Registry, and showed that the rate of decline in ppFEV1 was 0.81 less per year (95% CI
0.08, 1.54) in those using ivacaftor.[236]
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FIGURE 7.7: Forest plot of studies estimating the effect of ivacaftor on re-
lative change in ppFEV1 (Some CIs are approximations based on reported
p-values)
7.5 Discussion
7.5.1 Findings
This systematic review shows that there is consistent evidence across a number of studies
that ivacaftor is very beneficial in terms of all three outcomes studied. Although there are
variable definitions of what constitutes an exacerbation, all but four of the studies esti-
mated relatively similar RR of exacerbations, suggesting that ivacaftor reduces the risk of
exacerbations by approximately half. This did not appear to change with time, although
the only studies which reported the effects of more than one year of treatment did not
provide estimates of the SE or 95% CI. The four studies which reported very different
results were much smaller studies and the estimates had very large CIs. All four of these
studies estimated more extreme RR, two of a drastic reduction in the risk of exacerbations
when using ivacaftor and two estimating a small increase in risk of exacerbations, but in
all four studies the large CIs overlapped with the results from the other studies.
All the studies that reported the effects of ivacaftor on lung function showed a positive
effect. However, the results were more heterogeneous than the results on exacerbations,
with some studies showing more modest benefits of approximately a 5% improvement
in ppFEV1 and others showing improvements larger than 15%. There did not appear
to be any relationship between the length of follow-up and the estimated effect of tre-
atment. However, the one study which did investigate the effect of ivacaftor on rate of
lung function decline did suggest that the rate of decline was almost 1% less per year
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once treated with ivacaftor, suggesting that the treatment effect at specific time points
should grow over time.
Most studies included people with a wide range of characteristics, but there were some
studies that only included children, adults, people with severe lung disease, or people
with healthy lung function levels. Within all of these subgroups the effects of ivacaftor
were positive, with no obvious differences in treatment effect between the groups.
7.5.2 Limitations
In RCTs there is always a group with whom to compare those treated, as by design ap-
proximately half of the people eligible for the RCT will not receive treatment. However,
when considering observational studies, if we wish to be able to say something about the
treatment effect, we want to be able to estimate what would have happened to people had
they not received treatment. A lot of studies were excluded from this systematic review
because they only compared people to their baseline values, but without any group with
whom to compare them, we are unable to say anything about what might have happened
to them had they not received treatment.
In the observational studies that were included in this review there were two main com-
parator groups. Some studies matched people receiving treatment to controls who are
ineligible to receive treatment due to their genotype. Although matching will ensure that
patients are comparable at baseline, it cannot ensure that the matched control will have a
similar longitudinal change in variables that the person receiving treatment would have
had, had they not received treatment. There is an implicit assumption that people with
different CF-causing mutations matched on other baseline variables would have similar
disease progression. This assumption is not acknowledged in any of the papers and if
the assumption is not valid it would mean that the estimated treatment effects are not
accurate.
Other studies used people as their own controls, comparing the a period of time prior to
treatment to the time since treatment. This was more common for the outcome of exacer-
bations, where the risk of exacerbations in the year prior to treatment was compared to
the risk of exacerbations since treatment was initiated. Again, however, there is an im-
plicit assumption here that is not mentioned in the papers, that there have been no other
changes in health care in this time period. Over a short time period, it may be reasonable
that such an assumption would not be violated, but when looking longer term, it beco-
mes more likely that there could have been other changes that could affect the health of
individuals not related to the treatment.
Although we have only considered studies that provided ivacaftor to people with gating
mutations, we have not taken into account that some studies only included one specific
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gating mutation. We have therefore assumed that the effect of ivacaftor is comparable no
matter the specific gating mutation.
7.5.3 Conclusions
Although ivacaftor is a relatively new treatment there have already been many studies
published to investigate its effects and all of them have shown very strong positive re-
sults. However, given the newness of the treatment, there is still no conclusive evidence
of its long-term effectiveness. Furthermore, many of the observational studies initially
found through the search of this systematic review were excluded as they provided no
estimate of the causal effect of treatment due to having no control group.
Compared to the number of studies from the systematic review of DNase, there has cle-
arly been an increase in interest in using observational data to estimate the effects of
long-term treatment use, but it is unfortunate that in many cases the methods used are
inadequate to estimate a causal effect of treatment in an unbiased way.
Implications
• All studies show very promising results, but only a few studies have estimated the
effects of more than one year of treatment
• As almost all people who are eligible for ivacaftor are now receiving it, so it is im-
portant to consider who we can compare them with to be able to accurately estimate
treatment effects
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Chapter 8
Statistical Methods to Estimate
Effects of Ivacaftor
8.1 Introduction
The systematic review in the previous chapter demonstrated that ivacaftor has shown
very promising results so far. However most of the studies only followed patients for a
year after initiating ivacaftor, with just a few studies with longer follow-up out to four
years. In real world practice, people would generally be expected to continue receiving
ivacaftor indefinitely for the rest of their lives, so it is important to be able to continue to
estimate the effectiveness of the treatment long term.
Clearly, it is neither feasible nor ethical to continue to withhold treatment from some
of the eligible population which is what would be necessary to estimate the long-term
treatment effect using a RCT. However, in order to estimate a treatment effect, we do need
to have an estimate of what would happen to people long term if they were not receiving
ivacaftor, so that we can compare this to what has happened to people since they have
been receiving the treatment. Because everyone who is eligible to receive ivacaftor is now
receiving it, we no longer have a control group with whom to compare the treatment
group.
In this chapter, we will introduce two possible comparator groups that have been identi-
fied and that could be used to compare outcomes with long-term follow-up on ivacaftor
to those with long-term follow-up without ivacaftor. We also discuss the assumptions
underlying the use of these comparator groups. We introduce the use of negative con-
trols, which can be used to test the validity of the assumptions we must make in order
for the analyses to be correct. Finally, we introduce possible statistical analysis methods
that could be used when comparing these groups.
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8.2 Comparator Groups
As seen in the systematic review, in the absence of direct control patients, most observati-
onal studies have compared people now receiving ivacaftor either to people not receiving
ivacaftor because they do not have an eligible genotype, or to the people eligible for iva-
caftor in the time period prior to when ivacaftor was available. These two comparator
groups can be seen summarised in Figure 8.1. Ivacaftor is only available for people in
group B of Figure 8.1, this is the group of patients with an eligible genotype for ivacaftor
(G = 1) in the time period since ivacaftor has been available (P = 1) . The data from the
patients in group B allow us to measure what has happened to them since they started to
receive ivacaftor. However, to estimate the treatment effect, we also need to know what
would have happened to them had they not received treatment. Because everybody in
group B is receiving ivacaftor, we cannot directly measure this.
Ivacaftor
Pre- Post-
P = 0 P = 1
Genotype
Gating G = 1 A B
Other G = 0 C D
FIGURE 8.1: Division of CF population into four groups based on genotype
(rows) and time period (columns)
The other three groups of Figure 8.1 are not receiving ivacaftor, either because it was not
yet available (group A), or because they do not have an eligible genotype (group D), or
due to both of these reasons (group C). If we are willing to assume that all four of these
groups are comparable in terms of their long-term health trajectories, then we can simply
observe what happened in these groups (A, B and C) of patients over the same length
of follow-up as those in group B. We would then assume that what we observe in these
groups is what would have happened to those in group B had they not received ivacaftor,
and any difference observed between group B and the other groups would then be attri-
buted as the treatment effect of ivacaftor. We define this estimate of the treatment effect,
the ‘Naïve Treatment Effect’ (NTE); it is an estimate of the treatment effect assuming that
these different groups of patients are directly comparable. A more precise definition of
the NTE and the other treatment effects we consider is given in Section 8.3.1.
For example, for patients in group B who started receiving ivacaftor in 2012 and were
followed-up until 2016, we wish to estimate the effect of receiving ivacaftor for four years
compared to not receiving ivacaftor for four years. We could therefore compare them to
the four-year follow-up observed in group D, again from 2012 to 2016. Simply comparing
these two groups would assume that people with different genotypes have on average
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the same disease severity, i.e. that the genotype does not affect the outcome of interest.
This scenario is reflected in the DAG shown in Figure 8.2a. Here genotype is assumed to
have no effect except on the eligibility to receive ivacaftor. Thus in this setting, the final
outcome of interest could simply be compared between the two genotype groups.
X
G
P
H
Y
(A)
X
G
P
H
Y
(B)
X
G
P
H
Y
(C)
FIGURE 8.2: DAGs showing potential causal pathways between ivacaftor
(X), Genotype (G), time Period (P), covariates measuring Health at base-
line (H) and outcome (Y)
A number of studies have looked at comparing the long-term health between people with
different genotypes and overall the findings suggest that people with a gating mutation
eligible for ivacaftor have similar lung function decline and survival as people with a
class II mutation who form the majority of people with CF.[256, 257] This would suggest
that the causal pathways shown in Figure 8.2a may be valid. However, we also present
two other possible DAGs. In Figure 8.2b, genotype is now assumed to affect health at ba-
seline (which we take to be measured through observed covariates), but after accounting
for these baseline differences, genotype is assumed to not directly affect future health.
In this setting, genotype would be a confounder of the treatment effect that we wish to
estimate, but rather than adjusting for genotype (which is not possible due to perfect col-
linearity with ivacaftor), adjustment for the baseline covariates (H) would be sufficient to
control for this confounding, because adjusting for H would block the path from G to Y
not through X. (See Section 8.3.2 for details on the situation when there are additionally
some unmeasured baseline determinants of health).
The final scenario presented in Figure 8.2c shows genotype being directly associated with
the outcome of interest. In this situation, the NTE obtained from comparing group B
to group D would no longer be an unbiased estimate of the treatment effect, because
it would not be possible to correct for the differences between these groups due to ge-
notype. For the NTE to be an unbiased estimate of the treatment effect, we must there-
fore assume that after adjustment for baseline differences, genotype has no effect on the
outcome of interest, i.e. the scenarios shown in Figure 8.2a or Figure 8.2b. Furthermore,
in the scenario shown in Figure 8.2b, we must adjust for H, whereas this would not be
necessary in the scenario shown in Figure 8.2a.
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As well as comparing those currently receiving ivacaftor (group B) to those not eligible
for ivacaftor (group D), we could also compare outcomes in group B to outcomes in group
A. This would compare the four years since people have been receiving ivacaftor (2012
to 2016) to the four years directly preceeding the introduction of the ivacaftor (2008 to
2012) in the same group of patients. In this situation, we face the same predicament as in
the comparison of those eligible and not eligible for ivacaftor. The same three scenarios
are presented again in Figure 8.2, where in this analysis the time period (P) is a perfect
predictor of ivacaftor. We can adjust for any diffences between people at baseline, i.e.
whether the average health of people differed in 2008 compared to 2012, but must then
assume that the outcome trajectories have not changed between 2008-2012 and 2012-2016.
Over a longer period of time, we know that there have been improvements in the survival
and average health of the CF population thanks to the introduction of other treatments
and improvements in health care practice.[258] However, whether there would be an
observable effect over the eight year time period of our analysis is uncertain. For this
reason, we would ideally like to be able to test these assumptions of the comparability of
group B to group A, and also the comparability of group B to group D.
8.3 Negative Controls
For either of the analyses introduced in the previous section to provide unbiased treat-
ment estimates, we must assume that either genotype or time period has no direct effect
on our outcome of interest. This assumption could be valid for some outcomes and not
for others and therefore it would be good to be able to test the validity of these assump-
tions.
The use of a negative control analysis is a technique often utilised in biological laboratory
studies, where all analyses are repeated under identical conditions except that the active
substance of interest is not used. The results of the negative control analysis are therefore
excepted to be null, and if this is the case, it suggests that the results observed in the actual
analysis are due to the active substance of interest and not due to any other potential
sources of bias in the experiment.
Negative controls have not often been used in epidemiological studies, but it has been
proposed that they could be a useful tool in detecting bias in analyses, especially bias
due to unobserved confounding, which is often a key issue in observational studies.[259]
In our setting, we do not technically have any unobserved confounders of the association
between treatment and outcome, as we have observed for everyone the reason why they
are or are not receiving ivacaftor (i.e. their genotype and time period). However, because
these two variables cannot be accounted for in the analysis, we do wish to learn whether
there may be any bias from ignoring them in the analyses.
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In the literature on the use of negative controls in epidemiological studies, two types of
negative controls have been identified: negative exposure controls and negative outcome
controls.[259–261] A negative outcome control would be an outcome that is believed to
not be affected in any way by the exposure of interest.[262] As ivacaftor is generally
believed to be a ‘disease-modifying’ treatment, it is possible that the treatment affects
many different outcomes, and it is unlikely to be plausible to assume that ivacaftor would
have no effect on any of the health data collected in the registry.
We instead propose the use of a negative control exposure. A negative control exposure is
an exposure which is believed not to affect the outcome of interest, but except for this is as
similar as possible to the exposure of interest. In our setting, we have had to assume that
neither genotype nor time period is a cause of the outcome of interest except via its effect
on ivacaftor use. If we can identify groups that differ by genotype and/or time period,
but where neither group receives ivacaftor, we can test the assumptions that these have
no effect on the outcome. In the previous section, we identified two analyses to estimate
the NTE of ivacaftor: compare group B to group A, or compare group B to group D. In
neither case did we utilise group C, but this group can be used to assess whether these
four different groups of patients are comparable except for ivacaftor.
In the comparison of group B to group A, we assess how the outcome changed at the
end of the four year period prior to ivacaftor compared to the four year period since
its introduction. To test the assumption that time period has no effect on the outcome
after adjustment for baseline covariates, we can perform the same analysis, but compare
group D to group C, i.e. compare the same time periods, but in a group of patients where
ivacaftor was not introduced. We define the difference between these groups (or similarly
the difference between group A and group C when looking at whether there is an effect
of genotype) as the negative control effect (NCE). For the NTE estimate to be an unbiased
estimate of the true treatment effect, we expect the NCE estimate to be null.
Similarly, in the analysis comparing group B to group D, we assume that genotype has no
effect on outcomes after adjustment for baseline covariates. This can be tested, under the
assumption that the effect of genotype on outcome is the same in both time periods, by
performing the same analysis, but comparing group A to group C, i.e. comparing whet-
her genotype had an effect on the outcome before the introduction of ivacaftor. If this
result were non-null, it would suggest that genotype has a direct effect on the outcome
of interest (as shown in Figure 8.2c) and that the NTE estimate from the main analysis is
biased.
8.3.1 Negative-Control-Corrected Treatment Effect
The ideal result would be for the NCE to be zero, as this would suggest that the NTE
is an unbiased estimator of the true treatment effect. However, in reality, the estimate
Chapter 8. Statistical Methods to Estimate Effects of Ivacaftor 164
of the NCE will never be exactly zero, and even if it were, there would still be some
uncertainty around the estimate. To obtain a more reliable estimate of the true treatment
effect, we should therefore account for both the NCE estimate and its SE. The simplest
way to do this is to subtract the NCE estimator from the NTE estimator. We define this
as the negative-control-corrected treatment effect (NCCTE) estimator:
NCCTE = NTE−NCE (8.1)
This ‘difference in differences’ approach will be valid provided that the magnitude of the
effect not due to ivacaftor is the same in both populations.[263] For example, for the com-
parison of genotype groups, we would assume that any difference observed between the
groups does not change over time. Similarly, for the comparison of the same individuals
before and after the introduction of ivacaftor, we would assume that any change over
time observed in those ineligible for ivacaftor is the same as any change in those eligible
for ivacaftor apart from the influence of ivacaftor. Both of these assumptions are weaker
than the assumptions necessary for the NTE estimate to be an unbiased estimate of the
true treatment effect, as there we had to assume that there was no effect of time period
or genotype except the effect mediated through ivacaftor use. With the NCCTE estima-
tor, we allow for differences in the outcome by time period and genotype, but assume
that the differences are the same in the negative control comparison as in the comparison
between the groups receiving and not receiving ivacaftor.
The variance of the NCCTE estimator can be calculated as follows:
Var(NCCTE) = Var(NTE−NCE) = Var(NTE)+Var(NCE)− 2Cov(NTE,NCE). (8.2)
This means that in general we would need to know the covariance between the NTE
and the NCE. As estimates of the NTE and NCE are obtained from two separate models,
we will not generally be able to estimate this quantity analytically and thus a bootstrap
method will usually be necessary to obtain estimates of the variance of the NCCTE. Ho-
wever, in the analysis comparing the time period since ivacaftor to the time period before
ivacaftor, the NCE groups are completely independent of the NTE groups (i.e. the same
person cannot be in both analyses, because people cannot change genotype). As such,
the covariance of the two estimates is expected to be zero, meaning the variance of the
NCCTE will simply be the sum of the variances of the NTE and the NCE. This is not true
in the case of the analysis comparing those eligible for ivacaftor to those ineligible for
ivacaftor as the same individual can be in both the NTE analysis and the NCE analysis.
In summary, we have proposed two different analyses, each with a different negative
control:
• Analysis 1:
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– Naïve Treatment Effect:
∗ Compare outcomes post-ivacaftor to outcomes pre-ivacaftor in those eli-
gible for ivacaftor, i.e. group B vs group A
∗ NTEP = E(Y|H = h, P = 1, G = 1)− E(Y|H = h, P = 0, G = 1)
– Negative-Control Effect:
∗ Compare outcomes post-ivacaftor to outcomes pre-ivacaftor in those ine-
ligible for ivacaftor, i.e. group D vs group C
∗ NCEP = E(Y|H = h, P = 1, G = 0)− E(Y|H = h, P = 0, G = 0)
– Negative-Control-Corrected Treatment Effect:
∗ NCCTEP = NTEP −NCEP = E(Y|H = h, P = 1, G = 1) − E(Y|H =
h, P = 0, G = 1)− E(Y|H = h, P = 1, G = 0) + E(Y|H = h, P = 0, G = 0)
– Assumptions:
∗ NTEP assumes that P does not affect Y after adjustment for H
∗ NCCTEP assumes that the effect of P on Y is not modified by G
• Analysis 2:
– Naïve Treatment Effect:
∗ Compare outcomes in those eligible for ivacaftor to outcomes in those in-
eligible for ivacaftor in the four years since ivacaftor was introduced, i.e.
group B vs group D
∗ NTEG = E(Y|H = h, P = 1, G = 1)− E(Y|H = h, P = 1, G = 0)
– Negative-Control Effect:
∗ Compare outcomes in those eligible for ivacaftor to outcomes in those ine-
ligible for ivacaftor in the four years prior to the introduction of ivacaftor,
i.e. group A vs group C
∗ NCEG = E(Y|H = h, P = 0, G = 1)− E(Y|H = h, P = 0, G = 0)
– Negative-Control-Corrected Treatment Effect:
∗ NCCTEG = NTEG −NCEG = E(Y|H = h, P = 1, G = 1) − E(Y|H =
h, P = 1, G = 0)− E(Y|H = h, P = 0, G = 1) + E(Y|H = h, P = 0, G = 0)
– Assumptions:
∗ NTEG assumes that G does not affect Y after adjustment for H
∗ NCCTEG assumes that the effect of G on Y is not modified by P
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It can be seen that the NCCTE estimator is the same in both analyses, but this will only
be an unbiased estimator of the true treatment effect provided that the assumption of no
interaction between genotype and time period on the outcome is valid. Conversely, the
NTE estimates are different between the analyses, and will only both be unbiased if there
is no direct effect of either time period or genotype, i.e. E(Y|H = h, P = 0, G = 1) =
E(Y|H = h, P = 1, G = 0) = E(Y|H = h, P = 0, G = 0).
8.3.2 Unmeasured Covariates
As well as correcting for any direct effect of genotype or time period on the outcome,
the use of the negative controls can also correct for any effects of unmeasured covariates
on the outcome. Figure 8.3 shows three possible assumed causal pathways where now
some of the baseline covariates are unmeasured, U. In Figure 8.3a, neither genotype nor
time period affect any of the baseline covariates, measured or unmeasured, nor do they
directly affect the outcome. In this situation, the use of negative controls would not be
required to obtain an unbiased estimate of the treatment effect. However, in Figure 8.3b,
genotype and time period are now assumed to affect the baseline covariates. Previously,
when we had no unmeasured covariates, as shown in Figure 8.2b, we still did not require
the use of a negative control, as conditioning on the baseline covariates, H would have
been sufficient to control for the confounding by genotype and time period, and the NCE
estimate would be expected to be null. In the situation where we no longer assume that
all the baseline covariates have been measured, we would need to use negative controls
to obtain an unbiased estimate of the treatment effect. In this setting, the NCE estimate
would be the indirect effects of genotype and time period through the unmeasured ba-
seline covariates. In the setting shown in Figure 8.3c, the NCE would now be both the
direct effect of genotype and time period on the outcome, as well as the indirect effects
through the unmeasured baseline covariates.
X
G
P
H
U
Y
(A)
X
G
P
H
U
Y
(B)
X
G
P
H
U
Y
(C)
FIGURE 8.3: DAGs showing potential causal pathways between ivacaftor
(X), Genotype (G), time Period (P), measured covariates of Health at ba-
seline (H), Unmeasured covariates of health at baseline (U) and outcome
(Y)
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This suggests that even if we are willing to believe that genotype and time period have
no direct effect on the outcome after account for baseline differences between groups, the
use of a negative control is still beneficial as we no longer need to assume that we have
measured all of the important baseline variables.
8.3.3 Combined Model
Analyses 1 and 2 described above involve fitting four models. Rather than perform each
of these analyses separately, it is also possible to combine them into one analysis. One
of the main benefits of comparing all groups simultaneously is that ivacaftor is no lon-
ger perfectly collinear with either time period or genotype, meaning that the negative
controls can be included in the main model and the NCCTE estimate will then be di-
rectly estimated from the model.[264] For example, using all four groups, we could fit
the following model:
E(Y|H = h, P = p, G = g, X = x) = β0 + βhH + βpP + βgG + βxX, (8.3)
where X = P× G.
Here βx corresponds to the NCCTE, as both genotype and time period have been accoun-
ted for through βp and βg. However, we are still making the same assumption, as before,
that there is no interaction between P and G and it would not be possible to include an
interaction term between P and G, as P = 1, G = 1 ⇐⇒ X = 1. This analysis also makes
the further assumption that the effect of H is common among all four groups, whereas in
the previous analyses this effect could be different between analyses 1 and 2.
By combining all the groups into one model we increase our sample size which may
improve the efficiency. However, the NCCTE must now account for the uncertainty in
both the effect of genotype and the effect of time period, and therefore any improvements
in the variance of the estimates due to increases in sample size may be offset this.
8.4 Analysis Methods
Due to the longitudinal nature of the registry data, it would be common to use mixed-
effects models to account for the variability between individuals. However, as we are
only interested in the average effect of treatment, it would actually be possible to use sim-
pler methods and still obtain unbiased estimators of the treatment effect. In this section,
we will first introduce two simpler methods: marginal models and fixed-effects models,
before exploring the potential benefits and drawbacks of using mixed-effects models.
We introduce the methods with a continuous outcome, and will end the section with a
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discussion of any additional complexities when using count outcomes. All of the exam-
ples below are presented for the example of estimating the NTE, but by definition, the
negative-control analyses should be identical to the main analysis, except that treatment,
X, would be replaced by the negative control exposure, G or P.
8.4.1 Marginal Models
The simplest form of a marginal model is a generalised estimating equation assuming
an independent working correlation matrix, which is simply the ordinary least squares
estimator obtained through standard regression procedures. For example,
Yij = β0 + βxXij + βxtXijTij + βtTij + βhH ij + eij, (8.4)
where i refers to an individual, j refers to the visit number, T refers to time elapsed since
baseline (defined as the start of the pre-ivacaftor period or the start of the post-ivacaftor
period) and e is the residual error.
First we define the two treatment effects that we are interested in estimating. At the first
visit after treatment was initiated (j = 1), we hope that the treatment will have resulted in
an acute improvement in the outcome. This is the estimate given by βx, which we refer to
as the step-change treatment effect. Furthermore, if there is a decline in the outcome over
time, as estimated by βt, we hope that treatment can slow this decline, and this would be
estimated by βxt, which we refer to as the slope-change treatment effect.
Overall, the model specified in Equation 8.4 should provide an unbiased estimate of the
NTE, because j is not a confounder, i.e. receipt of the treatment is determined only by
genotype and time period, and not by additional individual characteristics. Furthermore,
it is expected that the baseline covariates contained in H can explain a lot of the variance
in outcome between individuals. However, if i remains a strong predictor of Y after
adjustment for H, then although this method will on average give unbiased results, it
will be very inefficient, as the error term e would be much larger than if i were somehow
accounted for.
Using standard regression methods assumes an independent working correlation matrix,
i.e. that observations from the same individual are not correlated. Violations of this as-
sumption only impact the efficiency of the estimation of the average treatment effect, but
do not result in bias.[265] A simple alternative is to assume exchangeability, which is that
all observations are equally correlated to one another. The benefit of assuming indepen-
dent or exchangeable working correlation matrices is that the observations do not have
to happen at specific times, so the exact time since baseline can be used for every obser-
vation. Other types of working correlation matrix can be used, such as designs which
allow observations that are closer together in time to be more strongly correlated to one
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another than observations further apart. However, these matrices now require visits to
happen at discrete intervals. In the UK CF Registry, visits are supposed to happen every
twelve months, so this may be a possibility, but any efficiency gained from better specifi-
cation of the working correlation matrix could be offset by ignoring the exact amount of
time elapsed since baseline.
Finally, it should be noted that the standard model-based estimates for the SE would be
incorrect as they would not account for the non-independence of observations from the
same individual. For this reason, it would be necessary to use a robust estimator of the
SE.
8.4.2 Fixed-Effects Regression
If between individuals there are large differences in the outcome even after accounting
for baseline covariates, then it is possible to use fixed-effects regression to further correct
for baseline differences between individuals. For this, we consider models of the form:
Yij = βi + βxXij + βxtXijTij + βtTij + eij. (8.5)
The main difference between Equation 8.4.2 and Equation 8.4 is that the single inter-
cept term, β0, has now been replaced by a separate intercept term for each person, βi.
However, another difference is that we no longer include the baseline covariates, H, in
this model. This is because every person now has a unique estimate for their ‘average’
outcome, βi, and the baseline variables H do not vary within an individual. Thus, the
effects of each individual baseline variable can no longer be estimated, but if we are only
interested in estimating the treatment effects then this is not an issue.
As with marginal models a robust estimator should be used to calculate SEs.
8.4.3 Mixed-Effects Regression
Rather than estimating a separate intercept term for every individual, mixed models only
estimate one intercept term and then also estimate how each individual varies around
this average. It is necessary to make an assumption about the distribution of these
random effects, and the most common assumption would be that they are normally dis-
tributed with mean zero and a common variance. Then, the mixed model only estimates
one intercept term and one variance term, rather than having to estimate a separate in-
tercept term for each individual.
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It is common to not only include a random intercept, but also a random slope, for exam-
ple:
Yij = β0 + βxXij + βxtXijTij + βtTij + βhH ij + ui0 + uitTij + eij, (8.6)
where ui0 is the random-intercept term and uit is the random-slope term allowing for
how different each individual is from average, β0 and βt respectively.
In a fixed-effects model, the intercepts are essentially estimated non-parametrically, i.e.
there is no distribution assumption behind the estimates. However, in the case of a
mixed-effects model, we must now specify the distribution of the effects, and a misspe-
cification of this could lead to bias in the estimated treatment effect, but would lead to
a gain in efficiency if it is correctly specified. One example would be that rather than a
common variance among all individuals as stated above, there could actually be less va-
riability among people receiving ivacaftor. For example a very effective treatment could
result in everybody having a healthy lung function and thus little variability between
people compared to those not receiving treatment. This type of heteroscedasticity can
easily be incorporated into mixed models, by choosing to estimate two separate varian-
ces for those receiving and not receiving ivacaftor, but it highlights how there are more
modelling decisions that need to be made when using mixed-effects models compared to
fixed-effects models or marginal models.
Finally, unlike with marginal and fixed-effects models, the standard model-based estima-
tes of the SE are consistent estimates of the true SE.
8.4.4 Models for Count Outcomes
All three methods introduced above can easily handle count outcomes, but there are a
number of technicalities which must be addressed.
Firstly, as previously discussed in Section 4.8, it is important to remember that due to non-
collapsibility, there is no unique treatment effect estimate with non-linear models. Fixed-
and mixed-effects models are conditional on the individual and estimate the within-
individual treatment effect, i.e. an estimate of what would be observed on average to
one person if they did or did not receive treatment. Conversely, marginal models do not
condition on the individual and thus will estimate the population average treatment ef-
fect. If no other covariates are included in the model, this would be the average effect
seen over the whole population if everyone did or did not receive treatment, but if ot-
her baseline covariates are included in the model, the estimate would be conditional on
these covariates. This is also an issue when comparing fixed- and mixed- effects models,
as when using a fixed-effects model we cannot condition on baseline covariates, whe-
reas this can be done in a mixed-effects model. Thus, even these two within-individual
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treatment effect estimates will not be expected to be the same. All of these treatment
effect estimators can be different whilst all still being correct and this makes compari-
sons between methods more difficult. It is therefore important to carefully consider what
each method is actually estimating and what is the treatment effect we are interested in
estimating.[266]
In Part II, we modelled the annual number of IV days from a zero-inflated negative bi-
nomial distribution, and in the case of a marginal model, this is still a possibility. Ho-
wever, fixed-effects models should not be used with logistic regression (which is used
for the zero-inflated part of the distribution). This is because a lot of individuals can ea-
sily end up with no variability in outcome between observations leading to estimation
problems.[267] Fixed-effects models can, however, be used for other types of non-linear
models, such as a negative binomial model.[268] This means that this method could be
used if we were willing to ignore the excess of zeroes. It is also computationally chal-
lenging to fit a mixed-effects model under a zero-inflated negative binomial distribution,
and there are no packages currently available in Stata which can fit this type of model.
The models for count outcomes will use a log link function. The NTE and NCE estimates
can then be expressed in terms of an IRR by taking the exponential of the coefficients
estimated from the models. In this case, we are again hoping that the coefficient for the
NCE estimate is null, i.e. an IRR of 1. The NCCTE estimate can then be obtained either
on the log scale:
log (NCCTE) = log (NTE)− log (NCE) , (8.7)
or directly as an IRR:
NCCTE =
NTE
NCE
. (8.8)
8.4.5 Comparison of Methods
Under the assumptions listed, all three methods should provide consistent estimators of
the treatment effect, and therefore one of the key criteria when assessing the methods
is their efficiency. As discussed in Section 8.4.1, using standard regression methods will
ignore the variability between individuals, which could lead to inefficiencies. However, if
a lot of the variability between individuals can be explained by other baseline covariates,
there may not be a noticeable decrease in the efficiency of this method compared to the
other two methods. In general, mixed-effects models require a large number of people
to be able to accurately estimate the random-effects, but this should not be an issue with
the UK CF Registry. However, this could cause issues with fixed-effects regression where
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a separate intercept will need to be estimated for each of the thousands of individuals.
Furthermore, each individual only has a small number of observations, making it difficult
to accurately estimate the fixed intercepts, which may affect the efficiency for estimating
the treatment effect.
Another key consideration is computation time. In general, the computation time requi-
red for marginal or fixed-effects models will be noticeably quicker than that required for
mixed-models. If only fitting one mixed-model, this might not be much of an issue. Ho-
wever, in order to estimate the NCCTE estimate, we generally need to use a bootstrap
procedure, meaning that any differences in computation time will be exacerbated. For
non-linear models, this is even more of an issue, because they are slower to fit, and there
can often be difficulties with achieving convergence for these models.
In the next chapter, when analysing the UK CF Registry to estimate the effects of ivacaf-
tor, we will use all three available methods to compare results. In the case of a continuous
outcome, such as lung function, we would expect all three methods to give similar results,
which could highlight issues if there are any stark differences between methods. We can
then assess whether the additional computation time for mixed-models has resulted in
noticeable gains in reducing the SE of the treatment effect estimates. For count outco-
mes, such as IV days, the estimates cannot be compared as the marginal and conditional
estimates are expected to be different.
173
Chapter 9
Estimating the Effects of Long-Term
Ivacaftor Use
9.1 Introduction
The systematic review in Chapter 7 showed that there is a lot of interest in ivacaftor and
specifically in its long-term effectiveness to assess to what extent it is ‘disease-modifying’.
The RCTs for ivacaftor showed very impressive results with a maximum follow-up time
of 48 weeks, and since then ivacaftor has generally been initiated in all eligible patients.
As previously discussed, to be eligible for ivacaftor CF patients must generally have a
gating mutation. There have also been studies that have investigated the effectiveness of
ivacaftor in people with a residual function mutation[269], but it is not generally avai-
lable for these people in the UK. This means the UK CF Registry could not be used to
investigate the effectiveness of treatment in this group of patients.
For people with a gating mutation, ivacaftor was initially introduced only in those pa-
tients over six years old. Since then, the minimum age has been lowered to two, but there
is still only a small amount of data for these younger patients in the UK CF Registry, es-
pecially as the lung function measures are not typically used in children under six. For
this reason, we restrict the analyses in this chapter to people over six years old.
Almost all people with CF in the UK who are aged over six and have a gating mutation
have been receiving ivacaftor since 2012.[270] This means we currently have four years of
follow-up data (up to the end of 2016). One of the key benefits of such long-term data is
in terms of lung function outcomes, where it is hoped that a disease-modifying treatment
can not only provide a step-change increase in lung function, but can also slow the rate
of lung function decline. This latter treatment effect is hard to measure with short-term
data. Figure 9.1 shows the two treatment effects we wish to estimate.
Since the introduction of ivacaftor, there have been a number of studies using observati-
onal data aiming to estimate it long-term effects. Due to the fact that almost all eligible
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FIGURE 9.1: Possible effects of ivacaftor on lung function in terms of a
one-off step-change or a long-term slope-change
people are now receiving treatment, most of these studies have compared people cur-
rently receiving treatment either to people without a gating mutation or to people with a
gating mutation but in the time period prior to the availability of ivacaftor. Steps to ens-
ure that these groups are comparable at baseline are often taken, such as adjusting for or
matching on baseline characteristics, but after this there is the assumption that these two
separate groups of patients would have had similar long-term health trajectories were it
not for ivacaftor. Studies have suggested that people with and without gating mutations
do have similar long-term health trajectories, suggesting that these comparisons may be
valid.[256, 257] However, it is known that the health of patients with CF has been impro-
ving with time, suggesting that pre- & post- comparisons may not be valid depending on
the length of follow-up being considered.[258]
In this chapter, we aim to estimate the effect of ivacaftor on lung function and the rate of
annual IV days. In the case of lung function, we wish to estimate the step-change effect
as the effect of ivacaftor on lung function after receiving treatment for one year, and also
the slope-change effect as the change in annual decline over four years. For annual IV
days, we estimate the IRR of IV days after using ivacaftor for one, two and three years.
We perform two analyses: 1) compare those currently receiving ivacaftor to people not
currently receiving ivacaftor due to not having a gating mutation, and 2) compare those
currently receiving ivacaftor to those with a gating mutation in the period prior to the
availability of ivacaftor. In both cases these analyses estimate the NTE. Further to this,
we use the negative control exposures as defined in Chapter 8 to estimate the NCE, which
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can be used to test the assumptions of the comparability of the group currently receiving
ivacaftor to the other groups. Finally, we use the NTE and NCE to estimate the NCCTE,
correcting for any differences between the groups not due to ivacaftor.
9.2 Methods
We divide the UK CF Registry data into four groups: A) People with a gating mutation
in years 2008 to 2012, B) People with a gating mutation in years 2012 to 2016, C) People
without a gating mutation in years 2008 to 2012, D) People without a gating mutation in
years 2012 to 2016. This is shown in Figure 9.2.
Ivacaftor
Pre- Post-
P = 0 P = 1
Genotype
Gating G = 1
A B
I=437 I=397
n=1,763 n=1,765
Other G = 0
C D
I=6,382 I=7,378
n=25,449 n=31,759
FIGURE 9.2: Number of people (I) and total number of observations (n)
per group
The following exclusion criteria were applied to observations, which resulted in some
people being entirely excluded if all their observations were excluded: observations post-
transplant (58 people excluded), observations where people were aged under six (1,479
people excluded), observations missing lung function measures (165 people excluded),
people without two consecutive visits [baseline visit and year 1 visit] (836 people exclu-
ded). There were also sixteen people who did not have a gating mutation, but who were
recorded to be receiving ivacaftor; these people were excluded from the analysis. These
exclusions and the final numbers in each group are shown in Figure 9.3.
9.2.1 Notation
The following notation will be used to explain the methods.
Let i denote the individual and j denote the visit. Individuals are observed at up to five
visits (j = 0, ..., 4) per group and baseline is defined as the visit where j = 0. If the same
individual is in more than one group, e.g. both in group A and group B, they have a visit
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FIGURE 9.3: Flowchart of people included in ivacaftor analysis
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j = 0 for Group A, which is separate from visit j = 0 in Group B. The total population is
split into four groups based on genotype, G, and time period P. Anybody with a gating
mutation in the time period 2012-2016 (G = 1 ∩ P = 1) is in the treatment group, X = 1,
and individuals without a gating mutation or in the pre-ivacaftor era (G = 0 ∪ P = 0)
do not receive treatment, X = 0. If an individual is included in both time periods, these
are treated separately, and this individual will have two separate baseline visits and two
separate follow-up periods.
We are interested in the effect of treatment, X, on outcomes Y. Each outcome is measured
four times, at visits j = 1, 2, 3 and 4, and we also record the exact time since baseline
that the visit took place, T. In the analyses, we will allow an interaction either between
treatment, X, and time T, or between treatment, X, and visit, j, to be able to estimate the
long-term effects of treatment use.
We also measured a number of variables related to health at baseline, H, but allow for
that fact that not all baseline measures of health related to the outcome may have been
measured. These unobserved baseline variables are referred to as U. We only use mea-
sures taken at baseline, as any variable measured after baseline would be on the causal
pathway between treatment and outcome.
In Figure 9.4 we present the assumed causal pathways between our variables of interest.
In Chapter 8, we introduced six possible DAGs for our investigation. In this analysis,
we assume the least restrictive of these DAGs that allow for causal pathways between all
variables forward in time (Figure 8.3c). Importantly, we allow both genotype and time
period to affect both measured and unmeasured baseline variables of health and also to
have a direct effect on the outcomes. The methods we introduce will allow us to estimate
an unbiased treatment effect even in this ‘worst-case’ scenario, and would therefore also
still provide unbiased estimates of the treatment effect even if some of the assumed causal
pathways are null.
9.2.2 Effects of Interest
We wish to estimate the effect of ivacaftor on two outcomes of interest: lung function and
annual number of IV days. The primary measure of lung function will be ppFEV1, but
we also perform supplementary analyses with ppFVC and ppFEF25−75. All three measu-
res are calculated using the GLI equations.[16] All three of these outcome measures are
continuous and will be modelled with linear models. In each case, we wish to estimate
the ‘step-change’, defined as the difference in absolute change in lung function between
baseline and one year in those receiving treatment to those not receiving treatment. We
also aim to estimate the ‘slope-change’, defined as the difference in absolute change in the
annual decline of lung function between year one and the end of follow-up. We assume
a linear slope of decline, as with only four visits there is not enough data to accurately
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FIGURE 9.4: DAG of assumed causal pathways for ivacaftor analysis bet-
ween ivacaftor (X), Genotype (G), time Period (P), measured covariates of
Health at baseline (H), Unmeasured covariates of health at baseline (U),
outcome (Y), and follow-up Time (T)
model non-linear slopes of decline. These two treatment effects are highlighted in Figure
9.1.
The annual number of IV days is a count outcome and in this chapter will be modelled
with a negative binomial distribution. This will ignore any excess of zeroes, which had
in previous chapters been accounted for using a zero-inflated negative binomial model.
Unlike with lung function, we do not expect there to be an average slope trajectory for the
rate of IV days over time, as although the number of IV days will vary year to year, there
is no overall trend. We therefore estimate the effect of ivacaftor on the rate of IV days at
three discrete time points: after one year of treatment, after two years of treatment and
after three years of treatment.
As explained in Chapter 8, we will perform two main comparisons: 1) Group B vs Group
A, and 2) Group B vs Group D. For each comparison we obtain an estimate of the treat-
ment effect of interest; this treatment effect estimate is termed the NTE. We also perform
the same analyses using negative controls: 1) Group D vs Group C, and 2) Group A vs
Group C. From this we obtain an estimate of the NCE. This is the estimated difference
between the groups not due to ivacaftor. We then obtain the NCCTE estimate by sub-
tracting the respective NCE from each NTE, (for IV days, this is done on the log scale).
This is summarised below:
• Analysis 1
– Naïve Treatment Effect (NTEP): Group B vs Group A
– Negative-Control Effect (NCEP): Group D vs Group C
– Negative-Control-Corrected Treatment Effect: NCCTEP = NTEP −NCEP
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• Analysis 2
– Naïve Treatment Effect (NTEG): Group B vs Group D
– Negative-Control Effect (NCEG): Group A vs Group C
– Negative-Control-Corrected Treatment Effect: NCCTEG = NTEG −NCEG
We also perform a third analysis in which all four groups are compared in a combined
model. This directly estimates the NCCTE estimate, and corrects for any differences in
outcome due to genotype or time period.
All three analyses make assumptions about the comparability of the groups. NTEP in
analysis 1 assumes that time period has no effect on the outcome (either direct or media-
ted through U), i.e. that all of the observed difference is due to ivacaftor. Similarly, NTEG
in analysis 2 assumes that genotype has no effect on the outcome (either direct or medi-
ated through U). In both cases, these assumptions can be relaxed through estimation of
the NCCTE. In the case of analysis 1, we now assume that any difference over time not
due to ivacaftor is the same as the difference observed over time in those without a ga-
ting mutation. In the case of analysis 2, the assumption is that any difference between the
genotype groups not due to ivacaftor is the same as it was in the time period prior to the
availability of ivacaftor. Analysis 3 combines both of these assumptions, and in this case
can be phrased in terms of interaction effects. Here, we assume that there is no interaction
between genotype and time period, i.e. that any changes in time between 2008-2012 and
2012-2016 are the same irrespective of genotype, and that any differences between the
two genotype groups have not changed over time, except for the introduction of iva-
caftor. Anaysis 3 also makes the additional assumption that the effect of other baseline
covariates included in the model is the same in all four groups.
9.2.3 Statistical Methods
We estimate the treatment effects using three types of model: marginal, fixed-effects and
mixed-effects models. We address each of these in turn in the following subsections.
Marginal Models
For lung function, we consider four different marginal models:
Yij = β0 + βxXij + βxtXijTij + βtTij + eij, (9.1)
Yij = β0 + βxXij + βxtXij j + βt j + eij, (9.2)
Yij = β0 + βxXij + βxtXijTij + βtTij + βhH ij + eij, (9.3)
Yij = β0 + βxXij + βxtXij j + βt j + βhH ij + eij. (9.4)
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In each case, βx is the step-change effect of treatment and βxt is the slope-change effect of
treatment.
In the models shown in Equations 9.1 and 9.2, we do not include any baseline health
variables and we refer to these models as unadjusted. Conversely, Equations 9.3 and 9.4
are adjusted models. If the DAG shown in Figure 9.4 is correct, then adjusting for H
will correct for some of the confounding due to genotype or time period. For this rea-
son, we would not expect the NTE to be the same between the unadjusted and adjusted
models, but the NCCTE estimate should be the same on average, as in the case of the
adjusted analysis, the NCE would correct for any direct effect of genotype or time period
on the outcome and any indirect effect mediated through unobserved baseline covari-
ates, while the unadjusted analysis would additionally correct for any indirect effects
mediated through the observed baseline covariates.
The models shown in Equations 9.1 and 9.3 differ from the models of Equations 9.2 and
9.4 in that the former models use the actual measured time since baseline (continuous
time), whereas the latter models assume that visits are all equally spaced at yearly inter-
vals (discrete time). We would expect to gain some precision by using the more accurate
continuous measure of follow-up time in the models.
For each model, we must also specify the working correlation matrix. We compare three
different choices: independent, exchangeable and unstructured working correlation ma-
trices. An independent working correlation matrix assumes that for each person the
outcomes observed at different visits are conditionally uncorrelated. An exchangeable
correlation matrix assumes that for each person all outcome measures have the same
conditional correlation. Finally, an unstructured correlation matrix allows estimates of
a separate correlation for every pair of outcomes. In the case of the unstructured cor-
relation matrix, visits must happen at evenly spaced intervals and for this reason, this
type of working correlation matrix can only be used when time is modelled as a discrete
variable.
For the annual number of IV days, we are interested in the treatment effect at three dis-
crete time-points and therefore we only use models using visit number, but again we can
either adjust for H or not, which should not matter for the final NCCTE estimates:
Yij = exp
(
γ0 + γj1 [j = k] + γxjXij1 [j = k] + vij + eij
)
, (9.5)
Yij = exp
(
γ0 + γj1 [j = k] + γxjXij1 [j = k] + γhH ij + vij + eij
)
, (9.6)
where evij ∼ Gamma(1/α, α), and k = 0, ..., 3. (9.7)
Here, the treatment effect estimates of interest are eγx1 , eγx2 and eγx3 , which correspond to
IRR at the end of years one, two and three respectively. As with lung function, we con-
sider independent, exchangeable and unstructured working correlation matrices. Note
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that the α is the estimate of overdispersion of the counts, but does not affect the interpre-
tation of the treatment effect estimates.
Fixed-Effects Models
For fixed-effect models, we only consider unadjusted models, as any differences due to
baseline covariates are incorporated into the person-specific intercept term. For lung
function, this results in the following two models:
Yij = βj + βxXij + βxtXijTij + βtTij + eij, (9.8)
Yij = βj + βxXij + βxtXij j + βt j + eij. (9.9)
And for IV days,
Yij = exp
(
γi + γj1 [j = k] + γxjXij1 [j = k] + vij + eij
)
, (9.10)
Yij = exp
(
γi + γj1 [j = k] + γxjXij1 [j = k] + γhH ij + vij + eij
)
, (9.11)
where evij ∼ Gamma(1/α, α), and k = 0, ..., 3. (9.12)
Mixed-Effects Models
As with marginal models, we consider four main forms of mixed-effects models corre-
sponding to whether time is measured continuously or discretely and whether measured
baseline health variables are included in the model:
Yij = β0 + βxXij + βxtXijTij + βtTij + ui0 + uitTij + eij, (9.13)
Yij = β0 + βxXij + βxtXij j + βt j + ui0 + uit j + eij, (9.14)
Yij = β0 + βxXij + βxtXijTij + βtTij + βhH ij + ui0 + uitTij + eij, (9.15)
Yij = β0 + βxXij + βxtXij j + βt j + βhH ij + ui0 + uit j + eij, (9.16)
where ui0 ∼ N
(
0, σ20
)
, uit ∼ N
(
0, σ2t
)
, and Cov
(
ui0, uit
)
= σ20t. (9.17)
Here, we allow for a random intercept and slope term, but assume that in each case
the random effects come from the same distribution for all people. We refer to this as a
combined covariance matrix structure. Alternatively, we can model the random effects
separately by group, if we believe that ivacaftor could result in people becoming more or
less variable. This results in a separate covariance matrix structure for each group. For
example, in analysis 1, comparing group B to group A, we would assume the following
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structure for the random effects:
ui0a ∼ N
(
0, σ20a
)
, uita ∼ N
(
0, σ2ta
)
, and Cov
(
ui0a, uita
)
= σ20ta, (9.18)
ui0b ∼ N
(
0, σ20b
)
, uitb ∼ N
(
0, σ2tb
)
, and Cov
(
ui0b, uitb
)
= σ20tb. (9.19)
For estimating the treatment effect on the rate of annual IV days, we only include a
random intercept term:
Yij = exp
(
γ0 + γj1 [j = k] + γxjXij1 [j = k] + ui0 + vij + eij
)
, (9.20)
Yij = exp
(
γ0 + γj1 [j = k] + γxjXij1 [j = k] + γhH ij + ui0 + vij + eij
)
, (9.21)
where evij ∼ Gamma(1/α, α), and ui0 ∼ N(0, σ20 ), and k = 0, ..., 3. (9.22)
Again we perform the analyses with two different covariance matrix structures: combi-
ned through all groups, or separate by group.
Estimation of Standard Errors
To analytically estimate the SE of the NCCTE it is necessary to be able to estimate the
covariance between the NTE and NCE. For analysis 1, where the NCE analysis is inde-
pendent of the NTE analysis (because the same person cannot be in both analyses), the
covariance will be zero and the SE of the NCCTE could be calculated as the sum of the
variances of the NCE and NTE. However, in the case of analysis 2, the same people will
be in both the NCE analysis and the NTE analysis. For this reason, in this case it will be
necessary to use a bootstrap procedure to obtain estimates of the SE in this case.
In order to ensure comparability between the methods, for these analyses we perform
a non-parametric boostrap with 1000 resamples and for each resample we calculate all
effect estimates, in order to obtain bootstrap estimates for the SEs, even those that could
have been obtained analytically.
9.3 Results
There were 397 people who received ivacaftor and fulfilled the inclusion criteria to be in-
cluded in the analysis. Overall, in this group, there were 1,765 observations, with a mean
follow up time of 3.5 years (SD 0.9). Figure 9.2 shows the breakdown for all four groups.
As expected, the available population without gating mutations is much larger than that
with gating mutations: 7,977 people (57,208 total observations) in those without gating
mutations compared to 467 people (3,528 observations) in those with gating mutations.
In those with a gating mutation, the number of inviduals in the pre- & post-ivacaftor
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phase are similar, but in those without a gating mutation we see a much larger number
in the post-phase than the pre-phase. This is due to the fact that for those receiving iva-
caftor, they needed to have a baseline measure directly prior to the year they started to
receiving ivacaftor, whereas in those without a gating mutation, there is no ivacaftor start
date, so people just needed two consecutive visits at any point in the period.
Table 9.1 shows a summary of baseline covariates by group. Overall, all four groups are
very similar, but there are some small systematic differences that can be noticed between
the groups in the pre-ivacaftor phase (groups A and C) compared to the groups in the
post-ivacaftor phase (groups B and D). The mean age is slightly higher in groups B & D,
due to these groups being from a later time period. These two groups also have longer
follow-up on average, suggesting less loss to follow-up in the post-ivacaftor phase. Furt-
hermore, there are higher numbers of people in the pre-ivacaftor phase (groups A and
C) who have CFRD and who receive mucolytic treatments. However, when comparing
those with a gating mutation (groups A and B) those without a gating mutation (groups
C and D) there are no obvious differences between these groups.
Variable
Group
A B C D
I=437 I=397 I=6,382 I=7,378
Ivacaftor 0 (0.0) 397 (100.0) 0 (0.0) 0 (0.0)
Total Follow-Up Time (Years) 3.12 (1.18) 3.49 (0.90) 3.07 (1.16) 3.35 (1.05)
Total Number of Visits 3.07 (1.15) 3.50 (0.88) 3.05 (1.11) 3.36 (1.01)
Baseline Age (Years) 20.4 (10.8) 22.4 (11.2) 20.9 (11.6) 21.9 (12.6)
Female 205 (46.9) 186 (46.9) 2,971 (46.6) 3,465 (47.0)
White Ethnicity 428 (97.9) 390 (98.2) 6,150 (96.4) 7,043 (95.5)
Baseline ppFEV1 71.0 (23.2) 69.7 (23.2) 71.6 (23.3) 72.0 (23.4)
Baseline ppFVC* 84.8 (19.4) 84.1 (18.9) 84.0 (19.5) 84.4 (19.6)
Baseline ppFEF25−75** 56.3 (31.3) 55.9 (32.4) 60.9 (32.8) 58.4 (31.0)
Baseline IV Days 18.4 (28.1) 20.2 (30.5) 17.6 (27.7) 18.6 (28.3)
Baseline Infection 358 (81.9) 350 (88.2) 4,847 (75.9) 5,948 (80.6)
Baseline CFRD 69 (15.8) 90 (22.7) 1,198 (18.8) 1,751 (23.7)
Baseline Smoker 9 (2.1) 9 (2.3) 154 (2.4) 201 (2.7)
Baseline Mucolytic Treatment 223 (51.0) 264 (66.5) 2,992 (46.9) 4,822 (65.4)
TABLE 9.1: Summary Statistics by Group (*ppFVC based on 14,556 obser-
vations. **ppFEF25−75 based on 5,711 observations)
By design, all people had a baseline visit (j = 0) and one visit in the year directly after
baseline (j = 1). The total number of possible visits post-baseline was 4, which 7,933
(54.4%) people had. However, a number of people missed a visit during follow-up rather
than missing the final visit, meaning that in total there were 8,620 (59.1%) people with
data out to four years post-baseline. The number of people with only 1 year of follow-up
was 1,667 (11.4%), only 2 years was 2,035 (13.9%) and only 3 years was 2,272 (15.6%).
Table 9.2 compares visit number to continuous follow-up time measured in years. On
average the two variables coincide as expected with visits generally happening every
year. The IQR shows that approximately 50% of visits generally happen between 0.9
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and 1.1 years since the previous visit. However, the range does show that there are a
number of people who do not always have regularly spaced visits, for example some
people’s second visit post-baseline actually happens only one year after baseline, whereas
for others it’s almost three years after baseline.
Continuous
Follow-Up Time
Visit Number
1 2 3 4
n=14,594 n=12,365 n=10,563 n=8,620
Mean (SD) 1,00 (0.23) 2.01 (0.26) 3.00 (0.29) 4.01 (0.30)
Median (IQR) 1.00 [0.93, 1.07] 2.00 [1.92, 2.11] 3.00 [2.87, 3.12] 4.00 [3.87, 4.14]
Range 0.03, 1.97 1.00, 2.96 2.00, 3.97 3.00, 4.97
TABLE 9.2: Comparison of continuous follow-up time to discrete visit
number
9.3.1 Estimated Effect of Ivacaftor on Lung Function
The full results of analysis 1 comparing those currently taking ivacaftor to those with a
gating mutation but in the time period before ivacaftor was available (group B vs A) are
presented in Figures 9.5 and 9.6, and Tables 9.3 and 9.4. In terms of the step-change at one
year, all methods gave similar estimates of the NTE. Across methods the estimate NTE
was around 6%. The smallest estimate was from an unadjusted marginal model with
an independent working correlation matrix using time measured continuously (estimate
5.17%, 95% CI 3.31% to 7.03%), and the largest estimate was from an adjusted marginal
model with an independent working correlation matrix using time measured continu-
ously (estimate 8.12%, 95% CI 6.38% to 9.44%). The NCE estimates (groups D vs C) were
all small and positive, suggesting a slight improvement in ppFEV1 over time not due to
ivacaftor. The smallest estimate was from an unadjusted marginal model with an un-
structured working correlation matrix and time measured at discrete intervals (estimate
0.22%, 95% CI -0.04% to 0.48%), and the largest estimate was from an adjusted marginal
model with an independent working correlation matrix and time measured continuously
(estimate 1.59%, 95% CI 1.21% to 1.98%). This resulted in the NCCTE being slightly lo-
wer than the NTE, but all methods still showed a statistically significant improvement in
lung function due to ivacaftor. The smallest NCCTE estimate was from an unadjusted
marginal model with an independent working correlation matrix using time measured
continuously (estimate 4.77%, 95% CI 2.87% to 6.67%), and the largest estimate was from
an adjusted marginal model with an independent working correlation matrix using time
measured continuously (estimate 6.53%, 95% CI 4.76% to 8.30%). Overall, all methods
gave very similar NCCTE estimates with largely overlapping CIs.
The results from different modelling approaches were also similar when considering the
effect of ivacaftor on the slope of lung function decline. The NTE estimates were all re-
latively similar, indicating approximately a 0.75% improvement in the rate of decline in
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the post- versus pre-ivacaftor phase. All but two of the estimates were statistically signifi-
cant. The smallest estimate was from an unadjusted marginal model with an independent
working correlation matrix using time measured continuously (estimate 0.48%, 95% CI
-0.42% to 1.39%), and the largest estimate was from an adjusted marginal model with an
independent working correlation matrix using time measured at discrete intervals (es-
timate 1.04%, 95% CI 0.30% to 1.79%). Once again, the NCE estimates were small and
positive suggesting a small improvement in the rate of lung function decline over time,
but many of these estimates were not statistically significant. The smallest estimate was
from an unadjusted mixed-effects model with separate random-effects by group using
time measured continuously (estimate 0.05%, 95% CI -0.09% to 0.19%), and the largest
estimate was from an adjusted marginal model with an independent working correla-
tion matrix using time measured at discrete intervals (estimate 0.60%, 95% CI 0.43% to
0.77%). This resulted in the NCCTE being lower than the NTE, estimating approximately
a 0.6% improvement in the rate of lung function decline. Overall, fifteen out of twenty
of the NCCTE estimates were statistically significantly different from zero. The smallest
estimate was from an adjusted marginal model with an independent working correla-
tion matrix using time measured continuously (estimate 0.35%, 95% CI -0.49% to 1.18%),
and the largest estimate was from an adjusted mixed-effects model using time measured
continuously (estimate 0.63%, 95% CI 0.12% to 1.15%).
The full results of analysis 2 comparing those eligible for ivacaftor to those ineligible for
ivacaftor due to genotype (group B vs D)are presented in Figures 9.7 and 9.8, and Tables
9.5 and 9.6. Overall, the results are very similar to those from analysis 1. When conside-
ring the step-change effect, the NTE estimates indicated an improvement in ppFEV1 of
between 5.5% and 6%, except for the unadjusted marginal models with an independent
working correlation matrix which gave a smaller estimate of 3.5%. The largest estimate
was from an adjusted marginal model with an unstructured working correlation matrix
and time measured at discrete intervals (estimate 6.03%, 95% CI 4.81% to 7.26%). The
NCE esimates were all estimated to be negative, suggesting that people with a gating
mutation actually had a slightly greater decline in lung function at one year of follow-up
when ivacaftor was not available. However, none of the NCE estimates were statistically
significantly different from zero. Again, the estimates from the marginal models with an
independent working correlation matrix were the most extreme, with the estimated dif-
ference between groups being between -1.57% and -1.06%. All other methods estimated
a much smaller difference of approximately -0.3%. The least extreme result was from an
unadjusted marginal model with an unstructured working correlation matrix and time
measured at discrete intervals (estimate -0.09%, 95% CI -1.23% to 1.05%). All methods
gave very similar estimates for the NCCTE. This is because the methods which had more
extreme estimates for the NTE, also had more extreme estimates for the NCE, which can-
celled each other out when calculating the NCCTE.
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The slope-effect estimates from analysis 2 were also similar to the slope effect estimates
from analysis 1, except that the SEs were generally slightly larger. This did not materially
impact the NTE estimates as all but one estimate was statistically significant. The estimate
that was not statistically significant was from an adjusted marginal model with an inde-
pendent working correlation matrix and time measured continuously (estimate 0.47%,
95% CI -0.14% to 1.09%). The largest estimate was from an adjusted mixed-effects mo-
del with time measured continuously (estimate 0.75%, 95% CI 0.38% to 1.13%). The NCE
estimates were all positive (but not statistically significant) suggesting a slower rate of de-
cline in those with a gating mutation even without ivacaftor. The smallest slope-change
estimate was from an unadjusted mixed-effects model with separate random-effects by
group using time measured at discrete intervals (estimate 0.15%, 95% CI -0.29% to 0.59%),
and the largest estimate was from an unadjusted marginal model with an independent
working correlation matrix using time measured continuously (estimate 0.43%, 95% CI
-0.45% to 1.32%). This small positive estimate for the NCE resulted in the NCCTE being
lower than the NTE and although all methods estimated an improvement in the rate of
lung function decline, none of them were statistically significant. The method with the
smallest p-value for the NCCTE slope-effect was an adjusted mixed-effects model with
time measured at discrete intervals (estimate 0.56%, 95% CI -0.02% to 1.13%).
Finally, the results from the combined analysis directly obtain the NCCTE estimate and
are presented in Figures 9.9 and 9.10, and in Tables 9.7 and 9.8. Again, the step-change
effect estimates indicated around a 6% improvement in lung function. The smallest esti-
mate was from an unadjusted marginal model with an independent working correlation
matrix using time measured continuously (estimate 4.88%, 95% CI 3.04% to 6.73%), and
the largest estimate was from an adjusted marginal model with an independent working
correlation matrix using time measured continuously (estimate 6.07%, 95% CI 4.33% to
7.82%). As with the other analyses, the estimates of the slope-change effect were all po-
sitive, but only thirteen out of twenty were statistically significant. The smallest estimate
was from an unadjusted marginal model with an independent working correlation ma-
trix using time measured at discrete intervals (estimate 0.32%, 95% CI -0.53% to 1.17%),
and the largest estimate was from an adjusted mixed-effects model using time measured
at discrete intervals (estimate 0.59%, 95% CI 0.07% to 1.10%).
We also present the results for two other lung function outcome measures (ppFVC and
ppFEF25−75) in Appendix F. The results for ppFVC were very similar to the results pre-
sented in this chapter, with strong evidence of an step-change increase in ppFVC at one
year and an estimated decrease in the slope of decline that was not always statistically
significant. For ppFEF25−75 the direction of the results was the same, but there was only
weak evidence of a step-change effect and none of the slope-change effect estimates were
statistically significant.
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FIGURE 9.5: Estimated step-change effect on ppFEV1 when comparing post-ivacaftor period to pre-ivacaftor period
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FIGURE 9.6: Estimated slope-change effect on ppFEV1 when comparing post-ivacaftor period to pre-ivacaftor period
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FIGURE 9.7: Estimated step-change effect on ppFEV1 when comparing those eligible for ivacaftor to those ineligible for ivacaftor
C
hapter
9.
Estim
ating
the
Effects
ofLong-Term
Ivacaftor
U
se
190
Independent
Exchangeable
Unstructured
By Group
Combined
Marginal
Fixed−Effects
Mixed−Effects
0.1
 
−1 −.5 0 .5 1 1.5 2
Slope−Change in ppFEV1
NTE
−1 −.5 0 .5 1 1.5 2
Slope−Change in ppFEV1
NCE
−1 −.5 0 .5 1 1.5 2
Slope−Change in ppFEV1
Continuous Time
Unadjusted
Discrete Time
Adjusted
NCCTE
Analysis 2: Ivacaftor Eligible & Ineligible − Slope−Change Effect
FIGURE 9.8: Estimated slope-change effect on ppFEV1 when comparing those eligible for ivacaftor to those ineligible for ivacaftor
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FIGURE 9.9: Estimated step-change effect on ppFEV1 from combined ana-
lysis comparing those currently receiving ivacaftor both to those currently
not receiving ivacaftor and those in the time period prior to the availability
of ivacaftor
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FIGURE 9.10: Estimated slope-change effect on ppFEV1 from combined
analysis comparing those currently receiving ivacaftor both to those cur-
rently not receiving ivacaftor and those in the time period prior to the avai-
lability of ivacaftor
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Model MatrixStructure H Time
Analysis 1: Pre- & Post Comparison - Step-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 5.17 0.95 3.31, 7.03 <0.001 0.40 0.23 -0.05, 0.85 0.080 4.77 0.97 2.87, 6.67 <0.001Discrete 5.19 0.88 3.47, 6.91 <0.001 0.37 0.21 -0.04, 0.77 0.077 4.82 0.90 3.05, 6.59 <0.001
Adjusted Continuous 8.12 0.89 6.38, 9.87 <0.001 1.59 0.20 1.21, 1.98 <0.001 6.53 0.90 4.76, 8.30 <0.001Discrete 7.82 0.83 6.20, 9.44 <0.001 1.48 0.18 1.13, 1.82 <0.001 6.34 0.84 4.69, 7.99 <0.001
Exchangeable
Unadjusted Continuous 5.81 0.60 4.64, 6.99 <0.001 0.36 0.13 0.10, 0.62 0.006 5.45 0.61 4.25, 6.65 <0.001Discrete 5.84 0.61 4.64, 7.03 <0.001 0.31 0.13 0.05, 0.57 0.020 5.52 0.62 4.31, 6.74 <0.001
Adjusted Continuous 6.18 0.60 5.00, 7.36 <0.001 0.47 0.13 0.21, 0.73 <0.001 5.71 0.61 4.51, 6.91 <0.001Discrete 6.19 0.61 4.99, 7.39 <0.001 0.42 0.13 0.16, 0.68 0.001 5.76 0.62 4.55, 6.98 <0.001
Unstructured Unadjusted Discrete 5.49 0.67 4.18, 6.79 <0.001 0.22 0.13 -0.04, 0.48 0.091 5.26 0.67 3.94, 6.58 <0.001Adjusted 6.17 0.66 4.87, 7.47 <0.001 0.45 0.13 0.18, 0.71 <0.001 5.72 0.67 4.41, 7.04 <0.001
Fixed-Effects Unadjusted Continuous 5.90 0.61 4.71, 7.10 <0.001 0.35 0.13 0.09, 0.62 0.008 5.55 0.62 4.33, 6.76 <0.001Discrete 5.92 0.62 4.71, 7.13 <0.001 0.30 0.13 0.03, 0.56 0.027 5.62 0.63 4.39, 6.85 <0.001
Mixed-Effects
Combined
Unadjusted Continuous 5.85 0.60 4.67, 7.03 <0.001 0.36 0.13 0.10, 0.61 0.006 5.49 0.61 4.30, 6.69 <0.001Discrete 5.86 0.61 4.67, 7.06 <0.001 0.31 0.13 0.05, 0.57 0.018 5.55 0.62 4.34, 6.76 <0.001
Adjusted Continuous 6.15 0.60 4.97, 7.32 <0.001 0.45 0.13 0.20, 0.70 <0.001 5.70 0.61 4.50, 6.89 <0.001Discrete 6.15 0.61 4.95, 7.34 <0.001 0.41 0.13 0.15, 0.67 0.002 5.74 0.62 4.52, 6.95 <0.001
By Group
Unadjusted Continuous 5.85 0.60 4.67, 7.03 <0.002 0.36 0.13 0.10, 0.61 0.006 5.50 0.61 4.30, 6.69 <0.002Discrete 5.87 0.61 4.67, 7.06 <0.001 0.31 0.13 0.05, 0.57 0.018 5.55 0.62 4.34, 6.77 <0.001
Adjusted Continuous 6.15 0.60 4.97, 7.32 <0.001 0.45 0.13 0.20, 0.70 <0.001 5.70 0.61 4.50, 6.89 <0.001Discrete 6.15 0.61 4.95, 7.34 <0.001 0.41 0.13 0.15, 0.66 0.002 5.74 0.62 4.53, 6.95 <0.001
TABLE 9.3: Estimated step-change effect on ppFEV1 when comparing post-ivacaftor period to pre-ivacaftor period
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Model MatrixStructure H Time
Analysis 1: Pre- & Post Comparison - Slope-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 0.48 0.46 -0.42, 1.39 0.30 0.09 0.11 -0.13, 0.31 0.40 0.39 0.48 -0.55, 1.32 0.42Discrete 0.49 0.42 -0.33, 1.32 0.24 0.13 0.10 -0.07, 0.34 0.19 0.36 0.43 -0.49, 1.21 0.41
Adjusted Continuous 0.87 0.41 0.05, 1.68 0.037 0.52 0.10 0.33, 0.71 <0.001 0.35 0.42 -0.49, 1.18 0.42Discrete 1.04 0.38 0.30, 1.79 0.006 0.60 0.09 0.43, 0.77 <0.001 0.45 0.39 -0.32, 1.21 0.25
Exchangeable
Unadjusted Continuous 0.67 0.25 0.19, 1.16 0.007 0.07 0.07 -0.07. 0.20 0.34 0.61 0.26 0.10, 1.12 0.020Discrete 0.69 0.25 0.19, 1.18 0.007 0.10 0.07 -0.03, 0.24 0.14 0.58 0.27 0.06, 1.10 0.028
Adjusted Continuous 0.78 0.25 0.29, 1.28 0.002 0.19 0.07 0.06, 0.33 0.006 0.59 0.26 0.08, 1.11 0.024Discrete 0.81 0.26 0.30, 1.31 0.002 0.23 0.07 0.09, 0.37 0.001 0.58 0.27 0.05, 1.11 0.032
Unstructured Unadjusted Discrete 0.74 0.27 0.21, 1.27 0.006 0.15 0.07 0.01, 0.28 0.033 0.59 0.28 0.04, 1.15 0.037Adjusted 0.81 0.28 0.26, 1.36 0.004 0.34 0.07 0.20, 0.48 <0.001 0.47 0.29 -0.11, 1.04 0.11
Fixed-Effects Unadjusted Continuous 0.69 0.25 0.20, 1.18 0.005 0.06 0.07 -0.08, 0.20 0.37 0.63 0.26 0.11, 1.14 0.017Discrete 0.70 0.25 0.21, 1.20 0.006 0.10 0.07 -0.04, 0.24 0.17 0.61 0.27 0.08, 1.13 0.023
Mixed-Effects
Combined
Unadjusted Continuous 0.68 0.25 0.20, 1.17 0.006 0.05 0.07 -0.09, 0.19 0.49 0.63 0.26 0.12, 1.14 0.015Discrete 0.70 0.25 0.21, 1.20 0.005 0.08 0.07 -0.06, 0.22 0.26 0.63 0.27 0.11, 1.15 0.018
Adjusted Continuous 0.79 0.25 0.30, 1.28 0.002 0.16 0.07 0.02, 0.30 0.023 0.63 0.26 0.12, 1.15 0.016Discrete 0.82 0.26 0.31, 1.32 0.001 0.19 0.07 0.06, 0.33 0.006 0.62 0.27 0.10, 1.15 0.020
By Group
Unadjusted Continuous 0.68 0.25 0.19, 1.16 0.007 0.05 0.07 -0.09, 0.19 0.49 0.63 0.26 0.12, 1.14 0.016Discrete 0.70 0.25 0.20, 1.20 0.006 0.08 0.07 -0.06, 0.22 0.26 0.62 0.27 0.10, 1.15 0.019
Adjusted Continuous 0.78 0.25 0.29, 1.27 0.002 0.16 0.07 0.02, 0.30 0.022 0.62 0.26 0.10, 1.13 0.019Discrete 0.80 0.26 0.30, 1.31 0.002 0.19 0.07 0.06, 0.33 0.005 0.61 0.27 0.08, 1.14 0.024
TABLE 9.4: Estimated slope-change effect on ppFEV1 when comparing post-ivacaftor period to pre-ivacaftor period
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Model MatrixStructure H Time
Analysis 2: Eligible & Ineligible Comparison - Step-Change Effect
NTE (B vs D) NCE (A vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 3.46 1.40 0.71, 6.21 0.014 -1.57 1.35 -4.22, 1.08 0.24 5.03 1.40 2.28, 7.79 <0.001Discrete 3.52 1.37 0.84, 6.19 0.010 -1.50 1.30 -4.03, 1.04 0.25 5.01 1.29 2.48, 7.54 <0.001
Adjusted Continuous 5.60 1.16 3.32, 7.88 <0.001 -1.10 1.13 -3.32, 1.11 0.33 6.70 1.30 4.16, 9.25 <0.001Discrete 5.32 1.13 3.09, 7.54 <0.001 -1.06 1.05 -3.12, 1.00 0.32 6.37 1.17 4.08, 8.67 <0.001
Exchangeable
Unadjusted Continuous 5.59 0.62 4.39, 6.80 <0.001 -0.32 0.59 -1.47, 0.82 0.58 5.92 0.79 4.37, 7.46 <0.001Discrete 5.62 0.62 4.39, 6.84 <0.001 -0.29 0.58 -1.44, 0.85 0.62 5.91 0.80 4.34, 7.47 <0.001
Adjusted Continuous 5.83 0.61 4.62,7.03 <0.001 -0.29 0.58 -1.42, 0.84 0.61 6.12 0.78 4.59, 7.65 <0.001Discrete 5.82 0.63 4.60, 7.05 <0.001 -0.25 0.57 -1.37, 0.87 0.66 6.07 0.79 4.51, 7.63 <0.001
Unstructured Unadjusted Discrete 5.46 0.64 4.21, 6.72 <0.001 -0.09 0.58 -1.23, 1.05 0.88 5.55 0.82 3.95, 7.16 <0.001Adjusted 6.03 0.63 4.81, 7.26 <0.001 -0.18 0.58 -1.31, 0.95 0.76 6.21 0.80 4.64, 7.77 <0.001
Fixed-Effects Unadjusted Continuous 5.90 0.61 4.71, 7.10 <0.001 -0.19 0.59 -1.34, 0.97 0.75 6.09 0.80 4.52, 7.66 <0.001Discrete 5.92 0.62 4.71, 7.13 <0.001 -0.16 0.59 -1.31, 0.99 0.78 6.08 0.81 4.50, 7.67 <0.001
Mixed-Effects
Combined
Unadjusted Continuous 5.73 0.61 4.54, 6.92 <0.001 -0.32 0.57 -1.43, 0.79 0.57 6.05 0.78 4.52, 7.59 <0.001Discrete 5.75 0.61 4.55, 6.95 <0.001 -0.22 0.57 -1.33, 0.89 0.70 5.96 0.79 4.42, 7.51 <0.001
Adjusted Continuous 5.84 0.61 4.65, 7.04 <0.001 -0.31 0.56 -1.40, 0.79 0.58 6.15 0.78 4.63, 7.67 <0.001Discrete 5.84 0.62 4.63, 7.05 <0.001 -0.20 0.56 -1.2, 0.90 0.72 6.04 0.78 4.50, 7.58 <0.001
By Group
Unadjusted Continuous 5.74 0.61 4.55, 6.92 <0.001 -0.32 0.57 -1.43, 0.79 0.57 6.06 0.78 4.53, 7.59 <0.001Discrete 5.75 0.61 4.55, 6.95 <0.001 -0.22 0.56 -1.32, 0.89 0.70 5.97 0.79 4.42, 7.51 <0.001
Adjusted Continuous 5.85 0.61 4.66, 7.04 <0.001 -0.30 0.56 -1.40, 0.79 0.59 6.15 0.78 4.63, 7.67 <0.001Discrete 5.85 0.62 4.64, 7.06 <0.001 -0.20 0.56 -1.29, 0.90 0.73 6.05 0.78 4.51, 7.58 <0.001
TABLE 9.5: Estimated step-change effect on ppFEV1 when comparing those eligible for ivacaftor to those ineligible for ivacaftor
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Model MatrixStructure H Time
Analysis 2: Eligible & Ineligible Comparison - Slope-Change Effect
NTE (B vs D) NCE (A vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 0.73 0.34 0.06, 1.40 0.033 0.43 0.45 -0.45, 1.32 0.34 0.30 0.61 -0.90, 1.50 0.63Discrete 0.70 0.31 0.09, 1.32 0.025 0.41 0.40 -0.38, 1.19 0.31 0.29 0.54 -0.76, 1.35 0.58
Adjusted Continuous 0.47 0.32 -0.14, 1.09 0.13 0.28 0.40 -0.51, 1.07 0.49 0.20 0.55 -0.88, 1.27 0.72Discrete 0.59 0.28 0.03, 1.14 0.040 0.27 0.35 -0.41, 0.95 0.44 0.32 0.47 -0.61, 1.24 0.50
Exchangeable
Unadjusted Continuous 0.70 0.19 0.33, 1.06 <0.001 0.20 0.23 -0.24, 0.64 0.37 0.50 0.29 -0.08, 1.07 0.091Discrete 0.67 0.19 0.29, 1.04 <0.001 0.17 0.23 -0.28, 0.63 0.45 0.49 0.30 -0.09, 1.08 0.099
Adjusted Continuous 0.72 0.19 0.34, 1.09 <0.001 0.22 0.22 -0.22, 0.66 0.32 0.49 0.29 -0.08, 1.07 0.094Discrete 0.70 0.19 0.32, 1.08 <0.001 0.20 0.23 -0.25, 0.65 0.39 0.51 0.30 -0.08, 1.09 0.093
Unstructured Unadjusted Discrete 0.65 0.20 0.27, 1.04 <0.001 0.15 0.24 -0.32, 0.61 0.53 0.51 0.29 -0.07, 1.08 0.084Adjusted 0.60 0.20 0.21, 0.98 0.003 0.25 0.23 -0.21, 0.71 0.28 0.35 0.31 -0.25, 0.95 0.26
Fixed-Effects Unadjusted Continuous 0.70 0.19 0.33, 1.06 <0.001 0.19 0.22 -0.25, 0.63 0.39 0.51 0.29 -0.06, 1.07 0.080Discrete 0.67 0.19 0.29, 1.04 <0.001 0.17 0.23 -0.28, 0.62 0.47 0.50 0.29 -0.08, 1.08 0.089
Mixed-Effects
Combined
Unadjusted Continuous 0.71 0.19 0.34, 1.07 <0.001 0.20 0.22 -0.23, 0.63 0.36 0.51 0.29 -0.06, 1.07 0.080Discrete 0.68 0.19 0.31, 1.05 <0.001 0.15 0.23 -0.29, 0.59 0.51 0.53 0.29 -0.04, 1.11 0.068
Adjusted Continuous 0.75 0.19 0.38, 1.13 <0.001 0.23 0.22 -0.20, 0.66 0.29 0.52 0.29 -0.04, 1.09 0.070Discrete 0.74 0.19 0.36, 1.11 <0.001 0.18 0.22 -0.26, 0.62 0.42 0.56 0.29 -0.02, 1.13 0.058
By Group
Unadjusted Continuous 0.70 0.19 0.33, 1.06 <0.001 0.20 0.22 -0.23, 0.63 0.36 0.50 0.29 -0.07, 1.06 0.084Discrete 0.68 0.19 0.30, 1.05 <0.001 0.15 0.23 -0.29, 0.59 0.51 0.53 0.29 -0.05, 1.10 0.071
Adjusted Continuous 0.75 0.19 0.37, 1.12 <0.001 0.23 0.22 -0.20, 0.66 0.29 0.52 0.29 -0.05, 1.08 0.073Discrete 0.73 0.19 0.35. 1.11 <0.001 0.18 0.22 -0.26, 0.62 0.43 0.55 0.29 -0.02, 1.13 0.060
TABLE 9.6: Estimated slope-change effect on ppFEV1 when comparing those eligible for ivacaftor to those ineligible for ivacaftor
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Model MatrixStructure H Time
Combined Analysis
Step-Change Effect
est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 4.88 0.94 3.04, 6.73 <0.001Discrete 4.93 0.87 3.22, 6.64 <0.001
Adjusted Continuous 6.07 0.89 4.33, 7.82 <0.001Discrete 5.78 0.83 4.15, 7.42 <0.001
Exchangeable
Unadjusted Continuous 5.78 0.60 4.61, 6.96 <0.001Discrete 5.80 0.61 4.61, 7.00 <0.001
Adjusted Continuous 5.91 0.60 4.73, 7.09 <0.001Discrete 5.90 0.61 4.70, 7.10 <0.001
Unstructured Unadjusted Discrete 5.57 0.63 4.33, 6.81 <0.001Adjusted 6.03 0.61 4.71, 7.10 <0.001
Fixed-Effects Unadjusted Continuous 5.90 0.61 4.71, 7.10 <0.001Discrete 5.92 0.62 4.71, 7.13 <0.001
Mixed-Effects
Combined
Unadjusted Continuous 5.84 0.60 4.66, 7.02 <0.001Discrete 5.85 0.61 4.66, 7.04 <0.001
Adjusted Continuous 5.91 0.60 4.73, 7.09 <0.001Discrete 5.90 0.61 4.71, 7.09 <0.001
By Group
Unadjusted Continuous 5.84 0.60 4.66, 7.02 <0.001Discrete 5.85 0.61 4.66, 7.05 <0.001
Adjusted Continuous 5.90 0.60 4.72, 7.08 <0.001Discrete 5.90 0.61 4.71, 7.10 <0.001
TABLE 9.7: Estimated step-change effect on ppFEV1 from combined ana-
lysis comparing those currently receiving ivacaftor both to those currently
not receiving ivacaftor and those in the time period prior to the availability
of ivacaftor
Model MatrixStructure H Time
Combined Analysis
Slope-Change Effect
est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 0.35 0.47 -0.58, 1.28 0.46Discrete 0.32 0.43 -0.53, 1.17 0.46
Adjusted Continuous 0.37 0.42 -0.46, 1.19 0.38Discrete 0.48 0.38 -0.26, 1.23 0.21
Exchangeable
Unadjusted Continuous 0.53 0.26 0.02, 1.04 0.043Discrete 0.51 0.26 -0.00, 1.03 0.052
Adjusted Continuous 0.53 0.26 0.02, 1.04 0.040Discrete 0.54 0.27 0.02, 1.06 0.041
Unstructured Unadjusted Discrete 0.49 0.26 -0.02, 1.00 0.061Adjusted 0.36 0.26 -0.16, 0.88 0.17
Fixed-Effects Unadjusted Continuous 0.55 0.26 0.04, 1.06 0.036Discrete 0.54 0.27 0.02, 1.06 0.043
Mixed-Effects
Combined
Unadjusted Continuous 0.55 0.26 0.04, 1.07 0.035Discrete 0.56 0.27 0.04, 1.08 0.036
Adjusted Continuous 0.58 0.26 0.07, 1.08 0.027Discrete 0.59 0.26 0.07, 1.10 0.027
By Group
Unadjusted Continuous 0.55 0.26 0.03, 1.06 0.037Discrete 0.55 0.27 0.03, 1.08 0.039
Adjusted Continuous 0.58 0.26 0.07, 1.09 0.026Discrete 0.58 0.27 0.06, 1.10 0.028
TABLE 9.8: Estimated slope-change effect on ppFEV1 from combined ana-
lysis comparing those currently receiving ivacaftor both to those currently
not receiving ivacaftor and those in the time period prior to the availability
of ivacaftor
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9.3.2 Estimated Effect of Ivacaftor on Rate of Annual IV Days
As with the lung function results, we present the results of the effect of ivacaftor on the
rate of annual IV days separately for each analysis. In all cases, as expected, the estimates
are more heterogeneous than was the case for the lung function analyses, and this is
due to the issue of non-collapsibility. In general, the estimates from the mixed-effects
models were more extreme than the results from marginal or fixed-effects models, which
were more similar to one another. Another issue encountered in these analyses is that
a number of the mixed-effects models did not reach convergence. This is shown in the
results tables and is the reason why some methods do not appear in the graphs of the
results.
The results of analysis 1 are presented in Figures 9.11, 9.12 and 9.13, and in Tables 9.9,
9.10 and 9.11. For analysis 1 neither of the adjusted mixed-effects models reached con-
vergence and hence only unadjusted mixed-effects models are presented. After one year,
the NTE estimates all showed a sharp decrease in the rate of IV days in the post- versus
pre-ivacaftor era: the smallest effect estimate was from an unadjusted marginal model
with an unstructured working correlation matrix (IRR 0.61, 95% CI 0.50 to 0.74), and
the largest effect estimate was from an unadjusted mixed-effects model with separate
random effects for each group (IRR 0.30, 95% CI 0.21 to 0.44). However, the NCE es-
timates were also all smaller than 1 and statistically significant, suggesting a decline in
the rate of IV days over time unrelated to ivacaftor. Here, the smallest effect estimate
was from an unadjusted marginal model with an unstructured working correlation ma-
trix (IRR 0.94, 95% CI 0.91 to 0.98), and the largest effect estimate was from an adjusted
marginal model with an independent working correlation matrix (IRR 0.79, 95% CI 0.74
to 0.83). This again resulted in the NCCTE estimates all being slightly closer to 1, but all
the results were still highly statistically significant, indicating a positive effect of ivacaf-
tor. The smallest NCCTE effect estimate was from an unadjusted marginal model with
an unstructured working correlation matrix (IRR 0.65, 95% CI 0.53 to 0.79), and the lar-
gest effect estimate was from an unadjusted mixed-effects model with separate random
effects for each group (IRR 0.33, 95% CI 0.22 to 0.49). The results were remarkably stable
over time with very similar effect estimates seen at two years and at three years.
The results of analysis 2 were very similar to those of analysis 1 and are shown in Figures
9.14, 9.15 and 9.16, and in Tables 9.12, 9.13 and 9.14. Unlike in analysis 1, in analysis 2 one
of the adjusted mixed-effects model did achieve convergence and these results are pre-
sented, however the model which allowed the random effects to differ between groups
still did not attain convergence. At the end of year one, the smallest NTE estimate was
from an adjusted marginal model with an unstructured working correlation matrix (IRR
0.62, 95% CI 0.52 to 0.73), and the largest effect estimate was from the adjusted mixed-
effects model (IRR 0.29, 95% CI 0.22 to 0.38). As with analysis 1, the NCE estimates were
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also smaller than one, suggesting that on average people with gating mutations had fe-
wer IV days per year than people with non-gating mutations even before ivacaftor was
available. The smallest NCE estimate was from an unadjusted marginal model with an
independent working correlation matrix (IRR 0.96, 95% CI 0.80 to 1.14), and the largest
effect estimate was from an adjusted marginal model with an independent working cor-
relation matrix (IRR 0.79, 95% CI 0.67 to 0.92). This resulted in the NCCTE estimates
being slightly closer to 1 than the NTE estimates, but all were still highly statistically sig-
nificant. The smallest effect estimate was from an unadjusted marginal model with an
unstructured working correlation matrix (IRR 0.66, 95% CI 0.54 to 0.81), and the largest
effect estimate was from an unadjusted mixed model with different random effects by
group (IRR 0.34, 95% CI 0.23 to 0.50). As with analysis 1, the results in years two and
three remained stable, suggesting the effect of ivacaftor on the rate of IV days does not
change over time.
Finally, the results of the combined analysis are shown in Figure 9.17, and in Tables 9.15,
9.16 and 9.17. Again, these analyses directly estimate the NCCTE. In this case, only one of
the four attempted mixed-effects models reached convergence. This was the unadjusted
model with one set of random effects. At one year, the smallest effect estimate was from
an unadjusted marginal model with an unstructured working correlation matrix (IRR
0.67, 95% CI 0.57 to 0.81), and the largest effect estimate was from the unadjusted mixed
model (IRR 0.38, 95% CI 0.27 to 0.54). As with the other two analyses, these results stayed
stable out to years two and three.
9.4 Discussion
All of the results that have been presented suggest quite a strong positive effect of iva-
caftor on both the step-change in lung function at one year and the rate of IV days out
to three years. The estimates of a change in the slope of lung function trajectory were
also suggestive of a beneficial effect of ivacaftor, but these results were not always statis-
tically significant. However, rather than just obtaining a general idea of the direction of
the effect of ivacaftor on the outcomes, it would be nice to be able to give a more specific
estimate of the treatment effect. Although the methods and analyses that we have con-
sidered were generally in agreement, there were a number of differences that sometimes
could change the message of whether we believe there is enough evidence in the data to
firmly conclude that the observed effects are real treatment effects. In the following sub-
sections, we will compare the different analyses and methods and give suggestions as
to whether some approaches may be more reliable than others for providing a summary
result and for recommendation for future analyses.
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NCCTE
Analysis 1: Pre− & Post Ivacaftor − Year 1
FIGURE 9.11: Estimated effect of ivacaftor on rate of annual IV days after one year of treatment when comparing post-ivacaftor
period to pre-ivacaftor period
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Analysis 1: Pre− & Post Ivacaftor − Year 2
FIGURE 9.12: Estimated effect of ivacaftor on rate of annual IV days after two years of treatment when comparing post-ivacaftor
period to pre-ivacaftor period
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Analysis 1: Pre− & Post Ivacaftor − Year 3
FIGURE 9.13: Estimated effect of ivacaftor on rate of annual IV days after three years of treatment when comparing post-ivacaftor
period to pre-ivacaftor period
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Analysis 2: Ivacaftor Eligible & Ineligible − Year 1
FIGURE 9.14: Estimated effect of ivacaftor on rate of annual IV days after one year of treatment when comparing those eligible
for ivacaftor to those ineligible for ivacaftor
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Analysis 2: Ivacaftor Eligible & Ineligible − Year 2
FIGURE 9.15: Estimated effect of ivacaftor on rate of annual IV days after two years of treatment when comparing those eligible
for ivacaftor to those ineligible for ivacaftor
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Analysis 2: Ivacaftor Eligible & Ineligible − Year 3
FIGURE 9.16: Estimated effect of ivacaftor on rate of annual IV days after three years of treatment when comparing those eligible
for ivacaftor to those ineligible for ivacaftor
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FIGURE 9.17: Estimated effect of ivacaftor on rate of annual IV days when comparing those currently receiving ivacaftor both to
those not currently receiving ivacaftor and those in the pre-ivacaftor period
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Model MatrixStructure H
Analysis 1: Pre- & Post Comparison - Year 1
NTE (B vs A) NCE (D vs C) NCCTE
IRR SE 95% CI p IRR SE 95% CI p IRR SE 95% CI p
Marginal
Independent Unadjusted 0.50 0.06 0.40, 0.62 <0.001 0.93 0.02 0.89, 0.97 <0.001 0.54 0.06 0.43, 0.67 <0.001Adjusted 0.43 0.07 0.32, 0.59 <0.001 0.79 0.02 0.74, 0.83 <0.001 0.55 0.09 0.40, 0.75 <0.001
Exchangeable Unadjusted 0.60 0.06 0.49, 0.73 <0.001 0.94 0.02 0.91, 0.98 0.002 0.64 0.07 0.52, 0.78 <0.001Adjusted 0.53 0.76 0.40, 0.69 <0.001 0.86 0.02 0.81, 0.91 <0.001 0.61 0.08 0.46, 0.81 <0.001
Unstructured Unadjusted 0.61 0.06 0.50, 0.74 <0.001 0.94 0.02 0.91, 0.98 0.003 0.65 0.07 0.53, 0.79 <0.001Adjusted 0.52 0.07 0.40, 0.71 <0.001 0.86 0.02 0.82, 0.91 <0.001 0.62 0.09 0.46, 0.82 0.001
Fixed-Effects Unadjusted 0.51 0.07 0.39, 0.68 <0.001 0.94 0.03 0.88, 1.00 0.047 0.55 0.08 0.41, 0.73 <0.001
Mixed-Effects
Combined Unadjusted 0.33 0.06 0.24, 0.48 <0.001 0.92 0.03 0.87, 0.98 0.014 0.36 0.07 0.25, 0.52 <0.001Adjusted Does not converge
By Group Unadjusted 0.30 0.06 0.21, 0.44 <0.001 0.92 0.03 0.86, 0.98 0.015 0.33 0.07 0.22, 0.49 <0.001Adjusted Does not converge
TABLE 9.9: Estimated effect of ivacaftor on rate of annual IV days after one year of treatment when comparing post-ivacaftor
period to pre-ivacaftor period
Model MatrixStructure H
Analysis 1: Pre- & Post Comparison - Year 2
NTE (B vs A) NCE (D vs C) NCCTE
IRR SE 95% CI p IRR SE 95% CI p IRR SE 95% CI p
Marginal
Independent Unadjusted 0.47 0.06 0.36, 0.60 <0.001 0.89 0.02 0.85, 0.94 <0.001 0.52 0.07 0.41, 0.67 <0.001Adjusted 0.30 0.04 0.22, 0.39 <0.001 0.76 0.02 0.71, 0.81 <0.001 0.39 0.05 0.29, 0.52 <0.001
Exchangeable Unadjusted 0.53 0.06 0.43, 0.67 <0.001 0.90 0.02 0.86, 0.94 <0.001 0.60 0.07 0.47, 0.75 <0.001Adjusted 0.35 0.04 0.28, 0.45 <0.001 0.83 0.02 0.78, 0.88 <0.001 0.43 0.05 0.33, 0.55 <0.001
Unstructured Unadjusted 0.51 0.06 0.41, 0.64 <0.001 0.90 0.02 0.86, 0.94 <0.001 0.57 0.07 0.45, 0.71 <0.001Adjusted 0.33 0.04 0.26, 0.43 <0.001 0.82 0.02 0.77, 0.87 <0.001 0.41 0.05 0.32, 0.52 <0.001
Fixed-Effects Unadjusted 0.40 0.06 0.30, 0.53 <0.001 0.87 0.03 0.81, 0.93 <0.001 0.46 0.07 0.35, 0.61 <0.001
Mixed-Effects
Combined Unadjusted 0.26 0.05 0.18, 0.36 <0.001 0.84 0.03 0.78, 0.90 <0.001 0.31 0.06 0.22, 0.44 <0.001Adjusted Does not converge
By Group Unadjusted 0.24 0.05 0.16, 0.34 <0.001 0.83 0.03 0.77, 0.90 <0.001 0.28 0.06 0.19, 0.42 <0.001Adjusted Does not converge
TABLE 9.10: Estimated effect of ivacaftor on rate of annual IV days after two years of treatment when comparing post-ivacaftor
period to pre-ivacaftor period
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Model MatrixStructure H
Analysis 1: Pre- & Post Comparison - Year 3
NTE (B vs A) NCE (D vs C) NCCTE
IRR SE 95% CI p IRR SE 95% CI p IRR SE 95% CI p
Marginal
Independent Unadjusted 0.42 0.06 0.32, 0.56 <0.001 0.86 0.03 0.81, 0.91 <0.001 0.49 0.07 0.37, 0.66 <0.001Adjusted 0.32 0.06 0.22, 0.45 <0.001 0.75 0.03 0.70, 0.81 <0.001 0.42 0.08 0.29, 0.61 <0.001
Exchangeable Unadjusted 0.49 0.06 0.39, 0.62 <0.001 0.89 0.02 0.85, 0.93 <0.001 0.55 0.07 0.43, 0.70 <0.001Adjusted 0.40 0.06 0.30, 0.53 <0.001 0.83 0.03 0.77, 0.88 <0.001 0.48 0.07 0.36, 0.65 <0.001
Unstructured Unadjusted 0.48 0.06 0.38, 0.61 <0.001 0.89 0.02 0.85, 0.94 <0.001 0.54 0.07 0.42, 0.69 <0.001Adjusted 0.40 0.06 0.29, 0.55 <0.001 0.81 0.03 0.76, 0.87 <0.001 0.49 0.08 0.35, 0.69 <0.001
Fixed-Effects Unadjusted 0.42 0.07 0.30, 0.58 <0.001 0.92 0.04 0.85, 0.99 0.023 0.46 0.08 0.33, 0.64 <0.001
Mixed-Effects
Combined Unadjusted 0.29 0.07 0.19, 0.44 <0.001 0.87 0.04 0.80, 0.95 0.001 0.33 0.08 0.21, 0.51 <0.001Adjusted Does not converge
By Group Unadjusted 0.27 0.06 0.17, 0.42 <0.001 0.87 0.04 0.80, 0.95 0.001 0.31 0.08 0.19, 0.49 <0.001Adjusted Does not converge
TABLE 9.11: Estimated effect of ivacaftor on rate of annual IV days after three years of treatment when comparing post-ivacaftor
period to pre-ivacaftor period
Model MatrixStructure H
Analysis 2: Eligible & Ineligible - Year 1
NTE (B vs D) NCE (A vs C) NCCTE
IRR SE 95% CI p IRR SE 95% CI p IRR SE 95% CI p
Marginal
Independent Unadjusted 0.51 0.06 0.41, 0.64 <0.001 0.96 0.09 0.80, 1.14 0.61 0.54 0.06 0.43, 0.67 <0.001Adjusted 0.43 0.05 0.34, 0.55 <0.001 0.79 0.06 0.67, 0.92 0.002 0.55 0.08 0.41, 0.72 <0.001
Exchangeable Unadjusted 0.59 0.05 0.50, 0.71 <0.001 0.93 0.06 0.81, 1.06 0.29 0.64 0.06 0.52, 0.78 <0.001Adjusted 0.48 0.05 0.39, 0.59 <0.001 0.81 0.06 0.70, 0.93 0.003 0.60 0.08 0.46, 0.77 <0.001
Unstructured Unadjusted 0.62 0.05 0.52, 0.73 <0.001 0.93 0.06 0.81, 1.06 0.27 0.66 0.07 0.54, 0.81 <0.001Adjusted 0.49 0.05 0.40, 0.60 <0.001 0.81 0.06 0.70, 0.93 0.003 0.60 0.08 0.47, 0.77 <0.001
Fixed-Effects Unadjusted 0.49 0.06 0.39, 0.61 <0.001 0.89 0.09 0.73, 1.07 0.22 0.55 0.08 0.41, 0.73 <0.001
Mixed-Effects
Combined Unadjusted 0.33 0.05 0.24, 0.45 <0.001 0.88 0.09 0.72, 1.07 0.20 0.37 0.07 0.26, 0.53 <0.001Adjusted 0.29 0.04 0.22, 0.38 <0.001 0.79 0.08 0.65, 0.95 0.014 0.37 0.06 0.26, 0.51 <0.001
By Group Unadjusted 0.30 0.05 0.21, 0.43 <0.001 0.88 0.10 0.71, 1.09 0.24 0.34 0.07 0.23, 0.50 <0.001Adjusted Does not converge
TABLE 9.12: Estimated effect of ivacaftor on rate of annual IV days after one year of treatment when comparing those eligible for
ivacaftor to those ineligible for ivacaftor
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Model MatrixStructure H
Analysis 2: Eligible & Ineligible - Year 2
NTE (B vs D) NCE (A vs C) NCCTE
IRR SE 95% CI p IRR SE 95% CI p IRR SE 95% CI p
Marginal
Independent Unadjusted 0.50 0.06 0.39, 0.64 <0.001 0.95 0.08 0.81, 1.11 0.51 0.52 0.07 0.41, 0.67 <0.001Adjusted 0.38 0.05 0.29, 0.49 <0.001 0.87 0.07 0.75, 1.02 0.090 0.43 0.06 0.32, 0.58 <0.001
Exchangeable Unadjusted 0.57 0.06 0.46, 0.70 <0.001 0.95 0.06 0.84, 1.08 0.47 0.60 0.07 0.48, 0.75 <0.001Adjusted 0.42 0.05 0.33, 0.53 <0.001 0.91 0.07 0.79, 1.06 0.23 0.46 0.06 0.35, 0.61 <0.001
Unstructured Unadjusted 0.56 0.06 0.46, 0.69 <0.001 0.96 0.06 0.84, 1.09 0.52 0.59 0.07 0.47, 0.74 <0.001Adjusted 0.41 0.05 0.32, 0.52 <0.001 0.91 0.07 0.79, 1.06 0.22 0.45 0.06 0.34, 0.60 <0.001
Fixed-Effects Unadjusted 0.48 0.06 0.38, 0.60 <0.001 1.03 0.11 0.84, 1.26 0.78 0.46 0.07 0.35, 0.61 <0.001
Mixed-Effects
Combined Unadjusted 0.31 0.05 0.22, 0.42 <0.001 0.96 0.11 0.78, 1.20 0.74 0.32 0.06 0.22, 0.45 <0.001Adjusted 0.27 0.04 0.20, 0.36 <0.001 0.89 0.10 0.73, 1.10 0.30 0.30 0.05 0.22, 0.42 <0.001
By Group Unadjusted 0.28 0.05 0.20, 0.40 <0.001 0.97 0.11 0.77, 1.21 0.77 0.29 0.06 0.20, 0.43 <0.001Adjusted Does not converge
TABLE 9.13: Estimated effect of ivacaftor on rate of annual IV days after two years of treatment when comparing those eligible
for ivacaftor to those ineligible for ivacaftor
Model MatrixStructure H
Analysis 2: Eligible & Ineligible Comparison - Year 3
NTE (B vs D) NCE (A vs C) NCCTE
IRR SE 95% CI p IRR SE 95% CI p IRR SE 95% CI p
Marginal
Independent Unadjusted 0.44 0.06 0.34, 0.56 <0.001 0.89 0.09 0.72, 1.09 0.26 0.49 0.07 0.37, 0.66 <0.001Adjusted 0.36 0.05 0.28, 0.48 <0.001 0.89 0.09 0.73, 1.08 0.24 0.41 0.07 0.29, 0.57 <0.001
Exchangeable Unadjusted 0.51 0.05 0.42, 0.62 <0.001 0.92 0.08 0.78, 1.10 0.36 0.55 0.07 0.43, 0.70 <0.001Adjusted 0.42 0.05 0.33, 0.54 <0.001 0.92 0.08 0.76, 1.10 0.34 0.46 0.07 0.34, 0.63 <0.001
Unstructured Unadjusted 0.49 0.05 0.40, 0.60 <0.001 0.92 0.08 0.77, 1.09 0.32 0.54 0.07 0.42, 0.69 <0.001Adjusted 0.41 0.05 0.32, 0.53 <0.001 0.90 0.08 0.75, 1.08 0.24 0.46 0.08 0.33, 0.63 <0.001
Fixed-Effects Unadjusted 0.44 0.06 0.34, 0.57 <0.001 0.95 0.11 0.75, 1.20 0.64 0.46 0.08 0.33, 0.64 <0.001
Mixed-Effects
Combined Unadjusted 0.31 0.06 0.21, 0.44 <0.001 0.90 0.12 0.69, 1.16 0.42 0.34 0.08 0.22, 0.52 <0.001Adjusted 0.28 0.05 0.20, 0.40 <0.001 0.86 0.11 0.67, 1.12 0.26 0.33 0.08 0.21, 0.51 <0.001
By Group Unadjusted 0.29 0.06 0.19, 0.43 <0.001 0.90 0.12 0.69, 1.18 0.44 0.32 0.08 0.20, 0.50 <0.001Adjusted Does not converge
TABLE 9.14: Estimated effect of ivacaftor on rate of annual IV days after three years of treatment when comparing those eligible
for ivacaftor to those ineligible for ivacaftor
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Model MatrixStructure H
Combined Analysis
Year 1
IRR SE 95% CI p
Marginal
Independent Unadjusted 0.54 0.06 0.43, 0.67 <0.001Adjusted 0.55 0.08 0.43, 0.73 <0.001
Exchangeable Unadjusted 0.64 0.06 0.53, 0.78 <0.001Adjusted 0.61 0.08 0.48, 0.78 <0.001
Unstructured Unadjusted 0.67 0.07 0.55, 0.81 <0.001Adjusted 0.62 0.08 0.48, 0.79 <0.001
Fixed-Effects Unadjusted 0.55 0.08 0.41, 0.73 <0.001
Mixed-Effects
Combined Unadjusted 0.38 0.07 0.27, 0.54 <0.001Adjusted Does not converge
By Group Unadjusted Does not convergeAdjusted Does not converge
TABLE 9.15: Estimated effect of ivacaftor on rate of annual IV days after
one year of treatment when comparing those currently receiving ivacaf-
tor both to those not currently receiving ivacaftor and those in the pre-
ivacaftor period
Model MatrixStructure H
Combined Analysis
Year 2
IRR SE 95% CI p
Marginal
Independent Unadjusted 0.52 0.07 0.41, 0.67 <0.001Adjusted 0.44 0.07 0.32, 0.60 <0.001
Exchangeable Unadjusted 0.60 0.07 0.48, 0.75 <0.001Adjusted 0.48 0.07 0.36, 0.64 <0.001
Unstructured Unadjusted 0.59 0.07 0.47, 0.74 <0.001Adjusted 0.47 0.07 0.36, 0.62 <0.001
Fixed-Effects Unadjusted 0.46 0.07 0.35, 0.61 <0.001
Mixed-Effects
Combined Unadjusted 0.32 0.06 0.23, 0.45 <0.001Adjusted Does not converge
By Group Unadjusted Does not convergeAdjusted Does not converge
TABLE 9.16: Estimated effect of ivacaftor on rate of annual IV days after
two years of treatment when comparing those currently receiving ivacaf-
tor both to those not currently receiving ivacaftor and those in the pre-
ivacaftor period
Model MatrixStructure H
Combined Analysis
Year 3
IRR SE 95% CI p
Marginal
Independent Unadjusted 0.49 0.07 0.37, 0.66 <0.001Adjusted 0.42 0.07 0.30, 0.59 <0.001
Exchangeable Unadjusted 0.55 0.07 0.43, 0.71 <0.001Adjusted 0.48 0.08 0.35, 0.65 <0.001
Unstructured Unadjusted 0.55 0.07 0.43, 0.70 <0.001Adjusted 0.48 0.08 0.35, 0.66 <0.001
Fixed-Effects Unadjusted 0.46 0.08 0.33, 0.64 <0.001
Mixed-Effects
Combined Unadjusted 0.34 0.08 0.22, 0.53 <0.001Adjusted Does not converge
By Group Unadjusted Does not convergeAdjusted Does not converge
TABLE 9.17: Estimated effect of ivacaftor on rate of annual IV days after
three years of treatment when comparing those currently receiving ivacaf-
tor both to those not currently receiving ivacaftor and those in the pre-
ivacaftor period
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9.4.1 Comparability of Groups
The key assumption of the NTE analyses is that the groups presented in Figure 9.2 are
comparable except for the introduction of ivacaftor. We aimed to test this assumption
through the use of negative controls and the results of these analyses suggested that
on the whole the assumption of comparability of the groups was reasonable. The NCE
estimates were all quite small and would likely not be deemed clinically significant. Some
of the estimates were, however, statistically significant, and this was generally due to the
very large sample size available in the non-gating mutation groups, which allowed very
precise estimation of the NCE. Nevertheless, the fact that the estimates were not exactly
zero and also tended to be in the same direction as the NTE estimates does suggest that
there could be some small biases in the NTE estimates. This bias can be accounted for by
calculating the NCCTE, which requires weaker assumptions about the comparability of
the groups. Therefore, it should generally be preferable to use the NCCTE estimates of
the NTE estimates.
The SEs of the NCCTE estimates were generally similar to the SEs of the NTE estimates,
meaning that this was not a concern for these analyses. This was because in analysis
1 we were able to obtain such precise estimates of the NCE and in analysis 2 the same
people were in both the NTE and the NCE resulting in a large covariance between the
two estimates. In the case of analysis 2, this meant that sometimes the SE of the NCCTE
was actually smaller than the SE of the NTE, as we gained precision through having the
same individuals in both the main and the negative control analyses. A situation where
there was only a relatively small negative control group could result in a much larger SE
for the NCCTE. Depending on the analysis, this could make it difficult for the NCCTE to
reach statistical significance, but this is not necessarily a bad thing, as the large SE would
reflect the uncertainty regarding the comparability of the groups.
One of the benefits of analyses one and two is that the NCE are obtained separately. This
allows us to directly see an estimate of how comparable the groups are. However, this be-
nefit is probably outweighed by the benefit of the combined analysis, which gives a direct
estimate of the NCCTE and which is generally more precise due to the larger sample size
of combining both groups. Furthermore, although the combined analysis includes com-
parison to both people of a different genotype and people from a different time period,
the overall assumption is actually the same as the assumption for the NCCTE estimates
of the separate analyses: that there is no interaction between the effects of genotype and
time period.
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9.4.2 Comparison of Statistical Methods
We considered three main types of models: marginal models, fixed-effects models and
mixed-effects models. In the case of the lung function analysis most of the methods gave
very similar results. However, the point estimates from the marginal models using an in-
dependent working correlation matrix were more divergent from the other methods and
also tended to have larger SEs. Checking the estimated correlations from exchangeable
and unstructured correlation matrices suggests that there is strong correlation in repeat
measures from the same individual and this would suggest that although marginal mo-
dels can be used, the working correlation matrix should allow for correlations between
the measures. Taking the unadjusted marginal model for the NTE of analysis 1: using an
exchangeable correlation matrix estimated the correlation between all measures for the
same individual to be 0.87, and using an unstructured correlation matrix, the correlati-
ons were all estimated to be between 0.82 and 0.91. This suggests that here the use of an
exchangeable working correlation matrix is sufficient as the correlations between measu-
res made at different time points do not vary much and furthermore the exchangeable
working correlation matrix does not need the visits to be equally spaced allowing it to be
used with the continuous measure of time.
For mixed-effects models, preliminary analyses suggested that the random effects struc-
ture should be separated by group, as it seemed that lung function measures generally
became less variable when taking ivacaftor. This finding was repeated in the final analy-
ses, where allowing separate random effects by group was shown to lead to a statistically
significantly better fit to the data. However, this change in random effects structure had
almost no effect on the treatment effect estimates, suggesting that as long as the random
effects specification is approximately correct it will not lead to any observable bias in the
estimation of fixed-effects terms.
For the lung function analyses, thanks to collapsibility, the estimands for all models are
the same and the observed estimates found across methods were similar as we expected.
This would suggest that when choosing an analysis approach, we should aim to choose
the method that could give the smallest SE. However, our results show that all analyses
also gave almost identical SEs. This means that in the case of lung function, it does not
matter whether one uses a marginal model (as long as an independent working correla-
tion matrix is not used), a fixed-effects model or a mixed-effects model.
When considering the analysis with the number of IV days as the outcome, the same
problem of using marginal models with an independent working correlation matrix was
observed. Although the correlation between observations was less than in the case of
lung function, it was still relatively large: the exchangeable working correlation matrix
estimated the correlation between observations from the same person to be 0.59, and the
unstructured working correlation matrix gave estimates between 0.47 and 0.73.
Chapter 9. Estimating the Effects of Long-Term Ivacaftor Use 212
With a non-linear model, we no longer expect the estimates from the different models to
be the same due to non-collapsibility, i.e. the estimands are different. This means we have
to consider what effect estimate we are interested in: the unadjusted marginal models
give the population-average effect, whereas the mixed-effects and fixed-effects models
estimate the subject-specific effect. The former is the effect we would see over the whole
population if everyone received ivacaftor compared to if nobody received ivacaftor. The
latter is the effect we would expect to see in one person when they are taking ivacaf-
tor compare to if they were not taking ivacaftor. Surprisingly, the effect estimates from
the fixed-effects models were actually closer to the estimates from the marginal model
than the estimates from the mixed-effects model. It is known that fixed-effects regression
should not be used with logistic models, but it has been suggested that this was not an
issue with negative binomial models.[268] However, in our analysis more than half of
the observed IV days outcomes are zeroes, which could be why these estimates do not
coincide with those of the mixed-effects models. Therefore, in the case of non-continuous
outcomes, we suggest either using marginal models or mixed-effects models and avoi-
ding fixed-effects models.
One further issue of non-linear models is that a number of the mixed-effects models did
not converge. This is generally an issue as the models become more complicated, i.e. by
using more complex random effects structures or adjusting for more variables. As our
results appear to suggest that adjusting for additional variables or using more complex
random effects structures make little difference, this should not affect our results and we
can safely just use the results from the simpler mixed-effects models that did converge.
9.4.3 Adjustment for Measured Baseline Health Variables
As shown in Figure 9.4, we expected the use of the negative control to correct the treat-
ment effect estimates whether observed measures of baseline health were adjusted for or
not. This appears to be correct, as generally the unadjusted and adjusted NCCTE esti-
mates were more similar to each other than the unadjusted and adjusted NTE estimates,
as the NCE estimates corrected for these differences. However, in reality, even the unad-
justed and adjusted NTE estimates were remarkably similar. This suggests that the four
groups were actually quite well balanced at baseline, which is what was shown in Table
9.1. If there had been imbalances in the groups at baseline, the use of the negative control
should still have been able to account for this, but additionally adjusting for H should
have decreased the SE of the treatment effect estimates. As this was not the case in our
analyses, the SEs were very similar regardless of adjustments.
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9.4.4 Accuracy of Time Measurement
For the lung function analysis, we performed all analyses twice, one using the precise
estimate of time since baseline and the other just using visit number (1, 2, 3 or 4). As
presented in Table 9.2, on average the visits do happen annually, which suggested that
ignoring the exact timing of the visits may not have a big impact on the results. It was ho-
ped, however, that using the more precise estimates of time could improve the efficiency
of the methods. The results of the analysis show that this was not the case, as there was
barely any difference in either the point estimates or the SEs of any of the results when
using continuous or discrete measures of time. This is actually a positive result though
as it suggests that there will be no bias in just using the discrete measure of time in situa-
tions where it is not appropriate to use the continuous measure of time, such as in the IV
days analysis or in any of the methods presented in Part II of this thesis. However, even
though it makes little difference, in situations where it is possible, it is probably best to
use the more accurate continuous measure of time.
9.4.5 Computation Time
There were two procedures which heavily affected the computation time of the analyses:
the bootstrap and the mixed-effects models. In isolation, neither of these procedures
resulted in unmanageable computation times, but put together the analyses would take
many days. Obviously, if the only correct method was a mixed-effects model and if it
were necessary to use a bootstrap to obtain the SEs then the computation time would
be unavoidable. However, the bootstrap can be avoided provided that the same person
is not in the NTE analysis and the NCE analysis, as in that situation, the covariance
between the two estimates is known to be zero. Similarly, the combined analysis directly
obtains the NCCTE, and so the bootstrap is not necessary there either. In fact, in the
analyses presented in this chapter, the bootstrap was only necessary to obtain the NCCTE
estimates of analysis 2. As the results of analysis 2 were very similar to those of analysis
1 and the combined analysis, it would suggest that we could have avoided the bootstrap
altogether.
9.4.6 Long-Term Effects of Ivacaftor
Finally, we present the results of the chosen method for each outcome. For lung function,
we use the combined analysis and an adjusted marginal model with an exchangeable
working correlation matrix and time measured continuously. Here, ivacaftor was esti-
mated to result in an step-change increase in ppFEV1 of 5.91% after one year of treatment
(95% CI 4.73% to 7.09%, p < 0.001). It also resulted in a decrease in the annual rate of
lung function decline of 0.53% (95% CI 0.02% to 1.04%, p = 0.040). For reference, if this
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group of people were not currently receiving ivacaftor their annual rate of lung function
decline was estimated to be -1.15% (95% CI -1.52% to -0.78%). This suggests that the rate
of lung function decline has almost been halved.
For IV days, we present both an estimate of the population-average effect and an esti-
mate of the subject-specific effect. Firstly, the population-average effect is taken from the
combined analysis using an unadjusted marginal model with an exchangeable working
correlation matrix. (We use the unadjusted rather then adjusted model here, so that the
effect estimates are truly marginal, which was not an issue with the lung function results).
Here, the IRR of IV days after one year of using ivacaftor was estimated to be 0.64 (95%
CI 0.53, 0.78), after two years the effect became slightly stronger, 0.60 (95% CI 0.48, 0.75),
and then slightly stronger again after three years, 0.55 (95% CI 0.43, 0.71).
For the subject-specific estimates we again use the combined analysis, but this time with
the unadjusted mixed-effects analysis. Here the estimated treatment effect at one year
was 0.38 (95% CI 0.27, 0.54), at two years was 0.32 (95% CI 0.23, 0.45), and at three years
was 0.34 (95% CI 0.22, 0.53). These subject-specific estimates are all stronger than the
population-average effect estimated, and this is what is generally expected to be observed
in non-linear models.
9.4.7 Comparison of Results to Other Studies
The systematic review in Chapter 7 identified two RCTs with one year of follow-up.
The estimated step-change effect on ppFEV1 in these studies was 10.0% (95% CI 4.3%
to 15.7%) and 10.5% (5.3% to 15.7%).[211, 213, 214, 216, 224] This is quite a bit larger than
the estimates from our study, but previous observational studies showed more compa-
rable results of between a 3.2% improvement and an 8.3% improvement.[236, 251] These
observational studies did only estimate the NTE, but as our NCE estimates were very
close to zero, it suggests that these estimates are also reliable.
Only one study had previously investigated the effect of ivacaftor on the rate of lung
function decline. In this study, which had three years of follow-up, the rate of annual
decline was estimated to decrease by 0.81% (95% CI 0.08% to 1.54%). Again this is a NTE,
and it is slightly larger than our NCCTE estimate, but overall they are similar estima-
tes.[236]
There have been a large number of studies that have looked at the RR of exacerbations
due to ivacaftor, but relatively fewer studies that investigated the effect of ivacaftor on
IV days. The studies that have included IV days as an outcome all looked at absolute
differences in IV days between baseline and follow-up and therefore did not estimate an
IRR as we did in our study. For this reason, we cannot directly compare our results to
any previous studies for this outcome.
Chapter 9. Estimating the Effects of Long-Term Ivacaftor Use 215
9.4.8 Limitations
One of the key strengths of our analysis is that we have assessed and hopefully corrected
for any differences between groups not due to ivacaftor. However, the methods used still
rely on the assumption that any differences between genotypes have not changed over
time, and similarly that any differences over time are the same regardless of genotype.
The fact that in our analyses the NCE were very close to zero suggests that the groups
were comparable anyway and therefore it seems reasonable to assume that the groups
remained comparable after the introduction of ivacaftor. However, if along with the in-
troduction of ivacaftor, there was also a change in healthcare policy only affecting those
receiving ivacaftor, e.g. if those receiving ivacaftor also started to attend the clinic for
more regular check-ups, then this could affect the validity of our analyses. We do not
know of any changes of any nationwide changes in healthcare practice that could have
had such an effect, but there remains the possibility that some local centres may have
started treated those on ivacaftor differently, which could affect the results.
One of the key aims of this work is to show how the effects of long-term treatment use
can be estimated. In this analysis, we are limited by the fact that ivacaftor has only been
available since 2012 and therefore we can only estimate the effects of receiving treatment
for four years. Over this four year period the different groups appeared to be more or less
comparable, which suggested that the use of the negative controls may not have actually
been necessary, as the NTE would still have provided good estimates of the treatment
effect. However, with longer follow-up time it seems likely that the comparability of the
groups would diminish, necessitating the use of the negative controls. For example, if we
wish to look at the effects of receiving treatment for ten years compared to never recei-
ving treatment, we would need to compare the most recent ten years to the ten years prior
to that. Expecting observations that are ten years apart to be directly comparable is much
less reasonable than assuming that observations that are four years apart are compara-
ble. Similarly, the long-term follow-up of people with different genotypes is more likely
to diverge as the length of follow-up time increases. Theoretically, the negative control
methods introduced here should still work even with much longer follow-up times, but
it would be interesting to assess that with real data once it is available.
A further issue is that ivacaftor is the first disease-modifying treatment available to pe-
ople with CF. This meant that we knew that everyone not receiving ivacaftor was not
receiving any other kind of disease modifying treatment and these people could then be
used as a control group. There are many treatments in the pipeline that will hopefully
bring disease-modifying treatments to a much larger number of people with CF. As the
number of people receiving these treatments increases, the ease of finding treatment-free
control groups will rapidly diminish. This is not a limitation of our current study, but it
does mean that the methods introduced here may not be applied so easily in the future
without adaptation.
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In our analyses, we modelled lung function trajectory over time linearly. As we only had
four lung function measures per person, it was not really possible to model the trajectory
non-linearly without risk of overfitting. Assuming a linear trajectory is the most common
way to model lung function in these types of analyses and one of the benefits of this is that
it is easily interpretable. However, long-term lung function decline is known to not be
linear and other modelling strategies such as including a quadratic term or using splines
could be considered.[20]
There are also known to be limitations to using IV days as a proxy for exacerbations, as
sometimes people will receive IVs despite not currently suffering from an exacerbation.
If these protective courses of IVs became less common once people started to receive
ivacaftor, then the results of our analyses would be biased overestimating the effect of
ivacaftor on improving exacerbation rates. However, given that the estimated effect was
so strong on decreasing the rate of IV days, it does not seem plausible that all of this
effect could come just from protective IV days, and therefore the results do suggest that
ivacaftor also reduces the rate of preventative IV days as well.
Finally, the average long-term lung function trajectories can become biased due to deaths
during follow-up. For example, if some people had very steep lung function declines in
the first couple of years of follow-up, but then subsequently died, long term the average
slope would be estimated to become more shallow even though this is not actually the
case for specific individuals. One possible solution to this issue is to use an approach
known as joint modelling. Joint models simultaneously model both the survival and
the longitudinal trajectories, and include terms to estimate how the two functions are
related.[271] This approach does have its own drawbacks as the results obtained refer
to a hypothetical group of people where nobody dies.[272] Depending on the length of
follow-up and the age of the people in the cohort this may or may not therefore pro-
vide sensible results. Furthermore, the survival models used in joint modelling cannot
actually be used to estimate the treatment effect on survival. This is because, the survi-
val trajectories are affected by the time-updating lung function measures, which are on
the causal pathway between treatment and survival. Therefore, a separate model would
need to be fit if interest was in the total effect of treatment on survival. It is for these
reasons, along with the fact that with our relatively short follow-up time there were not
many deaths, that we did not consider the use of joint models here.
9.4.9 Conclusion
The analyses presented in this chapter concord with previous studies that there is a very
beneficial effect of ivacaftor in terms of both improving lung function and reducing the
rate of annual IV days. Furthermore, there does appear to be evidence that the slope of
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lung function decline is slowed when taking ivacaftor, although longer follow-up would
be needed to confirm this finding.
Previous observational studies have relied on the assumption that the group of people
currently receiving ivacaftor are comparable either to themselves in the time period prior
to the availability of ivacaftor or to people who are not eligible to receive ivacaftor due to
genotype. In this study, we have shown how the use of negative controls can be used to
test these assumptions and if necessary to correct for any differences between the groups
not due to treatment. Over the four years of follow-up of this study, it appeared that
the assumption of comparability of groups was met, suggesting that the treatment effect
estimates from other observational studies are unlikely to be biased. Nevertheless, even
though the negative controls showed relatively little difference between the groups not
due to ivacaftor, we still believe that it is beneficial to incorporate this uncertainty into
the final treatment effect estimate.
Finally, there are a wide variety of methods that can be used with longitudinal data, and it
not always necessary to resort straightaway to mixed-effects models. These are the most
flexible of the models we considered, but if interest only lies in the average treatment
effect, then this can be obtained with much simpler methods that will also be computa-
tionally much quicker. However, in terms of both lung function and IV days, it appears
that the assumption of an independent working correlation matrix is unreasonable, and
for this reason standard regression methods should be avoided. Using an exchangeable
working correlation matrix appeared to be sufficient in our examples, but other types
of working correlation matrix could also be considered. Fixed-effects methods are also
a simple alternative, but our results suggest that they should be used with caution for
non-linear models.
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Chapter 10
Discussion
10.1 Summary of Findings
The main findings from this thesis can be summarised in four main sections: methods
for dealing with time-dependent confounding, the long-term effects of DNase, the use of
negative controls in observational studies, and the long-term effects of ivacaftor.
10.1.1 Time-dependent confounding
Two chapters of this thesis were devoted to issues surrounding time-dependent confoun-
ding. In Chapter 4, methods that can deal with time-dependent confounding were intro-
duced and then in Chapter 5 the performance of these methods under different scenarios
was investigated with simulation studies.
As a brief reminder, a time-dependent confounder is defined as a covariate measured
during follow-up that: 1) is affected by previous treatment, 2) affects the probability of
future treatment, and 3) affects the outcome of interest.[80] Time-dependent confounders
cannot generally be handled like baseline confounders, where for example they could
be adjusted for in a multivariable model, because of the fact that they are themselves
affected by previous treatment, meaning that as well as being confounders they are also
mediators of the total effect of treatment.
In this thesis, five methods were considered that can estimate treatment effects in the pre-
sence of time-dependent confounding: IPW of MSM[84], HA-MSM[87], g-formula[88],
g-estimation of SNM[90] and SCMM[93]. Although all of these methods can be used
to remove bias due to time-dependent confounding, there were no clear guidelines on
whether there are situations where one method would be preferred over another. IPW of
MSM is probably the most popular of the five methods, having recently become quite a
common method used in epidemiological research. However, this is believed to be due
to its perceived simplicity rather than due to any superiority of this method over other
methods.[92]
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The findings from the simulation studies in this thesis confirmed that in ideal settings
there was relatively little difference between the five methods. All five methods provi-
ded unbiased estimates of the treatment effect and there was relatively little difference
between the SEs of the methods. Ideal settings refers to a scenario where the following
assumptions are valid: no interference, positivity, consistency, and no unmeasured con-
founding. Furthermore, the models are assumed to be correctly specified in terms of
the parametric functional forms, short-term and long-term causal pathways, interaction
effects, the direction of causal pathways, and any censoring is accounted for.
Both IPW of MSM and HA-MSM performed very similarly to one another in all scena-
rios, but HA-MSM can provide estimates of effect modification by time-varying covaria-
tes. Standard IPW methods are agnostic on whether there is effect modification meaning
they do not provide biased results if there is effect modification, but they can only ever
give estimates of the population-average effect. Ensuring that the weights are combined
correctly through time is more difficult with HA-MSM than with the standard IPW met-
hod though, suggesting that unless there is particular interest in estimating any effect
modification that standard IPW methods be used over HA-MSM.
G-formula requires parametric models to be specified for all time-varying covariates and
the resulting estimates will be biased if any of these models are misspecified. In our
scenarios, we only had two time-varying confounders and the amount of bias from g-
formula was never noticeably more than from the other methods considered. However,
in other settings, where there might be many time-varying covariates the method could
quickly become very difficult to use. One benefit of g-formula over the other methods
considered is that it is very easy to compare many different types of long-term treatment
patterns. In this thesis, we have focussed on comparing taking treatment continuously
to never taking treatment, but g-formula could easily estimate the effects of other trajec-
tories, such as taking treatment for two years, stopping treatment for two years and then
restarting for another two years.
G-estimation of SNM was one of the methods that allowed for the estimation of effect
modification by time-varying covariates and in all scenarios studied in the simulations it
performed similarly to the other methods.
Finally, SCMM could only be used to estimate the one-year effect of treatment in our
situation. However, it was shown to be able to fully account for all confounding of this
short-term effect, (provided that all confounders are observed), meaning that the more
complex methods introduced in this thesis do not always have to be used when there is
time-dependent confounding. As this method is a much simpler method than the other
methods introduced, essentially being a multivariable regression model, we suggest this
as a good starting point for analyses to first look at the short-term effects, before deciding
whether to continue to investigate the long-term effects with the other available methods.
Chapter 10. Discussion 221
For our specific analysis, it was clear from the preliminary short-term analyses using
SCMM that there was modification of the treatment effect by time-varying covariates.
For this reason, it was most suitable to use either HA-MSM or g-estimation for the long-
term effects analyses. Although the other two methods could still be used to provide
unbiased estimates of the population-average effect of treatment.
Perhaps unsurprisingly, misspecification of the direction of causal pathways resulted in
biased treatment effect estimates for all five methods. However, IPW of MSM and HA-
MSM were shown to perform especially poorly in these situations. Truncation of extreme
weights reduced the bias in these situations, but in a real-life setting, it would be more
difficult to know when truncation of the weights would lead to less biased estimates. For
this reason, in situations where it is difficult to know the direction of causal pathways
with certainty, it is recommended not to use IPW or MSM or HA-MSM. This situation
would be common whenever data are collected at regular intervals, but the data are rela-
ted to the time period since the last data were collected.
10.1.2 Dornase Alfa
From the systematic review presented in Chapter 3, it is clear that there have not been
many studies investigating the effect of long-term DNase use. The longest study had four
years of follow-up and the results did suggest that the rate of decline of lung function was
slowed by DNase, but the study only had 60 participants.[60] No other study had longer
than two years of follow-up, but in general the findings were all positive that DNase im-
proved lung function and reduced the rate of pulmonary exacerbations. Almost all stu-
dies were, however, restricted to patients who already showed declines in lung function,
and therefore may not be applicable to people taking DNase with high lung function
levels.
In the UK CF Registry, we saw very variable rates of DNase use depending on CF cen-
tre, and this is generally due to different practices, where some centres routinely initiate
DNase when people reach a certain age (often 6 years old), whereas other centres wait
until lung function drops below a certain level (often 80%). Overall, there was clear con-
founding by indication in the UK CF population, with those taking DNase having worse
health on average, but there was a lot of overlap and positivity therefore did not appear
to be an issue for the analysis.
Based on the findings of the simulation studies, it appeared that any of the five methods
could be used to estimate the effects of DNase. However, there was uncertainty about
the direction of the causal pathway between DNase and IV days in a given year and
for this reason, IPW of MSM and HA-MSM, may perform particularly poorly if this is
misspecified.
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Initially, the data were analysed using SCMM to estimate the effect of one-year of DNase
use on lung function. The population-average estimates showed almost no effect of
DNase on lung function. However, there was evidence that the treatment effect was
modified by previous levels of lung function, with those with lower lung function seeing
improvements in lung function after one year of DNase use.
Long term, the effect modification by previous levels of lung function appeared to remain
important suggesting that either g-estimation or HA-MSM be used. The results from both
of these methods were very similar, estimating the treatment effect to remain more or less
stable between years one and five. This suggests that DNase does not alter the trajectory
of lung function decline, as at five-years the difference between untreated and treatment
was similar to what it was at one-year. The confidence intervals did, however, become
much larger at five years due to the smaller sample size of people who had continuously
used treatment for this period of time.
One of the main limitations of our study (and indeed most observational studies) was
that it is not possible to confirm whether confounding had been adequately accounted
for or whether there remained important unobserved confounders. For the lung function
analysis, the main confounder appeared to be previous lung function and once this was
included in the models, there was actually little effect of including a range of other po-
tential confounders. However, we also wished to investigate the effects of DNase on the
rate of IV days, and in these analyses, the results also found that DNase was having a
strong negative effect on the rate of IV days. It seems unlikely that this is a real effect of
DNase, and suggests that there are some unmeasured confounders that affect both the
probability of receiving DNase and the probability of receiving IVs.
One of the assumptions of all the methods we considered for this analysis is that visits are
equally spaced. As shown in Figure 2.2, annual assessments are in most circumstances
carried out very close to annually, but a small number of people do have much smaller
or bigger gaps between assessments. It is not clear if this may affect the results of the
analysis, but for the ivacaftor analyses carried out in Chapter 9, we were able to inves-
tigate whether using exact times of visits affected the analyses and there was almost no
affect. This suggests that the repeated visits are not so irregular as to cause any issues in
analyses of the registry data.
10.1.3 Negative Controls
The next treatment we wished to investigate was ivacaftor. This recent treatment is
thought to be the first ‘disease-modifying’ treatment available to a sub-group of people
with CF. Because it was shown to be so efficacious in trials, everybody in the UK who has
an eligible genotype is now receiving ivacaftor. Therefore, if we wish to estimate the ef-
fect of long-term treatment use in these people, it has been suggested that they should be
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compared to another group of people who cannot receive treatment but who otherwise
are similar. Negative controls are a tool that can be used to formally test the assumption
of the comparability of groups, i.e. to test whether there is any confounding, thus helping
to ensure there is no systematic bias in the analysis.[259]
In Chapter 8 we presented six different DAGs in Figures 8.2 and 8.3 showing possible
causal pathways in this situation where there is a perfect predictor of treatment, here ge-
notype or time period. In three of these scenarios we would expect there to be no bias
in analyses ignoring the perfect predictor of treatment. These are situations where the
perfect predictor of treatment has either no direct effect on the outcome or only indirect
effects on treatment through observed covariates, so that the indirect confounding ef-
fects can be accounted for through adjustment of the observed variables. If the perfect
predictor has an effect on the outcome, either directly or indirectly through unobserved
covariates, then the simple comparisons of the groups would be biased, and this would
be reflected in non-null results of the negative control analysis.
We defined three different estimators: the NTE, the NCE, and the NCCTE. The NTE is
obtained by comparing those receiving treatment to those not receiving treatment, igno-
ring any effect the perfect predictor of treatment may have on the outcome. The NCE is
an estimator of the effect of the perfect predictor of treatment on the outcome not me-
diated through treatment. The NCCTE is then an estimator of the effect of treatment on
outcome, correcting the NTE for any estimated effect of the perfect predictor of treatment
in the NCE analysis.
The simplest way to calculate an estimate of the NCCTE is to subtract the estimated NCE
from the estimated NTE. This assumes that the effect of the perfect predictor is the same
in the negative control groups as in the main analysis groups. In settings where the ne-
gative control groups are independent of the main analysis groups, the variance of the
NCCTE can be estimated as the sum of the variance of the NCE and the variance of the
NTE. However, in situations where the same person can be in both the negative control
analysis and the main analysis, there will likely be some covariance between the two ana-
lyses meaning that a bootstrap is necessary to obtain accurate estimates of the variance
of the NCCTE. In such settings, the variance of the NCCTE can actually be less than the
variance of the NTE, as the NCE analysis provides information on the comparability of
the groups without treatment.
In our setting, depending on the comparator group, we actually had two perfect predic-
tors of treatment: time period and genotype. We could therefore perform the analyses
described in the previous two paragraphs twice with different negative controls. Alter-
natively, by including the whole CF population in one analysis, neither time period or
genotype is a perfect predictor of treatment, and they can be included in a multivariable
model. However, this analysis does still make the same assumption as the negative cont-
rol analyses: namely that there is no interaction between the effects of genotype and time
Chapter 10. Discussion 224
period on the outcome.
10.1.4 Ivacaftor
Chapter 7 presented a systematic review of studies investigating the effects of ivacaftor
on lung function and pulmonary exacerbations. Even though ivacaftor has only been
available for a few years, there have already been a large number of studies investigating
the effects of ivacaftor. The length of these studies has mainly been limited by the time
ivacaftor has been available, but there are a number of recent studies with two to four
years of follow-up.
The longest RCTs had one-year of follow-up and these all showed very beneficial effects
of ivacaftor on lung function and the rate of exacerbations. However, due to the relatively
short follow-up time, it was not possible to estimate whether the treatment had resulted
in a change of the long-term lung function trajectory.
Due to that fact that almost all people eligible for ivacaftor are now receiving treatment,
observational studies have generally had to find control groups among people who could
not receive ivacaftor. This meant either doing a pre- and post- study comparing people in
the years prior to the availability of ivacaftor to the years since they have been receiving
it. This assumes that there have been no other changes in healthcare that could affect
the outcome over this time period. We know that the average health of people with
CF has been improving over time, but it is not clear if this would have an important
effect on an analysis with two to four years of follow-up.[258] Alternatively, studies have
compared people receiving ivacaftor with people who are not receiving ivacaftor due to
their genotype. Often these types of studies employ matching methods to ensure that
patients are matched on a number of baseline covariates. However, even with matching,
these comparisons assume that these groups of people would have had similar long-term
follow-up were it not for ivacaftor. Some studies have suggested that people with gating
mutations have similar long-term follow-up as those with a class II mutation[256, 257].
However, to obtain accurate estimates of the treatment effect, even small non-statistically
significant differences between groups should be accounted for.
Our analyses used negative controls to test the assumptions of these two comparison
groups. The results showed that over four years the different groups, defined by ge-
notype and time period, were generally comparable with only very small estimates of
the NCE. However, although this did not result in large differences in the point estimates
of the NTE and the NCCTE, the variance of the NCCTE was generally larger than that of
the NTE, reflecting the uncertainty in the comparability of the groups. This meant that
the final results were not always statistically significant.
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We also compared the use of three different analysis methods: marginal models, fixed-
effects models and mixed-effects models. Marginal models appeared to be appropriate
as long as an independent working correlation matrix was not used, as generally there
was strong correlation between measures from the same individual. Fixed-effects models
appeared to perform well for linear outcomes, but there appeared to be some issues with
the results when the outcome was non-linear. Mixed-effects models also performed well,
but the computation time was much slower and sometimes models would not reach con-
vergence. This was more of an issue when the outcome was non-linear and in analyses
where it was necessary to use a bootstrap procedure.
Overall, the analyses suggested a strong beneficial effect of ivacaftor, resulting in a step-
change increase in lung function over the first year of treatment. There then appeared
to be a clinically important reduction in the annual rate of lung function decline, which
was of marginal statistical significance. There also appeared to be a very strong effect
of ivacaftor on reducing the rate of IV days that appeared to remain stable throughout
follow-up.
The analyses suggested that the use of negative controls was not necessary as the groups
did appear comparable. However, this study only had four years of follow-up, and it
is plausible that any differences between groups may only become apparent over longer
periods of follow-up. For this reason, we recommend continued use of negative controls
in the future when estimating longer-term effects of ivacaftor.
10.2 Strengths and Limitations
This thesis has highlighted how registries can be used to estimate treatment effects spe-
cifically in settings where it would not be feasible to run RCTs, such as when estimating
long-term effects. Although RCTs will remain the gold-standard for estimating treatment
efficacy, there are a number of strengths to registries when compared to RCTs. Firstly, the
UK CF Registry contains long-term health data on over 99% of people with CF in the UK.
Although it will still generally be necessary to exclude a number of people from analy-
ses to avoid bias, the sample size available for analysis will often be much larger than
was available in RCTs. The results from the analyses in this thesis should therefore be
more generalisable to the whole CF population, rather than only those who fulfil strict
inclusion criteria of RCTs.
Another key strength of the analyse of registry data is that RCTs are generally only short-
term, and the long-term effects of treatment can be quite different to the short-term ef-
fects. This is particularly highlighted by the analysis in this thesis of the long-term effects
of DNase, where the short-term benefits of the treatment were not shown to translate
into a long-term change in the slope of lung function decline. The analyses in this thesis
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estimate effects of up to five years of treatment, but in theory the methods investigated
could be used to estimate much longer-term effects.
In this thesis, we have illustrated that suitable statistical methods exist which can be used
to estimate treatment effects using Registry data. The methods that are appropriate for
estimating long-term treatment effects will not always be the same and this is highlighted
by the very different statistical methods presented in Chapters 4 and 8, and the discus-
sion of their features, assumptions, and what they can and cannot be used to estimate.
None of the methods used in this thesis are new, but they are still not regularly used in
practice. This thesis provides novel assessments of the methods and shows how they can
be applied to Registry data. It is hoped that these analyses can be used as illustrations for
future research using CF or other national disease registries.
For the methods introduced in Chapter 4, the work from Chapter 5 highlights some po-
tential challenges that could be faced when attempting such analyses in practice and pro-
vides results concerning how the performance of the different methods can be affected in
different scenarios provides recommendations for when some methods should be prefer-
red over others. Data were simulated under six different scenarios, all of which were felt
could reflect the real UK CF Registry data. However, there are undoubtedly many other
scenarios which could also have been tested. One such example is the censoring scena-
rio, where data were censored based on observed data. Other types of censoring, such
as censoring based on unobserved features and interval censoring, were not considered.
Due to the low levels of drop-out in the UK CF Registry, different censoring scenarios
would probably not have had much of an impact on the findings. However, some people
in the UK CF Registry are interval-censored, meaning that they just happen to miss one
or two visits, before re-entering the Registry in later years. In the analyses in Chapter
6, these patients were censored as soon as they missed one visit, meaning that a lot of
data was dropped from the analyses. The methods considered for this analysis require
sequential visit data, so it was not possible to include their future visits in the analyses,
but if these patients were systematically different from other patients, for example, if they
were responding well to treatment and thus did not attend the clinic, this could affect the
validity of the results from this chapter. This was not an issue in Chapter 9, as the met-
hods considered in this chapter do not require sequential visits. The methods used in
Chapter 9 can, however, result in bias of the long-term trajectories due to deaths during
follow-up, and methods which aim to correct for this, such as joint modelling, were not
used due to their own limitations of referring to a hypothetical group of people where
nobody dies.[271, 272]
One key limitation of the analyses in Chapters 6 and 9 is the data quality of the Registry
data. While data quality is generally believed to be very good, there are some variables
which are thought to be less reliably recorded. For example, in Chapter 2, we highlighted
an issue with the reported proportion of patients who are receiving enzyme replacement
Chapter 10. Discussion 227
therapies, and it is not possible to know if such an issue also affects the DNase data. More
recently, as interest in long-term follow-up studies using registry data have become more
common, there have been improvements in ensuring that treatment data are captured
accurately, and therefore the ivacaftor data are believed to be more reliable. However,
even here exact start and end dates are not always reliably entered. It is also known that
levels of adherence to long-term treatments can be particularly poor, and thus, all of the
analyses in this thesis are estimating the effect of being prescribed a specific treatment,
rather than the actual effect of the treatment if it is taken as prescribed.
All of our analysis make use of the lung function measures taken specifically on the day
of the annual assessment. One strength of this approach is that it removes any ambiguity
around the direction of causal pathways. However, a single lung function measure does
not give any indication of the trajectory of lung function, which is often of more interest.
With only one measurement per year, it can be difficult to estimate the overall trajectory,
but if the collection frequency of lung function measures were increased or with more
years of data, it may have been possible to incorporate this into the analyses.
The data entry platform for the UK CF Registry is very comprehensive with a lot of data
able to be captured. However, not all fields are reliably collected, and this can be very
centre dependent. The key variables used for the analyses in this thesis, such as ppFEV1
and IV days have very low levels of missingness, but some variables that were considered
as potential confounders, such as smoking, have much higher levels of missingness. No
attempt has been made in this thesis to consider whether this type of missing data could
bias the results from the analyses, and this would be an important element of any future
work to ensure that analyses of registry data are robust.
Another limitation of the work presented in this thesis is that the outcomes used are not
always the same as those that would be used in a RCT, and hence findings are not always
directly comparable. This is particularly an issue when considering exacerbations or IV
days as an outcome. Most RCTs have a strict definition of what constitutes an exacerba-
tion, and the analyses then look at the effect of treatment on time to next exacerbation
or the rate of exacerbations in a given time period. In the UK CF Registry there is no
specific marker for whether a patient has suffered an exacerbation and IV days are used
as a proxy. For the analyses in this thesis, we chose to use the number of IV days, and to
look at the effect of treatment on the rate of IV days. It may have been possible to try and
recreate exacerbation data, by considering one course of IVs as an exacerbation, but this
transformation would not have been perfect as people often receive IVs even though they
are not suffering an exacerbation. Our analyses, therefore, answer a different question to
the analyses commonly used in RCTs: whether treatment reduces the use of IVs, com-
pared to whether treatment reduced the incidence of exacerbations. Although this limits
the comparability between our analyses and RCTs, reducing the number of IV days is still
seen as an important question, both for patients, as well as from a resource standpoint.
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10.3 Future Work
The analyses presented in this thesis investigate two very different CF treatments. There
are a number of other treatments already available that may be investigated in a way
similar to DNase, one such example would be azithromycin, which is an antibiotic that
is often prescribed to patients with CF. However, there has never been a RCT looking at
azithromycin use in CF and its use in CF is currently off-label in the UK.[273] In terms
of disease-modifying treatments, there are number of combination treatments in the pi-
peline that will combine ivacaftor with other treatments in order for people without ga-
ting mutations to receive these treatments. If these are licensed for use in the UK, then
it is likely that similar to with ivacaftor, all people who are eligible for them will receive
them. In such situations, it would therefore again be necessary to consider what compa-
rator groups are available and if the groups’ comparability can be tested through the use
of negative controls.
As well as estimating the effect of a treatment in isolation, it would also be of interest
to be able to estimate the effect of common combinations of treatment. It is thought
that some common treatments could have an antagonistic effect on one another, such as
azithromycin and tobramycin, which it would be important to investigate further.[274]
Furthermore, treatment burden is a common complaint among people with CF, and sim-
plifying the treatment burden of people with CF has been recognised as a top research
priority.[275] This may therefore entail future research into not only the long-term effecti-
veness of treatments, but also whether there are any effects of stopping treatments.
There are a number of other national CF registries around the world, and other members
of the CF-EpiNet group have used data from the US, Canadian and Danish CF regis-
tries.[276–278] The way data are collected and what data are collected can vary greatly
between registries and it is, therefore, not always easy to compare results obtained from
different registries. One key difference is the regularity of data collection, with some
registries collecting data monthly or quarterly and some collecting data on an encoun-
ter basis. The methods introduced in this thesis should be relevant as long as data are
collected at relatively regular intervals, but for data collected on an encounter basis, it
is likely that people who are sicker will have more encounters. It would probably be
necessary to account for this in analyses in order to ensure it does not result in any bias.
In this thesis, we have shown how the methods can be used with two different outcomes:
lung function and number of IV days. There are two of the most important outcome
measures in CF studies, but there are also a number of other outcomes that could be
important. Firstly, all of our studies excluded anyone under six years of age, because
lung function measures are not reliable before this age. In children under the age of six,
body mass index (BMI) is often used as an outcome. This is a continuous outcome and
therefore the analysis methods should be similar to those presented for lung function.
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However, the long-term trajectory of BMI is obviously very different to lung function.
In lung function, we approximated the trajectory linearly, which appeared a reasonable
assumption to aid interpretability of the results, but it is unlikely that a linear trajectory
of BMI would be realistic. Another key outcome of long-term studies would be survival.
The methods required for survival analyses are quite different from those used for lon-
gitudinal measures. However, there are a number of methods that have been developed
to investigate the effects of treatment on survival in the presence of time-dependent con-
founding, such as marginal structural Cox models[279], and structural nested cumulative
failure time models[280].
Our analysis of the effects of ivacaftor suggested that visits are on average equally spaced
apart and that ignoring the exact visit dates did not lead to any noticeable bias in the effect
estimates. However, it is not clear if this would always be the case and extensions to the
methods dealing with time-dependent confounding to account for non-equally spaced
visits could be desirable.
Throughout this thesis we have ignored any issues related to missing data. Fortunately,
the variables used for our analyses had very low levels of missingness meaning that very
few people were excluded from the analyses due to missing data. However, missing
data can lead to biased effect estimates unless restrictive assumptions are placed on the
missing data mechanisms.[281] Multiple imputation is a common method to account for
missing data, and previous work has shown how this method can be combined with IPW
of MSM and g-formula.[282–284] SCMM only use standard regression methods, sugges-
ting that there should not be any additional issues if using multiple imputation, but we
are not aware of any work investigating the use of multiple imputation with HA-MSM
or g-estimation.
Finally, it is known that lung function decline and survival are two very closely related
processes in CF.[285] Therefore if deaths during follow-up are not accounted for in some
way, the results associated with lung function can be biased, as the population-average
rate of decline would naturally become shallower over time due to survivor bias. For
the DNase analysis, g-formula and SCMM are not affected by this issue, as both met-
hods only use short-term models. The other methods, IPW of MSM, HA-MSM, and g-
estimation, utilised censoring weights to account for loss to follow-up. However, this
issue was not addressed in the analysis of the long-term effects of ivacaftor. Over the
four year period of this analysis, there were very few deaths, meaning that it is unlikely
to have led to substantial bias. However, in future work with longer follow-up, it is more
likely that this could become an issue. Joint modelling is an approach that can be used
to simultaneously model both longitudinal outcomes and survival, and there has already
been some work showing how joint models can be used in CF.[285–287] However, these
methods have not yet been used in any studies to estimate treatment effects in CF.
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10.4 Conclusions
In this thesis, we have shown that registry data can be used to estimate the long-term
effects of CF treatments. However, there are generally a number of complexities that
must be addressed when analysing longitudinal observational data. Two such issues are
time-dependent confounding or lack of a comparator group, for which suitable statistical
methods already exist to be able to obtain consistent estimators of the treatment effect. It
is usually necessary to make a number of untestable assumptions when performing these
analyses, for example no unmeasured confounding, but in the case of some assumptions
it is possible to formally test whether they seem plausible, allowing for an assessment of
how trustworthy any results from the analyses might be.
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Data resource basics
The UK Cystic Fibrosis Registry is a national, secure, central-
ized database sponsored and managed by the Cystic Fibrosis
Trust, with UK National Health Service (NHS) research eth-
ics approval and consent from each person for whom data
are collected. First established in 1995, it records longitu-
dinal health data on all people with cystic fibrosis (CF) in
England, Wales, Scotland and Northern Ireland, and to date
has captured data on over 12 000 individuals.
Cystic fibrosis is an inherited, chronic, progressive con-
dition occurring in around 1 in 2500 live births in the UK,
with around 200–300 new diagnoses annually. Children
are generally diagnosed in the first few months of life with
universal newborn screening being implemented in 2007 in
the UK, though some people are diagnosed into adulthood.
For instance, 29 people aged over 16 years were diagnosed
with CF in the UK in 2015.1 Patients diagnosed with CF
subsequently require intensive support from family and
health care services. Most patients die prematurely from
their disease through respiratory failure, and in the 1930 s
and 40 s survival beyond childhood was rare.2 There have
been impressive improvements in survival over subsequent
decades; for instance, the median life expectancy of chil-
dren with cystic fibrosis born in 1990 was estimated to be
40 years, double that of estimates 20 years earlier.3
In the UK, children with CF are treated in one of 33 spe-
cialist centres (associated with over 100 smaller network
clinics). At between 16 years and 18 years of age, children
transfer to one of 27 adult specialist centres. All centres
and network clinics routinely collect data in a standardized
fashion. When patients with CF attend a new CF centre in
the UK, they or their parents consent to information on
their health and treatment being collected and stored in the
CF Registry. The patient information and consent form
also covers the issue of linking registry data to the UK
Office for National Statistics. When transitioning to adult
services, the young adult is given the opportunity to con-
firm or withdraw consent. People with CF will also re-
consent if they change their primary centre of care. The
Registry records information about the health and
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This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
International Journal of Epidemiology, 2018, 9–10e
doi: 10.1093/ije/dyx196
Advance Access Publication Date: 3 October 2017
Data Resource Profile
Downloaded from https://academic.oup.com/ije/article-abstract/47/1/9/4316111
by London School of Hygiene & Tropical Medicine user
on 29 March 2018
Appendix A. Paper 1 - October 2017 250
treatment, and health care use (e.g. hospital days) and out-
comes of patients from diagnosis onwards. The Registry
contains personal identifiers, seen only by the local centre
team and CF Registry data managers. Reports generated
by the Registry are used as the evidence base for commis-
sioning care and pharmacovigilance of new therapies.
Harnessing the rich data in CF registries in the UK and be-
yond offers the opportunity to improve the lives of patients
with CF now, and to establish an essential data resource
for future research.
History of the registry
The UK CF Registry started as the UK CF Database, which
was established at the University of Dundee, Scotland, in
1995. Initially data were collected from 56 paediatric and
adult CF clinics, using standardized forms, and validated
through a system of double data entry, range checking and
error correction.4 Between 2005 and 2007, the Cystic
Fibrosis Trust rolled out a national UK-wide web-based sys-
tem, following new ethics approval and re-consent of all pa-
tients, with migration of the data to a new system. The data
collection system thus changed from a paper-based return
system to using the online ‘PortCF’ software which mim-
icked the data collection and storage system used by the
Cystic Fibrosis Foundation Patient Registry in the USA.
During this transfer there was extensive retrospective data
cleaning and checking. In 2012. the Registry commenced
production of reports that are used by the NHS England to
make payment by results (PbR) tariff payments to CF
centres. Linking the Registry to NHS reimbursement proc-
esses significantly improved the completion of data.
Recently, the PortCF system has been replaced by new UK
CF Registry software developed by the UK-based web de-
velopment specialists Net Solving Ltd. The new system has
been developed with patient involvement and includes
interactive elements that may, in due course, allow patients
to access their own data. The UK CF Registry has thus far
led to the production of 10 annual reports, with the latest
2015 data published in August 2016.1 The UK CF Registry
Steering Committee was established in 2007 to oversee de-
velopment of the Registry, annual reports and research gov-
ernance; it meets regularly and includes medical, sponsor
(Cystic Fibrosis Trust), commissioner, statistician, patient
and parent representation. It has recently set up a sub-
committee, the UKCF Registry Research Committee, to
allow more detailed oversight and governance of this area.
Data collected
The dataset contains: time-invariant variables, such as sex,
genotype and date of birth; and longitudinal variables that
change over time, such as weight and measures of lung
function. CF patients are seen in the outpatient clinic for a
comprehensive annual review, including evaluation of clin-
ical status, pulmonary function, microbiology of respira-
tory tract secretions and use of major CF-related therapies.
The minimum data collection requirement for the UK CF
Registry is an annual dataset, usually taken from the an-
nual review clinic visit. The data collected at the annual re-
view are indicated in the dataset, and can be distinguished
from ‘encounter’-based data collected in the interval be-
tween clinic visits. In this data resource profile, we only de-
scribe the annual review data which are the basis of the
CF-Epinet dataset described below. Some clinics use the
Registry to collect encounter data, but these are not sys-
tematically collected. Thus the data in the registry mostly
derive from the annual review, rather than being
encounter-based, though the annual review data include
certain summaries of information since the previous re-
view–for example. the number of days a patient has been
on intravenous antibiotics and the best % forced epiratory
volume in 1 s (FEV1) recorded in the previous year. Data
are collected in key areasincluding: demographics (includ-
ing genotyping and diagnosis data), hospital admissions
and intravenous therapies, pulmonary function, chronic
medications, culture and microbiology, health complica-
tions, nutritional assessment, physiotherapy, smoking,
socioeconomic status and outcomes (death and trans-
plants).4 Templates of the data collection forms showing
all variables collected are available to download from the
CF Registry portal as well as from the Cystic Fibrosis Trust
Registry web page. 5
Coverage
Of the 22 countries providing data to the wider European
Cystic Fibrosis Society Patient Registry,6 the UK CF
Registry is the largest national database and the most com-
plete in terms of coverage. Currently data on 12 201 pa-
tients are captured in the UK Registry (alive, dead or lost
to follow-up) with 9734 (79.8%) still in follow-up at the
end of 2015. In total there are data on over 100 000 annual
assessments. Figure 1 shows the cumulative count of pa-
tients captured in the Registry by year, including patients
who have died. Figure 1 also shows annual counts of an-
nual reviews, deaths, and losses to follow-up (defined as
patients with no annual reviews for 2 years in succession).
The number of people captured in the dataset has increased
year on year, with increases coinciding with the move to
the web-based system, followed by the incentivizing of
data collection for NHS funding purposes in England and
Scotland in 2012. The number of patients for whom a
‘complete’ dataset, defined as the data required to produce
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the range of key clinical outcomes relating to growth, lung
function and treatment presented in the annual reports,
was recorded at 82% in 2009, and this has increased year
on year, with the figure up to 89% for the latest (2015) an-
nual report.1
For the purposes of illustrating the longitudinal struc-
ture of the data, we consider the patient’s weight, since
weight is one of the most commonly collected outcomes in
the dataset, collected at 117 482 annual reviews on 12 201
patients between 1996 up to 2015 in the UK. A total 0f
78% of individuals had five or more weight measurements,
with a mean number of nine measurements. Figure 2 shows
all patient’s weight data, presented as age-standardized
z-scores7 plotted against age, with randomly selected indi-
vidual trajectories highlighted. Z-scores in adults were cal-
culated assuming the weight-for-age distribution at age 19.
Quality
Data quality is assured through a number of mechanisms.
For clinicians and others entering data into the Registry,
up-to-date user guides are available on the UK CF Registry
portal and contextual help text is available next to individ-
ual variables, to instruct users as to how to interpret the
question and use the software. Training videos are also
available to assist clinicians in entering and monitoring
data from their own clinic. Software functionality encour-
ages CF centres to monitor their own data on an ongoing
basis. A quality dashboard gives users an on-demand, at a
glance view of their data completeness as well as
summaries of key clinical indicators such as lung function,
with live benchmarks against national averages.
The Registry data collection software performs data
validation checks at point of entry. These include: the
enforcing of mandatory data; range checks for clinically
valid values; ensuring that only valid characters are
entered; and text and visual prompts to ensure that data
(including dates) are not illogical or conflicting and to en-
courage completion of core data. The Cystic Fibrosis Trust
also supports a Registry Annual Meeting in July each year.
This event is free to attend for all CF centre employees
who enter data onto the Registry, and is designed to show-
case current registry research and offer training and best
practice-sharing opportunities.
The Cystic Fibrosis Trust Registry team perform train-
ing and validation visits at CF centres, to ensure that users
are aware of data entry guidelines and encouraged to im-
prove the completeness and accuracy of their data. After
the data entry deadline on the 31 January each year,
Registry data managers and statisticians perform a variety
of data cleaning checks, such as tracking of patient transi-
tion from paediatric to adult clinics. Where longitudinal
analysis detects apparent inconsistencies that cannot be
automatically cleaned, the Registry team liaise directly
with CF centres to check and, where relevant, correct data.
Data resource use
Registry studies have been crucial in informing our under-
standing of the epidemiology, changing demographics,
Figure 1. Cumulative count of individuals captured in the registry and number with annual review data in each year (left panel). Count of deaths and
losses to follow-up (right panel).
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outcomes and treatments in CF. Two examples of analyses
of UK Registry data are provided in the text box.
In addition to epidemiological studies, the UK CF
Registry team produce reports on long-term drug safety
required by the European Medicines Agency (EMA). These
reports contain anonymized, aggregated data and allow
safety- and efficacy-monitoring of new therapies for cystic
fibrosis. There is also a facility to support Registry-based
clinical trials. For instance, the UK CF Registry is cur-
rently, via a specially designed study module, running a CF
Registry-based clinical trial, the cystic fibrosis (CF) anti-
staphylococcal antibiotic prophylaxis trial (CF START): a
randomized registry trial to assess the safety and efficacy
of flucloxacillin as a long-term prophylaxis agent for in-
fants with CF.8
Making use of the Port-CF system, with similar vari-
ables collected in the UK and USA, Goss and col-
leagues compare CF outcomes and use of treatments
between the two countries. Their cross-sectional ana-
lysis suggested that the USA does better in terms of
lung function in children, and one hypothesis raised is
that this may be due to more intensive treatment in
the early years in the USA.9
Studies making use of data from the UK CF Registry
are increasing,5–11,15,16 but relatively few have made
use of the longitudinal nature of the data. One longitu-
dinal study has assessed the impact of socioeconomic
status on outcomes and treatment use in the UK popu-
lation.7 More disadvantaged children with CF in the
UK were found to have significantly worse growth and
lung function, and were more likely to have chronic P.
aeruginosa infection. There was evidence that in the
NHS, clinicians in making decisions about treatments
for children take deprivation as well as disease status
into account, and this may mitigate some effects of so-
cial disadvantage. The study raises concerns about the
provision of therapies such as DNase to people living
in disadvantaged areas.
The Cystic Fibrosis Epidemiological Network
(CF-EpiNet)
In recognition of the potential to better harness data from
registries to improve patient outcomes, the Cystic Fibrosis
Trust have funded a Strategic Research Centre (CF-EpiNet)
focused on CF data and epidemiology. CF-EpiNet is focused
on: Registry enhancement; application of state-of-the art
Figure 2. Spaghetti plot for weight z-score versus age, illustrating the longitudinal nature of the data collected in the UKCF Registry. Each dot (n¼ 117
482) represents a weight z-score measure on a person in the dataset. The smoothed cross-sectional population average is shown in red (95% confi-
dence intervals) and 50 randomly selected individual trajectories are in black.
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statistical modelling techniques to longitudinal data; and
economic modelling. An important part of this project will
involve data cleaning, harmonization of variables over time
and the generation of a research-ready ‘CF-EpiNet’ dataset.
Algorithms and code for cleaning the data should allow re-
searchers to a obtain more up-to-date version of the data,
with extra years of longitudinal data added.
CF-EpiNet aims to develop a holistic view of how CF
impacts on patients across the life course, and to identify
modifiable targets for clinical and policy intervention (e.g.
early life exposures, access to therapies, educational sup-
port) by the application of modern statistical methods for
longitudinal analysis and by direct comparisons with inter-
national datasets. Key aims are to optimize the scientific
value of the Registry by linking it to data from other ad-
ministrative datasets, and by undertaking a quality of life
survey. The quality of life component of the project has
been developed within a portal, ‘My CF Registry’, allowing
patient-reported outcome measures to be entered directly
by patients. In the future, this portal could enable people
with CF to view their historical clinical data, self-report
data and opt into additional uses of Registry data that will
enhance the value of the Registry to the CF community.
Strengths and weaknesses of the Registry
Registries can provide valuable insights into variations in
clinical outcomes, quality of care and the safety and/or ef-
fectiveness of treatments. However, the usefulness and ap-
plicability of Registry data rely on the quality of several
aspects: the measurements and information recorded; the
accuracy of data input, data storage and export; and ap-
propriate data analysis and interpretation, bearing in mind
the inherent shortcomings of routinely collected data.17,18
A key strength of the UK CF Registry is the population-
level coverage. In the UK, the Registry is estimated to
capture almost all of the CF population; any consenting
patients attending NHS clinics will have annual data rou-
tinely collected into the database. Furthermore, the dataset
is of high quality, with robust systems for data cleaning
and checking. The UK dataset represents one of the largest
national CF datasets outside the USA,17 and this provides
the statistical power to precisely estimate parameters of
interest. The UK CF Registry contains a wide range of clin-
ical, health care and social information, allowing for ro-
bust adjustment for appropriate covariates in statistical
analyses. A further consequence of the high level of popu-
lation coverage in the UK, coupled with a universal health
care system, is that analyses can cover individuals across
the full range of the socioeconomic spectrum in the UK.
The unique Registry identification number facilitates longi-
tudinal research, an advantage over other registries which
rely on yearly snapshot population data. In addition, the
coverage for core variables summarized in the annual re-
ports, such as weight and %FEV1, are high.
One key limitation of the UK CF Registry compared
with some other CF registries is that it at present manda-
torily requires only annual review data, rather than all clin-
ical encounters, which limits some of the research
questions that can be addressed. There are also some gaps
in information collected, such as primary and secondary
non-CF-related care episodes. Data linkage to other na-
tional datasets has been a long-standing aim of the UK CF
Registry, and the CF-EpiNet project is exploring relevant
linkages to include those with primary and secondary care
databases, mortality data, census data, databases holding
area-level information on environmental exposures and the
National Pupil Database. For each of these, linkage poses
different ethical and practical challenges and strict data
protection guidelines are followed.
Common to many registries, in contrast to inception co-
horts, survival times of individuals in the UK dataset are
subject to left truncation because the Registry captures the
living population at the inception of the Registry and inci-
dent cases subsequent to this. This leads to potential sur-
vivor bias, whereby the living population at the outset of the
Registry represented healthier individuals from their respect-
ive birth cohorts who have survived to the point of being
included in the dataset. This is a common issue in registry
analyses. There are strong cohort effects in the data, which
are likely to represent a mixture of survivorship effects, and
the ‘true’ cohort effects representing improving treatment
over time, as demonstrated in other studies.7,19 With longer
follow-up, as the UK CF Registry matures, separating age
and cohort effects will become possible and eventually it
will be possible to analyse incident individuals alone, ensur-
ing that the longitudinal experience of all individuals from a
particular birth cohort will be captured.18 Making projec-
tions about outcomes for people with CF in the future will
always be a challenge, in particular because there have been
and continue to be substantial improvements in treatment
and care over a relatively short time period.
Data resource access
All the information in the UK CF Registry is held confiden-
tially and available only to two assigned members of the
UK CF Registry data management team. Clinical teams
can access only the data that relate to patients in their care,
and are required to validate their identity using two-factor
authentication before logging into the system. The system
also provides an audit trail for any data access. The CF
Registry is registered under the Data Protection Act (1998)
which was designed to provide a legal framework upon
International Journal of Epidemiology, 2018, Vol. 47, No. 1 10c
Downloaded from https://academic.oup.com/ije/article-abstract/47/1/9/4316111
by London School of Hygiene & Tropical Medicine user
on 29 March 2018
Appendix A. Paper 1 - October 2017 254
which to protect the privacy of personal data when used
with information technology.
Data are stored within secure Microsoft Azure data
centres in Ireland and Holland, which are certified as suit-
able for official government data, including health care
data. The database servers are not directly connected to
the internet; all administrative access is via a secure VPN
connection which requires a dedicated security certificate
to allow access. The application hosting environment has
been security-tested by certified security consultants. All
data are viewed and entered via a secure HTTPS web
portal.
NHS Research Ethics approval (Huntingdon Research
Ethics Committee 07/Q0104/2) has been granted for the
collection of data into the UK CF Registry. Each patient or
their parent provided written informed consent for collec-
tion of data in the registry as outlined above, and this in-
cludes for use of pseudonymized data in research. There is
a formal process for requesting access to the UK CF regis-
try, and an application form can be found using this link:
[www.cysticfibrosis.org.uk/registry]. In 2016 there were
29 applications for access to anonymized Registry data; 26
were approved after review by the UK CF Registry
Research Committee, with the remaining three requests
being withdrawn or rejected.
Profile in a nutshell
• The UK Cystic Fibrosis Registry is a national, secure,
centralized database sponsored and managed by the
Cystic Fibrosis Trust. It was set up to record longitu-
dinal health data on people with cystic fibrosis (CF)
in England, Wales, Scotland and Northern Ireland.
Containing data on almost all people with CF in the
UK, it is one of the largest and most complete na-
tional CF databases available.
• First established in 1995, to date the UK CF Registry
has captured data on over 12 000 individuals with a
combined total of more than 100 000 annual
assessments.
• Patient data are recorded in the Registry after a con-
firmed CF diagnosis and consent for data to be col-
lected has been obtained. Subsequently, health data
are added to the Registry at every annual
assessment.
• Data are collected in several key areas including:
demographics (including genotyping andand diagno-
sis data), hospital admissions and intravenous thera-
pies, pulmonary function, chronic medications,
culture andand microbiology, health complications,
nutritional assessment, physiotherapy, lifestyle and
outcomes (death and transplants).
• There is a formal process for requesting access to
the UK CF Registry. An application form and more
details can be found using the following link: [https://
www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-regis
try/apply-for-data-from-the-cf-registry].
Funding and competing interests
E.G. and R.C. work for the CF Trust; all other authors are part of
the CF-EpiNet Strategic Research Centre supported by a grant from
the Cystic Fibrosis Trust. S.C. is a principal investigator (PI) for a
CF Trust Registry-based pharmacovigilance (PASS) study for
Pharmaxis, and is a PI for a CF Trust Vertex-funded Registry-based
observational study. D.B. is a principal investigator for two CF
Trust Registry-based pharmacovigilance studies for Vertex and Teva
pharmaceutical companies. DTR is funded by the MRC on a
Clinician Scientist Fellowship (MR/P008577/1).
Acknowledgements
We thank people with cystic fibrosis and their families for consent-
ing to their data being held in the UK CF Registry, and NHS teams
in CF centres and clinics for the input of data into the Registry. We
also thank the UK Cystic Fibrosis Trust and the Registry Steering
Committee for access to anonymized UK CF Registry data.
References
1. Cystic Fibrosis Trust. UK Cystic Fibrosis Registry 2015 Annual
Data Report. London: CFT, 2015.
2. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mor-
tality and survival in the UK: 1947–2003. Eur Respir J 2007;29:
522–26.
3. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival
and population estimates to the year 2000. Thorax 199;46:
881–85 .
4. Mehta G, Sims EJ, Culross F, McCormick JD, Mehta A.
Potential benefits of the UK Cystic Fibrosis Database. J R Soc
Med 2004;97(Suppl 44):60–71.
5. Cystic Fibrosis Trust. Apply for Data From the UK CF Registry.
2017. https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-
registry/apply-for-data-from-the-cf-registry (11 September 2017,
date last accessed).
6. European Cystic Fibrosis Society. ECFS Patient Registry
Annual Reports. 2017. https://www.ecfs.eu/projects/ecfs-patient-
registry/annual-reports (11 September 2017, date last accessed).
7. Taylor-Robinson D, Smyth RL, Diggle P, Whitehead M. The ef-
fect of social deprivation on clinical outcomes and the use of
treatments in the UK cystic fibrosis population: A longitudinal
study. Lancet Respir Med 2013;1:121–28.
8. CF Start: A Randomised Registry Trial. 2017. http://www.
cfstart.org.uk (11 September 2017, date last accessed).
9. Goss CH, MacNeill SJ, Quinton HB et al. Children and young
adults with CF in the USA have better lung function compared
with the UK. Thorax 2015;70:229–36.
10. Adler AI, Shine BSF, Chamnan P, Haworth CS, Bilton D.
Genetic determinants and epidemiology of cystic fibrosis-related
diabetes: results from a British cohort of children and adults.
Diabetes Care 2008;31:1789–94.
10d International Journal of Epidemiology, 2018, Vol. 47, No. 1
Downloaded from https://academic.oup.com/ije/article-abstract/47/1/9/4316111
by London School of Hygiene & Tropical Medicine user
on 29 March 2018
Appendix A. Paper 1 - October 2017 255
11. Sims EJ, Mugford M, Clark A et al. Economic implications of
newborn screening for cystic fibrosis: a cost of illness retrospect-
ive cohort study. Lancet 2007;369:1187–95.
12. Sims EJ, Clark A, McCormick J et al. Cystic fibrosis diagnosed
after 2 months of age leads to worse outcomes and requires more
therapy. Pediatrics 2007;119:19–28.
13. Sims EJ, McCormick J, Mehta G, Mehta A; UK CF Database
Steering Committee. Newborn screening for cystic fibrosis is
associated with reduced treatment intensity. J Pediatr 2005;147:
306–11.
14. McCormick J, Sims EJ, Green MW, Mehta G, Culross F, Mehta
A. Comparative analysis of Cystic Fibrosis Registry data from
the UK with USA, France and Australasia. J Cyst Fibros Off J
Eur Cyst Fibros Soc. 2005 May;4(2):115–22.
15. Stanojevic S, Stocks J, Bountziouka V, Aurora P, Kirkby J,
Bourke S et al. The impact of switching to the new global lung
function initiative equations on spirometry results in the UK CF
registry. J Cyst Fibros 2014;13:319–27.
16. Stanojevic S, Bilton D, McDonald A et al. Global Lung Function
Initiative equations improve interpretation of FEV1 decline
among patients with cystic fibrosis. Eur Respir J 2015;46:
262–64.
17. Salvatore D, Buzzetti R, Baldo E et al. An overview of interna-
tional literature from cystic fibrosis registries. Part 4: update
2011. J Cyst Fibros 2012;11:480–93.
18. Gliklich RE, Dreyer NA, Leavy MB (eds). Registries for
Evaluating Patient Outcomes: A User’s Guide]. 3rd edn. Rockville
(MD): Agency for Healthcare Research and Quality (US), 2014.
19. Buzzetti R, Salvatore D, Baldo E et al. An overview of
international literature from cystic fibrosis registries: 1.
Mortality and survival studies in cystic fibrosis. J Cyst Fibros
2009;8:229–37.
International Journal of Epidemiology, 2018, Vol. 47, No. 1 10e
Downloaded from https://academic.oup.com/ije/article-abstract/47/1/9/4316111
by London School of Hygiene & Tropical Medicine user
on 29 March 2018
Appendix A. Paper 1 - October 2017 256
257
Appendix B
Paper 2 - April 2018
This appendix contains the published version of the paper entitled "Estimating long-term
treatment effects in observational data: a comparison of the performance of different
methods under real-world uncertainty". It was published in Statistics in Medicine in
April 2018.[11] This paper is based on the work found in Chapters 4 and 5.
As the first author of this paper, I carried out the simulation studies and analysis of the
UK CF registry data, drafted all sections of the paper, produced all figures and tables,
and prepared and approved the final version of the paper.
Student’s Signature:
Date: 29th January, 2019
Supervisor’s Signature:
Date: 29th January, 2019
RE S EARCH ART I C L E
Estimating long‐term treatment effects in observational
data: A comparison of the performance of different methods
under real‐world uncertainty
Simon J. Newsome1 | Ruth H. Keogh1 | Rhian M. Daniel2
1Department of Medical Statistics,
London School of Hygiene and Tropical
Medicine, London, UK
2Division of Population Medicine, Cardiff
University, Cardiff, UK
Correspondence
Simon Newsome, London School of
Hygiene and Tropical Medicine, Keppel
Street, London WC1E 7HT, UK.
Email: Simon.Newsome@lshtm.ac.uk
Funding information
Medical Research Council Methodology
Fellowship, Grant/Award Number: MR/
M014827/1; Wellcome Trust and the
Royal Society, Grant/Award Number:
107617/Z/15/Z; Cystic Fibrosis Trust
In the presence of time‐dependent confounding, there are several methods
available to estimate treatment effects. With correctly specified models and
appropriate structural assumptions, any of these methods could provide consis-
tent effect estimates, but with real‐world data, all models will be misspecified
and it is difficult to know if assumptions are violated.
In this paper, we investigate five methods: inverse probability weighting of
marginal structural models, history‐adjusted marginal structural models,
sequential conditional mean models, g‐computation formula, and g‐estimation
of structural nested models. This work is motivated by an investigation of the
effects of treatments in cystic fibrosis using the UK Cystic Fibrosis Registry
data focussing on two outcomes: lung function (continuous outcome) and
annual number of days receiving intravenous antibiotics (count outcome).
We identified five features of this data that may affect the performance of the
methods: misspecification of the causal null, long‐term treatment effects, effect
modification by time‐varying covariates, misspecification of the direction of
causal pathways, and censoring.
In simulation studies, under ideal settings, all five methods provide consistent
estimates of the treatment effect with little difference between methods.
However, all methods performed poorly under some settings, highlighting
the importance of using appropriate methods based on the data available.
Furthermore, with the count outcome, the issue of non‐collapsibility makes
comparison between methods delivering marginal and conditional effects diffi-
cult. In many situations, we would recommend using more than one of the
available methods for analysis, as if the effect estimates are very different, this
would indicate potential issues with the analyses.
KEYWORDS
causal inference, g‐computation formula, g‐estimation, inverse probability weighting, time‐dependent
confounding
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1 | INTRODUCTION
Advanced methods for causal inference in longitudinal observational studies are an important tool for investigating
treatment effects in nontrial settings where the presence of time‐dependent confounders generally precludes the use
of simpler conventional methods. Time‐dependent confounding is an issue in longitudinal studies when a time‐varying
covariate is affected by treatment, but this covariate then also subsequently affects the probability of receiving future
treatment as well as affecting the outcome of interest.1
In these situations, there are a number of methods available to researchers, and one of these methods, in particular,
inverse probability weighting (IPW) of marginal structural models (MSM), has become increasingly popular in applied
research. The increasing use of this method over other methods may in part be due to its relative simplicity, but it is not
clear if other methods may be better suited to some analyses. The methods investigated in this paper are motivated by
questions about the efficacy of long‐term treatment use in cystic fibrosis (CF) and the challenges for addressing these
using longitudinal observational data from a patient registry. In addition to IPW of MSM, we identified four other
methods, which could be used in this setting: history‐adjusted marginal structural models (HA‐MSM), sequential con-
ditional mean models (SCMM), g‐computation formula, and g‐estimation of structural nested models (SNM).
The primary aims of this paper are twofold: (1) to compare the ability and appropriateness of the different analysis
methods for addressing the questions of interest, including to estimate treatment effect modification and to handle
different outcome types and (2) to investigate the robustness of the different methods to handling practical challenges
arising in longitudinal observational data, such as uncertainty about the relative temporality of measures and loss to
follow‐up. In an ideal setting, where we could be sure that all assumptions are met and that all models are correctly
specified, any one of the available methods could be used to obtain consistent treatment effect estimates. However, in
reality, it can be difficult to know if assumptions hold and all models will be misspecified to some degree.
Section 2 of this paper gives more details about the UK CF Registry, the questions we wish to address, and specific
details of the data that present challenges. This is followed in Section 3 by an overview of the five different methods,
which we considered for the analysis of the Registry data. In Section 4, we present simulation studies investigating
the performance of these five methods with two different types of outcomes (normally distributed continuous data
and zero‐inflated negative binomial count data). An analysis of the UK CF registry data is presented in Section 5,
and finally, we discuss the implications of the results of the simulation studies and data analysis in Section 6.
2 | MOTIVATING EXAMPLE
2.1 | CF and the UK Cystic Fibrosis Registry
Cystic fibrosis is the most common life‐threatening inherited disease in white people, and in the UK, there are over
10 000 people living with the disease.2,3 Cystic fibrosis most seriously affects the lungs, where a build‐up in mucus
causes breathing difficulties and leads to an increase in respiratory infections. There are now many treatments available
that can help improve the health of people with CF, but many of these treatments are very time consuming and often
treatments are not stopped once started. This leads to an accumulation of treatments, and treatment burden is a
common complaint among people with CF.4
Almost all treatments currently used in CF care were approved following a successful clinical trial. However, a
limitation of many trials is that they are short in duration, whereas in practice, treatments are used long term. In most
cases, it would not be feasible to run trials for such long periods of times, and it could also be unethical to continue to
withhold treatment from patients if a strong short‐term benefit has been observed.
The UK CF Registry is a national database, which has collected annual data on almost all people with CF in the UK
since 2007. At an annual assessment, detailed information is obtained on many different measures of health status as
well as all the treatments received in the past year.5
This paper will focus on one common CF treatment, dornase alfa (DNase), which was licensed for use in the UK in
1994 after a randomised trial showed efficacy at improving lung function over a 6‐month period.6 Subsequent studies
have investigated the effects of up to 2 years' use of DNase, but in practice, patients generally continue to receive DNase
indefinitely once treatment has been started.7
To illustrate the potential of the statistical methods with different types of outcomes, this paper will consider the
effects of treatment on two important clinical outcomes: percent predicted forced expiratory volume in 1 second
(ppFEV1) (a continuous outcome measuring an individual's lung function) and annual number of days of intravenous
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antibiotic therapy (IV days) (a count outcome of the number of days an individual received intravenous antibiotics in a
given year). The decision to start prescribing DNase to a patient depends on many factors, including pretreatment mea-
sures of ppFEV1 and annual IV days, which are then in turn potentially affected by treatment use.
Figure 1 shows a directed acyclic graph (DAG) of the assumed causal pathways between key variables in the UK CF
Registry. Data are obtained at annual visits. Treatment status at visit t is denoted Xt, Ft denotes ppFEV1, and Vt denotes
IV days. We focus on patients not using treatment at a baseline visit 0, X0 = 0. At subsequent annual visits, their ppFEV1
on that day is recorded, and data about the previous year are also collected, such as which treatments they received
throughout the year and their total number of IV days.
The DAG visualises ppFEV1 at visit t−1 affecting treatment at visit t, annual IV days at visit t affecting treatment at
visit t, DNase use at visit t affecting all future measures of ppFEV1 and annual IV days, and direct longitudinal associ-
ations between ppFEV1 and annual IV days. There may also be other important baseline or time‐varying confounders,
which have not been included in the DAG for clarity. In this paper, we focus on investigating the effect of treatment on
lung function and IV days and how this effect might change with continued use of treatment over several years.
2.2 | Features and challenges in the analysis of this data
As is common with most observational data, there are a number of issues that need to be considered when approaching
the analysis of the UK CF Registry data.
One challenge is the use of the available methods with different types of outcomes. One of our outcomes of interest,
ppFEV1, is continuous and can be approximated by a conditionally normal distribution. All of the methods described in
this paper can easily accommodate such an outcome. However, the other outcome, annual IV days, is a count outcome
ranging from 0 to 365, which we model with a zero‐inflated negative binomial distribution. This can be harder to
incorporate into some of the methods, and we will discuss these issues in Section 3.7.
In addition to considering two different types of outcome, we have identified 5 key features of the analysis of the UK
CF registry. The first three of these question the ability and appropriateness of the different analysis methods for esti-
mating the treatment effect: whether there exists any treatment effect at all, whether there are only short‐term or also
long‐term effects, and whether there is effect modification of the treatment effect by time‐varying covariates. The second
category are challenges that may arise because of the nature of the data available to investigate the above questions.
Here, we consider the issues of censoring and uncertainty of the direction of causal pathways between variables.
The following subsections give further details on each of these five issues.
2.2.1 | Causal null hypothesis
The DAG shown in Figure 1 shows a causal effect of treatment on the outcomes of interest. To date, randomised trials
have demonstrated the efficacy of DNase treatment in improving ppFEV1, but no studies have yet shown a significant
effect of the treatment on reducing the rate of IV days. Furthermore, in a nontrial setting, where, for example,
adherence levels may not be as high as in clinical trials, the findings of a causal effect of treatment may not be
replicated. For this reason, methods that benefit from a degree of robustness to model misspecification at the causal null
would be attractive.
FIGURE 1 Directed acyclic graph of causal pathways between treatment (Xt), ppFEV1 (Ft), and IV days (Vt). Baseline and other time‐
varying confounders are not shown for clarity
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2.2.2 | Long‐term treatment effects
We define a long‐term treatment effect as an effect of Xt on Ys (s > t) not mediated via intermediate treatments. No
studies have previously looked at the effects of DNase beyond 2 years, and it therefore remains unknown how the effect
of treatment might change with length of use. Taking the example of ppFEV1, two possible ways in which the treatment
may affect the outcome are (1) the ppFEV1 trajectories of those receiving and not receiving treatment continue to grow
apart indefinitely through time or (2) after the initial increase in ppFEV1 that has been observed at the start of taking
treatment, the effectiveness of treatment may decrease with the two counterfactual trajectories no longer diverging.
These two hypothetical lung function trajectories compared with the trajectory when not receiving treatment are shown
in Figure 2. As it is unknown how the effect of treatment might change through time, it is important that the methods
are flexible enough to identify the true long‐term effects.
2.2.3 | Effect modification by time‐varying covariates
We hypothesise that the effect of treatment may depend on the previous levels of ppFEV1 and number of IV days. This is
because if a person starts treatment when they already have a healthy ppFEV1 level, it is unlikely that treatment could
further improve ppFEV1, whereas it is realistic that the treatment could be much more effective in an individual with an
lower ppFEV1. For informing practice, rather than just identifying the population average effect of treatment, it is
important to gain understanding of how the effect of treatment might change depending on other covariates, and for
this reason, it would be preferable to use a method that can test for the presence and estimate the strength of any effect
modification.
2.2.4 | Misspecification of the direction of causal pathways
The DAG in Figure 1 includes assumptions about the direction of the causal pathways. For some variables, the appro-
priate direction of the causal pathway is clear (eg, the pathway from total IV days in 1 year to ppFEV1 measured at the
end of the year). However, for other pathways, the appropriate direction for the arrow is less clear.
The direction of the causal pathway between treatment and number of IV days is particularly challenging. Both
variables are summaries of the previous year, and some individuals may have had lots of IV days at the start of the year,
which prompted them to start treatment, whereas others may have started treatment earlier, but then had IV days later
in the year. In reality, therefore, the causal pathway between Xt and Vt is likely to go both ways, but in many methods, it
will be necessary to specify just one direction for this pathway.
We have decided to focus on investigating the effect of Xt on Vt+1, as, due to temporality, this pathway can only be
directed this way, and to treat Vt as a confounder of this effect. In the real Registry data, we cannot know whether this is
misspecified or not, and therefore, it is important to understand the potential extent of the bias in treatment effect
estimates under different methods when the direction of this pathway has been misspecified.
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FIGURE 2 Two possible trajectories of lung function with long‐term dornase alfa treatment [Colour figure can be viewed at
wileyonlinelibrary.com]
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2.2.5 | Censoring
We are fortunate that there are very few people lost to follow‐up in the UK CF Registry, and each year, there are
relatively few deaths compared with the total number of people in the Registry. Nevertheless, it is possible that
the fact that some individuals are censored for either of these reasons may bias the results. Therefore, we also wish
to investigate how the different methods handle censoring. Although in reality there would likely be different pro-
cesses affecting the probability that an individual dies or is lost to follow‐up, in this paper, we only consider one
missing at random scenario where an individual's probability of being censored depends on previously measured
variables.
3 | METHODS
3.1 | Notation and assumptions
We discuss the statistical methods with generic notation. Consider a cohort followed up annually from visit t=0 up to
visit t=T. The treatment received at time t is denoted Xt, and each year, a person can receive (Xt=1) or not receive
(Xt=0) treatment during the period since the last visit. The outcome of interest, Yt, is also measured annually. We
assume that at each visit, Xt precedes Yt and define a 1‐year treatment effect to be the effect of Xt on Yt. We also have
baseline confounders, B, and time‐varying confounders, C.
Xt is a vector of the treatment history for an individual from visit 0 up to and including visit t, and we use the coun-
terfactual notation Y xt¼1t to refer to the outcome that would have been observed at visit t if an individual had received
treatment up to and including visit t.
For all methods, we make the following four assumptions: no interference, positivity, consistency, and no unmea-
sured confounding. No interference means that for a given individual, their counterfactual outcome Y xt is not affected
by the treatment that another individual receives.8 Positivity means that all individuals had a conditional probability
strictly greater than 0 and strictly less than 1 of receiving treatment at all visits given their history,
0 < PðXt ¼ 1jXt−1; Yt−1; Ct;BÞ< 1.9 Consistency means that for each individual, the counterfactual outcome under
the observed treatment is equal to the observed outcome,Yi ¼ Yxii when xi ¼ Xi.10 Finally, no unmeasured confounding
means that conditional on the past observed variables the treatment received at visit t is independent of the counterfac-
tual outcome, Y xtt ⫫ XtjXt−1; Yt−1; Ct;B. 1
The following subsections give an overview of the methods that are considered for the analysis of the UK CF
Registry. We introduce the methods with a continuous outcome in mind. Referring back to our motivating example
and the DAG in Figure 1, we can consider ppFEV1(Ft) to be the outcome of interest with IV days (Vt) acting as a
time‐dependent confounder. The count variable of IV days is also of interest as an outcome, and in Section 3.7, we
outline how the methods can be extended for use with a count outcome.
3.2 | IPW of marginal structural models
Inverse probability weighting of MSM11 has become an increasingly popular method to deal with time‐dependent con-
founding. We consider MSM of the following form:
E Y xtt
  ¼ β0 þ ∑
t
i¼1
βxi xi; (1)
where the βx1 to βxt represent separate effects for treatment at each visit, thereby allowing for long‐term treatment
effects. However, due to confounding, directly using the observed values and calculating E½YtjXt ¼ xt does not equate
to the counterfactual E½Y xtt .
Inverse probability weighting of the observations enables consistent estimation from an MSM by reweighting obser-
vations so that the levels of confounding variables become equally balanced between treated and untreated individuals.
This is achieved by assigning large weights to individuals who were estimated to be unlikely to receive the treatment
they actually received and downweighting observations for which there are lots of observations estimated to have
similar propensities to receive the same treatment history.
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To calculate the weights, one first estimates the propensity score, which is the probability of receiving treatment at
each visit:
P Xt ¼ 1jXt−1; Yt−1; Ct;Bð Þ ¼ expit β0 þ βXXt−1 þ βYY t−1 þ βCCt þ βBBð Þ: (2)
Then this model is used to calculate the estimated probability that each person received the treatment they actually
received, ie, for those who did receive treatment, we use the estimated probability from the above model and for those
who did not receive treatment, 1 minus the estimated probability. The probability of their treatment history is then the
product of these estimated probabilities from visit 1 up to visit t.
The inverse of the estimated probabilities can be used directly as the weights, but it is usually preferable to use so‐
called stabilised weights1 where the numerator of the weights is the probability of receiving treatment based on previous
treatment history and baseline covariates only,
SWt ¼ P
XtjXt−1;Bð Þ
P XtjXt−1; Yt−1; Ct;Bð Þ ¼∏
t
i¼1
P XijXi−1;Bð Þ
P XijXi−1; Yi−1; Ci;Bð Þ: (3)
A final MSM, such as that given in Equation 1, can then be fit where the observations are weighted using the
estimated weights. However, note that any baseline confounders included in the numerator of Equation 3 must also
be included in the MSM. This would result in a conditional estimate, meaning if a marginal estimate is desired then
no confounders should be included in the numerator.
Due to the fact that time‐varying covariates are not included in the MSM, this method does not allow for the
estimation of effect modification by time‐varying covariates. However, the method also does not need the assumption
that there is no effect modification and will estimate consistent population average effects even if the effect of treatment
is not uniform for the whole population.
Using stabilised weights helps to reduce the variability in the weights, but in cases where there are strong time‐vary-
ing predictors of treatment, the weights can remain highly variable that can lead to instability. Therefore, it can some-
times be preferable to truncate the most extreme weights, even though this may introduce some bias.12,13 In this paper,
we will present the results of IPW analyses with and without truncation of the stabilised weights to the 1st and 99th
percentile.
In the presence of censoring, it is also possible to incorporate censoring weights into the analysis. Similarly to the
previously described weights, we weight individuals with stabilised inverse weights of their estimated probability of
being censored before visit t,
LTFUWt ¼∏
t
i¼1
P LTFUið Þ
P LTFUijXi−1; Yi−1; Ci−1;Bð Þ: (4)
Using this method, we assume that future visits are missing at random, ie, censoring is affected by previously
measured variables. The estimated censoring weights can then be multiplied by the estimated stabilised weights to give
the weights to be used to account for bias due to both confounding and censoring.
3.3 | History‐adjusted marginal structural models
As stated in the previous section, one limitation of IPW of MSM is that effect modification of the treatment effect by
time‐varying covariates cannot be estimated. Therefore, in cases where the estimation of an interaction term is desired,
HA‐MSM are an extension to IPW of MSM, which do allow for this.14
In the standard MSM described in the Section 3.2, observations are reweighted based on all covariates measured
after baseline until the visit of the outcome of interest. In an HA‐MSM, the reweighting is done separately from each
time of treatment t up to the time of outcome, s (t ≤ s). Covariates measured prior to the treatment at time t can be
included in the final HA‐MSM in the same way as baseline covariates were included in the standard MSM.
Formally, the stabilised weights for exposure at time t on outcome at time s are given by
SWts ¼∏
s
i¼t
P XijXi−1;Bð Þ
P XijXi−1; Yi−1; Ci;Bð Þ; (5)
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and an example of the HA‐MSM could be given by
E Y xss jxt−1;yt−1; ct; b
  ¼ β0 þ βbbþ βcct þ βx xt−1 þ βyyt−1 þ∑
s
i¼t
βxi xi þ∑
s
i¼t
βinti xi yt−1: (6)
In Equation 6, we have included an interaction term between previous measures of the outcome (itself a time‐vary-
ing confounder) and treatment so as to allow the estimation of any effect modification.
As with IPW of MSM, it is also possible to estimate censoring weights, in this case estimating an individual's
probability of being censored between visits t and s and multiplying these weights with the stabilised weights.
3.4 | Sequential conditional mean models
Even in the presence of time‐dependent confounding, it is still possible to use standard regression methods, but these
methods can only estimate total effects.15 The total effect of a treatment, Xt, on an outcome Ys (s> t) would include
not only the direct effect of Xt on Ys and the indirect effects of Xt on Ys through time‐varying covariates but also the
indirect effect of Xt on Ys mediated through future exposures. It cannot, therefore, be used to investigate the effect of
receiving 2 years' treatment in our example, as some people discontinue treatment. For this reason, in the examples
here, this method is only used to estimate “short‐term” effects, which we define as the effect of 1‐year treatment on
the outcome measured at the end of the year.
These SCMM will give a consistent estimate of the 1‐year effect of treatment as long as we appropriately control for
all confounding effects of this short‐term effect. For example, the following short‐term model would suffice if the most
recent measures of all covariates were sufficient to remove confounding:
E YtjXt; Yt−1; Ct;Bð Þ ¼ β0 þ βX1Xt þ βX2 Xt−1 þ βY Y t−1 þ βCCt þ βBB: (7)
It is also possible to incorporate propensity scores into the SCMM to provide a doubly robust estimator. The propen-
sity score can be calculated as it was in the IPW method by using Equation 2, and this is then incorporated into the
SCMM as follows:
E YtjXt; Yt−1; Ct;B; ptð Þ ¼ β0 þ βX1Xt þ βX2Xt−1 þ βYY t−1 þ βCCt þ βBBþ βppt: (8)
Although this method cannot provide estimates for the effects of varying lengths of treatment duration, the simplic-
ity of the method is appealing, and these short‐term effect estimates can also be compared with the 1‐year treatment
effect estimates from the other methods. SCMM also form the first step of the next 2 methods: g‐computation formula
and g‐estimation of SNM.
3.5 | G‐computation formula
The g‐computation formula first described by Robins16 is another method that can deal with the issue of time‐dependent
confounding to give consistent estimates of long‐term treatment effects. In this method, short‐term models, ie, models for
1‐year time effects, for all time‐varying covariates (in our example, Y and C) are used to simulate counterfactual outcomes
under different treatment trajectories sequentially through time.
For example, the time‐varying continuous outcome Y could be modelled by Equation 7 and counterfactuals for Y1
could then be simulated setting everyone either receiving or not receiving treatment at visit 1:
~Yx1¼11 ¼ β^0 þ β^YY 0 þ β^CC1 þ β^BBþ β^X1 þ ~ε; (9)
~Yx1¼01 ¼ β^0 þ β^YY 0 þ β^CC1 þ β^BBþ ~ε; (10)
where ~ε is a random draw from a normal distribution whose standard deviation is the model‐estimated root mean
square error, resulting in simulated counterfactual measures.
Similar short‐term models would need to be specified for all time‐varying covariates C to allow the counterfactuals
for all covariates to be simulated at visit 1. In our example, we have one time‐varying confounder, which follows a zero‐
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inflated negative binomial distribution. Therefore, this was used to model the data and then to simulate random draws
for the count for each individual.
The process can then be repeated sequentially for all visits. For example, at visit 2, there would be four counterfac-
tuals simulated for each individual, corresponding to (1) receiving treatment at both visits, (2) at the first visit only, (3) at
the second visit only, or (4) never receiving treatment. These counterfactuals could be simulated, respectively, as follows:
~Y x1¼1;x2¼12 ¼ β^0 þ β^Y ~Yx1¼11 þ β^C ~Cx1¼12 þ β^BBþ β^X1 þ β^X2 þ ~ε; (11)
~Y x1¼1;x2¼02 ¼ β^0 þ β^Y ~Yx1¼11 þ β^C~Cx1¼12 þ β^BBþ β^X2 þ ~ε; (12)
~Y x1¼0;x2¼12 ¼ β^0 þ β^Y ~Yx1¼01 þ β^C ~Cx1¼02 þ β^BBþ β^X1 þ ~ε; (13)
~Y x1¼0;x2¼02 ¼ β^0 þ β^Y ~Yx1¼01 þ β^C~Cx1¼02 þ β^BBþ ~ε: (14)
The counterfactual outcomes under different treatment trajectories can then be compared with a MSM, eg,
E Y xtt
  ¼ β0 þ ∑
t
i¼1
βxixi: (15)
One well‐known drawback of the use of this method with non‐linear models is the g‐null paradox.16,17 This is an
issue whereby given a large enough sample size, the causal null hypothesis will always be rejected even if there is in
fact no treatment effect. This is due to the fact that the combination of different parametric models will be inconsistent
with the null hypothesis.
3.6 | G‐estimation of structural nested models
The final method we will consider is g‐estimation of SNM.18 This method has been used less than the previously
described methods, and this may partly be due to the perceived difficulty of applying the method with standard statis-
tical software.19 However, a recent paper by Vansteelandt and Sjolander revisits g‐estimation, showing how it can be
implemented with standard software.20
Similar to HA‐MSM, this method can estimate the effect of all treatments at visits t on outcomes at visits s where t≤s.
Starting from the short‐term model as in the SCMM, we obtain an estimate for the 1‐year effect of treatment, βX1 ,
E YtjXt; Yt−1; Ct;B; ptð Þ ¼ β0 þ β1Xt−1 þ β2Yt−1 þ β3Ct þ β4Bþ β5pt þ βX1Xt; (16)
where pt is the estimated propensity score.
The estimate βX1 can then be used to construct counterfactuals by subtracting the estimated 1‐year effect to be able
to see if there is any extra effect for additional years of treatment,
Hst ¼ Ys− ∑
s
u¼tþ1
βXs−uþ1Xu: (17)
It can be seen that in the case where t = s, Hst is simply equal to Ys as expected, whereas intermediate treatment
effects are subtracted if t< s. In the first iteration, as we only have an estimate for βX1 , we can only calculate Hst where
s ≤ t+1. However, this now allows us to estimate both the 1‐year and 2‐year effects with the following model:
E HsjjXj; Yj−1; Cj;B; pj
 
¼ β0 þ β1Xj−1 þ β2Yj−1 þ β3Cj þ β4Bþ β5pj þ βXs− jþ1Xj: (18)
Iteration of Equations 17 and 18 allows the estimation of all βXs− jþ1 where 1 ≤ j ≤ s and 1 ≤ s ≤ T.
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Similarly to HA‐MSM, g‐estimation is a method that allows the estimation of effect modification by time‐varying
covariates by including interaction terms in both Equations 17 and 18.
Censoring weights as described in Section 3.3 can also be incorporated into g‐estimation, weighting individuals by
their estimated probability of being censored between visits t and s.
3.7 | Use of methods with a count outcome
For our motivating example, we have 2 outcomes of interest, ppFEV1 and annual IV days. The first of these is a contin-
uous outcome, and all 5 of the methods can easily handle this outcome. More care is needed when considering annual
IV days, which is a count outcome ranging from 0 to 365.
Upon investigation, IV days can be considered approximately distributed by a zero‐inflated negative binomial distri-
bution. Modelling this outcome therefore requires two separate estimation procedures: (1) logistic regression to estimate
the odds of a count of zero IV days and (2) negative binomial regression to estimate the rate of IV days. Therefore, there
are two separate parts to the treatment effect: the estimated effect of treatment on having zero IV days (an odds ratio)
and the estimated effect of treatment on the number of IV days (a rate ratio).
For SCMM, this is not an issue, as one can simply fit a zero‐inflated negative binomial model to estimate both
effects. Similarly, IPW, HA‐MSM, and g‐computation formula can all handle different types of outcome by just changing
the final MSM, eg,
E Y xtt
  ¼ expit β0 þ ∑
t
i¼1
βxixi
 
exp γ0 þ ∑
t
i¼1
γxixi
 
: (19)
Unlike the other 4 methods, which can easily handle different types of outcome, the method of g‐estimation
described in Section 3.6 has until recently only been described for continuous outcomes. However, a recent paper has
shown how this method can be adapted to allow for a count outcome by modelling with a gamma distribution.21 This
allows for the estimation of the effect of treatment on the rate of IV days, but would still not allow for the decomposition
of the effect into the probability of a zero count and a rate, as the other methods do.
Another issue one needs to consider when modelling a count outcome is non‐collapsibility. Unlike with the contin-
uous outcome where, thanks to collapsibility, the marginal and conditional effects are the same, this no longer holds for
models suitable for count outcomes. Thus, the treatment effect on IV days will differ between methods depending on
whether the method delivers a marginal effect (IPW and g‐computation formula) or a conditional effect (SCMM,
HA‐MSM and g‐estimation).
3.8 | Overview of methods
Referring back to the five features of the UK CF Registry introduced in Sections 2.2.1 to 2.2.5, we would hope for any
method to estimate no treatment effect on average when there is no treatment effect, but the g‐null paradox may mean
that the g‐computation formula could perform poorly in this setting.
Except for SCMM, all methods can estimate long‐term treatment effects, and in all our analyses, we will include
separate terms for treatment at each visit making no assumptions about a continuous effect or a trend effect. SCMM will
only be used to estimate the short‐term treatment effect, but the method will consistently estimate this even if there are
longer term effects.15
In terms of effect modification, three of the methods (SCMM, g‐estimation, and HA‐MSM) allow interaction
terms, meaning that when this is of interest, only these methods can be used. IPW of MSM and g‐computation formula
can still be used to estimate population average effects even in the presence of effect modification by time‐varying covar-
iates, whereas the other three methods may show bias in estimating population average effects if there is in fact effect
modification and it is not explicitly modelled.
When there is censoring, three of the methods (IPW of MSM, HA‐MSM, and g‐estimation) can use censoring
weights to correct for the individuals who do not have full follow‐up. Censoring should not affect the short‐term models
used in SCMM, and similarly, the g‐computation formula uses the same short‐term models and then simulates follow‐
up without censoring.
With the exception of SCMM, it is normally advised to use a bootstrap procedure to obtain standard errors (SE). This
is because all the methods contain a number of steps of estimation and just using the final model‐based SE would fail to
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account for the uncertainty from the earlier steps.13,14,22,23 The bootstrap provides valid results as all of these methods
produce regular estimators.24
4 | SIMULATION STUDIES
The following section gives details of simulation studies that were performed to investigate how the features and
challenges identified in Section 2.2 (robustness to misspecification of the causal null, long‐term treatment effects, effect
modification by time‐varying covariates, misspecification of the direction of causal pathways, and censoring) affect the
performance of the five methods given in Section 3 (SCMM, IPW of MSM, HA‐MSM, g‐computation formula, and g‐esti-
mation of SNM).
The aims of the simulation studies are to understand how the performance of the analysis methods might be affected
by these challenges and to help provide a framework for the best analysis strategy for the real UK CF Registry data. The
simulation studies were performed following the guidelines given by Burton et al25 and full details of the design of the
simulation studies can be found in Supporting Information, with a summary below.
4.1 | Design of simulation studies
Datasets were simulated for six different scenarios as shown in Figure 3. In each DAG, the arrows highlighted in red
show the specific differences compared with the other scenarios.
The first scenario is the standard scenario, which will be the baseline with which to compare the other methods. In
this scenario, there is a 1‐year treatment effect, there are no direct long‐term effects, although there are long‐term effects
mediated through other time‐varying covariates. This is the scenario for which all the methods will be correctly speci-
fied and as such we would expect all methods to provide consistent estimates for the treatment effects in this scenario.
In the second scenario, we simulate without any treatment effect, and the third scenario adds long‐term direct
effects of treatment. In this case, the long‐term direct effects are actually negative effects, slightly counteracting the
beneficial 1‐year effects, resulting in a decrease in the treatment effect through time.
The fourth scenario simulates effect modification of treatment by time‐varying covariates. Although effect modifica-
tion is generally not shown in DAGs, we have included arrows in Figure 3 to help illustrate how the presence of effect
modification would change the treatment effect.
FIGURE 3 Simplified directed acyclic graphs showing data generation process for each of the 6 scenarios investigated. The real data were
generated for up to 5 visits, and there is additionally a baseline confounder, age, affecting all variables
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The fifth scenario concerns the direction of the causal pathway between treatment and IV days in the same year. In
our analysis, we will always analyse the data as if the direction of the causal pathway is from Vt to Xt, even when the
data have actually been simulated the other way around, ie, Xt affects Vt.
In the final scenario, individuals can either all be followed up for 5 visits, or there can be some censoring, whereby
“unhealthy” individuals are more likely to be censored at an earlier visit. This corresponds to a missing at random sce-
nario, whereby the probability of being censored depends on observed variables.
For each scenario, we simulated 1000 datasets, each with 7500 individuals. The data were generated so as to imitate
the observed data in the Registry as closely as possible. In the real data, there are many treatments that individuals
could be receiving and also many covariates that might be confounders. For the simulation studies, we kept just one
binary treatment, Xt, and the 2 outcome variables, ppFEV1(Ft) and annual IV days (Vt), which also act as time‐depen-
dent confounders. Lung function was simulated as a continuous variable with a normal distribution and IV days as a
count outcome following a zero‐inflated negative binomial distribution. In addition to these 3 variables, we also gener-
ated age from a beta distribution corresponding to what was observed in the real data to act as a baseline confounder.
For each method and each scenario, we run two analyses: the first considering ppFEV1 as the outcome and the sec-
ond annual IV days as the outcome. For each simulation, the coefficients corresponding to the treatment effects will be
stored. For SCMM, which can only measure short‐term effects, only the coefficient corresponding to 1 year of treatment
will be stored. For all other methods, we estimate the effects of up to 5 years' treatment use on ppFEV1 and up to 4 years'
treatment use on IV days. The reason for this difference is due to the 1‐year effect of treatment on lung function being
defined as Xt→Ft, whereas the 1‐year effect of treatment on IV days is Xt→Vtþ1. As such, there is always one extra year
of data available for the lung function outcome.
We will compare the methods based on the bias, empirical SE, and mean squared error (MSE). Although it is known
that the model‐based SE are biased for most of these methods, we will also store the estimated robust SE so as to
compare them to the empirical SE.
4.2 | Results of simulation studies
4.2.1 | Continuous outcome
In Figure 4, we present kernel density plots showing the results of the simulation studies for the normally distributed
continuous outcome. We only present results for the 1‐year effect and the 5‐year effect to show the 2 extremes of short‐
to long‐term effects. In all cases, the results for the 2‐ to 4‐year effects followed the trend between the 1‐year and 5‐year
effects. More details of the results can be found in Table S3.
As expected, all 5 methods to provide consistent estimates for the “standard” scenario where all the models are cor-
rectly specified. The only method that performs poorly here is using truncation with IPW, but this is also to be expected
as it is known that due to truncation the weights would no longer fully account for confounding. The 5‐year treatment
effect estimates are slightly biased, but when using a much larger sample size, all methods were unbiased; therefore, we
believe this residual bias is due to the sample size, which we have kept at 7500 individuals as it is unlikely that we would
ever obtain a larger sample from the UK CF Registry.
These findings are repeated for the scenarios where there is no treatment effect, where the treatment effect
decreases over time, and where there is censoring (provided that censoring weights are used for IPW, HA‐MSM, and
g‐estimation).
For the scenario where the causal pathway between a confounder and treatment is specified the wrong way round,
we find that the situation is the opposite: All methods are biased, but IPW and HA‐MSM perform comparatively well
when the weights are truncated. However, untruncated, they perform very poorly with very large variability and even
fail to converge on an estimate many times.
When considering effect modification by time‐varying covariates, all the methods can still be used to provide an estimate
for the population‐average effect. For the 1‐year effects, all the methods provided consistent estimates; however, at 5 years,
there was some noticeable bias for g‐estimation and HA‐MSM. These are the 2 methods that can incorporate the estimation
of effect modification by time‐varying covariates, and not including these interactions terms when they are in fact present
has introduced bias. Conversely, although IPW and g‐computation formula cannot estimate interaction terms, they do
not assume that there is no effect modification and can provide consistent estimates for the population‐average effect.
If the aim is to estimate the strength of any effect modification by time‐varying covariates, then it would be neces-
sary to use HA‐MSM, SCMM, or g‐estimation, and these results are presented in Figure 5 (and Table S4). We see that all
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3 methods perform similarly well in estimating interaction terms, although there is still some finite sample size bias,
and a much larger sample size would be needed to accurately estimate the interaction terms. Even in cases where there
is no effect modification, including an interaction term in the models did not introduce bias, and the methods correctly
estimate zero for the interaction term on average.
3 3.5 4 4.5
1 Year Effect
Standard Scenario
16 18 20 22
5 Year Effect
−1 −.5 0 .5 1
IPW
IPW (truncated)
HA−MSM
HA−MSM (truncated)
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No Effect Scenario
−4 −2 0 2 4
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Effect Modification Scenario
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Effect Estimates for Continuous Outcome
FIGURE 4 Kernel density plots showing the distribution of population‐average effect estimates for a continuous outcome. The vertical line
shows the correct effect. HA‐MSM, history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential
conditional mean models
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When considering the SE, only in SCMM and HA‐MSM did the model‐estimated SE approximate the empirical SE.
This is theoretically known in the case of SCMM with the propensity score known and, therefore, will be approximately
correct when the propensity score is well estimated. In the case of HA‐MSM, we believe this to be a peculiarity of our
simulation setting, and it is unlikely to be true generally. For this reason, for all methods other than SCMM, a bootstrap
procedure should be used to obtain reliable SE estimates. Comparing the methods, g‐computation formula consistently
shows the smallest empirical SE, followed by SCMM, g‐estimation, and HA‐MSM with similar SE and, finally, IPW with
the largest SE. In the scenario of reversed causal pathways, IPW and HA‐MSM had especially large SE when
untruncated weights were used.
4.2.2 | Count outcome
Unlike with the continuous outcome, due to the issue of non‐collapsibility, we do not compare the effect estimates for
the count outcome to a “correct” value. However, Figures 6 and 7 present the effect estimates and SE for both the odds
of a zero count and the rate of the count. As with the continuous outcome, more detailed results can be found in
Table S5.
Both IPW and g‐computation formula provide marginal effect estimates and in almost all cases provide very similar
estimates. The only setting where they do not provide similar estimates is the case of reversed causal pathways where
IPW performs very poorly with very large variability, as was also seen for the continuous outcome.
Considering the 3 methods that provide conditional effect estimates, we note that the methods are not in general
in agreement, and this is due to the fact that the final models condition on different subsets of variables. In the case
of g‐estimation, due to the fact that the method can only estimate a rate (rather than also accounting for the separate
process of excess zeroes), the estimates from this method are generally very different from all other methods.
The only case where all 5 methods are in agreement is when there is no treatment effect. Here, both the marginal and
conditional effect estimates are zero. This suggests that any method could be used to perform a test of the null hypothesis
of no treatment effect, but the strength of any effect estimates cannot directly be compared between methods.
The results for estimating interaction terms are presented in Figures 8 and 9 (Table S6). The findings are similar to
the case of interaction terms with continuous outcomes, except for the case of g‐estimation where even in the case
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−.3 −.2 −.1 0 .1 .2
HA−MSM
HA−MSM (truncated)
SCMM
G−Estimation
1 Year Effect
Standard Scenario (No Effect Modification)
−1.5 −1 −.5 0 .5
5 Year Effect
−1 −.9 −.8 −.7 −.6 −.5
1 Year Effect
Effect Modification Scenario
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Interaction Effect Estimates for Continuous Outcome
FIGURE 5 Kernel density plots showing the distribution of interaction effect estimates for a continuous outcome. The vertical line shows
the correct effect. HA‐MSM, history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential conditional
mean models
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where there is no effect modification in the data generation process, the method did not average on no effect modifica-
tion. This is again due to non‐collapsibility, where although there is no effect modification present when assuming the
data follow a zero‐inflated negative binomial distribution, there may be under different distributional models.
Similar to continuous outcomes, the model estimated SE from HA‐MSM and SCMM approximated the empirical SE
well, but again, we would recommend a bootstrap procedure to be used for all methods other than SCMM.
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FIGURE 6 Kernel density plots showing the distribution of population‐average effect estimates for the odds of a zero count. HA‐MSM,
history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential conditional mean models
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5 | DATA ANALYSIS
Based on the findings from the simulation studies, if the real causal pathways in the Registry data are similar to those
used in the simulation studies, all 5 available statistical methods would be suitable to investigate the effects of DNase on
ppFEV1 and annual number of IV days.
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FIGURE 7 Kernel density plots showing the distribution of population‐average effect estimates for the rate of a count outcome. HA‐MSM,
history‐adjusted marginal structural models; IPW, inverse probability weighting; SCMM, sequential conditional mean models
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FIGURE 8 Kernel density plots showing the distribution of interaction effect estimates for the odds of a zero count. HA‐MSM, history‐
adjusted marginal structural models; SCMM, sequential conditional mean models
0−.02 .02 .04
1 Year Effect
No Effect Scenario
0−.1 −.05 .05 .1
4 Year Effect
−.05 0 .05 .1 .15 .2 .25
HA−MSM
HA−MSM (truncated)
SCMM
G−Estimation
1 Year Effect
Standard Scenario (No Effect Modification)
0−.3 −.2 −.1 .1 .2
4 Year Effect
0−.25 −.2 −.15 −.1 −.05
1 Year Effect
Effect Modification Scenario
−.2 −.1 0 .1 .2
4 Year Effect
Log Rate of Count
Interaction Effect Estimates for Count Outcome
FIGURE 9 Kernel density plots showing the distribution of interaction effect estimates for the rate of a count outcome. HA‐MSM, history‐
adjusted marginal structural models; SCMM, sequential conditional mean models
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Unfortunately, the key challenge identified in the simulation studies was that misspecifying the direction of a causal
pathway will introduce bias no matter which method is used. In the Registry data, it is likely that the real direction of
the causal pathway between treatment (Xt) and annual IV days (Vt) is somewhere between the two extremes of the best‐
case scenario where Xt is only affected by Vt and the worse‐case scenario where Xt only affects Vt. In this setting, the
simulation studies showed that we might expect IPW and HA‐MSM to perform particularly poorly if the extreme
weights are not truncated. Nevertheless, we still perform the analysis here both with and without truncation to compare
the effect of truncating weights.
For these analyses, we must also consider the four assumptions highlighted in Section 3.1: no interference, positivity,
consistency, and no unmeasured confounding. Interference should not be an issue, because CF is a non‐infectious
condition. Furthermore, people with CF are generally kept out of direct contact with one another to avoid cross‐infec-
tion of respiratory microorganisms.4 The assumption of positivity was also considered to be valid for this investigation.
Although guidelines do exist to help advise when patients might benefit from DNase, it is not uncommon for patients to
receive or not receive treatment despite the guidelines. Once DNase treatment has been initiated, it is usual to continue
to receive the treatment indefinitely, but a number of people do also stop taking treatment for various reasons.
Furthermore, in the IPW analysis, there were no extreme weights, suggesting that the assumption of positivity held.
Consistency concerns the definition of the intervention. The standard dosage and frequency of DNase is 2.5 mg once
a day, but a small number of patients receive a different dosage or frequency. Unfortunately, dosage data are not
routinely collected in the Registry. However, consistency is considered to hold under an intervention defined as
“receives DNase as prescribed by doctor'.
All models included the time‐varying covariates ppFEV1 and IV days as both outcomes and confounders. The
analyses also adjusted for baseline confounders: age, sex, ethnicity, and genotype class (a binary marker of the severity
of the CF‐causing mutation). It is possible that there is residual confounding of the treatment‐outcome association and
there were a number of other covariates measured in the UK CF Registry that could have been adjusted for, eg, smoking
status or body mass index (BMI). However, there is a large amount of missing data in these variables, resulting in many
observations being dropped from the analyses if they were included. In sensitivity analyses based on the subset without
missing data adjusting for time‐varying smoking status and BMI had only a very small impact on the effect estimates.
Our analysis included 22 357 annual assessments from 3847 people. The median number of visits per person was 8
(IQR, 5‐9). DNase was used for at least 1 year by 2251 people (58.5%) and for at least 5 years by 823 people (21.4%).
Table 1 gives an overview of the people included in the analysis at baseline.
5.1 | Results of lung function analysis
Figure 10 presents the results of the estimated population‐average effect of DNase on ppFEV1 depending on length of
treatment use. At 1 year, all methods except g‐computation formula estimate that treatment has a negative effect on
ppFEV1. The results for SCMM, g‐computation formula, and g‐estimation are, however, not significant (P = .86, .89,
and .86, respectively), whereas IPW and HA‐MSM estimate a stronger, significant, negative effect (P < .001 and .005),
which does not change much upon truncation of the extreme weights. Looking at longer term effects, all methods
showed a trend with the treatment effect becoming more negative through time, with truncated IPW estimating the
largest difference in ppFEV1 between those taking and not taking treatment of −8.81% (95% CI, −10.50 to −7.12,
P < .001) and HA‐MSM the smallest effect of −1.52% (95% CI, −3.30 to 0.27, P = .097). Full results from this analysis
can be found in Table S7.
SCMM, and g‐estimation were also used to investigate effect modification of the treatment effect by time‐varying
ppFEV1. These results are presented in Figure 11 and show that treatment was estimated to be beneficial in people
with lower baselined ppFEV1. HA‐MSM estimated an intercept term of 3.32, with treatment becoming less beneficial
by 0.57 per 10% change in baseline ppFEV1. This equates to a beneficial effect for people with a baseline ppFEV1 below
58% and a negative effect for people with ppFEV1 above 58%. SCMM and g‐estimation estimated a more attenuated
interaction effect where treatment became less effective by 0.37 per 10% change in baseline ppFEV1. This means that
for these methods, treatment was estimated to be beneficial for people with a baseline ppFEV1 up to 73%.
Looking at the 5‐year treatment effect, the interaction between treatment and ppFEV1 was estimated to increase in
strength leading to a bigger differentiation in effect between those with low and high baseline ppFEV1. In the case of
HA‐MSM, the intercept was estimated to be 8.30 with a change in effect of −1.29 per 10% increase in ppFEV1, leading
to a boundary for a beneficial effect of 64%. G‐estimation showed a stronger interaction effect at 5 years of −2.69%, but
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due to the increased SE, this was not significant (P = .16). The full results from the analysis including the interaction
term can be seen in Table S8.
5.2 | Results of IV days analysis
Similarly to the ppFEV1 analysis, we generally estimated a negative effect when considering the population average
effect of DNase on the annual number of IV days. These results are shown in Figure 12 and can also be seen in more
detail in Table S9.
At 1 year, all methods estimated a strong, significant decrease in the odds of having zero IV days and an increase in
the overall rate of the number of IV days for those receiving treatment. As we observed in the simulation studies, the
estimates from g‐estimation were larger due to the fact that it does not estimate the odds of a zero count separately
to the overall rate.
TABLE 1 Descriptive baseline statistics of people included in data analysis. Mean (SD) are given for continuous variables and n (%) for
categorical variables
Variable
Received DNase During Follow‐Up?
No (n = 1596) Yes (n = 2251)
Age, y 20.8 (13.9) 16.0 (11.7)
ppFEV1 84.5 (19.9) 78.6 (20.5)
Annual IV days 5.8 (14.4) 10.6 (19.4)
Sex
Female 716 (44.9) 1081 (48.0)
Male 880 (55.1) 1170 (52.0)
Ethnicity
Caucasian 1547 (96.9) 2172 (96.5)
Other 49 (3.1) 79 (3.5)
Genotype class
High 909 (57.0) 1708 (75.9)
Low 310 (19.4) 183 (8.1)
Unassigned 377 (23.6) 360 (16.0)
G−Estimation
G−Formula
SCMM
HA−MSM (truncated)
HA−MSM
IPW of MSM (truncated)
IPW of MSM
1.0e+300−1.0e+300−6 −4 −2 0 2
Difference at 1 Year
−6 −4 −2 0 2
Difference at 2 Years
−8 −6 −4 −2 0 2
Difference at 3 Years
−10 −8 −6 −4 −2 0 2
Difference at 4 Years
−10 −8 −6 −4 −2 0 2
Difference at 5 Years
Change in ppFEV1
FIGURE 10 Plots showing the estimated population‐average effect of DNase treatment on ppFEV1. HA‐MSM, history‐adjusted marginal
structural models; IPW, inverse probability weighting; MSM, marginal structural models; SCMM, sequential conditional mean models
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The estimates for the 4‐year treatment effects were very similar to the 1‐year treatment effect estimates, so although
treatment was still not estimated to be beneficial, we did not observe a trend of divergence between the treated and
nontreated as was observed with ppFEV1.
The results including an interaction term between previous number of IV days and treatment are shown in
Figure 13. In people who had previously had zero IV days, treatment was estimated to decrease their odds of zero future
IV days by between 0.62 (HA‐MSM) and 0.73 (SCMM), but for every 10 additional previous IV days, the odds of zero
future IV days increased by between 1.16 (HA‐MSM) and 1.17 (truncated HA‐MSM). This means that treatment would
be estimated to become beneficial on the odds of zero future IV days in individuals who previously had more than
between 21 IV days (SCMM) or 32 IV days (HA‐MSM).
Considering the overall rate of IV days, the interaction effect was not significant for HA‐MSM but was for SCMM
and g‐estimation, where for people with zero previous IV days, treatment was estimated to increase the rate of future
IV days by between 1.12 (SCMM) and 1.36 (g‐estimation), and this was estimated to decrease by a rate of 0.98 (SCMM)
and 0.94 (g‐estimation) per 10 IV days, resulting in a treatment estimated to be beneficial for people with more than 56
previous IV days for SCMM or more than 50 previous IV days (g‐estimation).
By 4 years, the interaction present at 1 year modifying the effect of the odds of a zero count had attenuated from 1.16
to 1.08 and was no longer significant. However, there was moderate evidence of interaction when considering the
overall rate of IV days with treatment estimated to be beneficial at 4 years in those who had previously had more than
43 days (HA‐MSM) or 162 IV days (g‐estimation). Table S10 contains the full results from this analysis.
6 | DISCUSSION
We have investigated the suitability of five methods for estimating treatment effects in longitudinal observational data
using simulation studies and applied the methods to the UK CF Registry. The focus was on five features encountered in
G−Estimation
SCMM
HA−MSM (truncated)
HA−MSM
−5 0 5 10 15
Difference at 1 Year
−5 0 5 10 15
Difference at 2 Years
−10 0 10 20 30
Difference at 3 Years
−10 0 10 20 30
Difference at 4 Years
−20 0 20 40 60
Difference at 5 Years
Change in ppFEV1 − Intercept Term
G−Estimation
SCMM
HA−MSM (truncated)
HA−MSM
−2 −1 0
Difference at 1 Year
−2 −1 0
Difference at 2 Years
−4 −2 0
Difference at 3 Years
−4 −2 0
Difference at 4 Years
−8 −4 0
Difference at 5 Years
 Change in ppFEV1 − Interaction Term
FIGURE 11 Plots showing the estimated effect of DNase treatment on ppFEV1 with effect modification by previous measure of ppFEV1.
The intercept term is the estimated effect for an individual with ppFEV1 equal to 0 in the previous year, and the interaction effect is the
estimated change per 10 increase in the previous year's ppFEV1. HA‐MSM, history‐adjusted marginal structural models; SCMM, sequential
conditional mean models
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these investigations (Section 2.2). The suitability and performance of the methods differs depending on the research
question, the nature of the treatment effect of interest, and the features of the data. Here, we provide an overview
and recommendations based on our findings.
Our simulation studies showed that all the methods we considered are suitable for analysing registry data to inves-
tigate treatment effects in many scenarios. Specifically in the standard scenario, where all models are correctly specified,
all methods performed very similarly with little impact depending on the method chosen.
In the case of IPW, however, there were noticeable differences between the method with truncated and untruncated
weights. In most situations, the untruncated weights performed best, but in the situation of causal pathways being
misspecified, the truncated weights showed much better performance. In a real scenario, we would not know which
scenario we are in; it would therefore be difficult to know when weights should be truncated or not. It may be sensible
to only truncate when there are “extreme” weights, but there is no clear definition of how large a weight must be before
it is “extreme.” This would suggest, therefore, in situations where there is uncertainty in the correct direction of causal
pathways, that IPW not be used.
HA‐MSM performed similarly to IPW of MSM in cases where there is no effect modification, but as it is a more com-
plex method, it would be preferable to use standard IPW of MSM over HA‐MSM in most cases.
For measuring the 1‐year effect of treatment, SCMM would probably be the preferred method due to its good
performance in the simulation studies and its simplicity to implement. The obvious drawback is that the method cannot
be used to estimate long‐term effects like the other methods, but we recommend that this method be used alongside
other methods to check whether the more complex methods are in agreement with the 1‐year effect estimate of the
SCMM. In cases where the 1‐year effect estimate is markedly different between SCMM and another method, this could
act as a flag of potential issues with the analysis.
Another benefit of SCMM is that the model‐based standard errors will be approximately correct when the propensity
score is well estimated, meaning that the bootstrap does not need to be used and results can be obtained much faster
than using the other methods presented in this paper. The asymptotic SEs have been derived for IPW of MSM, but only
G−Formula
SCMM
HA−MSM (truncated)
HA−MSM
IPW of MSM (truncated)
IPW of MSM
.4 .6 .8 1 1.2
OR at 1 Year
.4 .6 .8 1 1.2
OR at 2 Years
.4 .6 .8 1 1.2
OR at 3 Years
.4 .6 .8 1 1.2
OR at 4 Years
Odds of Zero IV Days
G−Estimation
G−Formula
SCMM
HA−MSM (truncated)
HA−MSM
IPW of MSM (truncated)
IPW of MSM
1 1.2 1.4 1.6 1.8
RR at 1 Year
1 1.2 1.4 1.6 1.8
RR at 2 Years
1 1.2 1.4 1.6 1.8
RR at 3 Years
1 1.2 1.4 1.6 1.8
RR at 4 Years
Rate of IV Days
FIGURE 12 Plots showing the estimated population‐average effect of DNase treatment on annual IV days. HA‐MSM, history‐adjusted
marginal structural models; IPW, inverse probability weighting; MSM, marginal structural models; SCMM, sequential conditional mean
models
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in a time‐fixed setting,26 and the difficulty of deriving these in a longitudinal setting necessitate the use of the bootstrap
for all the methods other than SCMM.
G‐computation formula tended to perform as well as other methods, only performing poorly where other methods
also performed poorly. The SE were consistently smaller than for other methods, which would always be preferable in
cases where we are confident in the specified models for the time‐varying covariates. However, in cases where there is
SCMM
HA−MSM (truncated)
HA−MSM
.6 .8 1 1.2
OR at 1 Year
.6 .8 1 1.2
OR at 2 Years
.6 .8 1 1.2
OR at 3 Years
.6 .8 1 1.2
OR at 4 Years
Odds of Zero IV Days − Intercept Term
SCMM
HA−MSM (truncated)
HA−MSM
.8 1 1.2
OR at 1 Year
.8 1 1.2
OR at 2 Years
.8 1 1.2
OR at 3 Years
.8 1 1.2
OR at 4 Years
Odds of Zero IV Days − Interaction Term
G−Estimation
SCMM
HA−MSM (truncated)
HA−MSM
1.0e+300−1.0e+300
j
1 1.5 2
RR at 1 Year
1 1.5 2
RR at 2 Years
1 1.5 2 2.5
RR at 3 Years
1 2 3
RR at 4 Years
Rate of IV Days − Intercept Term
G−Estimation
SCMM
HA−MSM (truncated)
HA−MSM
.9 .95 1
RR at 1 Year
.9 .95 1
RR at 2 Years
.9 .95 1
RR at 3 Years
.9 .95 1
RR at 4 Years
Rate of IV Days − Interaction Term
FIGURE 13 Plots showing the estimated effect of DNase treatment on IV days with effect modification by previous number of IV days.
The intercept term is the estimated effect for an individual with 0 IV days in the previous year, and the interaction effect is the estimated
change per 10 increase in the number of IV days in the previous year. HA‐MSM, history‐adjusted marginal structural models; SCMM,
sequential conditional mean models
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misspecification, the SE remains small, and with real data, it is unlikely that all the assumptions necessary for
g‐computation formula would be completely correct, which could result in tight confidence intervals around an incor-
rect effect estimate. In our scenarios, we did not encounter any issue with the g‐null paradox. This is because, for the
g‐null paradox to arise it is necessary for treatment to affect a time‐dependent confounder without having any direct
or indirect effect on the outcome.27 In our “no effect scenario,” treatment had no effect on either lung function or IV
days, which are acting as both the outcome and the time‐dependent confounders.
For continuous outcomes, g‐estimation performed well with the SE generally lying between those of g‐computation
formula and IPW, with the advantage that the method can also estimate effect modification by time‐varying covariates,
without the drawbacks of unstable weights which were sometimes observed in HA‐MSM. However, with the count out-
come, g‐estimation used a gamma model rather than the zero‐inflated negative binomial model like the other methods
presented in this paper. This resulted in only one rate ratio compared with the two distinct effect estimates of the other
methods making comparison difficult. In situations where the count outcome is not as skewed as the annual IV days in
the UK CF registry data, g‐estimation may be a suitable method, but in our setting, the other methods were generally
preferable.
We outlined how all methods can handle a count outcome, with the outcome model being restricted to a gamma
model in g‐estimation. A further complexity of the count outcome is the issue of non‐collapsibility. In the simulations,
we found that when there is truly no treatment effect, both marginal and conditional estimates were correctly consistent
with there being no treatment effect. However, in cases where there is a treatment effect, comparison between marginal
and conditional estimates from different methods is not as useful.
In addition to the five methods considered in this paper, there are other methods that could have been considered
for estimation of treatment effects in the analysis of the Registry data. One such method is targeted maximum likelihood
estimation, which is related to the g‐computation formula.28 This method has previously been compared with both IPW
and the g‐computation formula.29-31
Considering the analysis of the UK CF Registry data, as hypothesised, there did appear to be effect modification of
the treatment effect by previous ppFEV1 and previous annual IV days. This resulted in the population average esti-
mates hiding the fact that treatment could be beneficial for a group of people. Therefore, in this situation, we would
prefer to use SCMM, HA‐MSM, or g‐estimation, which can estimate effect modification of the treatment effect by
time‐varying covariates. Due to the fact that we are unsure of the correct specification of some of the causal path-
ways, HA‐MSM may not be a suitable method as shown in the simulation studies. However, the results from all four
methods (Figure 11) were very similar, suggesting that the direction of the causal pathways may not be misspecified
and any of the methods may in fact be suitable.
There was also evidence of effect modification of the treatment effect on the annual number of IV days. However,
depending on the method used, treatment was not estimated to become beneficial until individuals had had over at least
21 IV days in the previous year. In our data, almost 80% of people had fewer than 21 IV days, meaning treatment would
only be beneficial in reducing IV days in a small subset of people if these results are reliable. However, a further issue
with the annual IV days is that people are not only prescribed IVs as a result of an exacerbation of symptoms, but some-
times they are prescribed as a protective measure to avoid a future exacerbation. It is plausible that people who are more
likely to be prescribed treatment are also more likely to be prescribed IVs and it may not be possible to account for this
confounding with the available data in the Registry. The issue of unmeasured confounding has not been considered in
this paper, because it is an assumption of all the considered methods that there is no unmeasured confounding, but it is
important to remember this when considering if the data available are suitable for the desired analysis.
Previous work using more traditional statistical methods has only investigated the effects of up to 2 years of DNase
treatment. We have shown in this paper how the data available in registries can be harnessed with appropriate statis-
tical methods to investigate the effects of longer term use of treatments. Many treatments for CF would actually be used
for more than 5 years, which was the maximum time‐frame considered in this paper due to the limited sample size with
follow‐up longer than 5 years, but as more data are collected in the UK CF Registry, further analyses with longer follow‐
up could be performed.
Unfortunately, as with a lot of observational data, there are high levels of missingness in some of the variables
collected in the UK CF Registry. As missing data were not the focus of this paper, we presented the results of the data
analysis with adjustment for variables that are considered to be the strongest confounders affecting the probability of
receiving treatment and outcomes, as these variables are also more widely collected. Furthermore, sensitivity analyses
suggested that including other potential confounders such as smoking status or BMI did not result in significant changes
to the results.
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In conclusion, in most settings, more than one of the available methods would be suitable for the types of analysis
considered in this paper. In many cases, therefore, it may be beneficial to consider using more than one available
method, to see if the results are consistent. Of course, in cases where 2 separate methods give the same effect estimate,
this does not mean it is correct, but does add some reliability to the results. In cases where the methods gave very
different effect estimates, this would act as a flag to re‐examine the data, the assumptions of the methods, and the
suitability of the analyses performed.
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Appendix C
Supplementary Tables & Figures to
Chapter 5
In Chapter 5 we only presented the results of the shortest- and longest-term effects. In
all cases, the bias, empirical standard error, model-based standard error and MSE was
smallest for the one-year effect and sequentially grew larger with longer-term effects.
Here we present the kernel density plots and the tables of results for the two-, three-,
and four- year results for the continuous outcome and the two- and three-year results for
the count outcome. The SCMM method is not included in any of the following figures
and tables, as this method only estimates the one-year effect, which was presented in the
Chapter 5.
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FIGURE C.1: Kernel density plots of two-, three- and four-year population-
average effect estimates for a continuous outcome (The vertical line shows
the correct effect)
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FIGURE C.2: Kernel density plots of two-, three- and four-year interaction
effect estimates for a continuous outcome (The vertical line shows the cor-
rect effect)
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Scenario Method n Cumulative 2 Year Treatment Effect (∑
2
i=1 φi) Cumulative 3 Year Treatment Effect (∑
3
i=1 φi)
Mean Bias Empirical SE Model SE MSE Mean Bias Empirical SE Model SE MSE
Standard
∑21 φi = 8.33
∑31 φi = 12.50
IPW of MSM 1000 8.34 0.010 0.32 0.52 0.10 12.53 0.026 0.46 0.65 0.21
IPW of MSM (truncated) 1000 7.87 -0.46 0.32 0.49 0.31 11.86 -0.64 0.45 0.62 0.61
HA-MSM 1000 8.31 -0.019 0.29 0.30 0.087 12.46 -0.039 0.40 0.40 0.16
HA-MSM (truncated) 1000 8.23 -0.096 0.29 0.30 0.095 12.32 -0.18 0.39 0.39 0.19
G-Formula 1000 8.30 -0.026 0.26 0.17 0.066 12.44 -0.065 0.35 0.20 0.12
G-Estimation 1000 8.38 0.052 0.24 0.32 0.060 12.61 0.11 0.35 0.54 0.14
No Effect
∑21 φi = 0.00
∑31 φi = 0.00
IPW of MSM 1000 -0.008 -0.008 0.32 0.52 0.10 0.005 0.005 0.45 0.65 0.20
IPW of MSM (truncated) 1000 -0.44 -0.44 0.32 0.49 0.30 -0.61 -0.61 0.45 0.62 0.57
HA-MSM 1000 -0.007 -0.007 0.31 0.30 0.093 -0.002 -0.002 0.40 0.40 0.16
HA-MSM (truncated) 1000 -0.052 -0.052 0.30 0.30 0.095 -0.13 -0.13 0.40 0.40 0.17
G-Formula 1000 -0.019 -0.019 0.27 0.17 0.072 -0.021 -0.021 0.36 0.20 0.13
G-Estimation 1000 -0.004 -0.004 0.25 0.32 0.061 -0.003 -0.003 0.35 0.55 0.12
Decreasing Effect
∑21 φi = 6.89
∑31 φi = 9.64
IPW of MSM 1000 6.83 -0.062 0.33 0.51 0.12 9.56 -0.082 0.46 0.65 0.22
IPW of MSM (truncated) 1000 6.38 -0.51 0.33 0.49 0.37 8.92 -0.72 0.46 0.62 0.73
HA-MSM 1000 6.74 -0.15 0.30 0.30 0.11 9.57 -0.073 0.41 0.40 0.17
HA-MSM (truncated) 1000 6.67 -0.22 0.30 0.30 0.14 9.43 -0.21 0.41 0.40 0.21
G-Formula 1000 6.82 -0.069 0.27 0.17 0.077 9.52 -0.12 0.36 0.20 0.14
G-Estimation 1000 6.92 0.027 0.24 0.32 0.061 9.72 0.079 0.37 0.54 0.14
Effect
Modification
∑21 φi = 4.21
∑31 φi = 6.24
IPW of MSM 1000 4.30 0.09 0.31 0.49 0.092 6.30 0.065 0.44 0.60 0.19
IPW of MSM (truncated) 1000 3.85 -0.36 0.31 0.47 0.22 5.69 -0.55 0.43 0.57 0.49
HA-MSM 1000 4.21 0.0005 0.28 0.30 0.079 6.32 0.078 0.39 0.38 0.16
HA-MSM (truncated) 1000 4.13 -0.768 0.28 0.29 0.084 6.18 -0.063 0.38 0.38 0.15
G-Formula 1000 4.18 -0.030 0.25 0.16 0.064 6.20 -0.041 0.34 0.18 0.12
G-Estimation 1000 4.39 0.18 0.24 0.32 0.091 6.55 0.31 0.35 0.53 0.22
Reversed Causal
Pathway
∑21 φi = 9.09
∑31 φi = 13.18
IPW of MSM 942 -27.87 -36.96 21.28 3.69 1818.41 -13.24 -26.42 29.12 4.75 1545.45
IPW of MSM (truncated) 1000 8.80 -0.29 0.35 0.54 0.21 12.57 -0.61 0.49 0.67 0.61
HA-MSM 926 1.22 -7.87 11.61 2.52 196.59 11.48 -1.70 12.48 2.93 158.51
HA-MSM (truncated) 1000 8.75 -0.34 0.29 0.20 0.30 12.62 -0.56 0.38 0.40 0.46
G-Formula 1000 8.04 -1.05 0.26 0.17 1.16 11.79 -1.39 0.34 0.19 2.05
G-Estimation 1000 7.97 -1.12 0.24 0.33 1.31 11.69 -1.49 0.35 0.56 2.35
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Scenario Method n Cumulative 2 Year Treatment Effect (∑
2
i=1 φi) Cumulative 3 Year Treatment Effect (∑
3
i=1 φi)
Mean Bias Empirical SE Model SE MSE Mean Bias Empirical SE Model SE MSE
Censoring
∑21 φi = 8.33
∑31 φi = 12.50
IPW of MSM 1000 8.16 -0.17 0.41 0.61 0.20 12.20 -0.30 0.61 0.81 0.46
IPW of MSM (truncated) 1000 7.66 -0.67 0.40 0.59 0.61 11.45 -1.05 0.60 0.77 1.46
HA-MSM 1000 8.26 -0.066 0.37 0.37 0.14 12.33 -0.17 0.50 0.53 0.28
HA-MSM (truncated) 1000 8.19 -0.14 0.36 0.37 0.15 12.18 -0.32 0.50 0.52 0.36
G-Formula 1000 8.27 -0.063 0.29 0.22 0.090 12.33 -0.17 0.41 0.27 0.19
G-Estimation 1000 8.32 -0.011 0.28 0.39 0.081 12.47 -0.034 0.44 0.68 0.20
TABLE C.1: Simulation study results of two- and three-year population-average effect for continuous outcome (Dt → Lt) (NA
signifies that the method does not estimate that effect)
Scenario Method n Cumulative 4 Year Treatment Effect (∑
4
i=1 φi)
Mean Bias Empirical SE Model SE MSE
Standard
∑41 φi = 16.40
IPW of MSM 1000 16.34 -0.055 0.61 0.80 0.38
IPW of MSM (truncated) 1000 15.45 -0.95 0.60 0.76 1.27
HA-MSM 1000 16.38 -0.018 0.50 0.52 0.25
HA-MSM (truncated) 1000 16.15 -0.25 0.50 0.52 0.31
G-Formula 1000 16.21 -0.19 0.44 0.24 0.23
G-Estimation 1000 16.53 0.13 0.49 0.81 0.25
No Effect
∑41 φi = 0.00
IPW of MSM 1000 0.028 0.028 0.62 0.81 0.38
IPW of MSM (truncated) 1000 -0.82 -0.82 0.62 0.78 1.05
HA-MSM 1000 -0.011 -0.011 0.52 0.53 0.27
HA-MSM (truncated) 1000 -0.25 -0.25 0.51 0.53 0.33
G-Formula 1000 -0.023 -0.023 0.47 0.24 0.22
G-Estimation 1000 -0.001 -0.001 0.51 0.84 0.26
Decreasing Effect
∑41 φi = 11.68
IPW of MSM 1000 11.62 -0.062 0.63 0.80 0.40
IPW of MSM (truncated) 1000 10.74 -0.94 0.63 0.77 1.27
HA-MSM 1000 11.87 0.19 0.53 0.53 0.32
HA-MSM (truncated) 1000 11.63 -0.049 0.53 0.52 0.28
G-Formula 1000 11.50 -0.18 0.46 0.24 0.25
G-Estimation 1000 11.78 0.10 0.51 0.82 0.27
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Scenario Method n Cumulative 4 Year Treatment Effect (∑
4
i=1 φi)
Mean Bias Empirical SE Model SE MSE
Effect
Modification
∑41 φi = 7.93
IPW of MSM 1000 7.95 0.019 0.57 0.71 0.32
IPW of MSM (truncated) 1000 7.14 -0.79 0.56 0.68 0.94
HA-MSM 1000 8.28 0.35 0.49 0.50 0.36
HA-MSM (truncated) 1000 8.03 0.097 0.49 0.49 0.25
G-Formula 1000 7.89 -0.037 0.44 0.22 0.19
G-Estimation 1000 8.41 0.48 0.47 0.79 0.46
Reversed Causal
Pathway
∑41 φi = 16.96
IPW of MSM 942 11.22 -5.74 21.78 5.61 1041.81
IPW of MSM (truncated) 1000 15.99 -0.97 0.66 0.85 1.37
HA-MSM 926 21.02 4.06 10.72 4.26 131.28
HA-MSM (truncated) 1000 16.16 -0.80 0.51 0.53 0.90
G-Formula 1000 15.19 -1.77 0.44 0.23 3.33
G-Estimation 1000 15.10 -1.86 0.49 0.85 3.69
Censoring
∑41 φi = 16.40
IPW of MSM 1000 15.86 -0.54 0.90 1.08 1.10
IPW of MSM (truncated) 1000 14.85 -1.55 0.88 1.03 3.16
HA-MSM 1000 16.12 -0.28 0.73 0.75 0.61
HA-MSM (truncated) 1000 15.84 -0.56 0.72 0.74 0.83
G-Formula 1000 16.01 -0.39 0.54 0.35 0.44
G-Estimation 1000 16.26 -0.14 0.67 1.08 0.47
TABLE C.2: Simulation study results of four-year population-average effect for continuous outcome (Dt → Lt) (NA signifies that
the method does not estimate that effect)
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Scenario Method n Cumulative 2 Year Interaction Effect (10∑
2
i=1 φinti ) Cumulative 3 Year Interaction Effect (10∑
3
i=1 φinti )
Mean Bias Empirical SE Model SE MSE Mean Bias Empirical SE Model SE MSE
No Effect
10∑21 φinti = 0.00
10∑31 φinti = 0.00
HA-MSM 1000 0.015 0.015 0.12 0.12 0.016 0.030 0.030 0.16 0.16 0.026
HA-MSM (truncated) 1000 0.023 0.022 0.12 0.12 0.016 0.055 0.055 0.16 0.16 0.028
G-Estimation 1000 0.002 0.002 0.10 0.13 0.010 0.009 0.009 0.14 0.21 0.020
Standard
10∑21 φinti = 0.00,
10∑31 φinti = 0.00
HA-MSM 1000 -0.12 -0.12 0.11 0.12 0.028 -0.28 -0.28 0.16 0.16 0.10
HA-MSM (truncated) 1000 -0.11 -0.11 0.11 0.12 0.024 -0.25 -0.25 0.16 0.16 0.085
G-Estimation 1000 -0.13 -0.13 0.093 0.12 0.025 -0.32 -0.32 0.14 0.21 0.12
Effect Modification
10∑21 φinti = −1.60
10∑31 φinti = −2.10
HA-MSM 1000 -1.48 0.12 0.12 0.12 0.027 -2.10 -0.003 0.15 0.16 0.023
HA-MSM (truncated) 1000 -1.47 0.13 0.12 0.12 0.031 -2.07 0.030 0.15 0.15 0.023
G-Estimation 1000 -1.53 0.071 0.094 0.12 0.014 -2.10 0.0007 0.13 0.19 0.018
TABLE C.3: Simulation study results of interaction effect for continuous outcome at two- and three-years (Results show change
in effect of Dt on Lt per 10 change in Lt−1) (NA signifies that the method does not estimate that effect)
Scenario Method n Cumulative 4 Year Interaction Effect (10∑
4
i=1 φinti )
Mean Bias Empirical SE Model SE MSE
No Effect
10∑41 φinti = 0.00
HA-MSM 1000 0.053 0.053 0.21 0.22 0.049
HA-MSM (truncated) 1000 0.11 0.11 0.21 0.21 0.057
G-Estimation 1000 0.010 0.010 0.20 0.32 0.039
Standard
10∑41 φinti = 0.00
HA-MSM 1000 -0.44 -0.44 0.22 0.22 0.24
HA-MSM (truncated) 1000 -0.37 -0.37 0.21 0.21 0.19
G-Estimation 1000 -0.51 -0.51 0.20 0.31 0.30
Effect Modification
10∑41 φinti = −2.50
HA-MSM 1000 -2.62 -0.12 0.19 0.20 0.053
HA-MSM (truncated) 1000 -2.56 -0.058 0.19 0.20 0.040
G-Estimation 1000 -2.51 -0.010 0.18 0.27 0.034
TABLE C.4: Simulation study results of interaction effect for continuous outcome at four-years (Results show change in effect of
Dt on Lt per 10 change in Lt−1) (NA signifies that the method does not estimate that effect)
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FIGURE C.3: Kernel density plots of two- and three-year population-
average effect estimates for the odds of a zero count
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FIGURE C.4: Kernel density plots of two- and three-year population-
average effect estimates for the rate of a count
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FIGURE C.5: Kernel density plots of two- and three-year interaction effect
estimates for the odds of a zero count
FIGURE C.6: Kernel density plots of two- and three-year interaction effect
estimates for the rate of a count
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Scenario Estimate Method n
Cumulative 2 Year Treatment Effect
Log Odds Ratio of Zero Count (∑2i=1 βi) Log Rate Ratio of Count (∑
2
i=1 γi)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Standard
Marginal
IPW of MSM 1000 2.31 0.061 0.066 -0.84 0.083 0.082
IPW of MSM (truncated) 1000 2.29 0.060 0.066 -0.81 0.083 0.081
G-Formula 1000 2.32 0.050 0.028 -0.85 0.048 0.040
Conditional
HA-MSM 1000 2.67 0.064 0.067 -0.96 0.040 0.039
HA-MSM (truncated) 1000 2.66 0.064 0.067 -0.96 0.039 0.038
G-Estimation 1000 NA NA NA -3.28 0.096 0.024
No Effect
Marginal
IPW of MSM 1000 0.0007 0.040 0.044 0.004 0.027 0.031
IPW of MSM (truncated) 1000 -0.016 0.040 0.043 0.021 0.025 0.028
G-Formula 1000 -0.002 0.033 0.015 0.002 0.017 0.010
Conditional
HA-MSM 1000 -0.00004 0.046 0.047 0.002 0.020 0.021
HA-MSM (truncated) 1000 -0.002 0.046 0.047 0.004 0.019 0.021
G-Estimation 1000 NA NA NA 0.001 0.035 0.024
Decreasing
Effect
Marginal
IPW of MSM 1000 1.80 0.050 0.057 -0.67 0.057 0.057
IPW of MSM (truncated) 1000 1.78 0.050 0.056 -0.65 0.056 0.055
G-Formula 1000 1.81 0.044 0.023 -0.69 0.032 0.025
Conditional
HA-MSM 1000 2.09 0.056 0.057 -0.74 0.031 0.031
HA-MSM (truncated) 1000 2.08 0.056 0.057 -0.74 0.030 0.030
G-Estimation 1000 NA NA NA -2.50 0.076 0.024
Effect
Modification
Marginal
IPW of MSM 1000 1.50 0.052 0.055 -0.77 0.036 0.038
IPW of MSM (truncated) 1000 1.49 0.052 0.054 -0.76 0.034 0.035
G-Formula 1000 1.51 0.041 0.021 -0.76 0.024 0.014
Conditional
HA-MSM 1000 1.69 0.055 0.056 -0.70 0.029 0.028
HA-MSM (truncated) 1000 1.68 0.055 0.056 -0.70 0.028 0.028
G-Estimation 1000 NA NA NA -1.62 0.056 0.023
Reversed
Causal
Pathway
Marginal
IPW of MSM 758 -1.81 5.47 0.81 0.12 0.99 0.11
IPW of MSM (truncated) 1000 1.75 0.078 0.082 -0.53 0.13 0.11
G-Formula 1000 1.71 0.054 0.027 -0.60 0.038 0.022
Conditional
HA-MSM 727 2.15 1.13 0.39 -0.78 0.73 0.38
HA-MSM (truncated) 1000 1.91 0.067 0.067 -0.62 0.044 0.043
G-Estimation 1000 NA NA NA -2.18 0.090 0.024
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Scenario Estimate Method n
Cumulative 2 Year Treatment Effect
Log Odds Ratio of Zero Count (∑2i=1 βi) Log Rate Ratio of Count (∑
2
i=1 γi)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Censoring
Marginal
IPW of MSM 1000 2.33 0.087 0.091 -0.90 0.065 0.063
IPW of MSM (truncated) 1000 2.27 0.086 0.090 -0.88 0.062 0.061
G-Formula 1000 2.37 0.069 0.039 -0.91 0.048 0.034
Conditional
HA-MSM 1000 2.72 0.090 0.094 -0.94 0.053 0.052
HA-MSM (truncated) 1000 2.71 0.089 0.093 -0.94 0.051 0.051
G-Estimation 1000 NA NA NA -3.30 0.14 0.15
TABLE C.5: Simulation study results of two-year population-average effects for count outcome (Dt → Vt+1) (NA signifies that
the method does not estimate that effect)
Scenario Estimate Method n
Cumulative 3 Year Treatment Effect
Log Odds Ratio of Zero Count (∑3i=1 βi) Log Rate Ratio of Count (∑
3
i=1 γi)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Standard
Marginal
IPW of MSM 1000 2.86 0.099 0.10 -1.08 0.12 0.11
IPW of MSM (truncated) 1000 2.83 0.099 0.10 -1.04 0.13 0.11
G-Formula 1000 2.87 0.075 0.042 -1.09 0.069 0.056
Conditional
HA-MSM 1000 3.34 0.10 0.10 -1.19 0.062 0.062
HA-MSM (truncated) 1000 3.33 0.10 0.10 -1.18 0.061 0.061
G-Estimation 1000 NA NA NA -3.88 0.13 0.031
No Effect
Marginal
IPW of MSM 1000 -0.0009 0.048 0.055 0.003 0.037 0.040
IPW of MSM (truncated) 1000 -0.027 0.048 0.054 0.028 0.034 0.036
G-Formula 1000 -0.002 0.041 0.020 0.002 0.022 0.013
Conditional
HA-MSM 1000 -0.001 0.055 0.057 0.001 0.028 0.028
HA-MSM (truncated) 1000 -0.007 0.055 0.057 0.006 0.027 0.028
G-Estimation 1000 NA NA NA 0.001 0.043 0.031
Decreasing
Effect
Marginal
IPW of MSM 1000 1.97 0.071 0.074 -0.77 0.065 0.066
IPW of MSM (truncated) 1000 1.94 0.071 0.074 -0.74 0.064 0.064
G-Formula 1000 1.98 0.056 0.030 -0.78 0.040 0.028
Conditional
HA-MSM 1000 2.39 0.078 0.079 -0.87 0.044 0.043
HA-MSM (truncated) 1000 2.37 0.078 0.079 -0.87 0.043 0.042
G-Estimation 1000 NA NA NA -2.60 0.093 0.031
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Scenario Estimate Method n
Cumulative 3 Year Treatment Effect
Log Odds Ratio of Zero Count (∑3i=1 βi) Log Rate Ratio of Count (∑
3
i=1 γi)
Mean Empirical SE Model SE Mean Empirical SE Model SE
Effect
Modification
Marginal
IPW of MSM 1000 1.66 0.067 0.069 -0.79 0.047 0.048
IPW of MSM (truncated) 1000 1.64 0.067 0.069 -0.76 0.043 0.043
G-Formula 1000 1.68 0.054 0.028 -0.67 0.030 0.018
Conditional
HA-MSM 1000 1.93 0.071 0.073 -0.77 0.039 0.039
HA-MSM (truncated) 1000 1.92 0.071 0.073 -0.77 0.038 0.038
G-Estimation 1000 NA NA NA -1.78 0.071 0.031
Reversed
Causal
Pathway
Marginal
IPW of MSM 758 1.28 20.79 132.06 -0.60 0.90 0.13
IPW of MSM (truncated) 1000 2.05 0.11 0.11 -0.67 0.14 0.10
G-Formula 1000 2.01 0.071 0.038 -0.70 0.049 0.029
Conditional
HA-MSM 727 3.51 2.76 1.54 -0.95 0.90 0.38
HA-MSM (truncated) 1000 2.29 0.099 0.097 -0.74 0.065 0.062
G-Estimation 1000 NA NA NA -2.44 0.11 0.032
Censoring
Marginal
IPW of MSM 1000 2.87 0.16 0.15 -1.09 0.10 0.10
IPW of MSM (truncated) 1000 2.77 0.16 0.15 -1.05 0.10 0.099
G-Formula 1000 2.89 0.11 0.065 -1.13 0.076 0.050
Conditional
HA-MSM 1000 3.35 0.16 0.16 -1.14 0.092 0.088
HA-MSM (truncated) 1000 3.32 0.16 0.16 -1.13 0.090 0.087
G-Estimation 1000 NA NA NA -3.88 0.20 0.22
TABLE C.6: Simulation study results of three-year population-average effects for count outcome (Dt → Vt+1) (NA signifies that
the method does not estimate that effect)
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Scenario Estimate Method n
2 Year Interaction Effect
Log Odds Ratio of Zero Count (14βint2 ) Log Rate Ratio of Count (14γint2 )
β Empirical SE Model SE β Empirical SE Model SE
No Effect Conditional
HA-MSM 1000 0.003 0.040 0.039 0.004 0.012 0.011
HA-MSM (truncated) 1000 0.002 0.039 0.039 0.005 0.012 0.011
G-Estimation 1000 NA NA NA -0.001 0.015 0.016
Standard
(no effect
modification)
Conditional
HA-MSM 1000 0.049 0.043 0.043 -0.010 0.023 0.019
HA-MSM (truncated) 1000 0.046 0.041 0.041 -0.009 0.023 0.018
G-Estimation 1000 NA NA NA 0.077 0.050 0.016
Effect
Modification Conditional
HA-MSM 1000 0.14 0.042 0.042 0.11 0.031 0.025
HA-MSM (truncated) 1000 0.15 0.041 0.040 0.12 0.027 0.023
G-Estimation 1000 NA NA NA -0.072 0.036 0.016
TABLE C.7: Simulation study results of two-year interaction effects for count outcome (Results show change in effect of Dt on
Vt+1 per 14 change in Vt) (NA signifies that the method does not estimate that effect)
Scenario Estimate Method n
3 Year Interaction Effect
Log Odds Ratio of Zero Count (14βint3 ) Log Rate Ratio of Count (14γint3 )
β Empirical SE Model SE β Empirical SE Model SE
No Effect Conditional
HA-MSM 1000 0.00002 0.041 0.040 0.005 0.015 0.015
HA-MSM (truncated) 1000 -0.002 0.041 0.040 0.007 0.014 0.014
G-Estimation 1000 NA NA NA 0.00005 0.018 0.018
Standard
(no effect
modification)
Conditional
HA-MSM 1000 0.033 0.053 0.051 -0.012 0.041 0.028
HA-MSM (truncated) 1000 0.030 0.051 0.050 -0.011 0.041 0.027
G-Estimation 1000 NA NA NA 0.031 0.068 0.019
Effect
Modification Conditional
HA-MSM 1000 -0.023 0.049 0.048 -0.001 0.031 0.028
HA-MSM (truncated) 1000 -0.025 0.048 0.047 0.001 0.030 0.027
G-Estimation 1000 NA NA NA -0.068 0.050 0.019
TABLE C.8: Simulation study results of three-year interaction effects for count outcome (Results show change in effect of Dt on
Vt+1 per 14 change in Vt) (NA signifies that the method does not estimate that effect)
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Abstract
Background: Dornase alfa (DNase) is one of the commonest cystic ﬁbrosis (CF) treatments and is often used for many years. However, studies
have not evaluated the effectiveness of its long-term use. We aimed to use UK CF Registry data to investigate the effects of one-, two-, three-, four-
and ﬁve-years of DNase use on lung function to see if the beneﬁts of short-term treatment use are sustained long term.
Methods: We analysed data from 4,198 people in the UK CF Registry from 2007 to 2015 using g-estimation. By controlling for time-dependent
confounding we estimated the effects of long-term DNase use on percent predicted FEV1 (ppFEV1) and investigated whether the effect differed by
ppFEV1 at treatment initiation or by age.
Results: Considering the population as a whole, there was no signiﬁcant effect of one-year's use of DNase; change in ppFEV1 over one year was
−0.1% in the treated compared to the untreated (p = 0.51) and this did not change with long-term use. However, treatment was estimated to be more
beneﬁcial in people with lower lung function (p b 0.001); those with ppFEV1 b 70% at treatment initiation, showed an increase in lung function
over one year that was sustained out to ﬁve years. The estimated effect of DNase did not depend on age (p = 0.35).
Conclusions: DNase improved lung function in individuals with reduced lung function, bringing a step-change in lung function, but no change in
the slope of decline. There was no evidence for a beneﬁt in lung function in those initiating treatment with ppFEV1 N 70%.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: DNase; Long-term treatment effect; Patient registry; UK Cystic Fibrosis Registry
1. Background
First licensed for use in the EU and the US in 1994, dornase
alfa (DNase) is now one of the commonest cystic fibrosis (CF)
treatments, used by almost 60% of people with CF in the UK in
2016 [1,2]. DNase is a mucolytic treatment administered via a
nebulizer, decreasing the viscosity of sputum in the airways,
aiming to aid in airway clearance, to improve lung function and
decrease pulmonary exacerbations [3].
In a phase III clinical trial, using DNase once or twice daily
over twenty-four weeks was shown to improve percent-
predicted FEV1 (ppFEV1) [4]. Subsequently, a number of
studies have examined the effect of longer-term use of DNase.
For example, after 96 weeks of follow-up, treatment was shown
to significantly improve ppFEV1 in children aged 6 to 10 [5,6].
Most studies have focused on the absolute effect of DNase
on lung function over a specified time period, i.e. on a step-
change effect. Its impact on the rate of lung function decline is
also important and this has been investigated in two studies.
These studies showed that during DNase use the rate of lung
function decline was less than the rate of decline in the same
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patients prior to starting treatment and also less than the rate of
decline in a comparator group of patients who never received
treatment [7,8]. Only one study has attempted to evaluate the
impact of using DNase for more than two years. This was a
matched study with 76 patients where it was found that those
receiving treatment over four years had a more gradual slope of
decline in ppFEV1 [9].
Until recently in the UK regional guidelines for CF use of
DNase varied, but DNase tended to be recommended when a
person's ppFEV1 fell below 80%. However, in 2014 a national
policy was approved allowing the use of DNase in anyone over
six years of age. Thus, more recently, some centres have begun
to routinely initiate DNase when a patient reaches six years of
age. These differences in treatment practices provide an
opportunity to use the UK CF Registry data to investigate the
long-term effects of DNase in a diverse population.
There are, however, some challenges that must be addressed
when attempting to use observational data for this purpose. The
main issue when estimating treatment effects is confounding by
indication, whereby more healthy individuals are less likely to
receive treatment. A simple comparison of treated and
untreated would therefore typically suggest that even an
effective treatment is associated with worse outcomes. A
further complexity of Registry data is that as it is longitudinal,
not only do confounding variables affect both the outcome of
interest and the probability of receiving treatment, but they are
also themselves affected by whether the patient was receiving
treatment or not in previous years. This issue is known as time-
dependent confounding and traditional statistical methods will
generally lead to biased results. There are several methods
available that can deal with time-dependent confounding
[10,11], including inverse probability weighted estimation of
marginal structural models, g-computation formula and g-
estimation. A recent investigation of the application of these
methods using registry data showed that for a continuous
outcome, such as lung function, g-estimation appeared to be the
most reliable and flexible, in particular by accommodating
estimation of treatment effect modification by a time-varying
covariate [12].
In this paper, we aimed to use the UK CF Registry to
investigate the effects of one-, two-, three-, four- and five-years
of DNase use on lung function. Furthermore, we aimed to
investigate whether there is evidence that treatment is more
effective in younger people, as has previously been reported
[7]. We also hypothesised that the effect of DNase may differ
depending on lung function, and as such we examined whether
there is evidence that the treatment effect is modified by
previous measures of lung function.
2. Methods
2.1. UK cystic ﬁbrosis registry
The UK Cystic Fibrosis Registry is a national database
managed by the Cystic Fibrosis Trust. Each year people with
CF attend an annual assessment at which data are collected on
their current health as well as on the treatments they have
received in the past year. More details about the registry can be
found in the data resource profile [13].
People were eligible for inclusion in the study if they had at
least two consecutive years of data in the Registry between
2007 and 2015, had not received DNase prior to 2007, had at
least one year of treatment-free data, were at least six years old,
had lung function data for at least two consecutive years and
had not received a lung transplant. The first visit for everyone
was therefore at a time when they were not and had never
before received DNase treatment. Follow-up data were
collected up to 2015, or were censored at death, transplant or
loss to follow-up. If people who started receiving DNase
stopped during their follow-up, they were censored at the time
they stopped treatment. Fig. 1 shows a flow chart of the number
of people included and excluded from the study population.
For this study, the primary outcome was change in lung
function expressed as absolute change over time in ppFEV1
calculated using the Global Lung Initiative (GLI) calculations
[14]. Secondary analyses with ppFVC and ppFEF25–75 as
outcomes were also conducted. All outcomes are observed
annually.
As well as previous measures of the outcome and DNase, we
also adjusted for the following time-varying variables: annual
number of hospital and home IV days, CF centre, other muco-
Total People in Registry Since 2007
n = 11,083
Recevied transplant before 2007
n = 166
Aged less  than 6
n = 1,284
Receiving DNase at first visit
n = 3,260
Missing Lung Function Data
n = 985
People with only one visit
n = 1,190
People included in analysis
n = 4,198
Never Used DNase
n = 1,814
DNase Use ≥ 1 year
n = 2,384
DNase Use ≥ 2 year
n = 1,741
DNase Use ≥ 3 year
n = 1,339
DNase Use ≥ 4 year
n = 1,050
DNase Use ≥ 5 year
n = 787
Exclusions
Fig. 1. Flowchart of people included in analysis.
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active treatments, smoking status, CF related diabetes (CFRD),
body mass index (BMI), allergic bronchopulmonary aspergil-
losis (ABPA) and infections (P. aeruginosa, S. aureus and B.
cepacia complex); and the following non-time-varying vari-
ables: age, gender, ethnicity and genotype class (as defined by
McKone et al) [15]. These were selected from the data collected
in the Registry as variables that could affect both lung function
and the decision to initiate DNase.
2.2. Statistical methods
In a preliminary exploration of the data, baseline covariates,
i.e. those measured at the first visit, were summarised in all
patients and separately in the following four subgroups: those
who never received DNase, those who received DNase for at
least one year, those who received DNase for at least five years,
and those who stopped DNase during follow-up. Time-varying
covariates were summarised across visits in the following five
groups: at a patient's first visit, at subsequent visits among
people not receiving DNase, at the first visit when people
received DNase, at subsequent visits among people receiving
DNase, and at the visit when people stopped receiving DNase.
We also performed a univariable linear regression to estimate
the crude difference in lung function between those receiving
and not receiving treatment.
Data were then analysed using g-estimation to investigate
the causal effect of up to five years of DNase use on lung
function [16]. A recent paper by Vansteelandt and Sjolander
has shown how to implement this method using standard
statistical software [17]. Full details of this method can be
found in the supplementary material to this paper. Briefly, the
method works iteratively by first estimating a one-year
treatment effect adjusting for the confounders of this effect,
then estimating any additional two-year treatment effect
adjusting for the relevant confounders of this effect and so on
until the maximum follow-up time of interest (five years in our
case). Thus, we obtain five different treatment effect estimates;
these are the estimated differences in lung function between
those using DNase for k years (k = 1, …, 5) and those never
receiving treatment, with the time-dependent confounding
having been adjusted for at each stage.
Evidence that the treatment effect is modified by age or by
previous lung function was investigated by including an
interaction term between the relevant variable and DNase use
at each visit.
For g-estimation, standard errors used to calculate p-values
and 95% confidence intervals were estimated using the non-
parametric bootstrap approach [18]. All analyses were per-
formed using Stata (version 15.0, Stata Corp, College Station,
Texas, USA).
3. Results
Overall, 4,198 people were included in the analysis, with a
combined total of 20,923 annual assessments. The median
number of follow-up visits per person was 5 (IQR 3–7). During
follow-up, 2,384 (56.8%) people received DNase for at least
one year, and most people who started using DNase continued
to receive it indefinitely, with only 441 (18.5%) people
stopping during follow-up. In total, 787 people had five or
more consecutive years of DNase use.
Table 1 summarises the variables that were considered as
confounders for the main analysis. When looking at this
summary of the data, we found that those taking DNase tend to
have worse symptoms. This is expected, because those needing
treatment are expected to be in worse health. This finding is
part of the phenomenon of confounding by indication.
Particularly, the mean ppFEV1 measured prior to visits when
people were not receiving DNase was 80% compared to 72%
prior to the visit when people started to receive DNase.
Furthermore, the group who ever received DNase had a higher
proportion of people with a high genotype class (76% vs 57%),
a higher proportion with CFRD (23% vs 18%) and had more
annual IV days (mean annual hospital IV days 10 vs 5, and
mean annual home IV days 9 vs 5). Table 1 also summarises
the group of people who stopped taking DNase during follow-
up, but there were no noticeable differences between this group
of people and those who continued to take DNase throughout
follow-up.
Results from the univariable analysis (row 1 of Table 2)
show that people receiving DNase had lower lung function
compared to those not receiving treatment throughout follow-
up. For example, at one year those receiving DNase had a lung
function on average 7.1% lower than those not receiving
treatment (95% CI -8.1% to −6.1%, p b 0.0001). Furthermore,
the average annual decline in ppFEV1 was 1.0% (95% CI 0.9%
to 1.2%) in those not taking DNase compared to 1.3% (95% CI
1.1% to 1.5%) in those receiving DNase.
The results from the causal analysis using g-estimation are
shown in Table 2 and Fig. 2. On a population level, we found
no significant effect of DNase on ppFEV1, with those on
treatment estimated to have an absolute change in lung function
of −0.1% over one year compared to someone not receiving
treatment (95% CI -0.6% to 0.4%, p = 0.65). However, by year
two this effect became more pronounced with an estimated
difference of −0.7% (95%CI–1.4% to 0.05%, p = 0.069), and
this trend continued out to year five, when it was estimated that
on average receiving treatment for 5 years, compared to never
receiving DNase, would result in an absolute change in lung
function of −3.3% (95% CI -4.9% to −1.7%, p b 0.0001).
We found strong evidence that the effect of treatment differs
depending on previous lung function (p b 0.001), with
beneficial effects seen in those with low lung function. This is
illustrated in Fig. 2, where beneficial effects are shown over the
5-year duration for people with baseline ppFEV1 b70%,
whereas for those with baseline ppFEV1 N70% the rate of
decline was steeper in those receiving treatment. For example,
for an individual with baseline ppFEV1 of 40%, initiating
DNase was estimated to result in a lung function 1.6% higher
after one year (95% CI 0.6% to 2.7%, p = 0.002) compared to
not initiating DNase. Conversely, for an individual with a
baseline ppFEV1 of 80%, initiating DNase was estimated to
result in a lung function 0.4% lower after one year (95% CI
-0.1% to 0.9%, p = 0.13) compared to not initiating DNase.
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The results from the g-estimation analysis provide informa-
tion on whether any impact of DNase on lung function is in the
form of a step change or whether the treatment modifies the
slope of decline. In the groups for which we found a beneficial
effect of treatment, the results were consistent with DNase
resulting in a one-off step change in lung function, rather than a
change in overall trajectory. Full results can be seen in Table 2,
but taking individuals who start treatment with a baseline
ppFEV1 of 40% as an example, the estimated difference in
absolute change in lung function at 5 years was of 1.2% (95%
CI -1.9% to 4.4%, p = 0.44), very similar to the 1.6% benefit
seen at one year.
We found no evidence that the effect of treatment on lung
function differed depending on age at treatment initiation, p =
0.61. (Results of this analysis can be found in the supplemen-
tary material).
We also performed analyses to investigate the effect of
DNase on FVC and FEF25–75 and these results can be seen in
supplementary material. The results from these analyses were
broadly similar to the findings from the FEV1 analysis.
4. Discussion
We used UK CF Registry data to estimate long-term effects
of DNase use, controlling for confounding by indication by
using state-of-the-art statistical methodology not previously
applied to CF registry data. In our study, for individuals with a
reduced lung function and not using DNase, we have shown
that initiating DNase treatment and using it for one year brings
a benefit such that ppFEV1 is higher after one year than it
would have been had those individuals not initiated DNase
treatment. This beneficial effect appeared to remain with
continued use of DNase out to five years, but with no overall
modification of the lung function trajectory, as the estimated
effect remained stable between years one and five.
One reason why it is important to estimate long-term effects
of treatment is to see if a treatment modifies overall lung-
function trajectory or just provides a one-off increase [19,20].
Fig. 3 shows two hypothetical lung-function trajectories for an
individual treated with DNase compared to the lung-function
trajectory of someone not receiving treatment. These trajecto-
ries show how treatment could either be disease modifying,
where the lung function of those receiving treatment continues
to grow wider apart from the lung function of those not
receiving treatment, or alternatively how the overall lung-
function trajectory could remain unchanged after an initial
increase.
Crude comparisons between those who received and did not
receive DNase clearly indicate that there is confounding by
indication, such that individuals taking DNase tend to have
worse health status than those not taking DNase. If this is not
appropriately handled in the analysis, any estimates of the
treatment effect would not have a causal interpretation. In this
study, we made use of appropriate statistical methods to address
the confounding by indication, accounting for the longitudinal
setting, thereby showing how registries can be used to evaluate
the long-term effects of treatment. Randomised controlled trials
(RCT) are the gold standard for establishing treatment efficacy,
but as previously discussed, it is preferable for a CF treatment
to alter lung function trajectory rather than to provide a one-off
improvement, and assessing change in trajectory requires
longer follow-up than would typically be feasible in trials
[21]. The analyses used in this paper take advantage of clear
heterogeneity in treatment practices as the proportion of
patients receiving DNase at individual CF centres ranges from
b20% to N80% [2]. As the groups who receive and do not
receive DNase include individuals with wide-ranging clinical
characteristics, the statistical methods used in this paper can
correct for confounding by indication as long as data on all
confounders have been collected. We were able to adjust for a
large number of variables using the data available in the UK CF
Table 2
Estimated Effect of DNase Use on percent predicted FEV1 compared to never taking DNase.
Years of DNase use
1 2 3 4 5
Est 95% CI Est 95% CI Est 95% CI Est 95% CI Est 95% CI
Results from univariable analysis
Estimated population average effect
−7.1 −8.1, −6.1 −8.6 −9.7, −7.4 −10.6 −11.9, −9.3 −12.6 −14.0, −11.1 −14.2 −15.9, −12.6
Results from G-Estimation Analysis
Estimated population average effect
−0.1 −0.6, 0.4 −0.7 −1.4, 0.05 −1.4 −2.3, −0.6 −2.5 −3.8, −1.3 −3.3 −4.9, −1.7
Estimated effect by baseline ppFEV1
20% 2.6 1.1, 4.2 2.0 −0.1, 4.2 0.9 −1.7, 3.6 3.0 −0.5, 6.5 4.1 −0.5, 8.7
40% 1.6 0.6, 2.7 1.0 −0.4, 2.5 0.1 −1.8, 1.9 0.9 −1.5, 3.3 1.2 −1.9, 4.4
60% 0.6 −0.01, 1.2 0.1 −0.9, 1.0 −0.8 −1.9, 0.4 −1.2 −2.7, 0.3 −1.6 −3.5, 0.3
80% −0.4 −0.9, 0.1 −0.9 −1.6, −0.2 −1.6 −2.6, −0.7 −3.3 −4.5, −2.0 −4.5 −6.2, −2.8
100% −1.4 −2.2, −0.6 −1.9 −3.0, −0.8 −2.5 −3.9, −1.0 −5.4 −7.4, −3.4 −7.3 −10.0, −4.6
Estimated change in effect per 10% change in baseline ppFEV1
−0.5 −0.8, −0.2 −0.5 −0.9, −0.1 −0.4 −0.9, 0.003 −1.0 −1.7, −0.4 −1.4 −2.2, −0.6
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Registry, but it is not possible to verify whether confounding by
indication has ever been completely dealt with and the causal
interpretation of our results therefore depends on the assump-
tion of no unmeasured confounding [22].
A previous registry study by Hodson et al. of the
European Epidemiologic Registry of Cystic Fibrosis esti-
mated a one-year treatment effect of DNase on ppFEV1 of
3.6% (95% CI 1.8% to 5.3%) and a two-year treatment
effect of 2.5% (0.7% to 4.4%) [7]. These are larger
population-average treatment effect estimates than obtained
in our study, but the population for those studies had lower
average baseline ppFEV1, who were the patients we found
benefitted most from treatment.
Only two previous studies have investigated the effects of
DNase in people with ppFEV1 N 80% and only one of these
Fig. 3. Examples of possible lung function trajectories depending on treatment
effect through time.
Fig. 2. Estimated mean difference in the change in ppFEV1 between dornase alfa users compared to non-users (dashed grey line), by years of treatment. The top-left
figure shows the estimated overall average population effect, with the remaining figures highlighting the differential effects based on ppFEV1 at treatment initiation.
The horizontal dashed grey line is the line indicating no treatment effect.
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included lung function as an outcome [23,24]. That study only
administered DNase for four weeks and found no effect of
treatment on ppFEV1: treatment effect 0.1% increase in
ppFEV1 [24]. In our study, for individuals with higher lung
function, those on DNase treatment had steeper trajectories of
lung function decline than comparable individuals not receiving
treatment. This may suggest that it would be more beneficial, in
terms of lung function outcomes, to wait until lung function
starts to decline before initiating DNase. However, as with all
observational studies, it is possible that unobserved con-
founders affect these results. With the rich Registry data, we
believe we have accounted for the covariates that could affect
both lung function and the probability of receiving DNase
treatment to account for confounding by indication, but it is
possible that there are some unmeasured health-related
variables that affected the decisions to initiate treatment in
these individuals. For example, although an individual may
have had a high lung function measurement at the previous
annual assessment, they may have been beginning to show
signs of lung function deterioration that was not picked up by
having only one lung function measure per year.
Upon initiation of DNase, most people continue to receive
the treatment indefinitely, with only very small numbers of
people stopping treatment. Due to this, with the sample size
available, it was not possible to estimate the effect of stopping
treatment. However, as we observed that treatment only
appeared to be beneficial in individuals with reduced lung
function, future studies could investigate whether treatment
needs to be continued in people who recover to higher levels of
lung function.
A major strength of this study is the use of the UK CF
Registry data, which are collected at regular intervals according
to a standardised protocol. The data include a large number of
variables that we could account for as potential confounders.
One of the main limitations of this study is that there are no data
available on levels of adherence to treatment. It is known to be
particularly hard to measure adherence levels, but previous
studies have estimated that average adherence levels to
nebulised therapies, such as DNase, may range between 60%
and 70% [25,26]. Specifically, for a longitudinal study, we may
expect adherence levels to be higher at treatment initiation and
decrease through time, which may partly explain why the
observed effects are not as pronounced as in RCT, where
adherence would typically be higher [27].
The UK CF Registry contains data on over 99% of people
with CF in the UK, but a large number of these people were
excluded from this analysis. The majority of these exclusions
were due to people who were already receiving DNase prior to
2007 or people aged under six, and this is not considered to be a
source of bias. Our results are applicable to people aged over
six and estimate the effects of the first five years of DNase use.
The method of g-estimation relies on having equally spaced
visits, and therefore a number of people were censored due to
missing lung function measurements during follow-up. We
used so-called ‘censoring weights’ within g-estimation, which
reweights individuals who remain in the study to account for
those lost to follow-up.
The analyses presented in this paper use the FEV1 measure
obtained on the date of a patient's annual review. An alternative
approach would be to use the best FEV1 measure obtained since
the last annual review. However, best FEV1 has only been
collected in the UK CF Registry since 2012 and the aim of this
paper, to estimate the effects of long-term DNase use, would
not be possible with the number of best FEV1 observations
available. The unknown timing of the best FEV1 measure
relative to the other measures would also present additional
challenges for the analysis. According the Registry protocol,
annual reviews take place at a time when the patient is stable,
and ongoing validation procedures indicate good adherence to
this protocol [28]. Furthermore, there is no evidence to suggest
that those receiving DNase are more likely to have their annual
review during an unstable period compared to those not
receiving DNase, meaning that using the FEV1 measure
obtained during the annual assessment should not result in
any bias.
It is also acknowledged that spirometry measures, such as
FEV1, may not be sufficiently sensitive to detect the early
stages of lung function decline, and it has been suggested that
other measures such as lung clearance index (LCI) may give a
better indication of early lung function deterioration [29,30].
Unfortunately, LCI is not collected in the UK CF Registry, so it
was not possible to investigate this. However, FEF25–75 is
collected in the registry, albeit less reliably than FEV1 (3320
FEF25–75 measurements compared to 20,923 FEV1 measure-
ments in this analysis), and the results showed similar findings
to the findings with FEV1, but with much larger confidence
intervals, reflecting the lack of measurements and increased
variability of this measure (see Supplement).
In conclusion, we have shown a beneficial long-term effect
of DNase in people with reduced lung function, but with no
overall change in lung-function trajectory. There is a differen-
tial effect of treatment based on lung function at treatment
initiation with no improvements in lung function seen in
individuals initiating treatment with ppFEV1 higher than 70%.
Finally, this study highlights the potential of registries in
investigating the effects of long-term treatment use and that
issues of confounding-by-indication can be addressed with
appropriate statistical methods.
Funding & competing interests
SJN, SBC, DB and RHK are part of the CF-EpiNet Strategic
Research Centre supported by a grant from the Cystic Fibrosis
Trust. RMD is supported by a Sir Henry Dale Fellowship
jointly funded by the Wellcome Trust and the Royal Society
(107,617/Z/15/Z). SBC is a principal investigator (PI) for a CF
Trust Registry-based pharmacovigilance (PASS) study for
Pharmaxis, and is a PI for a CF Trust Vertex-funded
Registry-based observational study. DB is a principal investi-
gator for two CF Trust Registry-based pharmacovigilance
studies for Vertex and Teva pharmaceutical companies. RHK is
supported by a Medical Research Council Methodology
Fellowship (MR/M014827/1).
7S.J. Newsome et al. / Journal of Cystic Fibrosis xx (2018) xxx–xxx
Please cite this article as: Newsome SJ, et al, Investigating the effects of long-term dornase alfa use on lung function using registry data, J Cyst Fibros (2018), https://doi.
org/10.1016/j.jcf.2018.08.004
Appendix D. Paper 3 - August 2018 303
Acknowledgements
We thank people with cystic fibrosis and their families for
consenting to their data being held in the UK CF Registry, and
NHS teams in CF centres and clinics for the input of data into
the Registry. We also thank the UK Cystic Fibrosis Trust and
the Registry Steering Committee for access to anonymized UK
CF Registry data.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.jcf.2018.08.004.
References
[1] Pulmozyme. 2500 U/2.5ml, nebuliser solution. Available from: Internet
https://www.medicines.org.uk/emc/medicine/1723.
[2] UK Cystic Fibrosis Registry Annual Data Report 2016 Internet. 2016.
Available from:file:///C:/Users/User/Downloads/2016 Registry Annual
Data Report (1).pdf.
[3] Bush A, Bilton D, Hodson M. Hodson and Geddes' Cystic Fibrosis. Taylor
& Francis; 2015; 694 Available from: Internet https://books.google.com/
books?id=x-3UMgEACAAJ&pgis=1.
[4] Fuchs H, Borowitz D, Christiansen D, Morris E, Nash M, Ramsey B, et al.
Effect of aerosolized recombinant human DNase on exacerbations of
respiratory symptoms and on pulmonary function in patients with cystic
fibrosis. N Engl J Med 1994;331(10):637–42.
[5] Quan JM, Tiddens HA, Sy JP, SG McKenzie, Montgomery MD,
Robinson PJ, et al. A two-year randomized, placebo-controlled trial of
dornase alfa in young patients with cystic fibrosis with mild lung function
abnormalities. J Pediatr 2001;139(6):813–20 Internet Available from:
http://www.ncbi.nlm.nih.gov/pubmed/11743506.
[6] Robinson PJ. Dornase alfa in early cystic fibrosis lung disease. Pediatr
Pulmonol 2002;34(3):237–41 Internet Available from: http://www.ncbi.
nlm.nih.gov/pubmed/12203856.
[7] Hodson ME, McKenzie S, Harms HK, Koch C, Mastella G, Navarro J,
et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report
from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 2003;
36(5):427–32 Internet Available from: http://www.ncbi.nlm.nih.gov/
pubmed/14520726.
[8] Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, et al.
Clinical use of dornase alpha is associated with a slower rate of FEV1
decline in cystic fibrosis. Pediatr Pulmonol 2011;46(6):545–53 Available
from:Internet http://www.ncbi.nlm.nih.gov/pubmed/21438174.
[9] Shah PL, Conway S, Scott SF, Rainisio M, Wildman M, Stableforth D,
et al. A case-controlled study with dornase alfa to evaluate impact on
disease progression over a 4-year period. Respiration 2001;68(2):160–4
Available from: Internet http://www.ncbi.nlm.nih.gov/pubmed/11287830.
[10] Daniel R, Cousens S, De Stavola B, Kenward M, Sterne J. Methods for
dealing with time-dependent confounding. Stat Med 2013;32(9):
1584–618 Available from: Internet https://doi.org/10.1002/sim.5686.
[11] Hernán MA, Robins JM. Causal Inference. Boca Raton chapman & hall/
CRC; 2018 Available from: Internet https://www.hsph.harvard.edu/
miguel-hernan/causal-inference-book/.
[12] Newsome S, Keogh R, Daniel R. Estimating long-term treatment effects in
observational data: a comparison of the performance of different methods
under real-world uncertainty. Stat Med 2018;37:2367–90.
[13] Taylor-Robinson D, Archangelidi O, Carr S, Cosgriff R, Gunn E, Keogh
R, et al. Data Resource Profile: the UK cystic fibrosis registry. Int J
Epidemiol 1 Feb 2018;47(1):9e–10e. https://doi.org/10.1093/ije/dyx196.
[14] Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al.
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the
global lung function 2012 equations. Eur Respir J 2012;40(6):1324–43.
[15] McKone E, Goss C, Aitken M. CFTR genotype as a predictor of prognosis
in cystic fibrosis. Chest 2006;130(5):1441–7.
[16] Robins J, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of
prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of
AIDS patients. Epidemiology 1992;3:319–36.
[17] Vansteelandt S, Sjolander A. Revisiting g-estimation of the effect of a
time-varying exposure subject to time-varying confounding. Epidemiol
Methods 2016;5(1):37–56 Available from:Internet http://www.degruyter.
com/view/j/em.ahead-of-print/em-2015-0005/em-2015-0005.xml.
[18] Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence
intervals, and other measures of statistical accuracy. Stat Sci 1986;1(1):
54–77.
[19] Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung
function: potential role in the early treatment of cystic fibrosis. J Cyst
Fibros 2012;11(2):78–83 Available from: Internet https://doi.org/10.1016/
j.jcf.2011.10.003.
[20] Konstan MW. Dornase alfa and progression of lung disease in cystic
fibrosis. Pediatr Pulmonol 2008;43(S9):S24–8 Available from: Internet
https://doi.org/10.1002/ppul.20858.
[21] Szczesniak R, Heltshe S, Stanojevic S, Mayer-Hamblett N. Use of FEV1
in cystic fibrosis epidemiologic studies and clinical trials: a statistical
perspective for the clinical researcher. J Cyst Fibros 2017;16(3):318–26.
[22] Hernán MA. The C-word: scientific euphemisms do not improve causal
inference from observational data. Am J Public Health 2018;108(5):
616–9.
[23] Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, et al.
Effect of treatment with dornase alpha on airway inflammation in patients
with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719–25.
[24] Amin R, Subbarao P, Lou W, Jabar a, Balkovec S, Jensen R, et al. The
effect of dornase alfa on ventilation inhomogeneity in patients with cystic
fibrosis. Eur Respir J 2011;37(4):806–12.
[25] Shakkottai A, Kidwell K, Townsend M, Nasr S. A five-year retrospective
analysis of adherence in cystic fibrosis. Pediatr Pulmonol 2015;50(12):
1224–9.
[26] Quittner A, Zhang J, Marynchenko M, Chopra P, Signorovitch J,
Yushkina Y, et al. Pulmonary medication adherence and health-care use
in cystic fibrosis. Chest 2014;146(1):142–51 Available from: Internet
https://doi.org/10.1378/chest.13-1926.
[27] Kettler L, Sawyer S, Winefield H, Greville H. Determinants of adherence
in adults with cystic fibrosis. Thorax 2002;57(5):459–64 Available from:
Internet http://thorax.bmj.com/cgi/doi/10.1136/thorax.57.5.459.
[28] Hoo Z, Curley R, Campbell M, Walters S, Wildman M. The importance of
data issues when comparing cystic fibrosis registry outcomes between
countries: are annual review FEV 1 in the UK only collected when
subjects are well? J Eval Clin Pract 2018:1–7 Available from: Internet
https://doi.org/10.1111/jep.12967.
[29] Davies J, Cunningham S, Alton E, Innes J. Lung clearance index in CF: a
sensitive marker of lung disease severity. Thorax 2008;63(2):96–7
Available from: Internet http://thorax.bmj.com/cgi/doi/10.1136/thx.2007.
088575.
[30] Pittman J, Rosenfeld M. Elementary, my dear Watson! The accumulating
evidence for the lung clearance index in monitoring early cystic fibrosis
lung disease. Am J Respir Crit Care Med 2017;195(9):1131–2.
8 S.J. Newsome et al. / Journal of Cystic Fibrosis xx (2018) xxx–xxx
Please cite this article as: Newsome SJ, et al, Investigating the effects of long-term dornase alfa use on lung function using registry data, J Cyst Fibros (2018), https://doi.
org/10.1016/j.jcf.2018.08.004
Appendix D. Paper 3 - August 2018 304
305
Appendix E
Supplementary Tables & Figures to
Chapter 6
Here we present the results of the analyses with percent predicted FVC and percent
predicted FEF25−75 as outcomes. These are both measures of lung function similar to
ppFEV1. The analyses presented are identical to the analysis of ppFEV1, starting with an
analysis of the one-year effect using SCMM, including estimating effect modification by
baseline age or previous lung function, and then estimating the one-, two-, three-, four-
and five-year effects using all available methods.
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FIGURE E.1: Estimated one-year effect of DNase on ppFVC depending on
baseline age or previous ppFVC
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FIGURE E.2: Estimated one-year effect of DNase on ppFEF25−75 depending
on baseline age or previous ppFEF25−75
Method 1 Year Treatment EffectEst. 95% CI p
Population Average -0.18 -0.57, 0.21 0.36
Modified by Age Intercept -0.21 -0.97, 0.54 0.58Interaction -0.012 -0.34, 0.31 0.94
Modified by Previous ppFVC Intercept 2.75 0.33, 5.17 0.026Interaction -0.35 -0.62, -0.075 0.012
TABLE E.1: Estimated one-year effects of DNase on ppFVC (The intercept
term is the estimated effect if the age or previous ppFVC is 0, and the inte-
raction term is the change in effect per 10 increase in the modifier)
Method 1 Year Treatment EffectEst. 95% CI p
Population Average -0.93 -3.04, 1.17 0.38
Modified by Age Intercept 0.34 -3.29, 3.97 0.85Interaction -0.87 -2.89, 1.16 0.40
Modified by Previous ppFEF25−75
Intercept 5.29 0.044, 10.53 0.048
Interaction -0.96 -1.79, -0.14 0.022
TABLE E.2: Estimated one-year effects of DNase on ppFEF25−75 (The inter-
cept term is the estimated effect if the age or previous ppFEF25−75 is 0, and
the interaction term is the change in effect per 10 increase in the modifier)
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Method 1 Year Treatment Effect Cumulative 2 Year Treatment Effect Cumulative 3 Year Treatment EffectEst. 95% CI p Est. 95% CI p Est. 95% CI p
IPW of MSM -1.23 -2.32, -0.14 0.027 -1.97 -3.32, -0.62 0.004 -2.50 -4.16, -0.84 0.003
IPW of MSM (truncated) -1.54 -2.31, -0.77 <0.0001 -2.41 -3.30, -1.51 <0.0001 -3.22 -4.27, -2.17 <0.0001
HA-MSM -0.87 -1.52, -0.23 0.008 -1.22 -1.84, -0.61 <0.0001 -0.93 -1.73, -0.14 0.021
HA-MSM (truncated) -0.72 -1.23, -0.21 0.006 -1.24 -1.82, -0.66 <0.0001 -1.10 -1.82, -0.39 0.003
G-Formula -0.27 -0.71, 0.16 0.22 -1.38 -2.02, -0.74 <0.0001 -2.40 -3.21, -1.58 <0.0001
G-Estimation -0.18 -0.58, 0.22 0.37 -1.04 -1.64, -0.45 <0.001 -1.36 -2.14, -0.58 <0.001
Method Cumulative 4 Year Treatment Effect Cumulative 5 Year Treatment EffectEst. 95% CI p Est. 95% CI p
IPW of MSM -4.13 -5.67, -2.59 <0.0001 -4.13 -5.92, -2.33 <0.0001
IPW of MSM (truncated) -4.62 -5.87, -3.37 <0.0001 -4.57 -6.03, -3.11 <0.0001
HA-MSM -1.26 -2.35, -0.18 0.023 -1.45 -2.96, 0.071 0.062
HA-MSM (truncated) -1.47 -2.44, -0.51 0.003 -1.71 -3.00, -0.41 0.010
G-Formula -3.98 -4.96, -3.01 <0.0001 -4.94 -6.08, -3.80 <0.0001
G-Estimation -1.81 -2.82, -0.80 <0.001 -2.04 -3.34, -0.75 0.002
TABLE E.3: Estimated cumulative population average effects of DNase on ppFVC
Method 1 Year Treatment Effect Cumulative 2 Year Treatment Effect Cumulative 3 Year Treatment EffectEst. 95% CI p Est. 95% CI p Est. 95% CI p
HA-MSM Intercept 0.083 -4.28, 4.44 0.97 0.46 -3.23, 4.14 0.81 2.56 -2.63, 7.75 0.33Interaction -0.11 -0.57, 0.36 0.65 -0.20 -0.60, 0.21 0.34 -0.41 -0.99, 0.18 0.17
HA-MSM (truncated) Intercept 1.49 -1.39, 4.37 0.31 0.96 -2.49, 4.41 0.59 4.02 -0.32, 8.36 0.070Interaction -0.25 -0.57, 0.059 0.11 -0.25 -0.63, 0.13 0.19 -0.59 -1.08, -0.11 0.016
G-estimation Intercept 2.75 0.35, 5.16 0.025 2.01 -1.54, 5.56 0.27 3.31 -1.70, 8.32 0.20Interaction -0.35 -0.62, -0.078 0.012 -0.36 -0.75, 0.038 0.076 -0.54 -1.09, 0.015 0.057
Method Cumulative 4 Year Treatment Effect Cumulative 5 Year Treatment EffectEst. 95% CI p Est. 95% CI p
HA-MSM Intercept 10.23 3.70, 16.75 0.002 9.78 1.53, 18.03 0.020Interaction -1.35 -2.07, -0.64 <0.001 -1.33 -2.24, -0.43 0.004
HA-MSM (truncated) Intercept 9.89 4.29, 15.49 <0.001 10.77 3.64, 17.90 0.003Interaction -1.33 -1.95, -0.71 <0.0001 -1.47 -2.26, -0.68 <0.001
G-estimation Intercept 8.77 2.30, 15.23 0.008 11.64 3.03, 20.24 0.007Interaction -1.22 -1.93, -0.51 <0.001 -1.57 -2.51, -0.63 0.001
TABLE E.4: Estimated cumulative effects of DNase on ppFVC modified by previous ppFVC (The intercept term is the estimated
effect if previous ppFVC was 0%, and the interaction term is the change in effect per 10% increase in previous ppFVC)
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Method 1 Year Treatment Effect Cumulative 2 Year Treatment Effect Cumulative 3 Year Treatment EffectEst. 95% CI p Est. 95% CI p Est. 95% CI p
IPW of MSM -1.49 -4.85, 1.88 0.39 -3.64 , -7.44, 0.16 0.061 -4.79 -10.16, 0.59 0.081
IPW of MSM (truncated) -1.47 -4.56, 1.62 0.35 -3.29 -6.79, 0.21 0.065 -4.66 -9.49, 0.18 0.059
HA-MSM -0.28 -2.54, 1.97 0.81 -0.93 -3.58, 1.73 0.49 -3.75 -7.78, 0.28 0.068
HA-MSM (truncated) -0.28 -2.49, 1.93 0.81 -0.77 -3.42, 1.88 0.57 -3.89 -7.86, 0.069 0.054
G-Formula -0.32 -2.53, 1.89 0.78 -1.89 -4.73, 0.95 0.19 -3.84 -7.37, -0.31 0.033
G-Estimation -0.93 -3.03, 1.16 0.38 -2.70 -5.37, -0.037 0.047 -4.92 -8.70, -1.15 0.010
Method Cumulative 4 Year Treatment Effect Cumulative 5 Year Treatment EffectEst. 95% CI p Est. 95% CI p
IPW of MSM -7.20 -14.31, -0.097 0.047 -3.94 -12.20, 4.33 0.35
IPW of MSM (truncated) -6.93 -12.84, -1.03 0.021 -4.95 -12.22, 2.33 0.18
HA-MSM -3.79 -8.87, 1.29 0.14 -3.33 -9.86, 3.20 0.32
HA-MSM (truncated) -4.13 -9.06, 0.81 0.10 -3.45 -10.00, 3.11 0.30
G-Formula -4.99 -9.28, -0.70 0.023 -6.32 -11.32, -1.32 0.013
G-Estimation -6.60 -11.54, -1.66 0.009 -5.00 -11.33, 1.33 0.12
TABLE E.5: Estimated population average effects of DNase on ppFEF25−75
Method 1 Year Treatment Effect Cumulative 2 Year Treatment Effect Cumulative 3 Year Treatment EffectEst. 95% CI p Est. 95% CI p Est. 95% CI p
HA-MSM Intercept 6.09 0.77, 11.42 0.025 5.04 -1.19, 11.28 0.11 3.44 -5.50, 12.39 0.45Interaction -0.95 -1.79, -0.11 0.027 -0.88 -1.84, 0.093 0.076 -1.03 -2.57, 0.50 0.19
HA-MSM (truncated) Intercept 6.16 0.87, 11.46 0.022 5.33 -0.87, 11.53 0.092 3.74 -4.89, 12.38 0.40Interaction -0.95 -1.79, -0.12 0.025 -0.89 -1.85, 0.071 0.070 -1.10 -2.56, 0.36 0.14
G-estimation Intercept 5.29 0.13, 10.45 0.045 4.16 -2.68, 11.01 0.23 1.50 -7.22, 10.22 0.74Interaction -0.96 -1.78, -0.15 0.021 -0.97 -2.08, 0.14 0.087 -0.86 -2.29, 0.57 0.24
Method Cumulative 4 Year Treatment Effect Cumulative 5 Year Treatment EffectEst. 95% CI p Est. 95% CI p
HA-MSM Intercept -3.49 -16.57, 9.58 0.60 -2.22 -20.52, 16.08 0.81Interaction 0.008 -2.17, 2.18 0.99 -0.13 -3.19, 2.94 0.94
HA-MSM (truncated) Intercept -2.17 -14.66,10.31 0.73 -1.85 -20.07,16.38 0.84Interaction -0.23 -2.29, 1.83 0.82 -0.21 -3.27, 2.85 0.89
G-estimation Intercept -0.62 -14.32, 13.08 0.93 -0.94 -18.56, 16.68 0.92Interaction -0.71 -2.90, 1.48 0.53 -0.32 -2.98, 2.35 0.82
TABLE E.6: Estimated cumulative effects of DNase on ppFEF25−75 modified by previous ppFEF25−75 (The intercept term is the
estimated effect if previous ppFEF25−75 was 0%, and the interaction term is the change in effect per 10% increase in previous
ppFEF25−75)
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Appendix F
Supplementary Tables & Figures to
Chapter 9
Here we present the results of the analyses with percent predicted FVC and percent
predicted FEF25−75 as outcomes. These are both measures of lung function similar to
ppFEV1. The analyses presented are identical to the analysis of ppFEV1, starting with an
analysis of the one-year effect using SCMM, including estimating effect modification by
baseline age or previous lung function, and then estimating the one-, two-, three-, four-
and five-year effects using all available methods.
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Analysis 1: Pre− & Post−Ivacaftor − Step−Change Effect
FIGURE F.1: Estimated step-change effect on ppFVC when comparing post-ivacaftor period to pre-ivacaftor period
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FIGURE F.2: Estimated slope-change effect on ppFVC when comparing post-ivacaftor period to pre-ivacaftor period
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FIGURE F.3: Estimated step-change effect on ppFVC when comparing those eligible for ivacaftor to those ineligible for ivacaftor
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FIGURE F.4: Estimated slope-change effect on ppFVC when comparing those eligible for ivacaftor to those ineligible for ivacaftor
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FIGURE F.5: Estimated step-change effect on ppFVC from combined ana-
lysis comparing those currently receiving ivacaftor both to those currently
not receiving ivacaftor and those in the time-period prior to the availability
of ivacaftor
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FIGURE F.6: Estimated slope-change effect on ppFVC from combined ana-
lysis comparing those currently receiving ivacaftor both to those currently
not receiving ivacaftor and those in the time-period prior to the availability
of ivacaftor
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Model MatrixStructure H Time
Analysis 1: Pre- & Post Comparison - Step-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 4.04 0.83 2.42, 5.66 <0.001 0.30 0.21 -0.12, 0.72 0.16 3.74 0.85 2.07, 5.42 <0.001Discrete 4.01 0.76 2.52, 5.51 <0.001 0.23 0.20 -0.15, 0.62 0.23 3.78 0.78 2.24, 5.31 <0.001
Adjusted Continuous 5.98 0.75 4.52, 7.44 <0.001 1.07 0.19 0.70, 1.44 <0.001 4.91 0.77 3.41, 6.41 <0.001Discrete 5.73 0.71 4.34, 7.11 <0.001 0.96 0.18 0.62, 1.31 <0.001 4.76 0.73 3.34, 6.18 <0.001
Exchangeable
Unadjusted Continuous 4.49 0.55 3.40, 5.57 <0.001 0.33 0.14 0.05, 0.60 0.021 4.16 0.57 3.04, 5.28 <0.001Discrete 4.49 0.56 3.39, 5.58 <0.001 0.28 0.14 0.00, 0.56 0.048 4.20 0.58 3.08, 5.33 <0.001
Adjusted Continuous 4.80 0.55 3.72, 5.87 <0.001 0.48 0.14 0.20, 0.75 <0.001 4.32 0.57 3.20, 5.43 <0.001Discrete 4.78 0.56 3.69, 5.87 <0.001 0.44 0.14 0.16, 0.72 0.002 4.34 0.58 3.21, 5.47 <0.001
Unstructured Unadjusted Discrete 4.27 0.61 3.07, 5.47 <0.001 0.24 0.14 -0.04, 0.52 0.090 4.03 0.63 2.80, 5.26 <0.001Adjusted 4.78 0.62 3.57, 6.00 <0.001 0.47 0.14 0.19, 0.75 0.001 4.31 0.64 3.06, 5.56 <0.001
Fixed-Effects Unadjusted Continuous 4.56 0.56 3.45, 5.67 <0.001 0.32 0.14 0.03, 0.60 0.029 4.24 0.58 3.10, 5.39 <0.001Discrete 4.56 0.57 3.44, 5.68 <0.001 0.27 0.15 -0.02, 0.55 0.065 4.29 0.59 3.14, 5.45 <0.001
Mixed-Effects
Combined
Unadjusted Continuous 4.50 0.55 3.41, 5.58 <0.001 0.38 0.14 0.10, 0.65 0.008 4.12 0.57 3.00, 5.24 <0.001Discrete 4.51 0.56 3.41, 5.60 <0.001 0.34 0.14 0.06, 0.61 0.018 4.17 0.58 3.04, 5.30 <0.001
Adjusted Continuous 4.76 0.55 3.68, 5.84 <0.001 0.51 0.14 0.24, 0.78 <0.001 4.25 0.57 3.14, 5.37 <0.001Discrete 4.76 0.55 3.67, 5.84 <0.001 0.47 0.14 0.20, 0.75 <0.001 4.28 0.57 3.16, 5.41 <0.001
By Group
Unadjusted Continuous 4.50 0.55 3.42, 5.58 <0.001 0.37 0.14 0.10, 0.65 0.008 4.12 0.57 3.00, 5.24 <0.001Discrete 4.50 0.56 3.41, 5.60 <0.001 0.34 0.14 0.06, 0.61 0.018 4.17 0.58 3.04, 5.30 <0.001
Adjusted Continuous 4.77 0.55 3.69, 5.84 <0.001 0.51 0.14 0.24, 0.78 <0.001 4.26 0.57 3.14, 5.37 <0.001Discrete 4.76 0.56 3.67, 5.85 <0.001 0.47 0.14 0.20, 0.75 <0.001 4.28 0.57 3.16, 5.41 <0.001
TABLE F.1: Estimated step-change effect on ppFVC when comparing post-ivacaftor period to pre-ivacaftor period
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Model MatrixStructure H Time
Analysis 1: Pre- & Post Comparison - Slope-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 0.47 0.40 -0.31, 1.25 0.24 0.02 0.10 -0.18, 0.21 0.85 0.45 0.40 -0.35, 1.24 0.27Discrete 0.50 0.37 -0.22, 1.21 0.17 0.07 0.09 -0.11, 0.25 0.46 0.43 0.37 -0.30, 1.15 0.25
Adjusted Continuous 0.76 0.36 0.06, 1.47 0.035 0.28 0.09 0.11, 0.46 0.002 0.48 0.37 -0.25, 1.20 0.20Discrete 0.91 0.34 0.24, 1.57 0.008 0.35 0.087 0.18, 0.52 <0.001 0.55 0.35 -0.13, 1.24 0.11
Exchangeable
Unadjusted Continuous 0.56 0.26 0.06, 1.06 0.030 -0.10 0.07 -0.24, 0.03 0.14 0.66 0.27 0.14, 1.18 0.013Discrete 0.58 0.26 0.07, 1.09 0.024 -0.08 0.07 -0.22, 0.06 0.28 0.66 0.27 0.13, 1.19 0.015
Adjusted Continuous 0.64 0.26 0.14, 1.14 0.013 0.00 0.07 -0.14, 0.14 0.96 0.64 0.27 0.11, 1.16 0.018Discrete 0.67 0.26 0.16, 1.19 0.010 0.03 0.07 -0.11, 0.17 0.69 0.64 0.28 0.10, 1.19 0.019
Unstructured Unadjusted Discrete 0.67 0.28 0.11, 1.22 0.018 -0.06 0.069 -0.20, 0.08 0.39 0.73 0.29 0.15, 1.30 0.013Adjusted 0.72 0.30 0.12, 1.31 0.018 0.07 0.07 -0.07, 0.21 0.35 0.65 0.32 0.03, 1.27 0.040
Fixed-Effects Unadjusted Continuous 0.57 0.26 0.06, 1.09 0.028 -0.12 0.07 -0.26, 0.02 0.10 0.69 0.27 0.16, 1.23 0.011Discrete 0.60 0.26 0.08, 1.12 0.023 -0.09 0.07 -0.24, 0.05 0.20 0.69 0.28 0.15, 1.23 0.012
Mixed-Effects
Combined
Unadjusted Continuous 0.63 0.26 0.13, 1.13 0.014 -0.14 0.07 -0.29, -0.01 0.042 0.77 0.27 0.25, 1.30 0.004Discrete 0.65 0.26 0.14, 1.15 0.012 -0.12 0.07 -0.26, 0.02 0.092 0.77 0.27 0.24, 1.29 0.005
Adjusted Continuous 0.69 0.26 0.19, 1.19 0.007 -0.04 0.07 -0.18, 0.10 0.60 0.73 0.27 0.20, 1.26 0.007Discrete 0.72 0.26 0.21, 1.23 0.006 -0.01 0.07 -0.15, 0.13 0.86 0.73 0.27 0.19, 1.27 0.008
By Group
Unadjusted Continuous 0.64 0.25 0.14, 1.14 0.012 -0.14 0.071 -0.28, -0.00 0.043 0.78 0.27 0.26, 1.31 0.003Discrete 0.66 0.26 0.16, 1.17 0.010 -0.12 0.07 -0.26, 0.02 0.095 0.78 0.27 0.25, 1.31 0.004
Adjusted Continuous 0.68 0.25 0.18, 1.18 0.007 -0.04 0.07 -0.18, 0.10 0.61 0.72 0.27 0.19, 1.24 0.007Discrete 0.71 0.26 0.20, 1.23 0.006 -0.01 0.07 -0.15, 0.13 0.87 0.73 0.28 0.19, 1.27 0.008
TABLE F.2: Estimated slope-change effect on ppFVC when comparing post-ivacaftor period to pre-ivacaftor period
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Model MatrixStructure H Time
Analysis 2: Eligible & Ineligible Comparison - Step-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 3.94 1.08 1.83, 6.05 <0.001 -0.11 1.12 -2.31, 2.08 0.92 4.05 1.25 1.60, 6.50 0.001Discrete 3.96 1.05 1.91, 6.01 <0.001 -0.01 1.07 -2.10, 2.08 0.99 3.98 1.15 1.72, 6.23 <0.001
Adjusted Continuous 5.29 0.96 3.40, 7.17 <0.001 0.23 0.98 -1.70, 2.15 0.82 5.06 1.17 2.78, 7.34 <0.001Discrete 5.10 0.94 3.25, 6.94 <0.001 0.28 0.91 -1.51, 2.06 0.76 4.82 1.06 2.75, 6.89 <0.001
Exchangeable
Unadjusted Continuous 4.46 0.56 3.37, 5.55 <0.001 -0.15 0.61 -1.34, 1.04 0.80 4.61 0.79 3.06, 6.16 <0.001Discrete 4.46 0.56 3.36, 5.57 <0.001 -0.09 0.62 -1.30, 1.12 0.88 4.55 0.80 2.99, 6.12 <0.001
Adjusted Continuous 4.72 0.56 3.63, 5.81 <0.001 -0.03 0.60 -1.21, 1.14 0.96 4.75 0.79 3.21, 6.30 <0.001Discrete 4.70 0.56 3.59, 5.80 <0.001 0.01 0.61 -1.18, 1.20 0.99 4.69 0.79 3.13, 6.24 <0.001
Unstructured Unadjusted Discrete 4.29 0.56 3.20, 5.38 <0.001 0.05 0.62 -1.16, 1.26 0.94 4.25 0.80 2.69, 5.80 <0.001Adjusted 4.80 0.56 3.70, 5.91 <0.001 0.13 0.61 -1.06, 1.32 0.83 4.67 0.79 3.12, 6.23 <0.001
Fixed-Effects Unadjusted Continuous 4.56 0.57 3.45, 5.67 <0.001 -0.24 0.62 -1.46, 0.99 0.70 4.80 0.81 3.20, 6.39 <0.001Discrete 4.56 0.57 3.44, 5.68 <0.001 -0.19 0.63 -1.43, 1.06 0.76 4.75 0.82 3.15, 6.35 <0.001
Mixed-Effects
Combined
Unadjusted Continuous 4.48 0.55 3.40, 5.56 <0.001 -0.06 0.60 -1.24, 1.11 0.91 4.55 0.78 3.01, 6.08 <0.001Discrete 5.50 0.56 3.41, 5.59 <0.001 0.01 0.61 -1.19, 1.21 0.99 4.49 0.79 2.95, 6.03 <0.001
Adjusted Continuous 4.68 0.55 3.60, 5.76 <0.001 0.04 0.59 -1.13, 1.20 0.95 4.64 0.78 3.12, 6.17 <0.001Discrete 4.68 0.56 3.59, 5.77 <0.001 0.11 0.60 -1.07, 1.29 0.86 4.57 0.78 3.04, 6.11 <0.001
By Group
Unadjusted Continuous 4.49 0.55 3.41, 5.56 <0.001 -0.05 0.60 -1.23, 1.13 0.93 4.54 0.78 3.00, 6.07 <0.001Discrete 4.50 0.56 3.41, 5.59 <0.001 0.03 0.61 -1.17, 1.23 0.96 4.46 0.79 2.92, 6.01 <0.001
Adjusted Continuous 4.68 0.55 3.60, 5.77 <0.001 0.05 0.59 -1.12, 1.21 0.94 4.64 0.78 3.11, 6.17 <0.001Discrete 4.68 0.56 3.58, 5.77 <0.001 0.13 0.60 -1.05, 1.31 0.83 4.55 0.78 3.01, 6.09 <0.001
TABLE F.3: Estimated step-change effect on ppFVC when comparing those eligible for ivacaftor to those ineligible for ivacaftor
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Model MatrixStructure H Time
Analysis 2: Eligible & Ineligible Comparison - Slope-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 0.66 0.30 0.07, 1.25 0.028 0.32 0.40 -0.46, 1.10 0.42 0.34 0.53 -0.69, 1.37 0.52Discrete 0.65 0.28 0.09, 1.20 0.022 0.29 0.37 -0.44, 1.01 0.43 0.36 0.47 -0.56, 1.27 0.44
Adjusted Continuous 0.49 0.28 -0.05, 1.03 0.073 0.14 0.37 -0.58, 0.86 0.70 0.35 0.49 -0.60, 1.30 0.47Discrete 0.57 0.26 0.05, 1.08 0.031 0.13 0.34 -0.53, 0.79 0.70 0.44 0.43 -0.41, 1.29 0.31
Exchangeable
Unadjusted Continuous 0.69 0.20 0.31, 1.08 <0.001 0.15 0.25 -0.34, 0.63 0.55 0.55 0.31 -0.07, 1.16 0.081Discrete 0.68 0.20 0.29, 1.07 <0.001 0.11 0.26 -0.39, 0.61 0.66 0.57 0.32 -0.05, 1.19 0.074
Adjusted Continuous 0.68 0.20 0.30, 1.07 <0.001 0.10 0.25 -0.39, 0.59 0.69 0.58 0.32 -0.04, 1.21 0.065Discrete 0.68 0.20 0.30, 1.07 <0.001 0.08 0.26 -0.43, 0.58 0.77 0.61 0.32 -0.02, 1.24 0.058
Unstructured Unadjusted Discrete 0.72 0.20 0.32, 1.11 <0.001 0.09 0.26 -0.42, 0.61 0.72 0.62 0.31 0.02, 1.22 0.043Adjusted 0.67 0.20 0.28, 1.06 <0.001 0.07 0.26 -0.44, 0.58 0.78 0.60 0.32 -0.02, 1.22 0.059
Fixed-Effects Unadjusted Continuous 0.70 0.20 0.32, 1.09 <0.001 0.13 0.25 -0.35, 0.62 0.59 0.57 0.31 -0.04, 1.18 0.068Discrete 0.69 0.20 0.30, 1.08 <0.001 0.10 0.26 -0.40, 0.60 0.70 0.59 0.32 -0.03, 1.21 0.064
Mixed-Effects
Combined
Unadjusted Continuous 0.74 0.20 0.35, 1.13 <0.001 0.07 0.25 -0.41, 0.55 0.78 0.67 0.31 0.07, 1.27 0.030Discrete 0.72 0.20 0.33, 1.10 <0.001 0.03 0.26 -0.47, 0.53 0.91 0.69 0.31 0.07, 1.30 0.028
Adjusted Continuous 0.74 0.20 0.36, 1.13 <0.001 0.04 0.25 -0.44, 0.53 0.86 0.70 0.31 0.09, 1.31 0.024Discrete 0.73 0.20 0.34, 1.11 <0.001 0.01 0.26 -0.50, 0.51 0.98 0.72 0.32 0.10, 1.34 0.023
By Group
Unadjusted Continuous 0.73 0.20 0.35, 1.12 <0.001 0.06 0.25 -0.43, 0.55 0.80 0.67 0.31 0.06, 1.28 0.031Discrete 0.71 0.20 0.32, 1.10 <0.001 0.02 0.26 -0.49, 0.53 0.95 0.70 0.32 0.08, 1.31 0.027
Adjusted Continuous 0.73 0.20 0.35, 1.12 <0.001 0.04 0.25 -0.45, 0.52 0.88 0.70 0.31 0.09, 1.31 0.025Discrete 0.72 0.20 0.34, 1.11 <0.001 -0.01 0.26 -0.52, 0.51 0.98 0.73 0.32 0.11, 1.35 0.022
TABLE F.4: Estimated slope-change effect on ppFVC when comparing those eligible for ivacaftor to those ineligible for ivacaftor
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Model MatrixStructure H Time
Combined Analysis
Step-Change Effect
est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 3.73 0.83 2.11, 5.34 <0.001Discrete 3.74 0.76 2.24, 5.23 <0.001
Adjusted Continuous 4.51 0.77 3.01, 6.02 <0.001Discrete 4.31 0.72 2.90, 5.72 <0.001
Exchangeable
Unadjusted Continuous 4.43 0.55 3.35, 5.51 <0.001Discrete 4.43 0.56 3.34, 5.52 <0.001
Adjusted Continuous 4.56 0.55 3.48, 5.64 <0.001Discrete 4.53 0.56 3.44, 5.62 <0.001
Unstructured Unadjusted Discrete 4.30 0.56 3.21, 5.40 <0.001Adjusted 4.59 0.56 3.5, 5.68 <0.001
Fixed-Effects Unadjusted Continuous 4.56 0.57 3.45, 5.67 <0.001Discrete 4.56 0.57 3.44, 5.68 <0.001
Mixed-Effects
Combined
Unadjusted Continuous 4.46 0.55 3.38, 5.55 <0.001Discrete 4.47 0.56 3.38, 5.57 <0.001
Adjusted Continuous 4.55 0.55 3.47, 5.62 <0.001Discrete 4.54 0.55 3.45, 5.62 <0.001
By Group
Unadjusted Continuous 4.46 0.55 3.38, 5.55 <0.001Discrete 4.47 0.56 3.37, 5.56 <0.001
Adjusted Continuous 4.55 0.55 3.47, 5.62 <0.001Discrete 4.53 0.56 3.45, 5.62 <0.001
TABLE F.5: Estimated step-change effect on ppFVC from combined ana-
lysis comparing those currently receiving ivacaftor both to those currently
not receiving ivacaftor and those in the time-period prior to the availability
of ivacaftor
Model MatrixStructure H Time
Combined Analysis
Slope-Change Effect
est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 0.45 0.40 -0.33, 1.24 0.26Discrete 0.44 0.37 -0.28, 1.17 0.23
Adjusted Continuous 0.51 0.37 -0.21, 1.23 0.17Discrete 0.59 0.34 -0.09, 1.26 0.087
Exchangeable
Unadjusted Continuous 0.59 0.27 0.07, 1.11 0.026Discrete 0.60 0.27 0.07, 1.12 0.026
Adjusted Continuous 0.62 0.27 0.10, 1.14 0.020Discrete 0.64 0.27 0.11, 1.17 0.018
Unstructured Unadjusted Discrete 0.61 0.26 0.10, 1.11 0.019Adjusted 0.59 0.26 0.08, 1.11 0.023
Fixed-Effects Unadjusted Continuous 0.62 0.27 0.09, 1.16 0.022Discrete 0.63 0.28 0.09, 1.17 0.022
Mixed-Effects
Combined
Unadjusted Continuous 0.69 0.27 0.17, 1.22 0.009Discrete 0.69 0.27 0.16, 1.22 0.010
Adjusted Continuous 0.72 0.27 0.20, 1.24 0.007Discrete 0.72 0.27 0.20, 1.25 0.007
By Group
Unadjusted Continuous 0.69 0.27 0.17, 1.21 0.010Discrete 0.70 0.27 0.17, 1.23 0.010
Adjusted Continuous 0.71 0.27 0.19, 1.23 0.008Discrete 0.73 0.27 0.20, 1.26 0.007
TABLE F.6: Estimated slope-change effect on ppFVC from combined ana-
lysis comparing those currently receiving ivacaftor both to those currently
not receiving ivacaftor and those in the time-period prior to the availability
of ivacaftor
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FIGURE F.7: Estimated step-change effect on ppFEF25−75 when comparing post-ivacaftor period to pre-ivacaftor period
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FIGURE F.8: Estimated slope-change effect on ppFEF25−75 when comparing post-ivacaftor period to pre-ivacaftor period
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FIGURE F.9: Estimated step-change effect on ppFEF25−75 when comparing those eligible for ivacaftor to those ineligible for
ivacaftor
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FIGURE F.10: Estimated slope-change effect on ppFEF25−75 when comparing those eligible for ivacaftor to those ineligible for
ivacaftor
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FIGURE F.11: Estimated step-change effect on ppFEF25−75 from combi-
ned analysis comparing those currently receiving ivacaftor both to those
currently not receiving ivacaftor and those in the time-period prior to the
availability of ivacaftor
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FIGURE F.12: Estimated slope-change effect on ppFEF25−75 from combi-
ned analysis comparing those currently receiving ivacaftor both to those
currently not receiving ivacaftor and those in the time-period prior to the
availability of ivacaftor
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Model MatrixStructure H Time
Analysis 1: Pre- & Post Comparison - Step-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 3.89 2.60 -1.20, 8.98 0.13 -0.57 0.62 -1.77, 0.64 0.36 4.45 2.64 -0.73, 9.63 0.092Discrete 3.85 2.50 -1.05, 8.74 0.12 -0.62 0.59 01.78, 0.54 0.30 4.46 2.54 -0.52, 9.45 0.079
Adjusted Continuous 5.69 2.41 0.97, 10.41 0.018 0.10 0.54 -0.95, 1.15 0.85 5.59 2.44 0.80, 10.37 0.022Discrete 4.94 2.31 0.41, 9.47 0.033 -0.08 0.53 -1.11, 0.95 0.88 5.02 2.35 0.41, 9.63 0.033
Exchangeable
Unadjusted Continuous 4.73 1.86 1.09, 8.37 0.011 -0.06 0.44 -0.92, 0.80 0.89 4.79 1.90 1.06, 8.52 0.012Discrete 4.69 1.87 1.02, 8.35 0.012 -0.17 0.44 -1.04, 0.70 0.70 4.86 1.92 1.10, 8.61 0.011
Adjusted Continuous 5.12 1.86 1.47, 8.77 0.006 0.02 0.43 -0.83, 0.87 0.96 5.10 1.91 1.37, 8.84 0.007Discrete 4.95 1.87 1.28, 8.61 0.008 -0.09 0.44 -0.95, 0.76 0.83 5.04 1.92 1.28, 8.80 0.009
Unstructured Unadjusted Discrete 4.70 1.99 0.80, 8.60 0.018 -0.30 0.43 -1.15, 0.55 0.49 5.00 2.05 0.99, 9.01 0.014Adjusted 5.00 1.92 1.23, 8.76 0.009 -0.24 0.43 -1.08, 0.61 0.59 5.23 1.97 1.37, 9.09 0.008
Fixed-Effects Unadjusted Continuous 4.83 1.93 1.05, 8.60 0.012 0.12 0.44 -0.75, 0.99 0.78 4.70 1.98 0.83, 8.58 0.017Discrete 4.82 1.94 1.02, 8.63 0.013 -0.02 0.45 -0.90, 0.86 0.97 4.84 1.99 0.94, 8.74 0.015
Mixed-Effects
Combined
Unadjusted Continuous 4.89 1.91 1.14, 8.64 0.011 -0.10 0.44 -0.95, 0.75 0.82 4.99 1.96 1.15, 8.83 0.011Discrete 4.82 1.91 1.07, 8.58 0.012 -0.18 0.44 -1.04, 0.69 0.69 5.00 1.96 1.15, 8.84 0.011
Adjusted Continuous 5.18 1.90 1.46, 8.90 0.006 -0.01 0.43 -0.86, 0.83 0.98 5.19 1.94 1.39, 9.00 0.007Discrete 5.03 1.90 1.30, 8.76 0.008 -0.09 0.44 -0.95, 0.76 0.83 5.12 1.95 1.30, 8.94 0.009
By Group
Unadjusted Continuous 4.84 1.89 1.14, 8.54 0.010 -0.07 0.44 -0.93, 0.79 0.87 4.91 1.93 1.12, 8.70 0.011Discrete 4.78 1.89 1.07, 8.49 0.012 -0.16 0.44 -1.03, 0.71 0.72 4.94 1.94 1.14, 8.74 0.011
Adjusted Continuous 5.10 1.87 1.43, 8.77 0.006 0.00 0.43 -0.84, 0.85 0.99 5.10 1.92 1.34, 8.85 0.008Discrete 4.96 1.88 1.28, 8.65 0.008 -0.09 0.44 -0.95, 0.76 0.83 5.06 1.93 1.28, 8.84 0.009
TABLE F.7: Estimated step-change effect on ppFEF25−75 when comparing post-ivacaftor period to pre-ivacaftor period
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Model MatrixStructure H Time
Analysis 1: Pre- & Post Comparison - Slope-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 1.83 1.32 -0.75, 4.40 0.17 0.99 0.31 0.38, 1.61 0.002 0.83 1.35 -1.81, 3.48 0.54Discrete 1.83 1.30 -0.73, 4.38 0.16 1.07 0.30 0.48, 1.66 <0.001 0.76 1.34 -1.87, 3.39 0.57
Adjusted Continuous 1.44 1.23 -0.97, 3.85 0.24 0.99 0.28 0.44, 1.53 <0.001 0.45 1.26 -2.02, 2.93 0.72Discrete 1.89 1.21 -0.49, 4.26 0.12 1.14 0.27 0.61, 1.66 <0.001 0.75 1.24 -1.68, 3.18 0.55
Exchangeable
Unadjusted Continuous 1.52 0.91 -0.27, 3.30 0.096 1.10 0.25 0.61, 1.59 <0.001 0.42 0.94 -1.42, 2.25 0.66Discrete 1.53 0.91 -0.25, 3.32 0.093 1.14 0.25 0.65, 1.62 <0.001 0.40 0.94 -1.44, 2.24 0.67
Adjusted Continuous 1.59 0.97 -0.30, 3.49 0.099 1.23 0.24 0.75, 1.70 <0.001 0.37 0.99 -1.56, 2.30 0.71Discrete 1.69 0.97 -0.21, 3.59 0.082 1.28 0.24 0.80, 1.76 <0.001 0.41 0.99 -1.54, 2.35 0.68
Unstructured Unadjusted Discrete 1.37 0.96 -0.51, 3.25 0.15 1.06 0.24 0.58, 1.53 <0.001 0.31 0.99 -1.62, 2.25 0.75Adjusted 1.26 0.96 -0.61, 3.14 0.19 1.27 0.24 0.81, 1.74 <0.001 -0.01 0.99 -1.95, 1.93 0.99
Fixed-Effects Unadjusted Continuous 1.53 0.94 -0.32, 3.37 0.10 1.16 0.26 0.65, 1.68 <0.001 0.36 0.97 -1.53, 2.26 0.71Discrete 1.53 0.94 -0.33, 3.38 0.11 1.19 0.26 0.67, 1.70 <0.001 0.34 0.97 -1.57, 2.25 0.73
Mixed-Effects
Combined
Unadjusted Continuous 1.33 0.90 -0.43, 3.10 0.14 1.07 0.25 0.58, 1.55 <0.001 0.27 0.93 -1.55, 2.08 0.77Discrete 1.38 0.90 -0.39, 3.15 0.13 1.11 0.25 0.62, 1.60 <0.001 0.27 0.93 -1.56, 2.10 0.77
Adjusted Continuous 1.44 0.98 -0.47, 3.35 0.14 1.22 0.24 0.75, 1.69 <0.001 0.22 0.99 -1.73, 2.16 0.83Discrete 1.56 0.98 -0.37, 3.48 0.11 1.27 0.24 0.80, 1.75 <0.001 0.28 1.00 -1.68, 2.25 0.78
By Group
Unadjusted Continuous 1.31 0.90 -0.46, 3.08 0.15 1.02 0.25 0.53, 1.51 <0.001 0.29 0.93 -1.53, 2.11 0.75Discrete 1.37 0.91 -0.40, 3.15 0.13 1.08 0.25 0.59, 1.58 <0.001 0.29 0.93 -1.54, 2.12 0.76
Adjusted Continuous 1.46 0.98 -0.46, 3.38 0.14 1.20 0.24 0.72, 1.68 <0.001 0.26 1.00 -1.70, 2.22 0.80Discrete 1.58 0.99 -0.35, 3.52 0.11 1.28 0.25 0.79, 1.76 <0.001 0.31 1.01 -1.67, 2.28 0.76
TABLE F.8: Estimated slope-change effect on ppFEF25−75 when comparing post-ivacaftor period to pre-ivacaftor period
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Model MatrixStructure H Time
Analysis 2: Eligible & Ineligible Comparison - Step-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 1.37 3.04 -4.59, 7.32 0.65 -4.48 3.12 -10.60, 1.63 0.15 5.85 3.97 -1.94, 13.64 0.14Discrete 1.22 2.99 -4.64, 7.07 0.68 -5.13 2.93 -10.88, 0.62 0.080 6.34 3.67 -0.85, 13.54 0.084
Adjusted Continuous 3.78 2.77 -1.66, 9.22 0.17 -3.36 2.71 -8.67, 1.94 0.21 7.15 3.66 -0.02, 14.31 0.051Discrete 3.21 2.65 -1.98, 8.40 0.23 -4.00 2.58 -9.07, 1.06 0.12 7.21 3.29 0.76, 13.66 0.028
Exchangeable
Unadjusted Continuous 4.18 1.84 0.58, 7.79 0.023 -1.00 2.16 0.58, 7.79 0.023 5.18 2.88 -0.47, 10.83 0.072Discrete 4.13 1.85 0.50, 7.77 0.026 -1.19 2.22 -5.55, 3.16 0.59 5.33 2.91 -0.38, 11.04 0.067
Adjusted Continuous 4.64 1.82 1.08, 8.20 0.011 -1.25 2.10 -5.37, 2.87 0.55 5.88 2.82 0.36, 11.41 0.037Discrete 4.47 1.83 0.89, 8.05 0.014 -1.45 2.15 -5.67, 2.78 0.50 5.92 2.83 0.38, 11.46 0.036
Unstructured Unadjusted Discrete 4.22 1.91 0.47, 7.97 0.027 -1.47 2.23 -5.85, 2.91 0.51 5.69 3.00 -0.19, 11.58 0.058Adjusted 4.53 1.87 0.86, 8.20 0.016 -1.63 2.17 -5.88, 2.61 0.45 6.16 2.92 0.43, 11.89 0.035
Fixed-Effects Unadjusted Continuous 4.83 1.93 1.05, 8.60 0.012 0.09 2.23 -4.27, 4.45 0.97 4.73 3.07 -1.28, 10.75 0.12Discrete 4.82 1.94 1.02, 8.63 0.013 -0.07 2.31 -4.59, 4.45 0.98 4.89 3.11 -1.21, 10.99 0.12
Mixed-Effects
Combined
Unadjusted Continuous 4.37 1.87 0.71, 8.04 0.019 -1.10 2.16 -5.34, 3.13 0.61 5.47 2.93 -0.26, 11.21 0.061Discrete 4.30 1.88 0.62, 7.98 0.022 -1.27 2.23 -5.63, 3.10 0.57 5.57 2.95 -0.20, 11.35 0.059
Adjusted Continuous 4.74 1.83 1.14, 8.33 0.010 -1.28 2.10 -5.40, 2.85 0.54 6.01 2.85 0.43, 11.59 0.035Discrete 4.56 1.84 0.96, 8.17 0.013 -1.46 2.15 -5.68, 2.76 0.50 6.03 2.85 0.44, 11.61 0.034
By Group
Unadjusted Continuous 4.35 1.85 0.72, 7.98 0.019 -1.09 2.17 -5.35, 3.17 0.62 5.44 2.93 -0.30, 11.17 0.063Discrete 4.29 1.87 0.63, 7.94 0.022 -1.26 2.25 -5.66, 3.14 0.58 5.55 2.95 -0.24, 11.33 0.061
Adjusted Continuous 4.75 1.83 1.17, 8.33 0.009 -1.20 2.12 -5.35, 2.95 0.57 5.95 2.86 0.34, 11.56 0.037Discrete 4.60 1.84 1.00, 8.20 0.012 -1.38 2.18 -5.65, 2.90 0.53 5.98 2.88 0.34, 11.62 0.038
TABLE F.9: Estimated step-change effect on ppFEF25−75 when comparing those eligible for ivacaftor to those ineligible for ivacaf-
tor
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Model MatrixStructure H Time
Analysis 2: Eligible & Ineligible Comparison - Slope-Change Effect
NTE (B vs A) NCE (D vs C) NCCTE
est. SE 95% CI p est. SE 95% CI p est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 1.35 0.98 -0.58, 3.27 0.17 1.03 1.38 -1.67, 3.74 0.45 0.31 1.72 -3.07, 3.69 0.86Discrete 1.41 0.95 -0.46,3.28 0.14 1.37 1.26 -1.11, 3.85 0.28 0.04 1.66 -3.21, 3.29 0.98
Adjusted Continuous 1.06 0.93 -0.76, 2.88 0.25 0.67 1.23 -1.74, 3.07 0.59 0.39 1.54 -2.63, 3.42 0.80Discrete 1.30 0.87 -0.41, 3.00 0.14 1.02 1.10 -1.15, 3.18 0.36 0.28 1.41 -2.48, 3.05 0.84
Exchangeable
Unadjusted Continuous 0.99 0.59 -0.17, 2.14 0.093 0.65 0.90 -1.11, 2.41 0.47 0.34 1.14 -1.90, 2.58 0.77Discrete 0.98 0.58 -0.16, 2.12 0.091 0.70 0.91 -1.08, 2.48 0.44 0.29 1.15 -1.97, 2.55 0.80
Adjusted Continuous 1.04 0.61 -0.15, 2.24 0.087 0.78 0.89 -0.96, 2.54 0.38 0.26 1.15 -1.99, 2.51 0.82Discrete 1.10 0.60 -0.09, 2.28 0.069 0.84 0.90 -0.93, 2.61 0.35 0.26 1.15 -2.00, 2.52 0.82
Unstructured Unadjusted Discrete 0.94 0.58 -0.21, 2.08 0.11 0.74 0.89 -1.01, 2.50 0.40 0.19 1.12 -2.00, 2.39 0.86Adjusted 1.09 0.60 -0.09, 2.27 0.070 0.93 0.90 -0.83, 2.69 0.30 0.16 1.13 -2.04, 2.37 0.88
Fixed-Effects Unadjusted Continuous 0.99 0.58 -0.16, 2.14 0.090 0.63 0.90 -1.13, 2.40 0.48 0.36 1.14 -1.88, 2.59 0.75Discrete 0.96 0.58 -0.18, 2.09 0.098 0.63 0.93 -1.19, 2.45 0.50 0.33 1.16 -1.96, 2.61 0.78
Mixed-Effects
Combined
Unadjusted Continuous 0.91 0.58 -0.24, 2.05 0.12 0.74 0.89 -1.00, 2.48 0.41 0.17 1.13 -2.05, 2.38 0.88Discrete 0.92 0.58 -0.21, 2.06 0.11 0.79 0.90 -0.98, 2.56 0.38 0.13 1.14 -2.11, 2.37 0.91
Adjusted Continuous 0.99 0.60 -0.19, 2.18 0.10 0.88 0.89 -0.87, 2.62 0.32 0.12 1.14 -2.12, 2.36 0.92Discrete 1.06 0.60 -0.12, 2.24 0.078 0.95 0.91 -0.83, 2.72 0.30 0.11 1.15 -2.14, 2.37 0.92
By Group
Unadjusted Continuous 0.94 0.58 -0.21, 2.08 0.11 0.71 0.89 -1.03, 2.44 0.43 0.23 1.13 -1.98, 2.44 0.84Discrete 0.95 0.58 -0.18, 2.09 0.10 0.77 0.91 -1.01, 2.54 0.40 0.18 1.14 -2.06, 2.43 0.87
Adjusted Continuous 1.00 0.60 -0.17, 2.18 0.095 0.85 0.89 -0.89, 2.59 0.34 0.15 1.14 -2.08, 2.38 0.89Discrete 1.06 0.60 -0.11, 2.23 0.077 0.92 0.91 -0.86, 2.70 0.31 0.14 1.15 -2.13, 2.40 0.90
TABLE F.10: Estimated slope-change effect on ppFEF25−75 when comparing those eligible for ivacaftor to those ineligible for
ivacaftor
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Model MatrixStructure H Time
Combined Analysis
Step-Change Effect
est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 4.77 2.56 -0.25, 9.80 0.063Discrete 4.79 2.48 -0.07, 9.64 0.053
Adjusted Continuous 5.75 2.36 1.12, 10.38 0.015Discrete 5.30 2.22 0.94, 9.65 0.017
Exchangeable
Unadjusted Continuous 4.93 1.86 1.30, 8.57 0.008Discrete 4.88 1.87 1.21, 8.54 0.009
Adjusted Continuous 5.27 1.83 1.68, 8.86 0.004Discrete 5.09 1.84 1.48, 8.69 0.006
Unstructured Unadjusted Discrete 4.90 1.93 1.12, 8.67 0.011Adjusted 5.09 1.89 1.39, 8.80 0.007
Fixed-Effects Unadjusted Continuous 4.83 1.93 1.05, 8.60 0.012Discrete 4.82 1.94 1.02, 8.63 0.013
Mixed-Effects
Combined
Unadjusted Continuous 5.06 1.90 1.33, 8.79 0.008Discrete 4.98 1.91 1.24, 8.71 0.009
Adjusted Continuous 5.35 1.86 1.70, 9.00 0.006Discrete 5.16 1.87 1.51, 8.82 0.006
By Group
Unadjusted Continuous 4.96 1.87 1.29, 8.62 0.008Discrete 4.89 1.88 1.21, 8.58 0.009
Adjusted Continuous 5.23 1.84 1.62, 8.85 0.004Discrete 5.09 1.85 1.46, 8.73 0.006
TABLE F.11: Estimated step-change effect on ppFEF25−75 from combined
analysis comparing those currently receiving ivacaftor both to those cur-
rently not receiving ivacaftor and those in the time-period prior to the avai-
lability of ivacaftor
Model MatrixStructure H Time
Combined Analysis
Slope-Change Effect
est. SE 95% CI p
Marginal
Independent
Unadjusted Continuous 0.72 1.34 -1.91, 3.34 0.59Discrete 0.64 1.33 -1.97, 3.25 0.63
Adjusted Continuous 0.67 1.15 -1.59, 2.93 0.56Discrete 0.80 1.09 -1.32, 2.93 0.46
Exchangeable
Unadjusted Continuous 0.37 0.93 -1.45, 2.19 0.69Discrete 0.39 0.93 -1.43, 2.20 0.68
Adjusted Continuous 0.36 0.92 -1.44, 2.15 0.69Discrete 0.42 0.91 -1.37, 2.22 0.64
Unstructured Unadjusted Discrete 0.35 0.90 -1.41, 2.11 0.70Adjusted 0.41 0.88 -1.32, 2.14 0.64
Fixed-Effects Unadjusted Continuous 0.33 0.96 -1.55, 2.22 0.73Discrete 0.34 0.97 -1.55, 2.24 0.72
Mixed-Effects
Combined
Unadjusted Continuous 0.26 0.92 -1.54, 2.05 0.78Discrete 0.28 0.92 -1.51, 2.08 0.76
Adjusted Continuous 0.26 0.91 -1.52, 2.05 0.77Discrete 0.33 0.91 -1.46, 2.12 0.72
By Group
Unadjusted Continuous 0.33 0.91 -1.46, 2.12 0.72Discrete 0.34 0.92 -1.46, 2.14 0.71
Adjusted Continuous 0.31 0.92 -1.50, 2.11 0.74Discrete 0.32 0.92 -1.47, 2.12 0.72
TABLE F.12: Estimated slope-change effect on ppFEF25−75 from combi-
ned analysis comparing those currently receiving ivacaftor both to those
currently not receiving ivacaftor and those in the time-period prior to the
availability of ivacaftor
